CLINICAL STUDY PROTOCOL  
 
 
NCT Number:   NCT02 605837 
 Study Title:  Oral Budesonide  Suspension (OBS) in  Adolescent and Adult  Subjects (11  to 
55 Years  of Age,  Inclusive)  with  Eosinophilic  Esophagitis:  A Phase 3  
Randomized,  Double -blind,  Placebo -controlled  Study  
 
 
Study Number:   SHP621 -301 
 
 
Protocol Version  and Date :   
Original Protocol: 31  Aug 2015 
Protocol Amendment 1: 17 Dec 2015 
Protocol Amendment 2 : 26 Jan 2018  
PROTOCOL:  SHP 621-301
TITLE: Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects 
(11 to 55 Y ears of Age, Inclusive ) with Eosinophilic Esophagitis: 
A Phase 3 Randomized, Double- blind, Placebo -controlled Study
DRUG: SHP621, oral budesonide s uspension (OBS)
IND: 103,173
EUDRACT NO.: Non-EUDRACT
SPONSOR: Shire ViroPharma, Incorporated (Shire) 
300 Shire Way , Lexington, MA 02421 USA
PROTOCOL 
HISTORY:Original Protocol:  31Aug 2015
This document contains confidential and proprietary information of Shire and is disclosed pursuant to 
confidentiality and non-disclosure obligations.  This inform ation should be used solely for the purposes for 
which it was provided and should not be copied, shared with, or disclosed to any third party without the express 
written consent of Shire.

Shire 
Protocol SHP621-301 CONFIDENTIAL 
Version 1.0 
PROTOCOL SIGNATURE PAGE 
Sponsor's (Shire) Approval 
Signature: 
, MD, PhD 
 
 Clini cal Development 
Acknowledgement 
I have read this protocol for Shire Study SHP621-301. -Date: 31 Aug 2015 31 Aug 2015 
Page 2 of91 
Title: Oral budesonide suspension (OBS) in Adolescent and Adult Subjects (11 to 55 years 
of age, inclusive) with Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, 
Placebo-Controlled Study 
I have fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the 
study, without written authorization from the sponsor. It is, however, permissible to provide 
the information contained herein to a subject in order to obtain their consent to participate. 
I agree to conduct this study according to this protocol and to comply with its requirements, 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonisation guidelines on Good Clinical 
Practice and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing. 
Conversely, should I decide to withdraw from execution of the study I will communicate my 
intention immediately in writing to the sponsor. 
Investigator Name and Address: 
(please hand print or type) 
Signature: ---------- ---------- ---------- ----Date: 

Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 3of 91
EMERGENCY CONTACT IN FORMATION
In the event of an SAE, the investigator must fax or e-mail the Shire Clinical Study  Adverse 
Event Form for Serious Adverse Events (SAEs) and Non-serious AEs as Required by 
Protocol within 24 hours to the Shire Global Pharmacovigilance and Risk Management 
Department. Applicable fax numbers and e -mail address can be found on the form (sent under 
separate cover). A copy of the Shire Clinical Study Adverse Event Form for SAEs and Non-
serious AEs as Required by Protocol must also be sent to the CRO medical monitor by fax or 
e-mail using the details below.
, MD
Email:  
Fax:  
For protocol -or safety -related issues during normal business hours (8am to 5 pm 
Eastern Standard Time) ,the investigator must contact the CRO medical monitor :
, MD
Phone: 
Mobile: 
Email:  
Fax:  
Forprotocol -or safety- related issues outside of normal business hours , the investigator 
must contact the CRO medical monitor :
, MD
Mobile: 
Email:  

Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 4of 91
PRODUCT QUALITY COMP LAINTS
Investigators are required to report investigational product quality  complaints to Shire within 
24hours. This includes any instances wherein the quality  or performance of a Shire product 
(marketed or investigational) does not meet expectations (eg,inadequate or faulty  closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg,wrong product such that the label and contents are different 
products).  For instructions on reporting AEs related to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint E
-mail Address
North and South America
European Union and Rest of World
Telephone num bers (provided for reference if needed):
Shire, Lexington, MA (USA)
 or 

Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 5of 91
TABLE OF CONTENTS
PROTOCOL  SIGNATURE P AGE ................................ ................................ ............................2
EMERGENCY CONTACT I NFORMATION ..........................................................................3
PRODUCT QUALITY COMP LAINTS ....................................................................................4
ABBREVIAT IONS ..................................................................................................................11
STUDY SYNOPSI S
.................................................................................................................13
STUDY SCHEDULE(S) ..........................................................................................................22
1. BACKGROUND INFORMATI ON.............................................................................27
1.1 Indication and Current Treatment Options
...................................................................27
1.2 Product Background and Clinical I nformation ............................................................27
2. STUDY OBJECTIVES AND PURPOSE ....................................................................28
2.1 Rationale for the Study .................................................................................................28
2.2 Study  Objectives ...........................................................................................................28
2.2.1 Primary  Objectives ................................................................................................28
2.2.2 Secondar y Objectives ............................................................................................29
2.2.3 Exploratory  Objective ............................................................................................29
3. STUDY DESIGN .........................................................................................................29
3.1 Study  Design and Flow Chart ......................................................................................29
3.2 Duration and Study  Completion Definition .................................................................31
3.3 Sites and Regions .........................................................................................................32
4. STUDY POPUL ATION...............................................................................................32
4.1 Inclusion Criteria
................................ ................................ ................................ ..........32
4.2 Exclusion Criteria ................................ ................................ ................................ .........33
4.3 Restrictions ...................................................................................................................35
4.4 Reproductive Potential ................................ ................................ ................................ .35
4.4.1 Female Contraception ............................................................................................35
4.5
Discontinuation of Subjects................................ ................................ ..........................36
4.5.1 Subject Withdrawal Criteria ..................................................................................36
Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 6of 91
4.5.2 Reasons for Discontinuation ................................ ................................ ..................36
4.5.3 Subjects “L ost to Follow -up” Prior to Last Scheduled Visit .................................37
5. PRIOR AND CONCOMITAN T TREATMENT .........................................................37
5.1 Prior Treatment .............................................................................................................38
5.2 Concomitant Treatment ................................................................................................38
5.2.1 Permitted Treatment ..............................................................................................38
5.2.2 Prohibited Treatment .............................................................................................39
6. INVESTIGAT IONAL PROD UCT ..............................................................................39
6.1 Identity of Investigational Product ...............................................................................39
6.1.1 Blinding the Treatment Assignment ......................................................................40
6.2 Administration of I nvestigational Product(s) ...............................................................40
6.2.1 Interactive Response Technology  for Investigational Product Management ........
40
6.2.2 Allocation of Subjects to Treatment ......................................................................41
6.2.3 Dosing ....................................................................................................................42
6.2.4 Unblinding the Treatment Assignment ..................................................................42
6.3
Labeling, Packaging, Storage, and Handling ...............................................................43
6.3.1 Labeling ................................ ................................ ................................ .................43
6.3.2 Packaging ...............................................................................................................43
6.3.3 Storage ...................................................................................................................44
6.3.4 Special Handling ....................................................................................................44
6.4 Drug Accountability .....................................................................................................44
6.5 Subject Compliance ......................................................................................................46
7.
STUDY PROCEDURES..............................................................................................46
7.1 Study Schedule .............................................................................................................46
7.1.1 Screening Period (Weeks -6 to 0) ..........................................................................46
7.1.1.1
Screening Visit (Visit -1) ................................ ................................ ............47
7.1.2 Place bo Lead -in Period (Weeks 0 to 4) .................................................................48
7.1.2.1 Placebo Lead -in Visit (Visit 0) ....................................................................48
7.1.3
Double- blind Treatment Period (Visits 1 -4): Weeks 4, 8, 12, and 16 (or 
Early Termination) .................................................................................................49
7.1.3.1
Baseline Visit (Visit 1): Week 4................................ ................................ ..50
Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 7of 91
7.1.3.2 Visits 2 and 3 (Weeks 8 and 12) ................................ ................................ ..51
7.1.3.3 Visit 4 (Week 16) ........................................................................................52
7.1.4 Follow -up Period ...................................................................................................53
7.1.4.1 Safety  Follow -up Contact (Visit 5): Week 20 .............................................53
7.1.5 Additional Care of Subjects after the Stud y
..........................................................53
7.2 Study  Evaluations and Procedures
...............................................................................53
7.2.1 Efficacy ..................................................................................................................54
7.2.1.1 Esophagogastroduodenoscopy  with Esophageal Biopsy  and 
Histopathologic Evaluation
.........................................................................54
7.2.1.2 Dysphagia Sy mptom Questionnaire ............................................................55
7.2.2
Safety.....................................................................................................................56
7.2.2.1 Medical and Medication History .................................................................56
7.2.2.2 Physical Examination (Including Height and Weight) ................................
56
7.2.2.3 Adverse Event Collection............................................................................57
7.2.2.4 Vital Signs ...................................................................................................57
7.2.2.5 Clinical L aboratory  Evaluations ..................................................................57
7.2.2.6 Pregnancy  Test ............................................................................................59
7.2.2.7 Dual -energy  X
-ray Absorptiometry  for Bone Mineral Densit y ..................59
7.2.3 Other Assessments .................................................................................................59
7.2.3.1 Health
-related Quality -of-life Assessment ..................................................59
7.2.3.2 Severity  of Disease Assessments ................................................................60
7.2.4 Clinical Pharmacology  Assessments .....................................................................60
7.2.5 Volume of Blood to Be Drawn from Each Subject ...............................................61
8. ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ..........................
62
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events ...........................................................................................................................62
8.1.1 Severity  Categorization ..........................................................................................63
8.1.2 Relationship Categorization ...................................................................................63
8.1.3 Outcome Categorization ........................................................................................64
8.1.4 Symptoms of the Disease under Study ..................................................................64
8.1.5 Clinical L aboratory  and Other Safet y Evaluations ................................ ................65
8.1.6 Pregnancy ...............................................................................................................65
8.1.7 Abuse, Misuse, Overdose, and Medication Error ..................................................66
8.2 Serious Adverse Event Procedures ................................ ................................ ...............67
Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 8of 91
8.2.1 Reference Safet y Information ................................ ................................ ................67
8.2.2 Reporting Procedures .............................................................................................67
8.2.3 Serious Adverse Event Definition .........................................................................67
8.2.4 Serious Adverse Event Collection Time Frame ....................................................68
8.2.5 Serious Adverse Event Onset and Resolution Dates .............................................68
8.2.6 Fatal Outcome ........................................................................................................68
8.2.7 Regulatory  Agency , Institutional Review Board, Ethics Committee, and Site 
Reporting
...............................................................................................................69
9. DATA MANAGEMENT AND STATISTICAL METHODS
.....................................69
9.1 Data Collection .............................................................................................................69
9.2 Clinical Data Management ...........................................................................................69
9.3
Data Handling Considerations......................................................................................70
9.4 Statistical Analy
sis Process ..........................................................................................70
9.5 Planned Interim Anal ysis, Adaptive Design, and Data Monitoring Committee ..........
70
9.6 Sample Size Calculation and Power Considerations....................................................71
9.7 Study  Population ..........................................................................................................71
9.8 Efficacy  Anal yses.........................................................................................................71
9.8.1 Primary  Efficacy  Endpoints ...................................................................................72
9.8.1.1 Missing Data Imputation .............................................................................73
9.8.2 Secondary  Efficacy  Endpoints ...............................................................................73
9.8.2.1 Key Secondary  Efficacy  Endpoint ..............................................................73
9.8.3 Exploratory  Efficacy  Endpoint ..............................................................................75
9.9 Safety  Anal yses............................................................................................................75
9.10 Other Anal yses.............................................................................................................76
9.10.1 Health
-related Quality -of-life Anal yses.................................................................76
9.10.2 Pharmacokinetic Analy ses.....................................................................................76
10. SPONSOR’S AND I NVEST IGATOR’S RESPONSIBIL
ITIES................................ .77
10.1 Sponsor’s Responsibilities ................................ ................................ ...........................77
10.1.1 Good Cli nical Practice Compliance .......................................................................77
10.1.2 Indemnity /Liability  and Insurance .........................................................................77
10.1.3 Public Posting of Study  Information .....................................................................77
Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 9of 91
10.1.4 Submission of Summary  of Clinical Study  Report to Competent Authorities 
of Member States Concerned and Ethics Committees ...........................................78
10.1.5 Study  Suspension, Termination, and Completion .................................................78
10.2
Investigator’s Responsibilities .....................................................................................78
10.2.1 Good Clinical Practice Compliance .......................................................................78
10.2.2 Protocol Adherence an d Investigator Agreement
..................................................79
10.2.3 Documentation and Retention of Records .............................................................79
10.2.3.1 Case Report Forms ......................................................................................79
10.2.3.2 Recording, Access, and Retention of Source Data and Study  
Documents ...................................................................................................80
10.2.3.3 Audit/I nspection ..........................................................................................80
10.2.3.4 Financial Disclosure ....................................................................................80
10.3 Ethical Considerations ..................................................................................................81
10.3.1 Informed Consent ..................................................................................................81
10.3.2 Institutional Review Board or Ethics Committee ..................................................81
10.4 Privacy  and Confidentiality ..........................................................................................82
10.5 Study  Results/Publication Policy .................................................................................83
11. REFERENCES .............................................................................................................84
12. APPENDI CES ..............................................................................................................86
LIST OF TABLES
Table 1
-1:Schedule of Assessments .......................................................................................22
Table 7
-1:Approximate V olume of Blood to Be Drawn from Each Subject .........................61
Table 8-1: Adverse Event Relatedness ....................................................................................64
Table 9
-1: Percentage of Responders for All Available Data (ie, Non- missing Data) b y 
Strata ......................................................................................................................73
Table 9
-2:Pharmacokinetic Parameters ................................ ................................ ..................76
LIST OF FIGURES
Figure 1: Study  Design Flow Chart .......................................................................................30
Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 10of 91
LIST OF APPENDICES
Appendix 1 Scales and Assessments ................................ ................................ ...............87
Appendix 2 Dysphagia Sy mptom Questionnaire ePRO for EoE ....................................88
Appendix 3
Patient Global I mpression of Severity.........................................................89
Appendix 4 Biosciences Generic Clinical Protocol Insert ..............................................90
Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 11of 91
ABBREVIATIONS
ACTH adrenocorticotropic hormone
AE adverse event
ANCOVA analysis of covariance
Auc tau area under the curve for the defined interval between doses
β-hCG beta-human chorionic gonadotropin
BID twice dail y
BMD bone mineral densit y
CFR Code of Federal Regulations
CI confidence interval
Cmax m
aximum concentration occurring at t max
CRA clinical research associate
CRF case report form
CRO contract r esearch organization
CYP450 3A4 cytochrome P450 3A4
DSG1 desmoglein 1
DSQ Dysphagia Sy mptom Questionnaire
DXA (DEXA) dual-energy  X -ray absorptiometry
EC ethics committee
EGD esophagogastroduodenoscopy
EIS external independent statistical
EMA Europe an Medicines Agency
EoE eosinophilic esophagitis
EoE-QoL-A  Adult Eosinophilic Esophagitis Qualit y of Life
ePRO electronic patient- reported outcome
EQ-5D- 3L EuroQol -5 Dimensions 3- level
EQ-5D EuroQol
EQ-5D-Y EuroQol 5 Dimensions Youth
EREFS EoE Endoscopic Reference Score
ET early termination
EU European Union
FAS full analy sis set
FDA Food and Drug Administration
GCP Good Clinical Practice
Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 12of 91
HIPAA Health Insurance Portability  and Accountability  Act
HPF high-powered field
HRQoL health
-related q uality  of life
hs at bedtime
ICH International Conference on Harmonisation
IRB Institutional Review Board
ITT intent -to-treat
IWRS interactive w eb-based response s ystem
Med ID medication information
MedDRA Medical Dictionary  for Regulatory  Activitie s
MI multiple imputation
OBS oral budesonide suspension
pc after meal
s
PedsQL -EoE Pediatric Quality  of Life Inventory  –EoE
PGA Physician Global 
Assessment
PGI-S Patient Global I mpression of Severity
PP per- protocol
PPI proton pump inhibitor
PT preferred term
qAM every  morning
SAE serious adverse event
SAP statistical analy sis plan
SAS®statistical analy sis sy stem
SOC system organ class
TEAE treatment -emergent adverse event
tmaxtime of maximum observed concentration sampled during a dosing 
interval
UK United Kingdom
US United States
Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 13of 91
STUDY SYNOPSIS
Protocol num ber:  SHP621 -301 Drug: SHP621, oral budesonide s uspension (OBS )
Title of the study: Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 
55Years of Age, Inclusi ve) with Eosinophilic Esophagitis: A Phase 3 Randomized, Double -blind, 
Placebo -controlled Study
Number of subjects (total and for each treatm ent arm):
Approximately 300subjects will be enrolled into the placebo lead-in period to allow for 228subjects 
(approximately 152and 7 6 per OBS and placebo treatment group , respectively )to be randomized into 
the double- blind treatment period.
Investigator(s):   Multicenter study
Site(s) and Region(s): 
Approximately 60sites in North America
Study period (planned ):
Oct 2015 to July 2018Clinical phase: 3
Objectives
Co-primary:
To demonstrate in a placebo -controlled trial that:
OBS induces a histologic response (eosinophilic count ≤6/high-powered field [HPF] ) in 
adolescent and adult subjects with eosinophilic esophagitis (EoE) over a 12-week course of 
therapy .
OBS reduces dysphagia, as measured by the Dysphagia Symptom Questionna
ire (DSQ), by at 
least 30% from baseline in adolescent and adult subjects with EoE over a 12-week course of 
therapy .
Key Secondary:
OBS reduces dysphagia, as measured by the DSQ score from baseline to the final treatment period 
evaluation (Visit 4). 
Secon dary:
To assess the response of endoscopically identified esophageal features to OBS as compared to 
placebo as measured by the EoE Endoscopic Reference Score (EREFS) 
To explore other responding criteria based on histology and DSQ
To assess the impact of O BS on pain, as measured by the DSQ
To evaluate the safety and tolerability of OBS over a 12-week course of therapy
To obtain 
OBS pharmacokinetic data in adult subjects with EoE
Exploratory:

Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 14of 91
Rationale:
Currently there is no approved medication for the treatment of EoE. This study is being conducted in 
order to provide safety and efficacy data demonstrating histologic response (as measu red by 
eosinophilic count ≤6/HPF)and improvement in dysphagia symptoms (as measured by the DSQ) 
following 12 weeks of treatment with OBS in adolescent and adult subjects with EoE . 
Investigational product, dose, and m ode of administration
OBS will be administered in 10mL at a concentration of 0.2 mg/mL (2mg dose), twice daily (in the 
morning [qAM] after meal s [breakfast, pc] and at bedtime [hs]) .The 0.2 m g/mL concentration of OBS 
and dosing regimens were selected for use in this Phase 3 study based onthe results of Study MPI 
101-06, a Phase 2 study in 93 adolescents and adult subjects with EoE and symptoms of dysphagia. 
Subjects were treated in Study MPI 101-06 with 2mg OBS twice daily to investigate the c o-prim ary 
endpoints of histologic response (defined as ≤6eosinophils/ HPF) and reduction in DSQ score from 
baseline to Week 12 of treatment . For the current study, the investigational product will be supplied in 
amber glass, multi -dose bottles with child -resistant caps. Each bottle will contain 210 mL of 
suspension with a budesonide concentration of 0.2 mg/mL, or 0.00 mg/mL (matching placebo). 
After the screening period, eligible subjects will enter a 4 -week single -blind placebo l ead-in period and
will receive 10 mL of OBS placebo twice daily (qAM, pc, and hs). At the end of the placebo lead-in
period, eligible subjects will enter a 12 -week double -blind treatment period ( baseline visit , Visit 1) and 
will be randomized to 1 of 2 treatment groups in a 2:1 ratio (approximately 152and 7 6 subjects for 
OBS and placebo twice daily treatment groups, respectively). Subjects will receive oral administration 
of 10 mL of 2mg investigational product twice daily (qAM, pc,and hs; 4 mg/day total), with no 
ingestion of food or liquids permitted for 30 minutes after study  drug administration:
Placebo twice daily group :  placebo qAM (pc) and hs
OBS twice daily group: OBS 10 mL of 0.2 mg/mL (2mg total) qAM ( pc)and hs
The total daily dose of budesonide will be 0 mg for each subject in the placebo group and 4mg for 
each subject in the OBS treatment group (Table 1 ). 
Table 1 : Total Daily Dose of OBS
Dose GroupOBS 
Concentration
(mg/mL)Volume 
per DoseMorning Dose 
(qAM, pc)Evening 
Dose (hs)Total 
Dose/Day
(mg/day)
Placebo 0.0 10 mL 0.0 mg 0.0 mg 0.0
OBS 0.2 10 mL 2.0 mg 2.0 mg 4.0
Abbreviations: hs=at bedtime; OBS=oral budesonide suspension; pc=after meal s; qAM=every 
morning
At the end of the 12-week double- blind treatment period (Visit 4), subjects who complete the study 
will have the opportunity to enroll in the treatment extension study. These subjects will continue on the 
blinded assigned treatment for 2-4 weeks as part of the screening prior to enrolling into the treatment 
extension study. 
Methodology:
This is a Phase 3, randomized, double- blind, multicenter , parallel -group, placebo -controlled study to 
evaluate the efficacy, safety, and tolerability of twice daily administration of OBS (qAM, pc,and hs) 
in adolescents and adults aged 11 -55 years, inclusive, with EoE and dysphagia. 
This study will comprise 3 periods: a 3-to 6-week screening period , 4-week single -blind placebo 
Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 15of 91
lead-inperiod , and 12 -week double -blind treatment period (Figure 1 ). Approximately 300subjects will 
be enrolled into the placebo lead-inperiod to allow for approximately 228subjects to be randomized 
in a 2:1 ratio (approximately 152and 7 6 per OBS and placebo treatment group, respectively ) into the 
double- blind treatment period. A minimum of 40 randomized subjects will be aged 11-17 years, 
inclusive.
Subjects who sign informed consent (or assent as applicable for subjects <18years) will be screened 
(Visit
-1). Subjects who meet eligibility criteria at the screening visit (Visit -1) and at the placebo 
lead-invisit (Visit 0) will enter the 4 -week placebo lead -inperiod to assess their ability to comply with 
twicedaily medication administration and assess whether there is a placebo response. Upon 
completion of the placebo lead -inperiod, subjects will return for the baseline visit (Visit 1) to confirm 
eligibility. Eligible subjects willbe randomized 2:1 into the double- blind treatment period and will be 
evaluated for efficacy and safety at Weeks 8, 12, and 16(Visits 2-4).Subjects who fail to meet all
eligibility criteria at Visits -1, 0,or 1will be considered screen failures. Subjec ts cannot be rescreened 
once they have been designated as a screen failure unless due solely to the use of a concomitant 
medication which can be stopped prior to rescreening . Subjects who discontinue will not be replaced.
Subjects will be required to visit the site up to 6 times over up to a 22-week period. A safety follow -up 
phone call will occur 4 weeks following the last dose of investigational product for subjects who 
discontinue prem aturely during the double -blind treatment period or who do not enroll in the treatment 
extension study .
Figure 1: Study Design Flow Chart
Abbreviations: BID=twice daily; EGD= esophagogastroduodenoscopy ; ET=early termination; 
OBS=oral budesonide suspension
Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 16of 91
Inclusion and exclusion criteria:
Inclusion Criteria:
The subject will not be considered eligible forthe study without meeting all of the following criteria 
(including test results):
1.Subject is able to provide written inform ed consent (subject, parent or legal guardian and, as 
appropriate, subject assent) to participat e in the study before completing any study-related 
procedures. 
2.Subject is male or female aged 11-55 years, inclusive ,at time of consent. 
3.Subject has histologic evidence of EoE with a peak eosino phil count of ≥15/HPF, from 2 
of3 
(proximal, mid -,and/or distal) levels of the esophagus at the s creening endoscopy .
4.Subject has a history of clinical symptoms of esophageal dysfunction (eg, eating problems, 
abdominal pain, heartburn, dysphagia, vomiting , food impaction, weight loss) intermittently or 
continuously at screening (Visit -1).
5.Subject must have experienced dysphagia (response of “yes” to question 2 on DSQ) on a 
minimum of 4 days and completed the DSQ on ≥70% of days inany 2consecutive weeks of the 
screening period and in the 2 weeks prior to the baseline visit (Visit 1).
6.Subject must not have proton pump inhibitor (PPI)–responsive EoE based on esophageal biopsies 
performed after the patient has been on at least 8 weeks of high-dose PPI therap y (high -dose 
therapy refers to the total daily dose, which may have been administered as a once -or twice daily 
dosing regim en). This may occur at the time of the qualifying esophagogastroduodenoscopy 
(EGD ; in which case the same PPI regimen must be contin ued),or this may have been done 
previously (in which case PPI therapy may have been stopped if there was no response to therapy 
based on esophageal biopsy results).
7.Subject w ill be on a stable (no changes) diet ≥3 m onths prior to the screening visit (Visi t -1).
8.Subject is willing and able to continue any dietary therapy, environmental therapy, and/or medical 
regimens (including gastric acid suppression; see exclusions below ) in effect at the screening visit 
(Visit -1).There should be no change to these re gimens during study participation.
9.All female subjects must have a negative serum pregnancy test (beta-human chorionic 
gonadotropin [β-hCG]) prior to enrol lment into the study . Females of childbearing potential must 
agree to continue acceptable birth control measures (eg, abstinence, stable oral contraceptives ,or 
double- barrier methods) throughout study p articipation.
10.Subject is willing and has an understanding and ability to fully comply with study procedures and 
restrictions defined in this protocol.
Exclusion Criteria:
Subjects are excluded from the study if any of the following exclusion criteria are m et:
1.Subject has any condition or abnormality (including laboratory abnorm alities), current or past, 
that, in the opinion of the principal investigator or medical monitor , would comprom ise the safety 
of the subject or interfere with or complicate the assess ment of signs or symptoms of EoE. Such 
conditions may include psychiatric problems; neurologic deficits or disease; developmental delay; 
cardiovascular, metabolic, or pulmonary disease; or previous gastroesophageal surgery . These 
should be discussed with t he medical monitor .
2.Subject has used immunomodulatory therapy within 8 weeks prior to the qualifying EGD or 
betw een the qualifying EGD and baseline visit ( Visit 1)or anticipates using immunomodulatory 
therapy during the treatment period (except for any ongoing regimen of allergy shots). Use of 
long-acting immunomodulatory therapy (eg, Rituxan) within 3 months of the qualifying EGD 
Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 17of 91
should be review ed with the medical monitor .
3.Subject has been using swallowed topical corticosteroid for EoE or systemic cortic osteroid for any 
condition within the 4 weeks prior to the qualifying EGD, betw een the qualifying EGD and 
baseline visit ( Visit 1),or anticipates use during the treatm ent period ; any temporary use or 
initiation of new steroid treatment during the study should be documented and discussed with the 
medical monitor prospectively but cannot occur within 4 weeks of the final EGD. 
4.Subject has been on inhaled or intranasal steroids and not on stable treatment for ≥3 months prior
to screening visit (Visit -1).Subjects on intranasal or inhaled steroids need to stay on stable 
treatment during study participation.
5.Subject has initiated, discontinued, or changed dosage regimen of PPIs, H2 antagonists, antacids, 
antihistamines, or leukotriene inhibitors for any conditi on (such as gastroesophageal reflux disease 
asthma or allergic rhinitis) within the 4 weeks prior to the qualifying EGD, betw een the qualifying 
EGD and baseline visit ( Visit 1), or anticipates changes in the use of such medications during the 
treatment per iod.  
6.Subject has been using cytochrom e P450 3A4 inhibitors (eg,ketoconazole, grapefruit juice) 
within the 2 weeks prior to the baseline visit ( Visit 1)or within 5 half-lives (whichever is greater)
or anticipates using such medications during the treatm ent period.  
7.Subject has an appearance on qualifying EGD of an esophageal stricture (high-grade), as defined 
by the presence of a lesion that does not allow passage of a diagnostic adult upper endoscope (eg, 
with an insertion tube diameter of >9 mm). 
8.Subject is on a pure liquid diet or the 6-food elimination diet .
9.Subject has had an esophageal dilation within the 3 months prior to screening (Visit -1).
10.Subject has presence of esophageal varices at the screening endoscop y.
11.Subject has any current disease of the gastrointestinal tract, aside from EoE, including 
eosinophilic gastritis, enteritis, colitis, or proctitis ; inflammatory bow el disease ; or celiac disease. 
12.Subject has other diseases causing or associated with EoE, including hypereosinophilic syndrom e, 
collagen vascular disease, vasculitis, achalasia, or parasitic infection.
13.Subject has current evidence of oropharyngeal or esophageal candidiasis.
14.Subject has acute or chronic viral infection or immunodeficiency condition, including 
tuberculosis, fungal , bacterial, viral/parasite infection, ocular herpes simplex, herpes esophagitis, 
or chicken pox/measles .
15.Subject has upper gastrointestinal bleeding within 4 weeks prior to the screening visit (Visit -1) or 
betw een the screening visit and baseline visit ( Visit 1).
16.Subject has evidence of active infection with Helicobacter pylori.
17.Subject has evidence of unstable asthma within 4 weeks prior to the screening visit (Visit -1) and 
betw een the screening visit and baseline visit (Visit 1).
18.Subject is female and pregnant or nursing.
19.Subject has a history of intolerance, hypersensitivity, or idiosyncratic reaction to budesonide (or 
any other corticosteroids) or to any other ingredients of the investigational product .
20.Subject has taken part in an investigational study within 6 months prior to the screening visit 
(Visit -1 ).
21.Subject has a history or high risk of noncompliance with treatment or regular clinic visits.
22.Subject has previously completed, discontinued, or withdrawn from this study.
Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 18of 91
23.Subject has participated in a previous clinical study involving OBS (SHP621).
Maximum duration of subject involvem ent in the study:
 Planned duration of screening period : 3-6 weeks
 Planned duration of placebo l ead-in period: 4 w eeks
 Planned duration of treatment period : 12 w eeks
 Planned duration of safety follow -up p eriod: 4 weeks
Endpoints and statistical analysis:
Subject Populations
 The safety setwill include all subjects who receive at least 1 dose of any double -blind 
investigational product . 
 The intent -to-treat (ITT) set will include all randomized subjects. Subjects will be analyzed 
according to their assigned treatment, regardless of the treatment actually received.
 The full analysis set (FAS) will include all randomized subjects who received at least 1 dose of a 
double- blind investigational product and have both an evaluable post-baseline biopsy in the 
treatment period (ie, peak eosinophil count is reported for at least 2 esophageal levels) and a 
post-baseline DSQ score .
 The per-protocol (PP) setwill include all subjects in the FAS excluding subjects with protocol 
violat ions. The PP set will be identified prior to unblinding the treatment assignments by a team 
consisting of, at a minimum, a physician and a statistician from Shire. 
 The pharm acokinetic setwill include all subjects in the safety set for whom the primar y 
pharmacokinetic data areconsidered sufficient and interpretable.
Prim ary Efficacy Endpoint s
The co -primary efficacy endpoints are the following :
 Histologic respon se, defined as a peak eosinophil count of ≤6/HPF across all available 
esophageal levels at the final treatment period evaluation (Visit 4 )
 Dysphagia symptom response, defined as ≥30% reduction in the DSQ combined score (questions 
2+3) from baseline to the final treatment period evaluation (Visit 4 )
Key Secondary Efficacy Endpoint
 Change in DSQ combined score (
questions 2 +3) from baseline to the final treatment period 
evaluation ( Visit 4 )
Secondary Efficacy Endpoints 
 Change in total endoscopy score, as measured by the EREFS classification, from baseli ne to the 
final treatment period evaluation (Visit 4)
 Peak eosinophil count <15/HPF across all available esophagus levels at the final treatment period 
evaluation (Visit 4)
 Peak eosinophil count ≤1/HPF across all available esophagus levels at the final treatment period 
evaluation (Visit 4)
 Change from baseline in the peak eosinophil count to the final treatment period evaluation 
(Visit 4) for each available esophageal level (proximal, mid -, and di stal)
Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 19of 91
 Change from baseline in the histopathologic epithelial features combined total score (grade and 
stage) to the final treatment period evaluation (Visit 4)
 Dysphagia symptom response (binary response) , defined as a ≥50% reduction in the DSQ 
combined score (questions 2+3), from baseline to the final treatment period evaluation (Visit 4 )
 Change from baseline in the DSQ combined score (questions 2+3) over time including 
post-baseline visits
 Cumulative distribution function curves for the change and the percent change in the DSQ score 
from baseline to the final treatment period evaluation (Visit 4)
 Overall binary response I, defined as a reduction in the DSQ score of ≥30% from baseline to the 
final treatment period evaluation (Visit 4) and a peak eosinophil count of ≤6/HPF across all 
esophageal levels at the final treatment period evaluation (Visit 4)
 Overall binary response II, defined as a reduction in the DSQ score of ≥50% from  baseline to the 
final treatment period evaluation (Visit 4) and a peak eosinophil count of ≤6/HPF across all 
esophageal levels at the final treatment period evaluation (Visit 4)
 Symptom response on DSQ + pain score (binary response) , defined a s ≥30% and 50% reductions 
in the DSQ combined score (questions 2+3+4) from baseline to the final treatment period 
evaluation (Visit 4)
 Symptom response on DSQ pain score (binary response) , defined as a ≥30% and 50% reduction 
in the DSQ score ( question 4), from baseline to the final treatment period evaluation (Visit 4)
Exploratory Efficacy Endpoint 
Safety Endpoints 
Safety param eters will include monitoring of AEs, physical examinations, stadiometry, vital signs
(temperature, systolic and diastolic blood pressure, pulse, and respiratory rate), weight and height 
assessments, dual-energy  X-ray absorptiometry (DXA) scans for bone mineral density (BMD )
measurements (for adolescents aged 11-17 years, inclusive) , clinical laboratory tests (hem atology, 
chemistry, urinalysis; serum pregnancy test, if appropriate ), and adrenocorticotropic hormone (ACTH) 
stimulation tests. To account for the effects of puberty in adolescent subjects (11-
17 years , inclusive ), 
BMD z-scores will be adjusted for height z -scores using the Bone Mineral Density in Childhood Study 
calculator (http://www.bmdcspublic.com).
Health Econom ics and Outcom es Research Endpoints 
 Change in Adult Eosinophilic Esophagitis Quality of Life (EoE -QoL- A) score from baseline to 
the final treatment period evaluation (Visit 4)
 Change in EuroQol (EQ-5D; EuroQol -5 Dimensions 3-level [EQ-5D-3L] or EuroQol -5 
Dimensions Youth [EQ-5D-Y], according to subject’s age)score from baseline to the final 
treatment period evaluation (Visit 4)
 Change in Pediatric Quality of Life Inventory –EoE (PedsQL -EoE) score from baseline to the 
final treatment period evaluation (Visit 4)
Pharm acokinetic Endpoints 
Pharm acokinetic param eters will be determined from the plasma concentration -time data for 
budesonide by non-compartmental analysis. The pharmacokinetic param eters will include, but not be 
limited to:

Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 20of 91
AUC tau Area under the curve for the defined interval betw een doses
Cmax Maximum concentration occurr ing at t max
tmax Time of maximum observed concentration sampled during a dosing 
interval
Statistical Methodology for Prim ary Efficacy Endpoint 
The co-primary efficacy endpoints will be analyzed based on the ITT set. Each of the co-primar y 
efficacy endpo intsis a binary response (ie,responders vs non-responders); the endpoint will be 
analyzed using a logistic regression model with theeffects of the treatment group, the age group
(either <18 years or ≥18 years) , and their interaction. The main -effect model will be considered the 
final definitive model if the interaction between thetreatment and age group is not statistically 
significant at the 10% level. The odds ratio of being a responder on each of the co-primary endpoints 
for the OBS 2 mg twice daily group vsplacebo group and associated 95% confidence interval ( CI)will 
be estimated from the final model. Subjects who withdraw  without providing efficacy data at the final 
treatment period evaluation (Visit 4, Week 16) will be classified as non-responder s in the prim ary 
efficacy analysis.
Additionally, the proportion of responders based on each of the co-prim ary endpoints for each 
treatment group will be summarized and their respective 95% CI will be reported. The difference in 
the proportion of responder s betw een the 2 treatment groups and the corresponding 95% CI will also 
be summarized.
The follow ing sensitivity and supportive analyses will be perform ed for the co -prim ary to evaluate the 
robustness of the results from the primary analysis methods: 
 Anal yses will be repeated using the FAS and the PP set.
 Analyses will be repeated by  considering subjects who withdraw  without providing efficacy data 
at the final treatment period evaluation (Visit 4) w ill be classified as responders.
Statistical Methodology for Key Secondary Efficacy Endpoint
The key secondary efficacy endpoint is defined as the change in the DSQ combined score 
(questions 2+3) from baseline to the final treatment period evaluation (Visit 4). The change from 
baseline DSQ score at the final treatm ent period evaluation (Visit 4) will be analyzed using an analysis 
of covariance (ANCOVA) model with treatment group and age group as factors and the baseline DSQ 
score as a continuous covariate.
Statistical Methodology for Secondary Efficacy Endpoints
Secondary subjective efficacy endpoints that are defined as:
 Binary response endpoints will be analyzed using the same logistic model as the co-primar y 
efficacy endpoints .
 Continuous endpoints will be analy zed as a change from baseline using an ANCOVA model that 
includes treatment group and age group as factors and baseline score as a continuous covariate .
The analyses for all secondary efficacy endpoints (including the key secondary efficacy endpoint) will 
be carried out using 2-sided tests at the 5% level of significance. For each of the secondary efficac y 
endpoints, the treatment difference , corresponding 95% CIfor the difference, and treatment 
comparison p -value for testing the null hypothesis of zero treatment effect based on the final statistical 
model (ie, either logistic regression model or ANCOVA model) will be provided.
Statistical Methodology for Safety Endpoints 
All safety measures, including AEs, physical examination, stadiometry, vital signs (temperature, 
systolic and diastolic blood pressure, pulse, and respiratory rate), w eight and height assessments, DXA 
scans for BMD measurements (for adolescents aged 11-17 years, inclusive), clinical laboratory results 
Shire CONFIDENT IAL 31Aug 2015
Protocol SHP621 -301 Version 1.0 Page 21of 91
(hematology, chemistry, urinalysis; serum pregnancy test, if appropriate), and ACTH stimulation will 
be descriptively summarized by treatment group at baseline and for each post -baseline visit.
The number and percent of subjects with TEAEs will be presented. TEAEs are defined as AEs that 
start or deteriorate on or after the date of the first dose of investigational product and no later than 
3days following the last dose of investigational product. However, for any subjects who die during the 
study (ie, the date of death is betw een the date of first dose of investigational product and the date of 
study discontinuation entered by the site, inclusive), all AEs (including those resulting in death) that 
occur during the study will be considered as TEAEs irrespective of the last dose and will be included 
in the TEAE summaries. 
Statistical Methodolo gy for Pharm acokinetic Endpoint(s) 
Summary statistics (number of observations, mean, standard deviation, coefficient of variation, 
median, maximum, minimum, and geometric mean) will be determined for all pharmacokinetic 
parameters by overall and by week. Plasma concentrations at each nominal sampling time will also be 
summarized using descriptive statistics .
Sample Size Justification
Based on at least a 30-percentage -point reduction in DSQ score, there is an expected difference 
betw een treatment response proportions of 69% and 45% in the OBS 2mg twice daily (qAM, pc, and 
hs) a
nd placebo groups, respectively. Atotal of 228subjects (152subjects random ized to OBS and 
76subjects randomized to placebo) are required to achieve 90% power at the significance level of 
0.0499 ( 2-sided) using a 2-group chi-square test with unequal allocation 2:1 to treatment groups (OBS 
2mg twice daily and placebo). With the specified number of subjects per treatment group, the study 
will be powered at 99% assuming histological response proportions of 40% and 3% in the OBS 2mg 
twice daily and placebo groups, respectively. The overall study power for the co-prim ary endpoi nts 
will be at least 85%. There fore, approximately 228 (approximately 152:76OBS and placebo subjects, 
respecti vely) will be randomized 
to the study to allow for a loss of approximately 5% of subjects due 
to dropouts or invalid data.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 22of 91
STUDY SCHEDULE(S)
Table 1-1: Schedule of Assessments
ProceduresScreeningPlacebo 
Lead-in Treatm ent PhaseSafety Follow -
up Telephone 
Contactp
Visit -1 Visit 0Randomization
Baseline/Visit 1Visit 2 Visit 3Visit 4 or 
EToVisit 5
Week -6 0 4 8 12 16 20
Window ≤6 weeks -- ±3 days ±3 days ±3 days ±3 days ±3 days
Informed consent/assent X
Medical history review X
Inclusion/exclusion criteria review X X X
Vital signsa; heightband weight assessment X X X X X X
EGD w ith endoscopy score (EREFS) and 
biopsyc X X
DSQ t raining and issue of handset X
Retrieval of DSQ h andset X
DSQ compliance assessment X X X X X
EQ-5DdX X
PedsQL -EoE (subjects 11 -17 years of age, 
inclusive )X X
EoE-QoL- A (subjects ≥18 years of age) X X
PGI-S X X X X
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 23of 91
Table 1-1: Schedule of Assessments
ProceduresScreeningPlacebo 
Lead-in Treatm ent PhaseSafety Follow -
up Telephone 
Contactp
Visit -1 Visit 0Randomization
Baseline/Visit 1Visit 2 Visit 3Visit 4 or 
EToVisit 5
Week -6 0 4 8 12 16 20
Window ≤6 weeks -- ±3 days ±3 days ±3 days ±3 days ±3 days
Physical examination X X X X X X
Tanner Staging AssessmenteX X
Clinical laboratory testsfX X X X X X
UrinalysisgX X X X X X
Pregnancy testhX X X X X X
Morning cortisol (target 6:00 -9:00 AM) X X X X
ACTH s timulation testing X X
Blood pharmacokinetic sampling (subjects 
≥18years of age)i X X
DXA Scan for BMD (subjects 11 -17years of 
age, inclusive )j X X
RandomizationkX
Investigational product supplied X X X X Xl
Investigational product administrationmTwice-daily administration of investigational product
Investigational product compliance 
assessmentX X X X
Concomitant medications and procedures X X X X X X X
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 24of 91
Table 1-1: Schedule of Assessments
ProceduresScreeningPlacebo 
Lead-in Treatm ent PhaseSafety Follow -
up Telephone 
Contactp
Visit -1 Visit 0Randomization
Baseline/Visit 1Visit 2 Visit 3Visit 4 or 
EToVisit 5
Week -6 0 4 8 12 16 20
Window ≤6 weeks -- ±3 days ±3 days ±3 days ±3 days ±3 days
recorded 
Revie w of adverse eventsnX X X X X X
Abbreviations: ACTH=adrenocorticotropic hormone; BMD=bone mineral densit y; DSQ=Dysphagia Symptom Questionnaire; DXA=dual -energy X-ray 
absorptiometry; EGD=esophagogastroduodenoscopy; EoE-QoL- A=Adult Eosinophilic Esophagitis Quality of Life; EQ-5D=EuroQol; EQ-5D-3L=EuroQol -5 
Dimension 3-level; EQ-5D-Y=EuroQol -5 Dimensions Youth ;EREFS=EoE Endoscopic Reference Score; hs=at bedtime; IWRS=interactive web-based response 
system; PedsQL -EoE=Pediatric Quality of Life Inventory – EoE; pc=after meal s; PGI -S=Patient Global Impression of Severity; qAM=every morning
aVital signs will be asses sed after the subject has been in a supine position for at least 5 minutes immediately prior to the assessment and will inclu de blood 
pressure (systolic and diastolic), heart rate, respirations, and temperature.
bHeight to be collected at screening visit (V isit -1)and Visit 4 for all subjects .Stadiometers are required for subjects 11 -17 years of age, inclusive, and w ill be 
used at Visit 1 and 4.
cPre-treatment endoscopy will be performed during the screening period (at least 2 weeks prior to placebo lead-invisit [Visit 0] to allow adequate time for 
processing and central review). Endoscopy should include esophageal (proximal, mid-, and/or distal), gastric, and duodenal biopsies. Final treatm ent 
evaluation EGD must include esophageal biopsies; gastric and du odenal biopsies may be done at the discretion of the investigator. Final treatment evaluation 
EGD should occur at or w ithin 7 days of the scheduled visit.  
dSubjects 11 -17 years of age , inclusive, will complete the EQ -5D-Y; subjects ≥18 years of age will c omplete the EQ -5D-3L. 
eTanner staging assessments will be performed for all subjects aged ≥11 years until investigator confirms subject is post pube rty.
fClinical laboratory tests will include the following: alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, total bilirubin, total protein, 
albumin, glucose, blood urea nitrogen, creatinine, sodium, potassium, chloride, calcium, carbon dioxide, hemoglobin, hematocr it, mean corpuscular 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 25of 91
Table 1-1: Schedule of Assessments
ProceduresScreeningPlacebo 
Lead-in Treatm ent PhaseSafety Follow -
up Telephone 
Contactp
Visit -1 Visit 0Randomization
Baseline/Visit 1Visit 2 Visit 3Visit 4 or 
EToVisit 5
Week -6 0 4 8 12 16 20
Window ≤6 weeks -- ±3 days ±3 days ±3 days ±3 days ±3 days
hemoglobin, mean corpuscular hemoglobin concentrati on, mean corpuscular volume, erythrocyte count, leukocyte count, neutrophils, lymphocytes, 
monocytes, eosinophils, basophils, and platelet count. All subjects must fast overnight prior to collection.
gUrinalysis parameters will include glucose, protein, spe cific gravity, pH, nitrite, bilirubin, ketones, hemoglobin, urobilinogen, and leukocyte esterase.
hThe serum pregnancy test will be performed for all female subjects at the screening visit (Visit -1) and final treatment evaluation (Visit 4). Urine pregnancy
tests will be performed at all other visits.
iBlood samples for pharmacokinetic analysis will be taken fr om adult subjects (aged ≥18 years). Subjects who do not participate in pharmacokinetic sampling 
will not be discontinued from the study and lack of participation will not be a considered protocol deviation. Blood samples for pharmacokinetic analysis will 
be obtained at the Week 8 or Week 12 visit at the following time points: pre -dose and at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post -dose. 
jThe baseline DXA scan may be performed any time during the placebo lead-in period after the subject has met all screenin g criteria and prior to 
blinded -treatment randomization. Baseline and post-treatment DXA scans should be performed using the same machine and software. Post-treatment DXA 
scan should occur at or within 7 days of the scheduled visit.
kRandomization will occu r via IWRS at the baseline visit (Visit 1) once the subject’s eligibility for study entry is confirmed. 
lInvestigational product will be dispensed at Visit 4 to subjects who consent to enroll in the treatment extension study.
mSubjects will receive oral adm inistration of 10 mL of investigational product twice daily (qAM, pc, and hs), with no ingestion of food or liquids permitted for 
30minutes after study drug administration.
nAE assessments at each visit and physical examination must include specific assess ments for signs of glucocorticoid excess (eg, moon facies, acne, hirsutism, 
mood swings, insomnia, and depression).
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 26of 91
Table 1-1: Schedule of Assessments
ProceduresScreeningPlacebo 
Lead-in Treatm ent PhaseSafety Follow -
up Telephone 
Contactp
Visit -1 Visit 0Randomization
Baseline/Visit 1Visit 2 Visit 3Visit 4 or 
EToVisit 5
Week -6 0 4 8 12 16 20
Window ≤6 weeks -- ±3 days ±3 days ±3 days ±3 days ±3 days
oIf subject discontinues study prematurely, the evaluations listed for Visit 4 are to be performed as completely as possible.
pFor subjects who withdraw from the study or do not continue into treatm ent extension study, a safety follow -up contact by phone will be perform ed 4weeks 
following the last dose of investigational product .
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 27of 91
1. BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Option s 
Eosinophilic esophagitis (EoE) is defined as “a chronic, immune/antigen -mediated esophageal 
disease characterized clinically  by symptoms related to esophageal dysfunction and 
histologically  by eosinophil- predominant inflammation” (Liacouras et al., 2011). Clinical 
symptoms of EoE often vary by age: Infants and toddlers present with feeding difficulties; 
school -aged children are more likely  to present with vomiting or pain; and adolescents and 
adults present with dysphagia and food impaction. When these symptoms are present, the 
diagnosis is confirmed by  finding eosinophilic inflammation of ≥15 eosinophils/high
-power ed
field (HPF) on at least 1 esophageal biopsy  and when other causes such as proton pump 
inhibi tor (PPI)-responsive esophageal eosinophilia are excluded ( Dellon et al., 2014a ; Furuta 
et al., 2007 ).The standards of care are diet therapies and off -lab el use o f glucocorticosteroids.
Esophageal dilation is used to temporarily  relieve symptoms but does not address underl ying 
inflammation. Given the clinical outcomes associated with EoE, including severe dysphagia, 
esophageal stricture, food impaction, and esophag eal perforation (Hirano and Aceves ,
2014;
Liacouras e
t al., 2011 ) and the fact that there are currentl y no FDA -approved treatments, there 
is a clear unmet medical need for a novel treatment for this disease.  
1.2 Product Background and Clinical Information
Oral budesonide suspension (OBS) consists of budesonide formulated in a viscous suspension 
that is designed to increase the residence time of budesonide on the surface of the esophagus 
after swallowing compared to a non-viscous suspension . Shire is developing OBS as a 
first-line therap y for EoE in adolescents and adults.
The nonclinical pharmacology , pharmacokinetics, and toxicity  and the clinical pharmacology , 
pharmac okinetics, and safety  of budesonide are well studied because budesonide is present in 
several US FDA -approved drug products. Budesonide is currently marketed for the 
management of Crohn’s disease, for asthma maintenance, for the treatment of allergic rhinitis, 
and for induction of remission in patients with active, mild to moderate ulcerative colitis. 
Budesonide has strong glucocorticoid receptor affinity  and is subject to considerable first pass 
metabolism by the liver with a short half-life. These attribu tes permit budesonide to act 
rapidly  and locall y in the gut mucosa for treatment of inflammatory  disorders such as Crohn’s 
disease and ulcerative colitis. Once absorbed into the systemic circulation, budesonide is 
rapidly  metabolized in the liver and inact ivated ( FDA , 2011).
The efficacy  of OBS for the treatment of EoE has been demonstrated in 
two Phase 2 studies in 
the OBS clinical development program. Studies MPI 101-01 and MPI 101- 06 evaluated the 
efficacy  of OBS in the treatment of EoE in children and adolescents aged 2-18 years and in 
adolescents and adults aged 11-40 years, respe ctively , by measuring histological response 
(defined as mean peak eosinophil count ≤6/HPF after treatment). Study  MPI 101 -06 also 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 28of 91
evaluated symptom response as measured by the Dysphagia Symptom Questionnaire (DSQ). 
The DSQ contains 4 questions related to consumption of solid food, the presence of d ysphagia 
and its severity , as well as pain. The DSQ score is calculated only from responses to the
questions related to dysphagia ,and this clinical outcome assessment was considered to be fit 
for purpose as a result of the MPI 101-06 study . Results from Study  MPI 101-01 
demonstrated a statistically  significant histologic response (eosinophil count ≤6/HPF) and 
remission (eosinophil count ≤1/HPF) in the medium -dose (1.4-2.0mg daily) and high-dose 
(2.8-4.0mg daily ) OBS groups compared to placebo following 12 weeks of treatment. 
In Study MPI101-06, a significant treatment effect for OBS vs placebo was shown for both 
the co-primary  efficacy endpoints of histologic response and change from baseline in 
dysphagia symptoms. Following 12weeks of twice daily  treatment (once in the morning after 
meal s[qAM, pc] and at bedtime [hs]), OBS -treated subjects demonstrated a highl y consistent 
reduction from baseline values for cellular (mean peak eosinophil count and histopathology  
features), organ (endoscopy  score) ,and holistic measures (Phy sician Global Assessment 
[PGA] and DSQ scores); these results were independent of the type of rater/reviewer (central 
pathologist, phy sician at the study  site, or subject). 
Alway s refer to the latest version of the SHP621 investigator’s brochure for the overall 
risk/benefit assessment and the most accurate and current information regarding the drug 
metabolism, pharmacokinetics, efficacy ,and safety of SHP621. 
2. STUDY OBJECTIVES AND PURPOSE
2.1 Rationale for the Study
Currently  there is no approved medication for the treatment of EoE. This study  is being 
conducted in order to provide safet y and efficacy  data demonstrating histologic response (as 
measured by eosinophilic count ≤6/HPF ) and improvement in dysphagia symptoms (as 
measured by the DSQ) following 12 weeks of treatment with OBS in adolescent and adult 
subjects with EoE .
2.2
Study Objectives
2.2.1 Primary Objectives
The co -primary  objectives of the study  areto demonstrate in a placebo- controlled trial that:
OBS induces a histologic response (eosinophilic count ≤6/HPF) in adolescent and adult 
subjects with EoE over a 12- week course of therapy .
OBS reduces dysphagia, as measured by the DSQ ,by at least 30% from baseline in 
adolescent and adult subjects with EoE over a 12-week course of therap y .
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 29of 91
2.2.2 Secondary Objectives
The key secondary  objecti ve of this study  is:
OBS reduces dysphagia, as measured by the DSQ score from baseline to the final 
treatment period evaluation (Visit 4). 
Additional secondary  objectives of the study  are:
To assess the response of endoscopicall y identified esophageal features to OBS as 
compared to placebo as measured b y the 
EoE Endoscopic Reference Score (EREFS) 
To explore other responding criteria based on histology  and DSQ
To assess the impact of OBS on pain, as measured by  the DSQ
To evaluate the safet y and tolerabil ity of OBS over a 12- week course of therapy  
To obtain OBS pharmacokinetic data in adult subjects with EoE
2.2.3 Exploratory Objective
Theexploratory  objective of this study  is:
3. STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 3, randomized, multicenter, double -blind, parallel
-group, placebo- controlled 
study  to evaluate the efficacy  and safet y of OBS treatment administered twice daily (qAM, 
pc, 
and hs) for 12weeks. The study  will be conducted in adolescents and adults, aged 
11-55 years, inclusive, with EoE and dy sphagia . 
Approximately  
300 subjects will be enrolled in the placebo lead-inperiod to allow for 
approximately  228 subjects to be randomized into the double -blind treatment period . A 
minimum of 40 randomized subjects will be aged 11-17 years, inclusive . Subjects will be 
randomized 2:1 (approximately  152and 76per OBS and placebo treatment group, 
respectivel y) to rec eive eithe r OBS 2 mg twice daily  (qAM, pc, and hs) or placebo twice dail y 
(qAM, pc, and hs) .  
This study  will consist of 3 periods: a 3-to 6-week screening period , 4-week single -blind 
placebo lead -inperiod, and a 12-week double -blind treatment period (see Figure 1).

Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 30of 91
Figure 1:Study Design Flow Chart
Abbreviations: BID=twice daily; EGD= esophagogastroduodenoscopy ; ET=end of treatment; OBS=oral 
budesonide suspension
The upper limit of 55 years, inclusive ,was selected for this study  population based on the low 
prevalence of EoE in older patients ( Dellon et al ., 2014a ) and the fact that the ty pe of EoE that 
develops in older patients is not amenable to anti-inflammatory  treatment alone ( Dellon et al.,
2014b). A natural history  study demonstrated that for every  decade of life, the odds of 
developing the fibrostenotic phenoty pe of EoE more than doubles (Dellon et al., 2014b). By 
age 55, fibrostenotic EoE occurs in approximately  80% 
of patients. Fibrostenotic disease is 
treated with dilatation and is not amenable to anti-inflammatory  treatment alone. Therefore, 
budesonide is not expected to be an effective treatment for the majority of patients above 
age55.
Subjects will be required to visit the site up to 6 times over up to a 22-week period. Following 
completion of the screening and placebo lead-invisits, subjects will be evaluated for 
eligibility  and 
safet y at Week 4 (Visit 1). Subjects who are eligible and randomized will be 
evaluated for efficacy  and safet y at Weeks 8,12, and 16 (Visits 2-4) and additionally  for 
safet y at follow -
up at Week 20(Visit 5; telephone contact ). Subjects who fail to meet all 
eligibility  criteria at Visits -1, 0 ,or 1 will be considered screen failures. Subjects cannot be 
rescreened once they  have been designated as a screen failure unless due solely  to the use of a 
concomitant medication which can be stopped prior to rescreening. Subjects who discontinue 
will not be replaced. 
The screening period will start when subjects sign informed consent (or assent as applicable 
for subjects <18yearsof age; screening visit [Visit -1]) and will be approximately  3- 6weeks 
in duration. During the screening period , all subjects will receive an upper endoscop y with 
histologic analysis of biopsy  specimens to confirm the diagnosis of EoE (eosinophil count of 
≥15/HPF from 2 of 3[proximal, mid-,and/or distal] levels of the esophagus ). In addition, 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 31of 91
subjects must complete the DSQ daily  during the screening period (3-6 weeks) and have at 
least 4 reported days with symptoms of dysphagia and completed the DSQ on ≥70% of days 
in any 2consecutive weeks. At the screening visit (Visit -1), subject s who are on a PPI must 
remain on the same dose of the PPI throughout the study ; if they are not taking a PPI, they 
must remain off of a PPI for the remainder of the study . After the screening period, eligible 
subjects will enter a 4-week single -blind placebo lead-inperiod and will receive 10mL of 
OBS placebo twice daily  (in the morning after meal s/breakfast [qAM, pc] and at bedtime 
[hs]). The placebo lead-inperiod will enable assessment of the subject’s ability  to comply 
with twice daily medication admi nistration and assess whether the subject experiences a 
placebo response. 
At the end of the placebo lead-inperiod, subjects will return for the baseline visit (Visit 1) to 
confirm eligibility . Subjects who continue to meet all eligibility  criteria (those with at least 
4reported dysphagia days and who completed the DSQ on ≥70% of days in the 2 weeks prior 
to randomization per daily  DSQ completion) will be randomized to receive either OBS or 
placebo during the 12 -
week double -blind treatment period. 
OBS will be administered in 10 mL at a concentration of 0.2 mg/mL (2mg dose ), twice dail y
. 
The 0.2 mg/mL concentration of OBS and dosing regimens were selected for use in this 
Phase 3 study  based on the results of Study MPI  101-06, a Phase 2 study  in 93adolescent and 
adult subject s with EoE and symptoms of dysphagia . Subjects were treated in 
Study MPI 101
-06 with 2mg OBS twice daily to investigate theco-primary  endpoints of 
histologic response (defined as ≤6 eosinophils/HPF) and reduction in DSQ score from 
baseline to Week 12 of treatment .For the current study , the investigational product will be 
supplied in amber glass, multi- dose bottles with child -resistant caps. Each bottle will contain 
210 mL of suspension with a budesonide concentration of 0.2 mg/mL, or 0.00 mg/mL 
(matching placebo).
At the end of the 12-week double -blind treatment period (Visit 4, Week 16), subjects who 
complete the study  will have the opportunity  to enroll in the treatment extension study . These 
subjects will continue on the blinded assigned treatment for 2 -4 weeks as part of the screening 
prior to enrolling into the treatment extension study . Subjects who do not enroll in the 
treatment extension study or who discontinue at any time during the SHP621 -
301(Induction) 
study  will receive a follow -
up phone call4weeks post last dose of investigational product
(Visit 5) .
3.2 Duration and Study Completion Definition
The subject’s maximum duration of participa tion is expected to be approximately  26 weeks, 
depending on the 3
-to 6-week screening period.
The study  will be completed in approximately 32months
.
The Study  Completion Date is defined as the date the final subject, across all sites, completes 
their final protocol -defined assessment. Please note that this includes the follow -up visit or 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 32of 91
contact, whichever is later. The Study  Completion Date is used to ascertain timing for study 
results posting and reporting.
A completer is a subject who completes all procedures and assessments up to and including  
Visit 4(Week 16), inclusive of the final treatment evaluation EGD .Subjects who do not 
enroll in the treatment extension study  or who discontinue prematurel y at any time during the 
SHP621-301 (Induction) study  will receive a follow - up phone call4weeks post last dose of 
the investigational product to which they were randomized .
3.3 Sites and Regions
Approximately  60 sites in North America will participate.
4. STUDY POPULATION
Each subject must participate in the infor med consent process and provide written informed 
consent/assent before any procedures specified in the protocol are performed.
4.1 Inclusion Criteria
The subject will not be considered eligible for the study  without meeting all of the following 
criteria (inclu ding test results) :
1.Subject is able to provide written informed consent (subject, parent or legal guardian ,and, 
as appropriate, subject assent) to participate in the study  before completing any 
study -related procedures.
2.Subject is male or female aged 11-55 y ears, inclusive ,at time of consent. 
3.
Subject has histologic evidence of EoE with a peak eosinophil count of ≥15/HPF, from 2 
of 3 (proximal, mid - ,and/or distal) levels of the esophagus at the screening endoscopy .
4. Subject has a history  of clinical symptoms of esophageal dysfunction (eg, eating 
problems, abdominal pain, heartburn, dysphagia, vomiting, food impacti on, weight loss) 
intermittently  or continuously  at screening (Visit -1).
5. Subject must have experienced dysphagia (response of “yes” to question 2 on DSQ) on a 
minimum of 4days and completed the DSQ on ≥70% of days inany 2 consecutive weeks 
of the screening period and in the last 2 weeks prior to the baseline visit (Visit 1). 
6. Subject must not have PPI-responsive EoE based on esophageal biopsies performed after 
the patient has been on at least 8 weeks of high-dose PPI therapy  (high-dose therapy  refers 
to the total daily  dose, which may  have been administered as a once -or twice daily dosing 
regimen). This may occur at the time of the qualify ing EGD (in which case the same PPI 
regimen must be continued) ,or this may have been done previousl y (in which case PPI 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 33of 91
therap y may have been stopped if there was no response to therapy  based on esophageal 
biopsy  results).
7. Subject will be on a stable (no changes) diet ≥3 months prior to the screening visit
(Visit -1).
8.
Subject is willing and able to continue any dietary  therap y, environmental therapy , and/or 
medical regimens (including gastric acid suppression; see exclusions below) in effect at 
the screening visit (Visit -1). There should be no change to these regimens during study  
participation.
9. All female subjects must have a negative serum pregnancy  test (beta-human chorionic 
gonadotropin [β-hCG]) prior to enrol lment into the study . Females of childbearing 
potential must agree to continue acceptable birth control measures (eg, abstinence, stable 
oral contraceptives, or double -barrier methods) throughout stud y participation.
10. Subject is willin g and has an understanding and ability  to fully  comply  with study  
procedures and restrictions defined in this protocol.
4.2 Exclusion Criteria
Subjects are excluded from the study  if an y of the following exclusion criteria are met : 
1. Subject has any condition or abnormality  (including laboratory  abnormalities), current or 
past, that, in the opinion of the principal investigator or medical monitor , would 
compromise the safety  of the subject or interfere with or complicate the assessment of 
signs or symptoms of Eo E. Such conditions may  include psy chiatric problems; neurologic 
deficits or disease; developmental delay ; cardiovascular, metabolic, or pulmonary  disease; 
or previous gastroesophageal surgery . 
These should be discussed with the medical 
monitor .
2. Subject hasused immunomodulatory  therap y within 8 weeks prior to the qualify ing EGD 
or between the qualify ing EGD and baseline visit (Visit 1) or anticipates using
immunomodulatory  therapy  during the treatment period (except for any ongoing 
regimen 
of allergy  shots) .Use of long-acting immunomodulatory  therap y (eg, Rituxan) within 
3months of the qualifying EGD should be reviewed with the medical monitor .
3. Subject has been using swallowed topical corticosteroid for EoE or systemic 
corticosteroid for any condition within the 4 weeks prior to the qualify ing EGD, between 
the qualify ing EGD and baseline visit (Visit 1),or anticipates use during the treatment 
period
; any temporary  use or initiation of new steroid treatment during the study  should be 
documented and discusse d with the medical monitor prospectively  but cannot occur 
within 4 weeks of the final EGD . 
4. Subject has been on inhaled or intranasal steroids andhas not been on stable treatment for 
≥3 months prior to screening visit (Visit -1).Subjects on intranasal orinhaled steroids 
need to stay  on a stable treatment during study  participation.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 34of 91
5. Subject has initiated, discontinued, or changed dosage regimen of PPIs, H2 antagonists, 
antacids, antihistamines, orleukotriene inhibitors for any condition (such as 
gastroes ophageal reflux disease, asthma or allergic rhinitis) within the 4 weeks prior to the 
qualify ing EGD, between the qualify ing esophagogastroduodenoscopy  (EGD )and 
baseline visit (Visit 1), or anticipates changes in the use of such medications during the 
treatment period .  
6.
Subject has been using cytochrome P450 3A4 (CYP450 3A4) inhibitors (eg,
ketoconazole, grapefruit juice) within the 2weeks prior to the baseline visit (Visit 1)or 
within 5 half-lives (whichever is greater) or anticipates using such medica tions during the 
treatment period .  
7.
Subject has an appearance on qualify ing EGD of an esophageal stricture (high -grade), as 
defined by the presence of a lesion that does not allow passage of a diagnostic adult upper 
endoscope (eg, with an insertion tube d iameter of >9 mm). 
8.Subject ison a pure liquid diet or the 6-food elimination diet .
9. Subject has had an esophageal dilation within the 3 months prior to screening (Visit -1).
10.Subject has presence of esophageal varices at the screening endoscopy .
11.
Subject ha s any current disease of the gastrointestinal tract, aside from EoE, including 
eosinophilic gastritis, enteritis, colitis, or proctitis; inflammatory  bowel disease ; or celiac 
disease. 
12. Subject has other diseases causing or associated with EoE, including hypereosinophilic 
syndrome, collagen vascular disease, vasculitis, achalasia, or parasitic infection.
13.Subject has current evidence of oropharyngeal or esophageal candidiasis.
14. Subject has acute or chronic viral infection or immunodeficiency  condition, includi ng 
tuberculosis, fungal, bacterial, viral/parasite infection, ocular herpes simplex, herpes 
esophagitis, or chicken pox/measles .
15. Subject has upper gastrointestinal bleeding within 4 weeks prior to the screening visit
(Visit -1) or between the screening vis itand baseline visit (Visit 1).
16.Subject has evidence of active infection with Helicobacter pylori.
17. Subject has evidence of unstable asthma within 4 weeks prior to the screening visit
(Visit -1) and between the screening visit and baseline visit (Visit 1).
18.
Subject is female and pregnant or nursing.
19. Subject has a history  of intolerance, hypersensitivity , or idiosy ncratic reaction to 
budesonide (or any other corticosteroids) or to any other ingredients of the investigational 
product .
20. Subject has taken part inan investigational study within 6 months prior to the screening 
visit (Visit -1).
21.Subject has a history  or high risk of noncompliance with treatment or regular clinic visits.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 35of 91
22.Subject has previously  completed, discontinued, or withdrawn from this study .
23.Subject has participated in a previous clinical study involving OBS (SHP621).
4.3 Restrictions
Subjects must adhere to the following restrictions for the duration of the study :
No change in exercise
No change in diet ( liquid diet for 3 day s or less is acceptable .)
Short course of systemic steroids are permitted to treat, for example, exacerbation of 
asthma but cannot be used 4 weeks prior to the final EGD .
No change in PPI use
No use of CYP450 3A4 inhibitors
An esophageal dilatation during the trial (
Dilatation is considered a treatment failure ,and 
the subject should be withdrawn from the study .)
4.4 Reproductive Potential
4.4.1 Female Contraception
All females must have a negative pregnancy  test at the screening visit (Visit -1), placebo 
lead-invisit (Visit 0),baseline visit (Visit 1), and Visits 1-4.A serum pregnancy  test will be 
performed at the screening visit (Visit -
1)and final treatment evaluation (Visit 4). Urine 
pregnancy  tests will be performed at all other visits.   
Female subjects should be either:
Pre-menar chal and Tanner Stage 1, or
Post-menopausal (
24 consecutive months of spontaneous amenorrhea and age 51 yearsor 
older ).
Be surgicall y sterile (having undergone one of the following surgical acts:  hysterectom y, 
bilateral tubal ligation, bilateral oophorec tomy  or bilateral salpingectomy ) and at least 
6weeks post -sterilization, or
Females of child- bearing potential must agree to abstain from sexual activity  that could 
result in pregnancy  or agree to use acceptable methods of contraception throughout the 
study period and for 30 day s following the last dose of investigational product.
Acceptable methods of contraception are:
 Intrauterine devices plus condoms
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 36of 91
 Double- barrier methods (eg,condoms and diaphragms with spermicidal gel or 
foam)
 Hormonal contraceptive s (oral, depot, patch, injectable, or vaginal ring), 
stabilized for at least 30 days prior to the screening visit (Visit -1), plus condoms .If 
hormonal contraceptives are used, they should be administered according to the 
package insert. Note: If subjects become sexually  active during the study , they should 
use one of the other acceptable methods noted above in addition to the hormonal 
contraceptive until it has been stabilized for 30 days.
4.5 Discontinuation of Subjects
A subject may withdraw from the study  at any time for any reason without prejudice to their 
future medical care by the physician or at the institution. The investigator or sponsor may 
withdraw the subject at any time (eg,in the interest of subject safet y).The investigator is 
encouraged to discuss withdrawal of a subject from investigational product with the medical 
monitor when possible.
If investigational product is discontinued, leading to subject discontinuation from the study , 
regardless of the reason, the evaluations listed for Visit 4are to be perfor med as completel y as 
possible. If investigational product is discontinued due to an AE, the subject may remain on 
study  to allow for completion of study  procedures. 
Whenever possible, all discontinued subjects should also undergo the protocol- specified 
follow -up. Comments (spontaneous or elicited) or complaints made by the subject must be 
recorded in the source documents. The reason for termination, date of stopping investigational 
product, and total amount of investigational product taken mu st be recorded in the case report 
form ( CRF )and source documents.
Subjects who discontinue will not be replaced. 
4.5.1 Subject Withdrawal Criteria
Medically  important events that in the opinion of the investigator or medical monitor would 
compromise the subjec t’s ability  to safel y continue in the study , including but not limited to 
an esophageal stricture requiring dilation and/or worsening signs and symptoms of EoE (eg, 
weight loss or increased dysphagia), would be considered a treatment failure and result in 
withdrawal of the subject from the study .
4.5.2 Reasons for Discontinuation
The reason for withdrawal must be determined by the investigator and recorded in the 
subject’s medical record and on the CRF. If a subject is withdrawn for more than 1reason, 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 37of 91
each reason should be documented in the source document and the most clinically  relevant 
reason should be entered on the CRF.
Reasons for discontinuation include but are not limited to:
 Completed
 Death
 AE
 Non-compliance with study  drug
 Non-compliance with study  proc edure
 Withdrawal by  subject
 Withdrawal by  parent/guardian
 Physician decision
 Study  terminated by  sponsor
 Site terminated by  sponsor
 Lost to follow -
up
 Pregnancy
 Trial screen failure
 Placebo responder
 Protocol deviation
 Other 
4.5.3 Subjects “Lost to Follow -up” Pr ior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact any subject lost to follow -up 
at any  time point prior to the last scheduled contact (offic e visit or telephone contact). At least 
1of these documented attempts must include a written communication sent to the subject’s 
last known address via courier or mail (with an acknowledgement of receipt request) asking 
that they return to the site for final safet y evaluations and return any unused investigational 
product.
5. PRIOR AND CONCOMITANT TREATMEN T
All non-study  treatment (including but not limited to herbal treatments, vitamins, behavioral 
treatment, and non-pharmacological treatment, such as psychotherapy , as appropriate)
received within 3months prior to the screening visit (Visit
-1) (or pharmacokinetic equivalent 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 38of 91
of 5half-lives, whichever is longer) and through the final study  contact (including 
protocol -defined follow -up period) must be recorded on the appropriate CRF page.
5.1 Prior Treatment
Prior treatment includes all tre atment , including but not limited to herbal treatments, vitamins, 
and non-pharmacological treatment such as psychotherap y ,as appropriate ,received within 
3months of the screening visit (Visit -1). Prior treatment information must be recorded on the 
appro priate CRF page.
5.2 Concomitant Treatment 
Concomitant treatment refers to all treatment taken between the dates of the first dose of 
investigational product and the end of the follow -up period, inclusive. Concomitant treatment 
information must be recorded on the appropriate CRF page.
The investigator may prescribe additional medications during the study , as long as the 
prescribed medication is not prohibited by the protocol. In the event of an emergency , any 
needed medications may be prescribed without prior approval, but the medical monitor must 
be notified of the use of any  prohibited medications immediately  thereafter.
5.2.1 Permitted Treatment
The following medications are allowed during the course of the study  if the subject has been 
on a stable dosing regimen (ie, same dose and frequency  in the previous 4 weeks prior to the 
endoscop yrequired for entrance to this study) and will continue this dosing regimen 
throughout study  participation. The investigator must contact the medical monitor
to discuss 
any changes to concomitant steroid regimens or for any medications not listed here that could 
impact the outcome of the study .
1.Inhaled or intranasal steroids for conditions other than EoE ; subject must be on stable 
treatment for ≥3 months prior to screening visit (Visit -1).
2.PPIs
3.H2 antagonists
4.Antacids
5.Antihistamines or antileukotrienes
6.Maintenance immunotherap y (allergy  shots)
Influenza and other routine required vaccinations are allowed during the study .
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 39of 91
5.2.2 Prohibited Treatment
The following medications and treatments are prohibited throughout the course of the study 
and prior to treatment, as specified:
1.Immunomodulatory  therapy  within 8 weeks prior to the qualify ing EGD or between the 
qualify ing EGD and baseline visit (Visit 1)or anticipated use of immunomodulatory  
therap y during the treatment period (except for any ongoing regimen of allergy  shots). 
Use of long-acting immunomodulatory  therap y (eg, Rituxan) within 3 months of the 
qualify ing EGD should be reviewed with the medical monitor .
2.Swallowed topical corticoster oid for EoE or systemic corticosteroid for any condition 
within the 4 weeks prior to the qualify
ing EGD, between the qualify ing EGD and baseline 
visit (Visit 1)or anticipated use during the treatment period ; any temporary  use or 
initiation of new steroid treatment during study  should be documented and discussed with 
the medical monitor prospectivel y but cannot occur within the 4 weeks of the final EGD .
3. Inhaled or intranasal steroids if <3 months prior to screening visit (Visit -1) 
4.PPIs, H2 antagonists, antacids, antihistamines, or leukotriene inhibitors for any condition 
(such as gastroesophageal reflux disease, asthma ,or allergic rhinitis) within the 4 weeks 
prior to the qualify ing EGD, between the qualify ing EGD and baseline visit 1, or 
anticipated chan ges in the use of such medications during the treatment period .
5.CYP450 3A4 inhibitors (eg ,ketoconazole, grapefruit juice) within the 2 weeks prior to the 
baseline visit (Visit 1) or within 5 half-lives (whichever is greater) or anticipated use of 
such med
ications during the treatment period . For an expanded list of CYP3A inhibitors, 
investigators should refer to the 2012 FDA Draft Guidance on Drug Interactions (FDA 
Guidance 2012) and use their clinical judgment with respect to specific medications.
6.Esophageal dilation within the 3 months prior to s creening (Visit -1)
7.Investigational study  treatment within 6months prior to the screening visit (Visit -1)
6. INVESTIGATIONAL PROD UCT
6.1 Identity of Investigational Product
The test product is OBS (oral budesonide suspension , 0.2 mg/mL) ,which will be provided in
multi- dose amber glass bottles, each containing 210mL.Additional information is provided 
in the current SHP621 investigator’s brochure .
The reference/comparator product is placebo, which will be provided inamber glass bottle
form with the same volume .
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 40of 91
6.1.1 Blinding the Treatment Assignment
Investigational product will be supplied in amber glass, multi- dose bottles with child- resistant 
caps. Each bottle contains 210mL of suspension with a budesonide concentration of 
0.2mg/mL .Inactive ingredients in OBS include dextrose, disodium edetate, citric acid, 
sodium citrate, potassium sorbate, polysorbate 80, glycerin, sodium benzoate, cherry  flavor, 
Magnasweet 110, acesulfame potassium, and water.
The placebo solution will also be supplied in amber glass multi- dose bottles with 
child- resistant caps. Placebo consists of all components of the investigational product solution 
with the exception of budesonide.
6.2 Administration of Investigational Product(s)
All investigational product and supplies (eg, dosing spoons ) will be provided by Shire or its 
designee. At each visit, subjects will be supplied with enough investigational product to last 
until the subsequent visit. The first dose of investigational product (placebo) for each subject 
will be administered in the clinic at the placebo lead-invisit (Visit 0).  The subject will 
continue with the e vening dosing regimen at home. 
OBS and placebo will besupplied in amber glass bottles and must be shaken well prior to 
administrati
on. T he appropriate dose will be dispensed using the graduated dosing spoon 
provided. For subjects who are minors (<18 years), a parent/guardian will be responsible for 
ensuring that the subject stake their investigational product appropriatel y. 
Subjects will be instructed not to eat or drink for 30 minutes after taking the investigational 
product . Activities such as brushing teeth or rinsing the mouth should also be avoided during 
this time interval. After 
30 minutes, it is recommended that the subjects rinse with water and 
spit.
Please refer to the Investigational Product Administration Manual for additional details.
6.2.1 Interactive Response Technology for Investigational Product Management
An interactive web-based response system(IWRS ) will be used for screening and enrolling 
subjects, recording subject visits, randomization, investigational product supply  dispensation 
and management, inventory  management and supply  ordering, investigational product 
expiration tracking and management, return of investigatio nal product, and emergency 
unmasking. Please refer to the Study  Manual for additional details regarding the IWRS .
The investigator or designee will access the IWRS at the screening visit (Visit -1) to record 
subject -
specific information (ie, unique subjec tnumber, date of birth, etc.). Subjects will be 
entered as screen failures or as entering the placebo lead-inperiod. Subjects cannot be 
rescreened once they  have been designated as a screen failure unless due solely  to the use of a 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 41of 91
concomitant medication that can be stopped prior to rescreening. For subjects who enter the 
placebo lead-inperiod, IWRSwill provide the assignment of placebo lead-in period 
medication to dispense. 
At the baseline visit (Visit 1), the investigator or designee will again acces s the IWRS to 
either document a screen failure or, if the subject has met all entry  criteria, to 
randomize the 
subject.  Sites will enter eligibility  criteria information prior to randomization. For 
randomized subjects, the I WRS will provide a medication identification (Med ID) number (ie, 
kit number to dispense for treatment).  
The IWRS will also be used for creating, tracking, and confirm ing inve stigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be 
provided to the site and site personnel will receive training.
The IWRS provider will provide a user manual and training to each site, with detailed 
instructions on use of the I WRS.
6.2.2 Allocation of Subjects to Treatment 
This study  consists of a single -blind lead-in period followed by a double -blind 
placebo- controlled study period. The actual treatment given to individual subjects during the 
double -blind period is determined by  a randomization schedule.
Subject numbers are assigned to all subjects as they consent to take part in the study . Within 
each site (numbered uniquely  within a protocol), the subject number is assigned to subjects 
according to the sequence of presentation for study participation.  
The randomization number represents a unique number corresponding to investigational 
product allocated to the subject once eligibility  has been determined following the placebo 
lead-inperiod .  
Individual subject treatment is automatically  assigned by  the I WRS .
Subjects will be randomized after confirmation of study eligibility  in a ratio of 2:1 via a 
computer -generated randomization schedule to receive OBS 2mg twice daily  (qAM, pc, 
and 
hs) or placebo. The randomization will be performed centrally  and stratified by age group 
(2strata total: <18 years vs≥18 years). The stratification will ensure a minimum of 
40subjects in the pediatric group (11-17 years, inclusive ). Permuted blocks of random sizes 
will be used to ensure that approximately  equal numbers of patients are assigned each 
treatment within strata.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 42of 91
6.2.3 Dosi ng
During the 4-week single -blind placebo lead-inperiod, all subjects will receive 10 mL of 
placebo twice daily (qAM, pc, and hs). During the 12-week double -blind treatment period, 
oral administration of 10 mL of investigational product will occur twice daily(qAM, pc, and 
hs), with no ingestion of food or liquids permitted for 30minutes after study  drug 
administration. Subjects randomized to OBS will receive 10 mL of 0.2 mg/mL  of OBS (2 mg) 
twice dail yfor a total daily  dose of 4mg.  
Investigational pr oduct doses that are required to be administered at the clinic include the first 
dose of placebo administered at the placebo lead-invisit (Visit 0),the first dose of 
randomized investigational product (OBS or placebo) administered at the baseline visit
(Visit 1)and all morning doses of investigational product administered at Visits 2-4.Subjects 
will Subjects will be required to eat breakfast at the clinic prior to self-administering these 
doses. Subjects canself-administer all other doses of placebo andinvestigational product at 
home . 
During the visit where the pharmacokinetic blood samples are collected (Visit 2 or Visit 3), 
subjects will be required to eat a moderate -fat breakfast on-site and will be instructed to take 
their morning dose at a set ti me to establish the schedule for post -dose sample collection .
6.2.4 Unblinding the Treatment Assignment
The treatment assignment must not be broken during the study  except in emergency  situations 
where the identification of the investigational product is requi red for further treatment of the 
subject. The investigator should contact the medical monitor and the sponsor as soon as 
possible after the i nvestigator has been unblinded.
In the event that the treatment assignment is broken, the date, the signature of the person who 
broke the code, and the reason for breaking the code are recorded in the IWRS and the source 
documents. Upon breaking the blind, the subject is withdrawn from the study  but should be 
followed up for safet y purposes. Any code breaks that occur must be reported to the contract 
research organization (CRO )and sponsor .Code break information is held by the 
pharmacist/designated person at the site and by the CRO medical monitor for the study  or 
designee.
There will be a provision for unblinding to ensure adequate treatment of the subject in the 
case of an emergency .
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 43of 91
6.3 Labeling, Packaging, Storage, and Handling
6.3.1 Labeling
Labels containing study  information and pack identification are applied to the investigational 
product(s) container. 
All investigat ional product is labeled with a minimum of the protocol number, Med ID, 
dosage form (including product name and quantity  in pack), directions for use, storage 
conditions, expiry  date (if applicable), batch number and/or packaging reference, the 
statements “For clinical trial use only”and/or “CAUTION: New Drug -Limited by Federal 
(or US) Law to Investigational Use ,” “Keep out of reach of children ,”and the sponsor’s name 
and address. Any additional labeling requirements for participating countries and/or 
controlled substances will also be included on the label.
Space is allocated on the label so that the site representative can record subject information. 
Additional labels (eg,those used when dispensing marketed product) may, on a case-by-case 
basis, be applied to the investigational product in order to satisfy  local or institutional 
requirements, but must not:
 Contradict the clinical study  label .
 Obscure the clinical study label .
 Identify  the study  subject by  name.
Additional labels may  not be added without the sponsor’s prior full agreement.
6.3.2 Packaging
Investigational product is packaged in the following labeled containers:
The sponsor will supply  the following medication to the study  sites in a blinded manner: OBS 
0.2 mg/mL or placebo in an 8-ounce amber glass bottle for multiple use. Three bottles will be 
packaged in an appropriately  labeled carton.
Changes to sponsor -supplied packaging prior to dosing may not occur without full agreement 
in advance b y the sponsor.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 44of 91
6.3.3 Storage
The investigator has overall re sponsibility  for ensuring that investigational product is stored in 
a secure, limited -access location. Limited responsibility  may be delegated to the pharmacy  or 
member of the stud y team, but this delegation must be documented.  
OBS and placebo must be st ored at 2-8ºC (36- 46ºF), protected from light.
Investigational products are distributed by the pharmacy  or nomin ated member of the study 
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels as they are distributed.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study  and that 
records are maintained; the temperature 
should be monitored continuously  by using either an 
in-house system, a mechanical recording device such as a calibrated chart recorder, or by 
manual means, such that both minimum and maximum thermometric values over a specific 
time period can be recorded and retrieved as required. Such a device (ie,certified min/max
thermometer) would require manual resetting upon each recording. The sponsor must be 
notified immediately  upon discovery  of any excursion from the established range.  
Temperature excursions will require site investigatio n as to cause and remediation. The 
sponsor will determine the ultimate impact of excursions on the investigational product and 
will provide supportive documentation as necessary .Under no circumstances should the 
product be dispensed to subjects until the impact has been determined and the product is 
deemed appropriate for use by  the sponsor.
The sponsor should be notified immediately  if there are any  changes to the storage area of the 
investigational product that could affect the integrit y of the product(s), eg,fumigation of a 
storage room .
6.3.4 Special Handling
The investigational product should be stored under refrigeration at 2 -8°C/36 -46°F at all times .
The investigational product should be protected from light and shaken well immediately  prior 
to each dose .
6.4 Drug Accountability
Investigators will be provided with sufficient amounts of the investigational product to carry 
out this protocol for the agreed-upon number of subjects. The investigator or designee will 
acknowledge receipt of the investigational product, documenting shipment content and 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 45of 91
condition. Accurate records of all investigational product dispensed, used, returned, and/or 
destroy ed must be maintained as detailed further in this section.
The investigator has overall responsibility  for administering/disp ensing investigational 
produc t.Where permissible, tasks may  be delegated to a qualified designee ( eg,a pharmacist) 
who is adequatel y trained in the protocol and who works under the direct supervision of the 
investigator. This delegation must be documented in the applicable study  delegation of 
authority form.
The investigator or his/her designee (as documented by the investigator in the applicable 
study  delegation of authority  form) will dispense the investigational product only to subjects 
included in this study  following the procedu resset out in the study  protocol. Each subject will 
be given onl y the investigational product carry inghis/her treatment assignment. All dispensed 
medication will be documented on the CRFs and/or other investigational product record. The 
investigator is responsible for assuring the retrieval of all study  supplies from subjects. The 
investigator or his/her designee will enter the unique subject identifier and initials on the 
investigational product kit labels as they  are assigned and dispensed.
No investiga tional product stock or returned inventory  from a Shire -sponsored study  may be 
removed from the site where originally  shipped without prior knowled ge and consent by the 
sponsor. If such transfer is authorized by the sponsor, all applicable local, state, and national 
laws must be adhered to for the transfer.
The sponsor or its representatives must be permitted access to review the supplies storage and 
distribution procedures and records provided that the blind of the study  is not compromised.
At the end of the study , or as instructed by the sponsor, all unused stock , subject -returned 
investigational product, and empty /used investigational product packaging are to be sent to a 
nominated contr actor on behalf of the sponsor. Investigational product being returne d to the 
sponsor’s designated contractors must be counted and verified by clinical site personnel and 
the sponsor (or designated CRO). For unused supplies where the original supplied 
tamper -evident feature is verified as intact, the tamper -evident feature must not be broken ,
and the labeled amount is to be documented in lieu of counting. Shipment return forms, when 
used, must be signed prior to shipment from the site. Validated electronic return systems (ie,
IWRS ) do not require a shipment form. Returned investigational product must be packed in a 
tamper -evident manne r to ensure product integrity . Contact the sponsor for authorization to 
return any investigatio nal product prior to shipment. Shipment of all returned investigational 
product must comply  with lo cal, state, and national laws.
Based on entries in the site drug accountability  forms, it must be possible to reconcile 
investigational products delivere d with those used and returned. All investigational products 
must be accounted for and all discrepancie s investigated and documented to the sponsor’s 
satisfaction.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 46of 91
6.5 Subject Compliance
Compliance with investigational product will be assessed at each st udy visit. Subjects must be 
instructed to bring their unused investigational product and empty /used investigational 
product packaging to every  visit. Drug accountability  must be assessed at the 
container/packaging level for unused investigational product that is contained within the 
original tamper -evident sealed container ( eg,bottles) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the 
drug accountability  form.
Visit to visit compliance of investigational product dosing willbe assessed by site personnel.
Site personnel must review the returned investigational product to assess compliance at every  
visit prior to dispensing addit ional investigational product. Any discrepancies should be 
reconciled with the subject immediatel y. Subjects who do not return their used and unused 
investigational product should be reminded to bring all used and unused investigational 
product at their next visit.
Subjects who have taken 70-130% of the investigational product will be assessed as being 
compliant with the study  protocol. Compliance will be assessed at e ach treatment visit. 
Visit to visit compliance of DSQ completion will also be assessed by site personnel. Protocol 
deviations will be documented for subjects who fail to complete the DSQ for 3or more days 
in a given week.
7. STUDY PROCEDURES
7.1 Study Schedule
The detailed study  procedures/assessments to be performed throughout the study  are outlined 
in the Schedule of Assessments (see Table 1-1) and must be referred to in conjunction with 
the instructions provided in this section. 
Prior to performing any study -related procedures (including those related to screening), the 
investigator or his/her designee must obtain written informed consent from the subjec t (as per 
local requirements). There must be documentation of consent (as per local requirements) 
indicatin g that the subject is aware of the investigational nature of the study  and the required 
procedures and restrictions, prior to performing any  study -related procedures.
7.1.1 Screening Period (Week s -6to 0)
The screening period starts when subjects sign informed consent. The screening period
will 
comprise 3-6 weeks, during which all procedures listed for the screening visit (Visit - 1) in 
Table 1-1shall be completed. The screening period will allow for the determination of 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 47of 91
eligibility  of each subject’s inclusion into the study .A subject should not be instructed to 
discontinue use of any medication or treatment to participate in this study  until infor med 
consent has been obtained. Subjects should not stop permitted medications or treatments that 
are effective and w ell tolerated to participate in this study (see Section 5.2.1).
Screening assessments may take place 
across several days to allow an appropriate time frame 
in which to complete all procedures and confirm study  eligibility . 
After the screening period, subjects who meet eligibility  criteria at the end of the screening 
visit (Visit -1) will enter the 4-week single -blind, placebo lead-inperiod. The placebo lead-in
period should not commence until all screening assessments required to confirm initial 
eligibili ty have been completed. If the subject does not meet eligibility  criteria following 
completion of screening assessments, the investigator or designee will document the subject 
as a screen failure in the IWRS.
A screen failure is a subject who has given informed consent and failed to meet the inclusion 
criteria and/or met at least 1 of the exclusion criteria and has not been randomized or 
administered randomized investigational product. Screen failures can occur at the screening , 
placebo lead-in,or baseline visits. Subjects cannot be rescreened once they have been 
designated as a screen failure unless the screen failure was due to a concomitant medication 
that can be discontinued; those subjects can be rescreened .
7.1.1.1 Screening Visit (Visit -1) 
The screening visit(Visit -1) assessments and procedures , beginning with informed consent, 
will be performed as outlined in Table 1-1.
The following procedures should be performed first:
Obtain subject c onsent (or assent as applicable for subjects <18 y ears).
Review elig ibility  criteria.
Review medical history .
Record vital signs (including blood pressure [systolic and diastolic], heart rate, 
respirations, and temperature), height, and weight.
Review current use of concomitant medications, including medications taken and 
procedures completed within 3months prior to the biopsy  required for entrance to this 
study . Note: Subjects who are on a PPI must remain on the same dose of the PPI 
throughout the study , and if they are not taking a PPI, they must remain off of a PPI for 
the remainder of the study .
Clinical chemistry , hematology , and urinal ysis laboratory  tests will be performed on all 
subjects; all subjects must fast overnight prior to collection.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 48of 91
The following order is recommended for the remaining procedures that will be performed at 
this visit or within the 6 -week screening period :
Dispense the DSQ electronic patient -reported outcome (ePRO )device for nightl y 
completion and train the subject on its use. In order to qualify  for study entry , subjects 
must have experience d dy sphagia (response of “yes” to question 2 on DSQ) on a
minimum of 4daysand completed the DSQ on ≥70% of days in any 2consecutive weeks 
of the screening period.
Perform a physical examination on all subjects. Adolescents (subjects ≤17 years) will als o 
undergo Tanner S taging Assessment .
Serum pregnancy  test will be performed on all female subjects. 
Perform EGD and biops y; both must be performed within the 6 weeks prior to the Placebo 
Lead -in Visit either at the investigative site or by a referring physician. Biopsy  specimens 
must be available to be sent to the central pathology  lab at least 2 weeks prior to the 
Placebo Lead -in Visit to allow sufficient time for processing and central review and 
determination of eligibility .
7.1.2 Placebo Lead -in Period (Week s 0to 4)
The placebo lead-inperiod will comprise 4 weeks, during which all procedures listed for the 
placebo visit (Visit 0) in Table 1-1 shall be completed .
During the 4-week single -blind placebo lead-in, all eligible subjects will self-administer 
10mLof placebo twice daily  (qAM, pc, and hs ). 
At the end of the placebo lead-inperiod, eligible subjects (those with at least 4 reported 
dysphagia days and completion of DSQ on ≥70% of days in the 2 weeks prior to baseline  
[Visit 1]) will be randomized andenter the 12-week double -blind treatment period (baseline 
visit).Subjects must be administrated placebo during the placebo lead-in period for 4weeks 
(±3days) prior to Visit 1 (baseline) to be eligible for randomization into the 12-week double -
blind treatment period .
7.1.2.1 Placebo Lead -in Visit (Visit 
0) 
The placebo lead-in visit (Visit 0) assessments and proce dures will be performed as outlined 
in Table 1
-1. 
The following procedures should be performed first:
Reassess eligibility  according to the inclusion/exclusion criteria and medical history .
Record vital signs (including blood pressure [systolic and diastolic], heart rate, 
respirations, and temperature) and weight.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 49of 91
Perform AE assessments.
Review concomitant medications and procedures.
Clinical chemistry ,hematology , and urinal ysis laboratory  tests; all subjects must fast 
overnight prior to collection.
The following order is recommended for the remaining procedures that will be performed at 
this visit:
Review DSQ dy sphagia episodes and compliance; re -dispe nse DSQ device to subject with 
instruction to continue completion of the DSQ nightly .
Perform a ph ysical examination and assess any  changes since screening.
Urine pregnancy  test for female subjects.  
Perform dual-energy  X-ray absorptiometry  (DXA )scan forbone mineral density  (BMD )
in subjects aged 11-17 years , inclusive ; the DXA scan may be performed any time during 
the placebo lead-inperiod, after the subject has met all screening criteria and prior to 
blinded- treatment randomization. Baseline and post-treatment DXA scans should be 
performed using the same machine and software.
Dispense placebo study  medication and review administration instructions. Subjects will 
self-administer the first dose of placebo in the clinic after eating breakfast. Site person nel 
will record the date and time of the first placebo dose in the source documents. Beginning 
on the evening of Visit 0, the subject will take their second dose at home and continue 
with the twice dail y (qAM, pc, and hs) dosing regimen.
7.1.3 Double -blind Treat ment Period (Visits 1-4): Weeks 4, 8, 12 ,and 1 6(or Early 
Termination )
The double -blind treatment period will comprise 12weeks, during which all assessments and 
procedures listed for Visits 1 -
4in Table 1-1 shall be completed.
During this period, a3-day visit window will bepermitted , unless otherwise specified .Visit 
windows are calculated based upon the date of the placebo lead -invisit (Visit 0).
Subjects who continue to meet all eligibility  criteria will be randomized 2:1 to receive either 
OBS twice daily (qAM, pc, 
and hs) or placebo twice daily (qAM, pc, and hs). The 
investigator or assigned site staff will access the IWRS to randomize the subject and dispense 
the investigational product. Subjects who fail to meet eligibility  criteria at the baseline visit
(Visit 1) will be documented as screen failures in the I WRS.
Subjects who complete the 12-week double -blind treatment period will have the opportunity  
to enroll in the treatment extension study . These subjects will continue on the blinded 
assigned treatment for 2-4 weeks as part of the screening prior to enrolling into the treatment 
extension study . Subjects who do not enroll in the treatment extension study  or who 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 50of 91
discontinue prematurely  at any time during the SHP621 -301 (Induction) study  will receive a 
follow -up phone call 4 -weeks post last dose of investigational product.
7.1.3.1 Baseline Visit (Visit 
1): Week 4
Subjects will return to the site for the baseline visit (Visit 1) to confirm eligibility . The 
baseline visit (Visit 
1) assessments and procedures will be performed as outlined in Table 1-1.
The following procedures should be performed first:
Reassess eligibility  according to the inclusion/exclusion criteria and medical history .
Record vital signs (including blood pressure [systolic and diastolic], heart rate, 
respirations, and temperature) and weight. Perform stadiometry  in subjects aged 
11-17 years, inclusive. 
Perform AE assessments, including specific assessments for signs of glucocorticoid 
excess. Any  AE that occurs during this visit will be recorded in the CRF and considered a 
TEAE.
Review concomitant medications and procedures.
Clinical chemistry , hematology , and urinal ysis laboratory  tests; all subjects must fast 
overnight prior to collection.
Morning cortisol (performed between 6:00 and 9:00 AM). Subjects should be instructed 
not to take the morning dose of investigational product until after the morning cortisol test 
has been performed. 
Administer adrenocorticotropic hormone (ACTH) stimulation testing; the typeof 
synthetic and route of admi nistration will be 
perlocal lab discretion . Additional cortisol 
samples will be drawn at 30 and 60 minutes following stimulation testing.
The following order is recommended for the remaining procedures that will be performed at 
this visit:
Review study  medication dosing compliance.
Review DSQ dy sphagia episodes and compliance; re -dispense DSQ device to subject with 
instruction to continue completion of the DSQ nightly .
Administer health- related quality -of-life(HRQoL) assessments including the EuroQol 
(EQ-5D) , Pediatric Quality  of Life Inventory –EoE (PedsQL -EoE), and Adult 
Eosinophilic Esophagitis Quality  of Life ( EoE-QoL-A)as age-appropriate.
Administer PGI -S of disease assessment. 
Perform a ph ysical examination and assess any  changes since screening.
Re-administer urine pregnancy  test for female subjects.  
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 51of 91
Dispense investigational product (OBS or placebo) according to IWRS randomization and 
review administration instructions. Subjects will self-administer the first dose of 
investigational product in the clinic during this visit after breakfast . Site personnel will 
record the date and time of the first randomized dose in the source documents. Beginning 
on the evening of Visit 1, the subject will take their first dose at home and continue with 
the twice daily (morning and evening) dosing regimen. For subjects who are minors (<18 
years), a parent/guardian will be responsible for ensuring subject takes their 
investigational product appropriatel y.
Following all blood draws, subjects can eat breakfast and take their morning dose of 
investigational product.
7.1.3.2 Visit s 2and 3(Weeks 8and 12)
Subjects will return to the site for Visit 2(Week 8) and Visit 3(Week 12). Assessments at 
these visits will be performed as outlined in Table 1 -
1.
The following procedures should be performed first:
Record vital signs (including blood pressure [systolic and diastolic], heart rate, 
respirations, and temperature) and weight.
Perform AE assessments, including specific assessments for signs of glucocorticoid 
excess. Any  AE that occurs during this visit will be recorded in the CRF and considered a 
TEAE.
Review concomitant medications and procedures.
Clinical chemistry , hematology , and urinal ysis laboratory  tests; all subjects must fast 
overnight prior to collection.
Morning cortis ol (performed between 6:00 and 9:00 AM). Subjects should be instructed 
not to take the morning dose of study  medication until after the morning cortisol test has 
been performed. 
Collect blood samples for pharmacokinetic analy sis for adult subjects. Subjec ts will be 
instructed to take their morning dose at a set time to establish the schedule for post-dose 
sample collection.
The following order is recommended for the remaining procedures that will be performed at 
this visit:
Review DSQ dy sphagia episodes an
d compliance; re -dispense DSQ device to subject with 
instruction to continue completion of the DSQ nightly .
Administer PGI -S assessment. 
Perform a ph ysical examination and assess any  changes since screening.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 52of 91
Re-administer urine pregnancy  test for female subjects.  
Dispense investigational product (OBS or placebo) and review investigational product 
dosing compliance.
Following all blood draws, subjects can eat breakfast and take their morning dose of 
investigational product.
7.1.3.3 Visit 4(Week 16)
Subjects will return to the site for Visit 4(Week 16). Assessments at this visit will be 
performed as outlined in Table 1
-1.
The following order is recommended for the procedures that will be performed at this visit:
Record vital signs (including blood pressure [systolic and diastolic], heart rate, 
respirations, and temperature), height, and weight. Perform stadiometry  in subjects aged 
11-17 years, inclusive.
Perform AE assessments, including specific assessments for signs of glucocorticoid 
excess. Any  AE that occurs d uring this visit will be recorded in the CRF and considered a 
TEAE.
Review concomitant medications and procedures.
Clinical chemistry , hematology , and urinal ysis laboratory  tests; all subjects must fast 
overnight prior to collection.
Morning cortisol (perf ormed between 6:00 and 9:00 AM). Subjects should be instructed 
not to take the morning dose of investigational product until after the morning cortisol test 
has been performed. 
Administer adrenocorticotropic hormone (ACTH) stimulation testing; the typeof
synthetic and route of administration will be per local lab discretion. Additional cortisol 
samples will be drawn at 30 and 60 minutes following stimulation testing. 
Retrieve DS Q
handset and review D SQcompliance .
Administer HRQoL  assessments including the EQ-5D, PedsQL -EoE, and EoE-QoL-Aas 
age-appropriate.
Administer PGI -S assessment. 
Perform a physical examination and assess any changes since screening .Adolescents 
(subjects ≤17 y ears) will also undergo Tanner Staging Assessment.
Re-administer serum pregnancy  test for female subjects.  
Perform DXA scan for BMD in subjects aged 11 -17 years, inclusive . DXA scan should be 
completed at or within 7days of this visit. Baseline and post-treatment DXA scans should 
be performed using the same machine and soft ware.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 53of 91
Perform EGD and biopsy .EGD should be completed at or within 7 days of the scheduled 
visit.
For eligible subjects continuing into the treatment extension study , obtain informed 
consent for the treatment extension study , dispense investigational produ ct (OBS or 
placebo) according to IWRS randomization and review investigational product dosing 
compliance.
Following all blood draws, subjects can eat breakfast and take their morning dose of 
investigational product if they  are continuing in the treatment e xtension study .
7.1.4 Follow -up Period
The follow -up period for this protocol is 4 weeks from the last dose of investigational 
product . Subjects who do not enroll in the treatment extension study  or who discontinue 
prematurel y at any time during the study  will receive a follow -up 4 phone call at Visit 5 
(Week 20) to query  for SAEs, AEs, and concomitant treatments (Section 7.1.4.1 ).
7.1.4.1 Safety Follow -up Contact (Visit 5): Week 20
Assessments at this 
time, as outlined in Table 1-1, will include the following:
Review concomitant medications and procedures .
Perform AE assessments, including specific assessments for signs of glucocorticoid 
excess. Any  AE that occurs during this visit will be recorded in the CRF and considered a 
TEAE; all AEs and SAEs that are not resolved at the time of this contact will be followed 
to closure .
7.1.5 Additional Care of Subjects a fter the Study
No after care is planned for this study for those 
subjects who do not enroll in the treatment 
extension study .
7.2 Study Evaluations and Procedures
The full title and details about who completes the scales used in this study  is included in 
Appendix 1 .
All assessments listed below will be performed by the subject and/or a qualified/trained site 
staff as indicated in the assessment description. For subject -complet ed assessments, trained 
site staff should not assist the subject in completing assessments in such a manner that it 
would influence their responses. Site staff should review the completed assessment to ensure 
completeness.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 54of 91
If an answer is marked in error, the subject may  correct it by  drawing a single line through the 
error and initialing and dating the change; however, corrections can onl y be made to scales by  
the subject during a study  visit and changes must not be made to subject -completed scales 
after the visit has been completed. Assessments are to be performed according to the schedule 
shown in Table 1-1.
7.2.1 Efficacy
7.2.1.1 Esophagogastroduodenoscopy with Esophageal Biopsy and Histopathologic 
Evaluation
The EGD with endoscopy  score and biopsy  will be performed during the study  as outlined in 
Table 
1-1. 
An EGD with esophageal, gastric and duodenal biopsies will be required for study 
participation; the peak eosinophil count per HPF from each esophageal level will be used as a 
primary  measure of efficacy . The quali fying/baseline EGD with biopsies must be performed 
bya physician at the investigative sitewithin the 6weeks prior to placebo lead-invisit 
(Visit
1).Biops y specimens must be available to be sent to the central pathology  lab by at 
least 2weeks prior tothe placebo lead-invisit to allow sufficient time for processing and 
central review and determination of eligibility .
Multiple specimens (at least 2 biopsies from each of 3 levels , 
6 specimens total) will be 
obtained from the proximal (3 cm below the cricophary ngeus muscle), mid-esophagus (mid -
point between the cricophary ngeus muscle and the gastroesophageal junction), and distal 
(3cm above the gastroesophageal junction) .Biopsy  tissue will be placed in 3 separate vials 
(1vial for each of the levels) and sent to the central pathology  laboratory for processing of 
tissue into slides . Acentral pathologist will determine histologic eligibility  for study  entry. 
Peak eosinophil counts of ≥15/HPF in specimens from 2 or more levels of the esophagus will 
be a requirement for study  entry, as determ ined by a central pathologist. Eosinophil counts, 
histopathologic featu res, and gross endoscopic findings will be evalu ated and scored for each 
EGD. Eight histopathologic epithelial features (basal layer hyperplasia, eosinophil density , 
eosinophil microabscesses, eosinophil surface layering , dilated intercellular spaces, surface 
epithelial alteration, dyskeratotic epithelial cells, lamina propria fibrosis ) will be scored 
ona 
4-point scale (0=normal, 3=worst) for both the severity  of the abnormalit y (ie grade) and the 
amount of tissue affected by  the abnormality  (ie, stage) . 
Endoscopic findings with separate evaluations of the proximal and distal esophagus will be 
recorded with respect to 5 categories by the endoscopist : 1) exudates or plaques (grade 0–2); 
2) fixed esophageal rings (grade 0–3); 3) edema (grade 0–1); 4) furrows (grade 0–1); and 5) 
strictures (grade 0–1). An endoscop y score for each category  will be calculated and summed 
for each anatomic location (proximal and distal). The maximum endoscopy score is 10 points 
for each location, and a Total Endoscopy  Score is thesum of the scores for the proximal and 
distal locations.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 55of 91
In addition, the general appearance of the stomach and duodenum will be assessed by the 
endoscopist. Biopsies will be taken from the stomach and duodenum for the screening EGD 
as follows: gastric body  (greater curvature): 2 specimens, gastric antrum: 2 specimens, and 
duodenum (third part or distal): 2 specimens. Biopsies from the stomach should be submitted 
in one vial; biopsies from the duodenum should be submitted in a separate vial to the central 
pathology  laboratory  for processing of tissue into slides. If the pre-treatment biopsy  identifies 
eosinophilia in the stomach and/or duodenum, the subject will be excluded from the study . 
At the Week 16visit (Visit 4) or at early  termination (ET) , and EG D with esophageal biopsies 
(at least 2biopsies from each of 3 levels [proximal, mid-, and distal] )is required. Endoscopic 
findings will be recorded by the endoscopist.  Biopsies will be sent to the central laboratory 
for processing . A central pathologist will evaluate the slides. Gastric and duodenal biopsies 
may be repeated at the discretion of the investigator , but are not required .
7.2.1.2 Dysphagia Symptom Questionnaire
Subjects’ dy sphagia s ymptoms will be evaluated using a DSQ ePRO device ( Appendix 2). 
The questionnaire will be completed by subjects daily  for a minimum of 3weeks during the 
screening period , during the 4-week placebo lead -inperiod , and during the 12 -week treatment 
period. Each evening before bedtime, subjects will be asked to indicate if they experienced 
dysphagia symptoms (eg, food passing slowly  or food sticking) during that day. Subject must 
have experienced dysphagia (response of “yes” to question 2 on DSQ) on a minimum of 
4days total and completed the DSQ on ≥70% of days in any 2 consecutive weeks of the 
screening period and in the 2 weeks prior to the baseline visit (Visit 1).Subjects must fill out 
the DSQ at least 5or more day sduring a given week in order to be compliant.
Calculations will be performed on daily  ePRO entries from the screening period ,during a 
2-week interval prior to the baseline period ,and prior to each study  visit during the baseline 
and treatment period
s. The DSQ score for the co-primary  endpoint and secondary  endpoints 
will be calculated by summing the scores of responses to questions 2 and 3 only. Questions 1 
and 4 will be excluded from the DSQ score:
DSQ score =
   (Sum of points from questions 2+3 in the daily  DSQ)×14
Number of diaries reported with non -missing d ata
The DSQ + pain score for the secondary  endpoints will be calculated by summing the scores 
of responses to questions 2, 3, and 4. Question 1 will be excluded from the DSQ + pain score.
DSQ + pain score =(Sum of points from questions 2+3+4 in the dail y DSQ)×14
Number of diaries reported with non -missing data
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 56of 91
The DSQ pain score for the secondary  endpoint will be calculated by summing the scores of 
responses to Question 4 only .
DSQ pain score =(Sum of points from 
question 4 in the daily  DSQ)×14
Number of diaries reported with non- missing data
7.2.2 Safety
The name and address of each third- party  vendor (eg,clinical laboratory) used in this study 
will be maintained in the investigator’s and sponsor’s files.
7.2.2.1 Medical and Medication History
Medical History
The investigator must record all clinicall y or medically  relevant information regardless of 
how much time has elapsed since the date of any diagnosis. Medical history  will be classified 
as EoE or non-EoE by the investigator. The EoE medical history  must include any prior 
history  of esophageal strictures and esophageal dilations.
Medication History
Refer to Section 5.1for full details on collection of prior treatment.
Prior treatment information , including any prior treatments for EoE (eg, dietary , medication, 
orother) ,must be recorde d on the appropriate CRF page.
7.2.2.2 Physical Examination (Including Height and Weight)
Abnormalities
identified at the screening visit (Visit -1) will be documented in the subject’s 
source documents and on the medical history  CRF. Change s after the screening visit (Visit -
1) 
will be captured as AEs on the AE CRF page, as deemed b y the investigator.
Physical examination assessments at each visit should also include specific assessments for 
signs of glucocorticoid excess (eg, moon faces, acne, hirsutism, mood swings, insomnia, and 
depression). Physical examination at the screening visit (Visit
-1) will also include Tanner 
Staging Assessments 
for subjects < 18 years of age.
Height will be collected at the screening visit (Visit -1) and Visit 4 for all subjects. 
Stadiomet ers will be used to measure height at Visit 1 and Visit 4 forsubjects aged 
11-17 years, inclusive . Statural height will be measured by trained site staff using a stabilized 
stadiometer. The same stadiometer should be used for the baseline and post treatment 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 57of 91
measurements. Standard measuring procedures should be followed (eg, removal of socks, 
shoes ,and hats; calibration frequency ). Please refer to the study  manual for additional details.
7.2.2.3 Adverse Event Collection
At each study  visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred since the previous visit (eg,“Have you had any health problems since your last 
visit?”). AEs are collected from the time informed consent is signed. (Please refer to 
Section8.)
AE assessments at each visit should also include specific assessments for signs of 
glucocorticoid excess 
(eg, moon facies, acne, hirsutism, mood swings, insomnia, and 
depression).
7.2.2.4 Vital Signs
Vital signs will be conducted after the subject has been supine for at least 5 minutes 
immediately  prior to the assessment and will include blood pressure (systolic and diastolic), 
heart rate, respirations, and temperature . Blood pressure should be determined by cuff (using 
the same method, the same arm, and inthe same position throughout the study ). Any 
clinically  significant deviations from baseline (Visit 1) vital signs that are deemed clinicall y 
significant in the opinion of the investigator areto be recorded as an AE.
7.2.2.5 Clinical Laboratory Evaluations
All clinical laboratory  assays will be performed according to the laboratory ’s normal 
procedures. All s
ubjects must fast overnight prior to collection of c linical laboratory  tests.
Reference ranges are to be supplied by the laboratory  and will be used to assess the clinical 
laboratory  data for clinical significance and out-of- range pathological changes. The 
investigator should assess out-of- range clinical laboratory  values for clinical significance, 
indicating if the value(s) is/are not clinically  signific ant orclinicall y significant. Abnormal 
clinical laboratory  values, which are unexpected or not explained by the subject’s clinical 
condition, may , at the discretion of the investigator or sponsor, be repeated as soon as possible 
until confirmed, explained, or r esolved.
The following clinical laboratory  assessments will be performed: 
Biochemistry
alkaline phosphatase 
aspartate aminotransferase
alanine aminotransferaseblood urea nitrogen 
creatinine
sodium 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 58of 91
total bilirubin
total protein
albumin
glucose potas sium 
chloride 
calcium
carbon dioxide
Hematology
hemoglobin 
hematocrit 
mean corpuscular hemoglobin
mean corpuscular hemoglobin concentration
mean corpuscular volume
erythrocyte count
leukocyte countneutrophils
lymphocytes
monocytes
eosinophils
basophils
platelet count
Urinalysis
glucose
protein
specific gravity
pH
nitritebilirubin
ketones
hemoglobin
urobilinogen
leukocyte esterase
Other tests
serum pregnancy
urine pregnancymorning cortisol (6:00- 9:00 AMcollection)
ACTH stimulation testing
ACTH stimulation testin g will be performed by measuring the levels of cortisol in the blood 
following the injection of a synthetic form of ACTH. The typeof synthetic and route of 
administration will beperlocal lab discretion. Blood samples will be collected just prior to 
and approximately  30 and 60 minutes following the injection. 
In the event of clinically significant abnormal laboratory  test results, follow -up laboratory 
tests may be conducted. Any clinicall y significant abnormalities noted in the laboratory  tests 
will be discussed with the medical monitor .
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 59of 91
7.2.2.6 Pregnancy Test 
A serum β-hCG pregnancy  test is performed on all female subjects at the screening visit
(Visit -1) and the final treatment evaluation visit (Visit 4 )or ETvisit. A urine pregnanc y test 
is performed on all female subjects at the placebo lead-invisit (Visit 0), baseline visit (Visit 
1), Visit 2, and Visit 3or if pregnancy  is suspected.
7.2.2.7 Dual -energy X -ray Absorptiometry for Bone Mineral Density
DXA (also referred to as DEXA ) scans for determination of BMD will be performed in
subject saged 1 1-17 years, inclusive, as outlined in Table 1-1.
The sites for DXA measurement will be the lumber spine (L1-L4 preferred) and total body 
less head (Bachrach, 2011; Gordon, 2008 ; International Society  for Clinical Densitometry , 
2013). The same DXA machine and software should be used for the baseline and 
post-treatment scans. The DXA manufacturer, model ,and software version should be 
recorded in the CRF.
7.2.3 Other Assessments
7.2.3.1 Health -related 
Quality -of-life Assessment
EuroQol -5 Dimension s 3-level Questionnaire 
The EuroQol -5D Dimensions 3-level (EQ -5D-3L ; for subjects ≥18 years) and the EuroQol -5 
Dimensions Youth (EQ-5D-Y ; for subjects 11-17 yearsof age, inclusive ) will be performed 
during the stud y as outlined in Table 
1-1.
The EQ -5D-3 L is a standardized measure of health status for use in adult populations that was 
developed by the EuroQol Group in order to provide a simple, generic measure of health for 
clinical and economic appraisal ( EuroQol Group, 1990). The EQ- 5D-3 L provides a simple 
descriptive profile and a single index value for health status that can be used in the clinical 
and economic evaluation of healthcare as well as in population hea lth survey s. It consists of a 
5-item descriptive system that measures 5dimensions of health, including mobility , self -care, 
usu
al activities, pain/discomfort, and anxiety /depression. Each dimension is represented by a 
single item with 3levels of responses. The EQ-5D-3L will be completed by the subject. The 
EQ-5D-3 L should take the subject a fewminutes to complete.
The EQ -5D-Y is a self -report version of the EQ -5D that was developed by  the EuroQol Group 
for use in younger populations (Wille et al., 2010). The EQ-5D-Yprovides a simple 
descriptive profile and a single index value for healt h status that can be used in the clinical 
and economic evaluation of healthcare as well a s in population health survey s.It consists of a 
5-item descriptive system that measures 5 dimensions of health, including mobility , looking 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 60of 91
after myself, doing usual activities, having pain or discomfort, and feeling worried, sad,or 
unhappy . Each dimension is represented by a single item with 3 levels of responses. The 
EQ-5D-Y w ill be completed by  the subject and should take a few minutes to complete .
Pediatric Qualit y of Life –EoE Questionnaire
The PedsQL -EoE questionnaire will be completed bysubjects 11-17 years of age, inclusive,
and their parent or legal guardian, as outlined in Table 
1-1.
The PedsQL -EoE is a modular , disease -specific instrument designed to measu re HRQoL in 
children and adolescents (2-18 years of age) with EoE (Franciosi , 2013; PROQOLID ). The
PedsQL -EoE module consists of
33 items for children and teenagers encompassing the 
following 7 scales: 1)Symptoms I (6 items; chest/throat/stomach pain and nausea/vomiting), 
2) Symptoms II (4items; trouble swallowing), 3) Treatment (5 items; treatment barriers), 4) 
Worry  (6 items; worries about treatment and disease), 5)Communication (5 items; 
communication with others about EoE), 6) Food and Eating (4 items; food and eating allergies 
and limitations), and7) 
Food Feelings (3 items; emotions associated with food allergies). The 
PedsQL -EoE should take the subject and parent approximately  10minutes to complete.
Adult Eosinophilic Esophagitis Quality of Life Questionnaire
The EoE -QoL-A will be performed in subjects 
≥18 y ears of age as outlined in Table 1-1.
The EoE- QoL-A is a disease -specific measure of HRQoL  in adult patients (≥18 yearsof age)
with EoE (Taft et 
al.,2011 ). The EoE-QoL- A consists of a 37-item test with 5subscales: 
eating/diet impact, social impact, emotional impact, diseas e anxiety ,and choking anxiety . The 
EoE-QoL-A will be completed by the subject and sho
uld take the subject approximately  15
minutes to complete.
7.2.3.2 Severity of Disease Assessments
Patient Global Impression of Severity 
The PGI -S will be performed in all subjects as outlined in Table 
1-1.
The PGI-S is a global index (Appendix 3) that canbe used to rate the severity  of a specific 
condition -in this case, dysphagia in EoE. Subjects will be asked to rate the severity  of their
dysphagia 
over the last 7 days using a 5- point scale .
7.2.4 Clinical Pharmacology Assessments
Blood samples will be collected from adult subjects (≥18 yearsof age) as outlined in Table 
1-1to measure plasma concentrations of budesonide. Subjects who do not participate in 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 61of 91
pharmacokinetic sampling will not be discontinued from the study ,and lack of participation 
will not be a co nsidered protocol deviation. 
Actual pharmacokinetic blood sample collection times vstime of dosing will be monitored. 
The sponsor’s expectation is that the investigator will ensure that every  effort will be made to 
collect all pharmacokinetic blood sampl es at the precise protocol scheduled time. 
Pharmacokinetic blood collection must not deviate from the nominal collection time set forth 
in the protocol by more than ± 5 minutes forsamples drawn within 4hours post-dose or by 
more than ± 15 minutes for samples drawn after 4 hours post-dose. Samples drawn outside 
these parameters will be considered a protocol deviation.
Blood samples (4mL) for pharmacokinetic anal ysis will be drawn by  direct venipuncture into 
K2EDTA tubes, capped and mixed by  inversion (×3) , and chilled immediately  on crushed ice. 
The actual blood collection time will be recorded in the subject’s source documents and on 
the appropriate CRF page (24 -hour format). After apply ing a tourniquet, venous blood will be 
drawn with a disposable needle . If a catheter is used, the first milliliter of blood on each 
sampling occasion will be discarded. Saline can be used to keep catheters patent .
Within 15minutes following each sample collection, the blood tubes will be centrifuged at 
approximately  1500 g (15 minutes, 4°C). The separated plasma will be decanted into 
appropriatel y labeled primary  and backup polypropylene tubes via a plastic pipette. All 
samples will be stored nominally  at -20°C, and the freezer temperature will be controlled, 
monitored, and recorded during the storage period until the samples are shipped to the 
designated bioanal ytical laboratory  for analy sis.
For additional information detailing sample handling, storage
,and shipment, see Appendix 4 .
7.2.5 Volume of Blood to B e Drawn f rom Each S ubject
Table 7-1: Approximate Volume of Blood to B e Drawn from Each Subject
AssessmentSample Volume 
(mL)Number of 
SamplesApproxim ate Total 
Volume (mL)
Pharm acokinetic samplesa5 9 45
Safety Biochemistry and -hCGb6 6 36
ACTH 2 4 8
Cortisol 2 4 8
Hem atology 2 6 12
Total mL 109
Abbreviations: ACTH=adrenocorticotropic hormone; β -hCG=beta- human chorionic gonadotropin
aIf a catheter is used, the first mL is to be discarded; then take 4 mL into approp riate tube for pharmacokinetic 
sample.  A total of 5 mL of blood drawn has been used in determination of sample volume.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 62of 91
Table 7-1:Approximate Volume of Blood to B e Drawn from Each Subject
AssessmentSample Volume 
(mL)Number of 
SamplesApproxim ate Total 
Volume (mL)
b-hCG testing is for females only.
During this study , it is expected that approximately  109 mLof blood will be drawn from all 
subject s, regardless of sex.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of 
blood to be drawn may vary according to the 
instructions provided by the manufacturer or 
laboratory  for an individual assessment; however, the total volume drawn over the course of 
the study  should be approximately  109 mL. When more than 1 blood assessment is to be done 
at the time point/period, if they require the same type of tube, the assessments may be 
combined.  
8. ADVERSE AND SERIOUS 
ADVERSE EVE NTS ASSESSMENT
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events
An AEis any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory  finding), symptom, or disease temporally  associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product (ICH Guidance E2A 1995).  
All AEs are collected from the time the informed consent is signed until the defined follow- up 
period stated in Section 7.1.4. This includes events occurring during the screening phase of 
the study , regardless of whether 
or not investigat ional product is administered. Where 
possible, a diagnosis rather than a list of symptoms should be recorded. If a diagnosis has not 
been made, then each symptom should be listed individually .All AEs should be captured on 
the appropriate AE pages in the CRF and in source documents. In addition to untoward AEs, 
unexpected benefits outside the investigational product indication should also be captured on 
the AE CRF.
All AEs must be followed to closure (the subject’s health has returned to his/her baseline 
status or all variables have returned to normal), regardless of whether the subject is still 
participating in the study. Closure indicates that an outcome is reached, stabilization achieved 
(the investigato r does not expect any further improvement or worsening of the event), or the 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 63of 91
event is otherwise explained. When appropriate, medical tests and examinations are 
performed so that resolution of event(s) can be documented.
8.1.1 Severity Categorization
The severity of AEs must be recorded during the course of the event including the start and 
stop dat es for each change in severity .An event that changes in severit y shou ld be captured as 
a new event. Worsening of pre -treatment events, after initiation of investigatio nal product, 
must be recorded as new AEs (for example, if a subject experiences mild intermittent 
dyspepsia prior to dosing of investigational product, but the dyspepsia becomes severe and 
more frequent after first dose of investigational product has been administered, a new AE of 
severe d yspepsia [with the appropriate date of onset] is recorded on the appropriate CRF).
The medical assessment of severit y is determined by using the following definitions:
Mild: A type of AE that is usually  transient and may require only minimal treatment 
or therapeutic intervention. The event does not generall y interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention.  
The event interferes with us ual activities of dail y living, causing discomfort but 
poses no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily  living, or significantly  
affects clinical status, or may  require i ntensive therapeutic intervention.
8.1.2 Relationship Categorization
A physician/investigator must make the assessment of relationship to invest igational product 
for each AE. The investigator should decide whether, in his or her medical judgment, there is 
a reasonable possibility  that the event may  have been caused by  the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related .” Otherwise, if there is any valid reason, even if undetermin ed or untested, for 
suspecting a possible cause -and-effect relationship between the investigational product and 
the occurrence of the AE, then the AE should be considered “related ”based on the definitions 
in Table 8-1. The causality  assessment must be doc umented in the source document.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 64of 91
Table 8-1:Adverse Event Relatedness
Term Relationship Definition
Not Related Unrelated to study drug.
Possibly RelatedA clinical event or laboratory abnormality with a reasonable time sequence to 
administration of study drug, but which could also be explained by concurrent 
disease or other drugs or chemicals.
Probably RelatedA clinical event or laboratory abnormality with a reasonable time sequence to 
administration of study drug, unlikely to be attributable to concurrent disease or 
other drugs and chemicals and which follows a clinically reasonable response on 
de-challenge.  The association of the clinical event or laboratory abnormality must 
also have some biologic plausi bility, at least on theoretical grounds.
Definitely RelatedThe event follows a reasonable temporal sequence from administration of the study 
drug, follows a known or suspected response pattern to the study drug, is confirmed 
by improvement upon stopping the study drug (de-challenge), and reappears upon 
repeated exposure (re-challenge).  Note that this is not to be construed as requiring 
re-exposure of the patient to study drug; however, the determ ination of definitely 
related can only be used when recurre nce of event is observed.
8.1.3 Outcome Categorization
The outcome of AEs must be recorded during the course of the study  on the CRF. Outcomes 
are as follows:
 Fatal
 Not Recovered/Not Resolved
 Recovered/Resolved
 Recovered/Resolved With Sequelae
 Recovering/Reso lving
 Unknown
8.1.4 Symptoms of the Disease u nder Study
Symptoms of the disease under study  should not be classed as AEs as long as they are within 
the normal day-to-day fluctuation or expected progression of the disease and are part of the 
efficacy  data to be collected in the study ; however, significant worsening of the symptoms 
should be recorded as an AE.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 65of 91
8.1.5 Clinical Laboratory and Other Safety Evaluations
A change in the value of a clinical laboratory  or vital sign assessment can represent an AE if 
the change is clinically  relevant or if, during treatment with the investigational product, a shift 
of a parameter is observed from a normal value to an abnormal value, or a further worsenin g 
of an already  abnormal value. When evaluating such changes, the extent of dev iation from the 
reference range, the duration until return to the reference range, either while continuing 
treatment or after the end of treatment with the investigational product, and the range of 
variation of the respective parameter within its reference range, must be taken into 
consideration.
If, at the end of the treatment phase, there are abnormal clinical laboratory or vital sign values 
which were not present at the pre-treatment value observed closest to the start of study  
treatment, further investigations should be performed until the values return to within the 
reference range or until a plausible explanation (eg,concomitant disease) is found for the 
abnormal values.
The investigator should decide, based on the above criteria and the clinical cond ition of a 
subject, whether a change in a clinical laboratory or vital sign parameter is clinicall y 
significant and therefore represents an AE.
8.1.6 Pregnancy
All pregnancies are to be reported from the time informed consent is signed until the defined 
follow -up period stated in Section 7.1.4.
Any report of pregnancy  for any female study  participant must be reported within 24 hours to 
the Shire Global Pharmacovigilance and Risk Management Department using the Shire 
Investigational and Marketed Products Pregnanc y Report Form. A copy  of the Shire 
Investigational and Marketed Products Pregnancy  Report Form (and any  applicable follow -up 
reports) must also be sent to the CRO/Shire medical monitor using the details specified in the 
emergency  contact information sectio
n of the protocol. The pregnant female study  participant 
must be withdrawn from the study .
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infant. It is the responsibility  of the investigator to obtain this information 
within 30 calendar days after the initial notification and approximately  30 calendar days 
postpartum.
Pregnancy  complications such as spontaneous abortion/miscarriage or congenital abnormalit y 
are considered SAEs and must be reported using the Shire Clinical Study  Adverse Event 
Form for SAEs and Non-serious AEs as Required by Protocol . Note: An elective abortion is 
not considered an SAE.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 66of 91
In addition to the above, if the investigator determines that the pregnancy  meets serious 
criteria, itmust be reported as an SAE using the Shire Clinical Study  Adverse Event Form for 
SAEs and Non-serious AEs as Required by Protocol as well as the Shire Investigational and 
Marketed Products Pregnancy  Report Form. The test date of the first positive serum/urine 
-HCG test or ultrasound result will determine the pregnancy  onset date.
8.1.7 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the 
sponsor according to the SAE reporting proce dure whether or not they  result in an AE/SAE as 
described in Section 8.2. Note: The 24 -hour reporting requirement for SAEs does not apply  to 
reports of abuse, misuse, overdose, or medication errors unless
 these result in an SAE. 
The categories below are n ot mutually  exclusive; the event can meet more than 1 category .
 Abuse –Persistent or sporadic intentional intake of investigational product when used 
for a non-medical purpose (eg,to alter one’s state of consciousness or get high) in a 
manner that may  bedetrimental to the individual and/or society
 Misuse –Intentional use of investigational product other than as directed or indicated at 
any dose (Note: this includes a situation where the investigational product is not used as 
directed at the dose prescri bed by  the protocol)
 Overdose –Intentional or unintentional intake of a dose of an investigational product 
exceeding a pre -specified total daily  dose of 4 mg of the product.
 Medication Error –An error made in prescribing, dispensing, administration, and/or 
use of an investigational product. For studies, medication errors are reportable to the 
sponsor only  as defined below.
Cases of subjects missing doses of the investigational product are not considered reportable as 
medication errors.
Medication errors s
hould be collected/reported for all products under investigation.
The administration and/or use of the unassigned treatment is/are alway s reportable as a 
medication error.
The administration and/or use of an expired investigational product should be considered as a 
reportable medication error.
All investigational product provided to pediatric subjects should be supervised by the 
parent/legall yauthorized representative/caregiver.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 67of 91
8.2 Serious Adverse Event Procedures
8.2.1 Reference Safety Information
The reference for safet y information for this study  is the investigator brochure ,which the 
sponsor has provided under separate cover to all investigators.
8.2.2 Reporting Procedures
All initial and follow -up SAE reports must be reported by the investigator to the Shire Global
Pharmacovigilance and Risk Management Department andthe CRO medical monitor within 
24 hours of thefirst awareness of the event. Note: The 24-hour reporting requirement for 
SAEs does not apply  to reports of abuse, misuse, overdose, or medication errors (see Section 
8.1.7) unless they  result in an SAE.
The investigator must complete, sign, and date the Shire Clinical Study  Adverse Event Form 
for SAEs and Non-serious AEs as Required by Protocol and verify  the accuracy  of the 
information recorded on the form with the corresponding 
source documents (Note: Source 
documents are not to be sent unless requested) and fax or e-mail the form to the Shire Global 
Pharmacovigilance and Risk Management Department. A copy of the Shire Clinical Study 
Adverse Event Form for SAEs and Non-serious AEs as Required by Protocol (and any 
applicable follow -up reports ) must also be sent to the CRO medical monitor using the details
specified in the emergency contact information section of the protocol .
8.2.3 Serious Adverse Event Definitio n
A Serious Adverse Event (SAE) is any untoward medical occurrence (whether considered to 
be related to investigational product or not) that at any  dose:
 Results in death
 Is life-threatening. Note: The term “life-threatening ”in the definition of “serious” refers 
to an event in which the subject was at risk of death at the time of the event; it does not 
refer to an event which hy pothetically  might have caused death if it was more severe.
 Requires inpatient hospitalization or prolongati on of existing hospita lization. Note: 
Hospitalizations, which are the result of elective or previousl y scheduled surgery  for 
pre-existing conditions, which have not worsened after initiation of treatment, should 
not be classified as SAEs. For example, an admission for a previou sly scheduled ventral 
hernia repair would not be classified as an SAE; however, complication(s) resulting 
from a hospitalization for an elective or previously  scheduled surgery that meet(s) 
serious criteria must be reported as SAE(s).
 Results in persistent or significant disability /incapacity
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 68of 91
 Is a congenital abnormality /birth defect
 Is animportant medical event. Note: Important medical events that may not result in 
death, be life-threatening, or require hospitalization may be considered an SAE when, 
based upon appropriate medical judgment, they may jeopardize the subject and may 
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency  room or at home; blood dyscrasias or convulsions 
that do not result in inpatient hospitalization; or the development of drug dependency  or 
drug abuse.  
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationshi p to study ) are collected from the time the subject signs the 
informed consent until the defined follow -up period stated in Section 7.1.4 and must be 
reported to the Shire Global Pharmacovigilance and Risk Management Department andthe 
medical monitor within 24 hours of the first awareness of the event. 
In addition, any SAE(s) considered “related” to the investigational product and discovered by 
the investigator at any interval after the study  has completed must be reported to the Shire 
Global Pharmacovigi lance and Risk Management Department within 24 hours of the first 
awareness of the event.
8.2.5 Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The 
resolution date is the date the event no longer meets serious criteria, the date the symptoms 
resolve, or the event is considered chronic. In the case of hospitalizations, the hospital 
admission and discharge dates are considered the onset and resolution dates, respectivel y.
In additio n, any signs or symptoms experienced by the subject after signing the informed 
consent form, leading up to the onset date of the SAE, or following the resolution date of the 
SAE must be recorded as an AE, if appropriate.
8.2.6 Fatal Outcome
Any SAE that results in the subject’s death (ie,the SAE was noted as the primary  cause of 
death) must have “fatal”checked as an outcome with the date of death recorded as the 
resolution date. For all other events ongoing at the time of death that did not contribute to the 
subject’s death, the outcome should be considered as not resolved, without a resolution date 
recorded.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 69of 91
For any SAE that results in the subject’s death or any ongoing events at the time of death, the 
action taken with the investigational product should be recorded as “dose not changed” or 
“not applicable” (if the subject never received investigational product).
8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting
The sponsor and the clinical CRO areresponsible for notify ing the relevant regulatory 
authorities/US central Institutional Review Boards ( IRBs)of related, unexpected SAEs.
In addition ,the sponsor and the clinical CRO areresponsible for notify ing active sites of all 
related, unexpected SAEs occurring during all interventional studies across theSHP621
program.  
The investigator is responsible for notify ing the local IRB, local ethics committee ( EC), or the 
relevant local regulatory  authority  of all SAEs that occur at his or her site as required.
9. DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information requir ed by the 
protocol on the CRF. A study  monitor will visit each site in accordance with the monitoring 
plan and review the CRF data against the source data for completeness and accuracy .  
Discrepancies between source data and data entered on the CRF will be address ed by 
qualified site personnel. When a data discrepancy warrants correction, the correction will be 
made by authorized site personnel. Data collection procedures will be discussed with the site 
at the site initiation visit and/or at the investigator’s meeting. Once a subject is randomized, it 
is expected that site personnel will complete the CRF entry  within approximately  3 business 
days of the subject’s visit.
9.2 Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management 
plan. Quality  control and data validation procedures are applied to ensure the validity  and 
accuracy  of the clinical d atabase.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using compu terized and manual procedures. Data queries requiring clarification 
are to be communicated to the site for resolution. Only  authorized personnel will make 
corrections to the clinical database, and all corrections are documented in an auditable 
manner.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 70of 91
9.3 Data Handling Considerations
Data that may potentially  unblind the treatment assignment ( ie,investigational product serum 
concentrations, treatment allocation, and investigational product preparation/accountability  
data) will be handled with special care during the data cleaning and review process. These 
data will be handled in such a way that, prior to unblinding, any data that may unblind study 
team personnel will be presented as blinded information or otherw ise will not be made 
available. If applicable, unblinded data may be made available to quality  assurance 
representatives for the purposes of conducting independent drug audits. 
9.4 Statis tical Analysis Process
The study  will be analy zed by the sponsor or its agent. All statistical analyses will be 
performed using SAS®(SAS I nstitute, Cary , NC, USA) version 9.1 or higher.
The statistical analysis plan (SAP)will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other study information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications. The 
SAP will also include a description of how missing, unused and spurious data will be 
addressed.
In addition to a final SAP for the final analysis, a separate interim SAP for the interim 
analysis will be finalized prior to unblinding and performing the analysis to preserve the 
integrit y of the statistical analysis and study  conclusions . The SAP for the final analysis will 
be finalized prior to final database lock and performing analysis (ie, unblinding )to preserve 
the integrit y of the statistical a nalysis and study  conclusions. 
9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee
A planned interim analysis for each of the co-primary  endpoints will take place after 50% of 
all randomized s ubjects have either completed the study  or prematurely  withdraw nfrom the 
study , whichever comes first. The purpose of the unblinded interim analy sis is to reassess the 
appropriateness of assumptions used for each of co-primary  efficacy  endpoints when the 
study  was designed. The reassessment of the sample size will utilize the conditional power 
approach under certain conditions that do not inflate the type I error (Mehta and Pocock ,
2011). The planned interim analy sis will be conducted by an external independent statistical 
(EIS) group; the individuals involved in the day-to-day conduct of the trial will not be 
involved in the interim analysis or have access to the results of the interim analysis. The 
Sponsor will only be notified by the EIS group if any recommendation of increasing the 
sample size is needed from the conditional power ; this will be detailed in the pre-specified 
interim SAP including a potential maximum sample size to be increased if deemed necessary .
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 71of 91
A very minimal fraction of alpha (0.0001) will be spent at the interim analy sis as the trial will 
not stop due to the interim results. The final analysis will use 4.99% for each of the 
co-primary  endpoints in order to preserve an overall ty pe I error at 5% level.
9.6 Sample Size Calculation and Power Considerations
Based on at least a 30-percentage -point reduction in DSQ score, there is an expected 
difference between treatment response proportions of 69% and 45% in the OBS 2mg twice 
daily  (qAM, pc, 
and hs) and placebo groups, respectivel y. A total of 228 subjects 
(152subjects randomized to OBS and 76subjects randomized to placebo) arerequired to 
achieve 90% power at the significance level of 0.0499 
(2-sided) using a 2-group chi-square 
test with unequal allocation 2:1 to treatment groups (OBS 2 mg twice daily  and placebo). 
With the specified number of subjects per treatment group, the study  will be powered at 99% 
assuming histological response proportions of 40% and 3% in the OBS 2 mg twice dailyand 
placebo groups, respectively . The overall study  power for the co-primary  endpoints will be at 
least 85%. Therefore, approximately  228 ( approximately  152:76OBS and placebo subjects, 
respectivel y) will be randomized to the study  to allow for a loss of approximatel y 5% 
of 
subjects due to dropouts or invalid data . 
9.7 Study Population
The safety setwill include all subjects who receive at least 1 dose of any double -blind 
investigational product. 
The intent -to-treat (ITT) set will include all randomized subjects. Subje cts will be analy zed 
according to their assigned treatment, regardless of the treatment actuall y received.
The full analysis set (FAS) will include all randomized subjects who received at least 1 dose 
of a double -blind investigational product and have both an evaluable post-baseline biops y in 
the treatment period ( ie, peak eosinophil count is reported for at least 2 esophageal levels) and 
a post -baseline DSQ score.
The per-protocol (PP) set will include all subjects in the FAS excluding subjects with 
protoc ol violations. The PP set will be identified prior to unblinding the treatment 
assignments b y a team consisting of, at a minimum, a physician and a statistician from Shire. 
The pharmacokinetic setwill include all subjects in the safet y set for whom the primary 
pharmacokinetic data are considered sufficient and interpretable.
9.8 Efficacy Analyses
The primary , key secondary ,and secondary  efficacy  analyses will be performed on the ITT
set 
and presented b y treatment group.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 72of 91
Data collected at the baseline visit (Visit 1) will be used as the baseline for all efficacy  
analyses.
9.8.1 Primary Efficacy Endpoints
The co-primary  efficacy  endpoint s are the following:
Histologic response, defined as a peak eosinophil count of ≤6/HPF across all available 
esophageal levels at the final treatment period evaluation (Visit 4)
Dysphagia symptom response, defined as ≥30% reduction in the DSQ combined score 
(questions 2+3) 
from baseline to the final treatment period evaluation ( Visit 4)
The co-primary  efficacy  endpoints will be analy zed based on the ITT set. Each of the 
co-primary  efficacy  endpoints is a binary  response (ie,responders vs non-responders); the 
endpoint will be analyzed using a logistic regression model with effects of treatment group, 
age group (either <18 years or ≥18years) , and their interaction. The main -effect model will be 
considered the final definitive model if the interaction between treatment and age group is not 
statistically  significant at the 10% level. The odds ratio of being a responder on each of the 
co-primary  endpoints for the OBS 2mg twice daily  group vs placebo group and associated 
95% confidence interval (CI)will be estimated from the 
final model. Subjects who withdraw 
without providing efficacy  data at the final treatment period evaluation (Visit 4,Week 16) 
will be classified as non -responders in the primary  efficacy  anal ysis.
Additionally , the proportion of responders based on each of the co -primary  endpoints for each 
treatment group will be summarized ,and their respective 95% CI will be reported. The 
difference in the proportion of responders between the 2 treatment groups and the 
corresponding 95% CI will also be summarized.
The following sensitivity  and supportive analyses will be performed for the co-primary  to 
evaluate the robustness of the re sults from the primary  anal ysis methods: 
Analy ses will be repeated using the FAS and the PP set.
Analy ses will be repeated by considering subjects who withdraw without providing 
efficacy  data at the final treatment period evaluation (Visit 4) and will be classified as 
responders.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 73of 91
9.8.1.1 Missing Data Imputation
Method 1: Distribution -based Imputation
The subjects with missing co -primary  efficacy  endpoints will be assigned randomly  according 
to the distribution of responders with available data for each of the co-primary  endpoints (ie, 
those with non
-missing data) across the 2 treatment groups by  strata (see Table 9 - 1). 
Table 9-1: Percentage of Responders for All Available Data (ie, Non-missing Data) by 
Strata
Strata No Yes
<18 years X0% X1%
≥18 years Y0% Y1%
For instance, if there are N subjects with missing data in strata 1 (age <18 years), then 
X0%*N subjects will be randomly  assigned as non-responders and X1%*N subjects will be 
randomly  assigned as responders .
Conversel y, if there are M subjects with missing data in strata 2 (age ≥18 years), the Y0%*M 
subjects will be randomly  assigned as non-responders and Y1%*N subjects will be randomly 
assigned as responders.
Method 2: Multiple Imputations
Multiple imputati on (MI) methods will utilize the SAS procedures PROC MI and PROC 
MIANALYZE. The MI procedure will involve fitting a logistic regression model with the 
binary  outcome (responders vs non-responders) as the dependent variable and the age group 
and the treatme nt group as the independent variables. The MI procedure will generate 
10version datasets 
with binary  outcome imputed from the subjects with complete data. Once 
the missing values are imputed and each dataset is created, the results will be appropriatel y 
pooled across the multiply  imputed estimated regression coefficients and their standard errors 
using PROC MI ANALYZE.
Other sensitivity  analy ses will be explored ,
and details will be provided in the SAP.
9.8.2 Secondary Efficacy Endpoints
9.8.2.1 Key Secondary Efficacy En dpoint
The key secondary  efficacy  endpoint is defined as the change in DSQ combined score 
(questions 2+3) from baseline to the final treatment period evaluation (Visit 4). The change 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 74of 91
from baseline DSQ score at the final treatment period evaluation (Visit 4) will be analyzed 
using an analysis of covariance (ANCOVA) model with treatment group and age group as 
factors and the baseline DSQ score as a continuous covariate.
The additional secondary efficacy  endpoints are the following:
Change in total endoscopy  score, as measured by the EREFS classification, from baseline 
to the final treatment period evaluation (Visit 4)
Peak eosinophil count <15/HPF across all available esophagus levels at the final treatment 
period evaluation (Visit 4)
Peak eosinophil count ≤1/HPF across 
all available esophagus levels at the final treatment 
period evaluation (Visit 4)
Change from baseline in the peak eosinophil count to the final treatment period evaluation 
(Visit 4) for each available esophageal level ( proximal, mid -, and distal)
Change from baseline in the histopathologic epithelial features combined total score 
(grade and stage) to the final treatment period evaluation (Visit 4)
Dysphagia sy mptom response (binary  response), defined as a  ≥50% reduction in the DSQ 
combined score (questions 2+3), from baseline to the final treatment period evaluation 
(Visit 4)
Change from baseline in the DSQ combined score (questions 2+3) over time including 
post baseline visits
Cumulative distribution function curves for the change and the percent change in the DSQ 
score from baseline to the final treatment period evaluation (Visit 4)
Overall binary  response I, defined as a reduction in the DSQ score of ≥30% from baseline 
to the final treatment period evaluation (Visit 4) and a peak eosinophil count of ≤6/HPF 
across all esophageal levels at the final treatment period evaluation (Visit 4 )
Overall binary  response II, defined as a reduction in the DSQ score of ≥50% from 
baseline to the final treatment period evaluation (Visit 4) and a peak eosinophil count of 
≤6/HPF across all esophageal levels at the final treatment period evaluation (Visi t 4)
Symptom response on DSQ + pain score (binary  response), defined as ≥30% and 50% 
reductions in the DSQ combined score (questions 2+3+4) from baseline to the final 
treatment period evaluation (Visit 4)
Symptom response on DSQ + pain score (binary  respon se), defined as a ≥30% and 50% 
reduction in the DSQ score (question 4), from baseline to the final treatment period 
evaluation (Visit 4)
The binary  response endpoints will be analyzed using the same logistic model as the 
co-primary  efficacy  endpoints.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 75of 91
Cont inuous endpoints will be analyzed as a change from baseline using an ANCOVA model 
that includes treatment group and age group as factor sand baseline score as a covariate.
The analyses for all secondary  efficacy  endpoints (including the key secondary  efficacy 
endpoint) will be carried out using 2-sided tests at the 5% level of significance. For each of 
the secondary  efficacy  endpoints, the treatment difference , 
corresponding 95% CIfor the 
difference, and treatment comparison p-value for testing the null hypothesis of zero treatment 
effect based on the final statistical model (ie, either logistic regression model or ANCOVA 
model) will be provided.
9.8.3 Exploratory Efficacy Endpoint
The exploratory  endpoint that will be explored isthe following:
9.9 Safety Analyses
Safety  data will be presented for the safet y set by treatment group.
The safety  data collected at the baseline visit (Visit 1) or the last preceding visit if not 
collected at V isit 1will be used as the baseline value for safet y analyses.
TEAEs are defined as AEs that start or deteriorate on or after the first dose of investigational 
product (Visit
1)and no later than 3 days following the last dose of investigational product.
However, for any subjects who die during the study  (ie, the date of death is between the date 
of first dose of investigational product and the date of study  discontinuation entered by the 
site, inclusive), all AEs (including those resulting in death) that o ccur during the study  will be 
considered as TEAEs irrespective of the last dose and will be included in the TEAE 
summaries.
AEs will be coded using MedDRA . The number of events, incidence, and percentage of 
TEAEs will be calculated overall by system organ class (SOC ), preferre d term (PT), and 
treatment group. TEAEs will be further summarized by severit y and relationsh ip to 
investigational product. AEs related to investigational product, AEs leading to withdrawal, 
SAEs, and deaths will be similarly  summarized/listed.
Safety  parameters will include monitoring of AEs, physical examinations, stadiometry , vital 
signs (temperature, systolic and diastolic blood pressure, pulse, and respiratory  rate), weight 
and height assessments, DXA scans for BMD measurements (for adolescents aged 
11-17 years, inclusive), clinical laboratory  tests (hematology , chemistry , urinaly sis; serum 
pregnancy  test, if appropriat e), and ACTH stimulation tests. To account for the effects of 
puberty in adolescent subjects (11-17 yearsof age, inclusive ), BMD z-scores will be adjusted 
for height z-scores using the Bone Mineral Density  in Childhood Study calculator .Safet y 

Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 76of 91
parameters will be descriptively  summarized by  treatment group at baseline and for each post-
baseline visit.
9.10 Other Analyses
9.10.1 H ealth -related Quality -of-life Analyses
The health economic s and outcomes research endpoints that will be explored are the 
following:
EoE-QoL-A Questionnaire ( Taft et al. , 2011)
EQ-5D (EQ -
5D-3L or EQ -5D-Y, accordin g to subject’s age)
PedsQL -EoE
The sub-modules of the EoE-QoL-A and PedsQL -EoE will be assessed in addition to the 
overall score with a focus on emotional and physical elements. For all HRQoL  analyses, 
change from baseline to the final treatment period e valuation (Visit 4) will be assessed.
9.10.2 Pharmacokinetic Analyses
Pharmacokinetic parameters will be determined from the plasma concentration -time data for 
budesonide b y non -compartmental anal ysis.  
The pharmacokinetic endpoints will include but not be limit ed to those listed in Table 9-2.
Table 9-2: Pharmacokinetic Parameters
Param eter Defin ition
AUC 0-tau Area under the curve for the defined interval betw een doses
Cmax Maximum concentration occurring at t max
tmax Time of maximum observed concentration sampled during a dosing interval
Summary  statistics (number of observations, mean, standard deviation, coefficient of 
variation, median, maximum, minimum, and geometric mean) will be determined for all 
pharmac okinetic parameters by overall and by week. Plasma concentrations at each nominal 
sampling time will also be summarized using descriptive statistics.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 77of 91
10. SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicabl e regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements.  
The name and address of each third- party vendor (eg,CRO) used in this study  will be 
maintained in the investigator’s and sponsor’s files, as appropria te.
10.1 Sponsor’s Responsibilities
10.1.1 Good Clinical Practice Compliance
The study  sponsor and any third party to whom aspects of the study  management or 
monitoring have been delegated will undertake their assigned roles for this study  in 
compliance with all appli cable industry  regulations, ICH GCP Guideline E6 (1996), EU 
Directive 2001/20/EC, as well as all applicable national and local laws and regulations.
Visits to sites are conducted by representatives of the study  sponsor and/or the company 
organizing/managin g the research 
on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and CRFs in accordance with current GCP and the respective local and 
(inter)national governme nt regulations and guidelines. Records and data may additionally  be 
revie wed b y auditors or by  regulatory  authorities.
The sponsor ensures that local regulatory  authority  requirements are met before the start of 
the study . The sponsor (or a nominated designee) is responsible for the preparation, 
submission, and confirmation of receipt of any regulatory  authorit y approvals required prior 
to release of investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmac eutical Industry Guidelines. If appropriate, a copy  of the indemnity  document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in place p rior to the start 
of the study .An insurance certificate is supplied to the CRO as necessary .
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites.
Information included in clinical study  registries may include participating investigators’ 
names and contact information.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 78of 91
10.1.4 Submission of Summary of Clinical Study Report to Competent Authorities of 
Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study report to the competent authority  of 
the member state(s) concerned as required by regulatory  requirement(s) and to comply  with 
the community  guideline on GCP. This requirement will be fulfilled within 6 months of the 
end of the study  completion date for pediatric studies and within 1 year for non-pediatric 
studies as per guidance.
10.1.5
Study Suspension, Termination, and Completion
The sponsor may suspend or terminate the study , or part of the study, at any time for any 
reason. If the study  is suspended or terminated, the sponsor will ensure that applicable sites, 
regulatory  agencies and IRBs/EC s are notified as appropriate. Additionally , the 
discontinuation of a registered clinical study ,which has been posted to a designated public 
website , will be updated ac cordingl y.
10.2 Investigator’s Responsibilities
10.2.1 Good Clinical Practice Compliance
The investigator must undertake to perform the study  in accordance with ICH GCP Guideline 
E6 (1996), EU Directive 2001/20/EC, and applicable regulatory  requirements and guidelines .
It is the investigator’s responsibility  to ensure that adequate time and appropriatel y trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potenti al for recruiting the 
required number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriatel y qualified persons to whom the 
investigator has delegated significant study -related tasks, and shall, upon request of the 
sponsor, provide documented evidence of any licenses and certifications necessary  to 
demonstrate such qualification. Curriculum vitae for investigators and sub- investigators are 
provided to the study  sponsor (or designee) before starting t he stud y.
If a potential research subject has a primary  care physician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordinating principal investigator is appointed to review the final clinical study  report for 
multicenter studies. Agreement with the final clinical study  report is documented by the 
signed and dated signature of the principal investigator (single -site study ) or coordinating 
principal investigator (multicenter study ), in compliance with Directive 2001/83/EC as 
amended b y Directive 2003/63/EC and I CH Guidance E3 ( 1995 ). 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 79of 91
10.2.2 Protocol Adherence and Investigator Agreement
The investigator and any co-investigators must adhere to the protoc ol as detailed in this 
document. The investiga tor is responsible for enrolling only those subjects who have met 
protocol eligibility  criteria. Investigators arerequired to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspe nds or terminates the study  at their site, the investigator will promptly 
inform the sponsor and the IRB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational product, containers, and other study  materials 
to the sponsor. Upon study  completion, the investigator will provide the sponsor, IRB/EC, 
and regulatory  agenc y with final reports and summaries as required by (inter)national 
regulations.
Communication with local I RBs/ECs, to ensure accurate and ti mely information is provided at 
all phases during the study , may be done by the sponsor, applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator according to national provisions 
and will be documented in the invest igator agreement.
10.2.3 Documentation and Retention of Records
10.2.3.1 Case Report Forms
Electronic CRFs are supplied by the CRO and should be handled in accordance with 
instructions from the sponsor.
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded onto CRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or designee as state d in the site delegation log.
All data will have separate source documentation; no data will be recorded directl y onto the 
CRF.
All data sent to the sponsor must be endorsed b y the investigator.
The clinical research associate ( CRA )/study  monitor will verify the contents against the 
source data per the monitoring plan. If the data are unclear or contradictory , queries are sent 
for corrections or verification of data.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 80of 91
10.2.3.2 Recording, Access, and Retention of Source Data and Study Documents
Original source data tobe reviewed during this study  will include but are not limited to
subject’s medical file,original clinical laboratory  reports, and histology  and pathology 
reports.
All key  data must be recorded in the subject’s medical records.
The investigator must perm it authorized representatives of the sponsor ; the respective 
national, local, or foreign regulatory  authorities ; the IRB/EC ; and auditors to inspect facilities 
and have direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC ,or regulatory  inspectors) may check the CRF 
entrie s against the source documents. The consent form includes a statement by which the 
subject agrees to the monitor/auditor from the sponsor or its representatives, national or local 
regulatory  authorities, or the IRB/EC, having access to source data ( eg,subject’s medical file, 
appointment books, original laboratory
 reports, X -rays,etc.).
These records must be made available within reasonable times for inspection and duplication, 
if required, by a  properly  authorized representative of any regulatory  agency  (eg,the US 
FDA, EMA, UK Medicines and Healthcare products Regulatory  Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requireme nts and may  not be 
destroy ed without written permission from the sponsor.
10.2.3.3 Audit/Inspection
To ensure compliance with relevant regulations, data generated by this study  must be 
available for inspection upon request by  representatives of, for example, the US FDA (as well 
as other US national and local regulatory  authorities), the EMA, the Medicines and Healthcare 
products Regulatory  Agency , other regulatory  authorities, the sponsor or its representatives, 
and the IRB/EC for each site.
10.2.3.4 Financial Disclosure
The investigator is required to disclose any financial arrangement during the study  and for 
1year after, whereb y the outcome of the study could be influenced by the value of the 
compensation for conducting the study , or other payments the investiga tor receiv ed from the 
sponsor. The following information is collected: any  significant pay ments from the sponsor or 
subsidiaries such as a grant to fund ongoing research, compensation in the form of equipment,
retainer for ongoing consultation ,or honoraria; any proprietary  interest in investigational 
product; any significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 
2(b) ( 1998).
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 81of 91
10.3 Ethical Considerations
10.3.1 Informed Consent
It is the responsibility  of the investigator to obtain written informe d consent (or assent as 
applicable for subjects <18yearsof age) from all study  subjects prior to any study -related 
procedures includ ing screening assessments. All consent documentation must be in 
accordance with applicable regulations and GCP. Each subje ct or the subject’s legally
authorized representative, as applicable, is requested to sign and date the subject ’sinformed 
consent form or a certified translation ,if applicable, after the subject has received and read (or 
been read) the written subject information and received an explanation of what the study 
involves, including but not limited to the objectives, potential benefits and risk, 
inconveniences, and the subject’ s rights and responsibilities. A copy  of the informed consent 
documentation (ie,a complete set of subject information sheets and fully  executed signature 
pages) must be given to the subject or the subject’s legall y authorized representative, as 
applicable. This document may require transl ation into the local language. Signed consent 
form s must remain in each subject’s study  file and must be available for verification at any 
time.
Within the source documents, site personnel should document instruction of and 
understanding by the parent/legally authorized representative/caregiver of the safe, 
responsible storage and administration of investigational product to the study  subject.
The principal investigator provides the sponsor with a copy  of the consent form consent (or 
assent as applicable for subjects <18yearsof age)that was reviewed by the IRB/EC and 
received their favorable opinion/approval. A copy  of the IRB’s/EC’s written favorable 
opinion/approval of these documents must be provided to the sponsor, prior to the start of the 
study  unless it is agreed to and documented (abiding by regulatory  guidelines and national 
provisions) prior to study  start that another party  (ie,sponsor or coordinating principal 
investigator) is responsible for this action. Additionally , if the IRB/EC requires modification 
of the sample subject information and consent document provided by the sponsor, the 
documentation supporting this requirement must be provided to the sponsor.
10.3.2 Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved by the sponsor or their designee), relevant supporting 
information ,and all types of subject recruitment information to the IRB/EC for review, and 
all must be approved prior to site initiation .
For sites with in the EU, the applicant for an EC opinion can be the sponsor or the investigator 
or,for multicenter studies ,the coordinating principal investigator or sponsor, according to 
national provisions.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 82of 91
Responsibility  for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any 
revisions of all informed consent (or assent as applicable for subjects <18yearsof age) 
documents and amendments to the protocol unless there is a subject safet y issue.
Investigational product supplies will not be released until the CRO has received written 
IRB/EC approval of and copies of revised documents.
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of 
the progress of the study  and of any changes made to the protocol, but in any case at least 
once a year; for sites within the EU, this can be done by  the sponsor or the investigator or ,for 
multicenter studies ,the coordinating principal investig ator, according to national provisions. 
The investigator must also keep the local IRB/EC 
informed of any serious and significant 
AEs.
10.4 Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study , must, where 
applicable, compl y with HIPAA of 1996. A site that is not a covered entity  as defined by 
HIPAA must provide documentation of this fact to the CRO/sponsor .
The confidentialit y of records that may be able to identify  subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives 
reviews their medical records and data collected during the study .These records and data 
may, in addition, be reviewed by others including the following: independent auditors who 
validate the data on behalf of the sponsor; third parties with whom the sponsor may develop, 
register, or market SHP621 ; national or local regulatory  authorities; and the IRBs/ECs which
gave approval for the study  to proceed. The sponsor and/or its representatives accessing the 
records and data will take all reasonable precautions in accordance with applicable laws, 
regulations, and guidelines to maintain the confidentiality  of subjects’ identities.
Subjects are assigned a unique identify ing number; 
however, their initials and date of birth 
may also be collected and used to assist the sponsor to verify  the accuracy  of the data (eg,to 
confirm that laboratory  results have been assigned to the correct subject).
The results of studies –containing subjects’ unique identify ing number, relevant medical 
records, and possibly  initials and dat es of birth –will be recorded. They  may  be transferred to 
and used in other countries which may not afford the same level of protection that applies 
within the countries where this study  is conducted. The purpose sof any such transfer would 
include support ingregulatory  submissions, conduct ingnew data analyses to publish or 
present the stud y results, or answ eringquestions asked by  regulatory  or health authorities.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 83of 91
10.5 Study Results/Publication Policy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timel y manner regardless of whet her the outcomes are 
perceived as positive, neutral, or negative. Additionally , Shire adheres to external guidelines 
(eg,Good Publication Practices 2) when forming a publication steering committee, which is 
done for large, multicenter Phase 2-4 and certai n other studies as determined by Shire. The 
purpose of the publication steering committee is to act as a non -commercial body  that advises 
or decides on dissemination of scientific study  data in accordance with the scope of this 
policy .
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information.
The review is aimed at protecting the sponsor’s proprietary  information existing eithe r at the 
commencement of the study or generated during the study .To the extent permitted by the 
publisher and copyright law, the principal investigator will own (or share with other authors) 
the copyright on his/her publications. To the extent that the principal investigator has such 
sole, joint or shared rights, the principal investigator grants the sponsor a perpetual, 
irrevocable, ro yalty
-free license to make and distribute copies of such publications.
The term “publication” refers to any public disclos ure including original research articles, 
review articles, oral presentations, abstracts and posters at medical congresses, journal 
supplements, letters to the editor, invited lectures, opinion pieces, book chapters, electronic 
postings on medical/scientif ic websites, or other disclosure of the study results, in printed, 
electronic, oral ,or other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any background information provided by the sponsor that is necessary  to 
include in any  publication of study  results, or necessary  for other scholars to verify  such study 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be subm itted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 days to 
allow for filing of a patent application.
If the study  is part of a multicenter study , the first publication of the study  results shall be 
made by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter 
publication of the compiled and anal yzed study results. If such a multicenter publication is not 
submitted to a journal for publication by the sponsor within an 18-month period after 
conclusion, abando nment, or termination of the study  at all sites, or after the sponsor confirms 
there shall be no multicenter study  publication of the study  results, an investigator may 
individually  publish the study  results from the specific site inaccordance with this section. 
The investigator must, however, acknowledge in the publication the limitations of the 
single -site data being presented.
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 84of 91
Unless otherwise required by the journal in which the publication appears, or the forum in 
which it is made, authorship will com ply with the International Committee of Medical Journal 
Editors current standards. Participation as an investigator does not confer any rights to 
authorship of publications.
11. REFERENCES 
Bachrach LK, Sills IN, Section on Endocrinology . Clinical report—Bone densitometry  in 
children and adolescents. Pediatrics 2011;127:189
-194.
Bone Mineral Density  i n Childhood Study  ( BMDCS). Available at:
http://www.bmdcspublic.com. Accessed August 5, 2015. 
Dellon ES, Jensen ET, Martin CF, et al. Prevalence of eosinophilic esophagitis in the United 
States. Clin Gastroenterol Hepatol 2014a;12(4):589 -96.
Dellon ES, Kim HP, Sperry  SL, et al. A phenoty pic analysis shows that eosinophilic 
esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc 2014b;79(4):577-85.
EuroQol Group. EuroQol--a new facility  for the measurement of health -related qualit y of life. 
Health Policy  1990;16(3):199 -208.
Food and Drug Administration. Uceris pharmacology  review. NDA 203- 634. 2011.
Franciosi JP, Hommel KA, Bendo CB. PedsQL  eosinophil ic esophagitis module: feasibility , 
reliability , and validity . J Pediatr Gastroenterol Nutr 2013;57(1):57 -66.
Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: 
a systematic review and consensus recommendations for diagnosis and treatment. 
Gastroenterology  2007;133(4):1342-63.
Gordon CM, Bachrach LK, Carpenter TO, et al. Duel energy  X-ray absorptiometry 
interpretation and reporting in children and adolescents: The 2007 ISCD pediatric official 
positions. J Clin Densi tometry  2008;11:43 -58.
Hirano I, Aceves S. Clinical Implications and Pathogenesis of Esophageal Remodeling in 
Eosinophilic Esophagitis. Gastro Clin North Am 2014;43(2):297 -316.
International Societ y for Clinical Densitometry . 2013 Official Positions—Adult & Pediatric. 
2014:1 -20.
Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus 
recommendations for children and adults. J Allergy  Clin I mmunol 2011;128 (1):3-20. 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 85of 91
Mehta CR, Pocock SJ. Adaptive increase in sample size when int erim results are promising: a 
practical guide with examples. Stat Med 2011;30(28):3267-84.
Patient- Reported Outcome and Quality  of Life Instruments Database (PROQOLID). 
Available at: http://www.proqolid.org . Accessed August 24, 2015. 
Taft TH, Kern E, Kwia tek MA. The adult eosinophilic oesophagitis quality  of life 
questionnaire: a new measure of health -related quality  of life. Aliment Pharmacol Ther 
2011t;34(7):790-8.
Wille N, Badia X, Bonsel G, et al. Development of the EQ-
5D-Y: a child- friendl y version of
the EQ -5D. Qual L ife Res 2010;19(6):875-86. 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 86of 91
12. APPENDICES
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 87of 91
Appendix 1 Scales and Assessments
The following scales/assessments will be utilized in this study :
Full Title of Scale/Assessment Completed By
DSQ Subject
EQ-5D Subject
PedsQL -EoE (subjects 11 -17 years of a ge, inclusive ) Subject and parent or legal 
guardian
EoE-QoL- A (subjects ≥18 years of age) Subject
PGI-S Subject
Tanner Staging Assessment Site
EREFS Site
Abbreviations: DSQ=Dysphagia Symptom Questionnaire; EoE -QoL- A=Adult Eosinophilic Esophagitis Quality 
of Life; EQ -5D=EuroQol; EREFS=EoE Endoscopic Refe rence Score; PedsQL- EoE=Pediatric Quality of Life 
Inventory –EoE; PGI -S=Patient Global Impression of Severity
A separate master file containing each scale/assessment listed above will be provided to the 
site. Updates to scales/assessments during the study (if applicable) will be documented in the 
table above ,and a new master file containing the revised scale/assessment will be provided to 
the site. 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 88of 91
Appendix 2 Dysphagia Symptom Questionnaire ePRO for EoE

Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 89of 91
Appendix 3 Patient Global Impression of Severity
How would you rate the overall severity  of your dysphagia (difficult y swallowing) over the 
past 7 days?
Rating Description
0 No dysphagia
1 Mild dysphagia
2 Moderate dysphagia
3 Severe dysphagia
4 Very  severe dysphagia
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 90of 91
Appendix 4 Biosciences Generic Clinical Protocol Insert
Blood Sample Collection
Blood samples will be collected at the times specified inTable 1-1to measure plasma 
concentrations of budesonide . Potential metabolites may  also be determined as appropriate.
Blood samples 4 mLfor pharmacokinetic analysis will be drawn by in-dwelling catheters or 
direct venipuncture into K2EDTA tubes, capped and mixed by inversion (x3),and chilled 
immediately  on 
crushed ice. The actual time that the sample was obtained will be recorded in 
the subject’s source document and on the appropriate CRF page. After apply ing a tourniquet, 
venous blood will be drawn with a disposable needle. If a catheter is used, the first milliliter 
of blood on each sampling occasion will be discarded. Saline can be used to keep catheters 
patent.
1.1 Blood/Plasma Sample Handling
Samples should be kept on crushed ice until plasma is separated as soon as possible after 
collection within <15minutes, unless advised otherwise by refrigerated centrifugation (4C, 
1500 rpm 15 minutes). The separated plasma will be decan
ted into appropriatel y labeled 
polypropylene tubes via a plastic pipette. All samples will be stored at approximately  -20C 
or colder and the freezer temperature will be controlled, monitored, and recorded during the 
storage period until they are transferr ed in the frozen state to a designated bioanal ytical 
contract laboratory . Samples will remain frozen at -
20C or colder until analy sis.
Plasma sample tubes for bioanaly sis 
must be freezer -safe and identified with freezer -safe 
labels provided b y the central laboratory . The labels will contain the following information:
 Study  number
 Subject identifier (randomization number)
 Matrix identifier (plasma)
 Visit
 Nominal time
1.2 Shipment of Plasma Samples
Plasma samples should be double -bagged to contain leaks and packed with a sufficient 
quantity  of dry  ice to ensure that they  remain frozen for at least 72 hours to allow for delay s in 
shipment. All applicable shipping regulations must be followed. Shipments should be 
scheduled so that no samples arrive on the weekend and should be shipped Monday  to
Wednesday  only . 
Shire CONFIDENT IAL 31 Aug 2015
Protocol SHP621 -301 Version 1.0 Page 91of 91
Plasma samples, along with the corresponding documentation, will be shipped to:
PPD
2 Tesseneer Drive
Highland Heights, KY 41076, USA
Email: 
Phone:   or , 
Fax:  
Plasma samples will be stored nominally  at -20C prior to and after analysis at Covance until 
their disposal is authorized by  Shire.
1.3 Assay Methodology
Drug analysis will be performed at Covance under the guidance of the NCE group atShire. 
Plasma sample analy sis will be performed according to the bioanaly tical study  plans prepared 
for the stud y. 
Plasma samples will be analyzed at Covance for budesonide using the most current validated 
bioanaly tical method. 
In additio n, 
selected plasma samples may be used to investigate incurred sample 
reproducibility  (full details will be described in the bioanal ytical study  plan). The presence of 
other metabolites or artifacts may  be monitored or quantified as appropriate.
Raw data w ill be stored in the archives at Covance .

PROTOCOL:  SHP 621-301
TITLE: Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects 
(11 to 55 Y ears of Age, Inclusive ) with Eosinophilic Esophagitis: 
A Phase 3 Randomized, Double- blind, Placebo -controlled Study
DRUG: SHP621, oral budesonide s uspension (OBS)
IND: 103,173
EUDRACT NO.: Non-EUDRACT
SPONSOR: Shire ViroPharma, Incorporated (Shire) 
300 Shire Way , Lexington, MA 02421 USA
PROTOCOL 
HISTORY:Original Protocol:  31Aug 2015
Protocol Amendment 1: 17 Dec 2015
This document contains confidential and proprietary information of Shire and is disclosed pursuant to 
confidentiality and non-disclosure obligations.  This inform ation should be used solely for the purposes for 
which it was provided and should not be copied, shared with, or disclosed to any third party without the express 
written consent of Shire.

Shire 
Protocol SHP621-301 CONFIDENTIAL 
Amendment 1 17 December 2015 
Page 2 of98 
PROTOCOL SIGNATURE PAGE 
Sponsor's (Shire) Approval 
 MD 
 
  Clinical Development Date: 
Acknowledgement 
I have read this protocol for Shire Study SHP621-301. 
Title: Oral budesonide suspension (OBS) in Adolescent and Adult Subjects (11 to 55 years 
of age, inclusive) with Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, 
Placebo-Controlled Study 
I have fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsor 's representative. 
I understand that the information in this protocol is confidential and should not be disclosed, 
other than to those directly involved in the execution or the scientific/ethical review of the 
' study , without written authorization from the sponsor. It is, however , permissible to provide 
the information contained herein to a subject in order to obtain their consent to pmticipate. 
I agree to conduct this study according to this protocol and to comply with its requirements , 
subject to ethical and safety considerations and guidelines, and to conduct the study in 
accordance with International Conference on Harmonisation guidelines on Good Clinical 
Practice and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my pmticipation as an investigator for this study. 
I understand that the sponsor may decide to suspend or prematurely te1minate the study at any 
time for whatever reason ; such a decision will be communicated to me in writing. 
Conversely , should I decide to withdraw from execution of the study I will communicate my 
intention immediately in writing to the sponsor. 
Investigator Name 
(please hand print or type) 
= 
Signature: ---------------------------------Date: 

Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 3of 98
SUMMAR Y OF CHANGES F ROM PREVIOUS VERSION
The SHP62 1-301 protocol is amended to include the addition of safety - related stopping 
criter ia and a diet stratification factor . Additional edits, as captured in the below table, were 
made to Protocol Amendment 1 to improve the clarity  of the protocol and/or correct minor 
inconsistencies. Note that correction of typos and grammatical errors are not captured in the 
below table.
New text indicated in bold; deleted text indicated in strikethrough.
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
16 Dec 2015Global Amendment
Descript ion of Change Section(s) Affected by Change
Changed from:
, MD, PhD
, Clinical Development
To:
, MD
, Clinical DevelopmentProtocol Signature page; Sponsor 
Medical Monitor
Changed from:
 
To:Emergency Contact Information 
Page
“Each bottle contains approxim ately 210mL of suspension…” Study Synopsis, Investigational 
product, dose, and mode of 
admin istration; Section 3.1, Study 
Design; Section 6.1, Identity of 
Investigational Product
…the investigational product will be supplied in amber glass, multi -
dose bottles w ith child -resistant caps and refrigerated through outthe 
study (in the clinic and subj ect’s hom e).Study Synopsis, Investigational 
product, dose, and mode of 
administration; Section 3.1, Study 
Design; Section 6.1.1, Blinding the 
Treatment Assignment
A minimum of 40 randomized subjects will be aged 11-17 years, 
inclusive.
The randomization will be perform ed centrally and stratified by 
age group (2 strata total: <18 years or ≥18 years) and diet 
restriction for EoE or other health -related conditions (no diet 
restriction or any diet restriction). The stratification by age will Study Synopsis, Methodology; 
Section

Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 4of 98
ensure a minimum of 40 subjects in the pediatric group (11 -17 
years, inclusive). The stratification by age and diet restriction will 
ensure balance between treatm ent groups for the respective 
stratification factors.
Subjects cannot be rescreened once it is confirmed they do not m eet 
inclusion/exclusion criteria unless the screen failure was due to a 
concom itant medication that can be discontinued prior to 
rescreening; those subjects may be rescreened. they have been 
designated as a screen failure unless due solely to the use of a 
concomitant medication which can be stopped prior to rescreening
Other reasons for rescreening (ie, reasons unrelated to 
inclusion/exclusion criteria) must be discussed prospectively with 
the m edical monitor.Study Synopsis, Methodology; 
Section; Section 3.1, Study Design; 
Section 6.2.1, Interactive Response 
Technology for Investigational 
Product Management; Section 7.1.1, 
Screening Period (Weeks -6 to 0)
6. If PPI responsiveness was excluded by a previous EGD an d 
biopsy, th ehistorical EGD and biopsy must have been perform ed 
after the patient had been on a m inimum of 6 weeks of high -dose 
PPItherapy .
Rationale: Inclusion criterion is modified to allow  entry of subjects 
with at least 6 weeks of historical data de monstrating PPI 
responsiveness since the duration of PPI needed to exclude PPI 
responsiveness may vary by local standard of care.Study Synopsis, Inclusion Criteria; 
Section 4.1, Inclusion Criteria
4. Subject has been on inhaled or intranasal steroids and has not been 
on stable treatment for ≥3 months prior to screening visit (Visit -1). 
Subjects on intranasal or inhaled steroids need to stay on a stable 
treatment during study participation. Subject has been on intranasal 
steroids and has not been on stable treatm ent for a m inimum of 
4weeks prior to the qualifying EGD. After the qualifying EGD,
subjects with seasonal allergic rhinitis may resume (or discontinue) 
intranasal corticosteroids based on the subject's usual treatm ent 
regim en for allergy season .Study Synopsis, Exclusion Criteria; 
Section 4.2, Exclusion Criteria
5. Subject has initiated, discontinued, or changed dosage regimen of 
PPIs, H2 antagonists, antacids, antihistamines , or leukotriene 
inhibitors.Study Synopsis, Exclusion Criteria; 
Section 4.2, Exclusion Criteria
20. Subject has taken part in an interventional investigational study 
related to EoE within 6 months prior to the screening visit (Visit -1), 
and orinvestigational study within 30 days prior to the screening 
visit (Visit -1).Study Synopsis, Exclusion Criteria; 
Section 4.2, Exclusion Criteria
24. Subject anticipates using sucralfate during the study.
Rationale: Sucralfate is added as an exclusionary medication since the 
medication may interfere with oral budesonide esophageal adh erence 
and may potentially impact efficacy.Study Synopsis, Exclusion Criteria; 
Section 4.2, Exclusion Criteria
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 5of 98
Changed:
Symptom response on DSQ + pain score (binary response), defined as 
≥30% and 50% reductions in the DSQ combined score (questions 
2+3+4) from baseline to the final treatment period evaluation (Visit 4)
To:
Change in the DSQ + pain score (questions 2+3+4) from baseline to 
the final treatment period evaluation (Visit 4)
Rationale: The binary response criteria in the DSQ (30% and 50%) 
were i ntended only for the DSQ combined score (questions 2+3).  
Therefore, this secondary efficacy endpoint pertaining to DSQ + pain 
score (questions 2+3+4) has been corrected.  Study Synopsis, Secondary Efficacy 
Endpoints; Section 9.8.2, Secondary 
Efficacy End points
Changed:
Symptom response on DSQ pain score (binary response), defined as 
≥30% and 50% reductions in the DSQ score (question 4) from baseline 
to the final treatment period evaluation (Visit 4)
To:
Change in the DSQ pain score (question 4) from bas eline to the final 
treatment period evaluation (Visit 4)
Rationale: The binary response criteria in the DSQ (30% and 50%) 
were intended only for the DSQ combined score (questions 2+3).  
Therefore, this secondary efficacy endpoint pertaining to DSQ pain 
score (question 4) has been corrected.  Study Synopsis, Secondary Efficacy 
Endpoints; Section 9.8.2, Secondary 
Efficacy Endpoints
“dual -energy X -ray absorptiometry (DXA) scans for bone mineral 
density (BMD) and body composition measure ments …”Study Synopsi s, Safety Endpoints, 
Statistical Methodology for Safety 
Endpoints; Section 7.1.2.1, Placebo 
Lead -in Visit (Visit 0);Section 7.1.3.3, 
Visit 4 (Week 16) ; Section 7.2.2.7, 
Dual -energy X -ray Absorptiometry 
for Bone Mineral Density; Section 
9.9, Safety Analyse s
“…the endpoint will be analyzed using the Cochran -Mantel -
Haenszel (CMH) test a logistic regression model with the effects of 
the treatment group adjusting for age group (ei ther < 18 years or 
≥18years) and diet restriction for EoE or other health -related 
conditions (no diet restriction or any diet restriction) and their 
interaction. The main effect model w ill be considered the final 
definitive model if the interactions betwe en the treatment and age 
group is not statistically significant at the 10% level. Theadjusted 
odds ratio of being a responder on each of the co -prim ary endpoints for 
the OBS 2 mg twice daily group vs placebo group and associated 95% 
confidence interval (C I) will be estimated from the final model 
provided. ”
Each of the co -prim ary efficacy endpoints will be analyzed 
using a logistic regression with the effects of treatm ent 
group, age group (either <18 years or ≥18 years) and diet Synopsis, Statistical Methodology for 
Primary Efficacy Endpoint; 
Section 9.8.1, Primary Efficacy 
Endpoi nts
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 6of 98
restriction for EoE or other health -related conditions (no 
diet restriction or any die t restriction). The odds ratio of 
being a responder on each of the co -prim ary endpoints for 
the OBS 2 m g twice daily group vs placebo group and 
associated 95% confidence interval (CI) will be estim ated 
from  the final model. Subjects who withdraw without 
providing efficacy data at the final treatm ent period 
evaluation (Visit 4, Week 16) will be classified as non -
responders in the prim ary efficacy analysis .
Expected response and dropout rates are based on observation 
from  the Phase 2 study (MPI 101 -06).Synopsis, Sample Size Justification; 
Section   9.6, Sample Size Calculation 
and Pow er Considerations
Added row  for continuous DSQ completion Schedule of Assessments
No change in exercise (other than seasonal changes in sports or 
activities). Intense exercise should be avoided unless part of an 
established exercise routine.
Short course of systemic steroids (≤7 days) are permitted to 
treat…
Stable treatm ent with intranasal or inhaled corticosteroids. 
For subjects with perennial allergic rhinitis and stable asthma, 
the topical corticosteroid must be maintained at the same dose 
throughout the study.  For subjects with seasonal allergic 
rhinitis, it is permissible after the qualifying EGD to resume 
(or discontinue) intranasal corticosteroids based on the 
subject's usual treatm ent regim en for allergy season.  All 
topical corticosteroid dosing changes , including those for 
seasonal allergic rhinitis, should be avoided within 4 weeks 
prior to the Week 16 EGD. Subjects who require a change in 
inhaled corticosteroid treatment for an asthm a exacerbation 
should be discussed with the m edical m onitor.
No use of sucralfate d uring the study as this may interfere with 
the adherence of OBS .Section 4.3, Restrictions
An urgent safety review will be conducted within 7 days by the 
sponsor if one or m ore of the following criteria are m et:
Death that is considered related to the stu dy drug
Two SAEs of similar type (defined as same or similar Medical 
Dictionary for Regulatory Activities [MedDRA] higher level 
group code) and considered related to the study drug
The urgent review will be perform ed by a sponsor safety review 
group, which will include the study Pharm acovigilance and Risk 
Managem ent (PVRM) physician and the PVRM Therapeutic Area 
Head.  The PVRM Therapeutic Area Head, not the PVRM 
physician involved in the study, m ay be unblinded as part of this 
urgent safety review, if requ ired.  Following the sponsor’s review 
of safety data, one of the following actions will be taken with 
respect to study status:Section 4.5.4, Safety -related Stopping 
Rules
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 7of 98
Continue study with protocol unchanged
Continue study with m odifications to the protocol
Terminate study
Subject safety will be m onitored on a continuous basis during this 
study until the last subject com pletes his or her last scheduled 
study visit/assessment.
Rationale: Safety -related stopping rules are added to provide for an 
urgent safety review if criteria for related SAEs are m et.  
1. Inhaled or intranasal steroids for conditions other than EoE; subject 
must be on stabl e treatment for ≥3 months prior to screening visit 
(Visit -1), except for seasonal allergic rhinitis, see Section 4.3.Section 5.2.1, Permitted Treatment
3.  Inhaled or intranasal steroids if initiated or changed in dose
<3months prior to screening visit (Visit -1).   (Seasonal nasal 
corticosteroid use for seasonal allergic rhinitis is per mitted; 
changes within 4 weeks of scheduled EGD should be avoided).
4.  Initiation or change in dosing frequency of PPIs, H2 antagonists, 
antacids, antihistamines, or leukotriene inhibitors…
8.  Sucralfate use during the treatm ent periodSection 5.2.2, Prohibited Treatment
OBS and placebo should be refrigerated at 2 -8ºC (36 46ºF) 
throughout the study (in the clinic and subject’s home).
After 30 minutes, it is recommended that the subjects will be 
instructed to rinse with water and spit , particularly after the bedtime 
dose.Section 6.2, Administration of 
Investigational Product(s)
The randomization will be performed centrally and stratified by age 
group (2 strata total: <18 years orvs≥18 years) and diet restriction 
for EoE or other health -related conditions (no diet restriction or 
any diet restriction) . The stratification by age will ensure a minimum 
of 40 subjects in the pediatric group (11 -17 years, inclusive). The 
stratification by age and diet restriction will ensure balance 
between treatm ent groups for the respective stratification factors. 
Fixed block randomization will be used to ensure that approximately 
equal numbers of patients are assigned each treatment within strata. 
 
Rationale: As the presence of dietary therapy may impact a subject’s 
response to therapy, a stratification factor based on baseli ne diet is 
added to ensure balance between treatment groups. Section 6.2.2, Allocation of Subjects 
to Treatment
Visit to visit compliance of DSQ completion will also be assessed by 
site personnel. Protocol deviations will be documented for subjects 
who f ail to complete the DSQ for 3 or more days in a given week.Section 6.5, Subject Compliance
Perform  stadiometry in subjects aged 11 -17 years, inclusive. Section 7.1.1.1, Screening Visit (Visit 
-1)
Perform stadiometry in subjects aged 11 17 years, inclusive. Section 7.1.3.1, Baseline Visit (Visit 
1): Week 4

Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 8of 98
Endoscopic findings with separate evaluations of the proximal and 
distal esophagus will be recorded with respect to 5 categories by the 
endoscopist: 1) exudates or plaques (grade 0-2); 2) fixed esophag eal 
rings (grade 0 –3); 3) edema (grade 0 -21); 4) furrow s (grade 0 –21)…Section 7.2.1.1, 
Esophagogastroduodenoscopy w ith 
Esophageal Biopsy and 
Histopathologic Evaluation
Visit to visit com pliance of DSQ completion will also be assessed by 
site personnel. P rotocol deviations will be docum ented for subjects 
who fail to com plete the DSQ for 3 or m ore days in a given week.
Calculations will be performed on daily ePRO entries from the 
screening period, during a 2 week interval prior to the baseline period, 
and prior to each study visit during the baseline and treatment periods.Section 7.2.1.2, Dysphagia Symptom 
Questionnaire
Standard measuring procedures should be follow ed (eg, removal of 
socks, shoes, and hats ; calibration frequency ). The stadiometer must 
be calibrated at least once daily, and as feasible, within 4 hours of 
measurement. All measure ments should be recorded to the nearest 
10thof a centim eter (1 mm).Section 7.2.2.2,  Physical Examination 
(Including Height and Weight)
All subjects with an abnormal ACTH stimulation test or urinary 
or serum glucose level must be followed closely until resolution.  
For subjects who discontinue from  the treatm ent period at any 
time and have an abnorm al ACTH stimulation test at the early 
term ination visit, subjects w ill be scheduled for repeat testing 
approximately 6 weeks post last dose of investigational product to 
ensure that ACTH levels have norm alized .Section 7.2.2.5, Clinical Laboratory 
Evaluations
PedsQL -EoE m odule consists of 3335items… Section 7.2.3.1, He alth-related 
Quality -of-life Assessment, Pediatric 
Quality of Life –EoE Questionnaire
The EoE -QoL-A consists of a 37 30-item test Section 7.2.3.1, Health -related 
Quality -of-life Assessment, Adult 
Eosinophilic Esophagitis Quality of 
Life Questionnaire
All data from the investigator will have separate source…
The data from  the central pathologist will be recorded directly 
onto paper CRFs.  Section 10.2.3.1, Case Report Forms
Added protocol history details. Section 12, Appendix 1 Protocol 
History
Edited former Appendix 1 to Appendix 2
Specified age groups for EQ -5D-3L, EQ-5D-Y and Tanner Staging 
assessments.Section 12, Appendix 2 Scales and 
Assessments
See Appendix 1 for protocol history , including all amendments.
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 9of 98
EMERGENCY CONTACT IN FORMATION
In the event of an SAE, the investigator must fax or e-mail the Shire Clinical Study  Adverse 
Event Form for Serious Adverse Events (SAEs) and Non-serious AEs as Required by 
Protocol within 24 hours to the Shire Global Pharmacovigilance and Risk Management 
Departme nt. Applicable fax numbers and e -mail address can be found on the form (sent under 
separate cover). A copy of the Shire Clinical Study  Adverse Event Form for SAEs and Non-
serious AEs as Required by Protocol must also be sent to the CRO medical monitor by fax or 
e-mail using the details below.
, MD
Email:  
Fax:  
For protocol -or safety -related issues during normal business hours (8am to 5 pm 
Eastern Standard Time) ,the investigator must contact the CRO medical monitor :
, MD
Phone: 
Mobile: 
Email: 
Fax:  
For protocol -or safety- related issues outside of normal business hours , the investigator 
must contact the CRO medical monitor :
, MD
Mobile: 
Email:  

Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 10of 98
PRODUCT QUALITY CO MPLAINTS
Investigators are required to report investigational product quality  complaints to Shire within 
24hours. This includes any instances wherein the quality  or performance of a Shire product 
(marketed or investigational) does not meet expectations (eg,inadequate or faulty  closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg,wrong product such that the label and contents are different 
products).  For instructions on report ing AEs related to product complaints, see Section 8.
Please use the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint E
-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for reference if needed):
Shire, Lexington, MA (USA)
 or 

Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 11of 98
TABLE OF CONTENTS
PROTOCOL  SIGNATURE P AGE ................................ ................................ ............................2
SUMMARY OF CHANGES F ROM PREVIOUS VERSI ON..................................................3
EMERGENCY CONTACT I NFORMATION ..........................................................................9
PRODUCT QUALITY COMP LAINTS ..................................................................................10
ABBREVIAT IONS ..................................................................................................................17
STUDY SYNOPSI S
.................................................................................................................19
STUDY SCHEDULE(S) ..........................................................................................................28
1. BACKGROUND INFORMATI ON.............................................................................32
1.1 Indication and Current Treatment Options ...................................................................32
1.2 Product Background and Clinical I nformation ............................................................32
2. STUDY OBJECTIVES AND PURPOSE ....................................................................33
2.1 Rationale for the Study .................................................................................................33
2.2 Study  Objectives ...........................................................................................................33
2.2.1 Primary  Objectives ................................................................................................33
2.2.2 Secondary  Objectives ............................................................................................34
2.2.3 Exploratory  Objective ............................................................................................34
3. STUDY DESIGN .........................................................................................................34
3.1 Study  Design and Flow Chart ......................................................................................34
3.2 Duration and Study  Completion Definition .................................................................36
3.3 Sites and Regions .........................................................................................................37
4. STUDY POPUL ATION................................ ................................ ...............................37
4.1 Inclusion Criteria................................ ................................ ................................ ..........37
4.2 Exclu sion Criteria .........................................................................................................38
4.3 Restrictions ................................ ................................ ................................ ...................40
4.4 Reproductive Potential ................................ ................................ ................................ .40
4.4.1 Female Contraception ............................................................................................40
4.5
Discontinuation of Subjects................................ ................................ ..........................41
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 12of 98
4.5.1 Subject Withdrawal Criteria ................................ ................................ ..................42
4.5.2 Reasons for Discontinuation ..................................................................................42
4.5.3 Subjects “L ost to Follow -up” Prior to Last Scheduled Visit .................................43
4.5.4 Safety -related Stopping Rules ...............................................................................43
5. PRIOR AND CONCOMITANT TREATMENT .........................................................44
5.1 Prior Treatment .............................................................................................................44
5.2 Concomitant Treatment ................................................................................................44
5.2.1 Permitted Treat ment ..............................................................................................44
5.2.2 Prohibited Treatment .............................................................................................45
6. INVESTIGAT IONAL PROD UCT ..............................................................................46
6.1 Identity  of Investigational Produc t
...............................................................................46
6.1.1 Blinding the Treatment Assignment ......................................................................46
6.2 Administration of I nvestigational Product(s) ...............................................................46
6.2.1 Interactive Response Technology  for Investigational Product Management ........
47
6.2.2 Allocation of Subjects to Treatment ......................................................................47
6.2.3 Dosing ....................................................................................................................48
6.2.4 Unblinding the Treatment Assignment ..................................................................48
6.3
Labeling, Packaging, Storage, and Handling ...............................................................49
6.3.1 Labeling .................................................................................................................49
6.3.2 Packaging ...............................................................................................................50
6.3.3 Storage ...................................................................................................................50
6.3.4 Special Handling ....................................................................................................51
6.4 Drug Accountability .....................................................................................................51
6.5 Subject Compliance ......................................................................................................52
7.
STUDY PROCEDURES................................ ................................ ..............................52
7.1 Study  Schedule ................................ ................................ ................................ .............52
7.1.1 Screening Period (Weeks -6 to 0) ..........................................................................53
7.1.1.1
Screening Visit (Visit -1) ................................ ................................ ............53
7.1.2 Placebo Lead -in Period (Weeks 0 to 4 ) .................................................................54
7.1.2.1 Placebo Lead -in Visit (Visit 0) ................................ ................................ ....54
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 13of 98
7.1.3 Double- blind Treatment Period (Visits 1 -4): Weeks 4, 8, 12, and 16 (or 
Early Termination) .................................................................................................55
7.1.3.1
Baseline Visit (Visit 1): Week 4..................................................................56
7.1.3.2 Visits 2 and 3 (Weeks 8 and 12) ..................................................................57
7.1.3.3
Visit 4 (Week 16) ........................................................................................58
7.1.4 Follow -up Period ...................................................................................................59
7.1.4.1 Safety  Follow -up Contact (Visit 5): Week 20 .............................................59
7.1.5 Additional Care of Subjects after the Study ..........................................................59
7.2 Study  Evaluations and Procedures
...............................................................................59
7.2.1 Efficacy ..................................................................................................................60
7.2.1.1 Esophagogas troduodenoscopy  with Esophageal Biopsy  and 
Histopathologic Evaluation
.........................................................................60
7.2.1.2 Dysphagia Sy mptom Questionnaire ............................................................61
7.2.2 Safety .....................................................................................................................62
7.2.2.1 Medical and Medication History .................................................................62
7.2.2.2 Physical Examination (Including Height and Weight) ................................
62
7.2.2.3 Adverse Event Coll ection ............................................................................63
7.2.2.4 Vital Signs ...................................................................................................63
7.2.2.5 Clinical L aboratory  Evaluations ..................................................................63
7.2.2.6 Pregnancy  Test ............................................................................................65
7.2.2.7 Dual -energy  X
-ray Absorptiometry  for Bone Mineral Densit y ..................65
7.2.3 Other Assessments .................................................................................................65
7.2.3.1 Health
-related Quality -of-life Assessment ..................................................65
7.2.3.2 Severity  of Disease Assessments ................................................................66
7.2.4 Clinical Pharmacology  Assessments .....................................................................67
7.2.5 Volume of Blood to Be Drawn from Each Subject ...............................................68
8. ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ..........................
68
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events ...........................................................................................................................68
8.1.1 Severity  Categorization ..........................................................................................69
8.1.2 Relationship Categorization ...................................................................................69
8.1.3 Outcome Categorization ........................................................................................70
8.1.4 Symptoms of the Disease under Study ..................................................................70
8.1.5 Clinical L aboratory  and Other Safet y Evaluations ................................................71
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 14of 98
8.1.6 Pregnancy ................................ ................................ ................................ ...............71
8.1.7 Abuse, Misuse, Overdose, and Medication Error ..................................................72
8.2 Serious Adverse Event Proce dures ...............................................................................73
8.2.1 Reference Safet y Information ................................................................................73
8.2.2 Reporting Procedures .............................................................................................73
8.2.3 Serious Adverse Event D efinition .........................................................................73
8.2.4 Serious Adverse Event Collection Time Frame ....................................................74
8.2.5 Serious Adverse Event Onset and Resolution Dates .............................................74
8.2.6 Fatal Outcome ........................................................................................................74
8.2.7 Regulatory  Agency , Institutional Review Board, Ethics Committee, and Site 
Reporting
...............................................................................................................75
9. DATA MANAGEMENT AND STATISTICAL METHODS
.....................................75
9.1 Data Collection .............................................................................................................75
9.2 Clinical Data Management ...........................................................................................75
9.3 Data Handling Considera tions ......................................................................................75
9.4 Statistical Analy
sis Process ..........................................................................................76
9.5 Planned Interim Anal ysis, Adaptive Design, and Data Monitoring Committee ..........
76
9.6 Sample Size Calculation and Power Considerations....................................................77
9.7 Study  Population ..........................................................................................................77
9.8 Efficacy  Anal yses.........................................................................................................77
9.8.1 Primary  Efficacy  Endpoints ...................................................................................78
9.8.1.1 Missing Data Imputation .............................................................................79
9.8.2 Secondary  Efficacy  Endpoints ...............................................................................79
9.8.2.1 Key Secondary  Efficacy  Endpoint ..............................................................79
9.8.3 Exploratory  Efficacy  Endpoint ..............................................................................81
9.9 Safety  Anal yses................................ ................................ ................................ ............81
9.10 Other Anal yses................................ ................................ ................................ .............82
9.10.1 Health- related Quality -of-life Anal yses.................................................................82
9.10.2 Pharmacokinetic Analy ses.....................................................................................82
10. SPONSOR’S AND I NVEST IGATOR’S RESPONSIBIL
ITIES................................ .82
10.1 Sponsor’s Responsibilities ................................ ................................ ...........................83
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 15of 98
10.1.1 Good Clinical Practice Compliance ................................ ................................ .......83
10.1.2 Indemnity /Liability  and Insurance .........................................................................83
10.1.3 Public Posting of Study  Information .....................................................................83
10.1.4 Submission of Summary of Clinical Study  Report to Competent Authorities 
of Member States Concerned and Ethics Committees ...........................................84
10.1.5 Study  Suspension, Termination, and Completion .................................................84
10.2
Investigator’s Responsibilities .....................................................................................84
10.2.1 Good Clinical Practice Compliance .......................................................................84
10.2.2 Protocol Adherence and Investigator Agreement ..................................................85
10.2.3 Documentation and Retention of Records .............................................................85
10.2.3.1 Case Report Forms ......................................................................................85
10.2.3.2 Recording, Access, an d Retention of Source Data and Study  
Documents ...................................................................................................86
10.2.3.3 Audit/I nspection ..........................................................................................86
10.2.3.4 Financial Disclosure ....................................................................................86
10.3 Ethical Considerations ..................................................................................................87
10.3.1 Informed Consent ..................................................................................................87
10.3.2 Institutional Review Board or Ethics Committee ..................................................87
10.4 Privacy  and Confidentiality ..........................................................................................88
10.5 Study  Results/Publication Policy .................................................................................89
11. REFERENCES .............................................................................................................90
12. APPENDI CES ..............................................................................................................92
LIST OF TABLES
Table 1
-1:Schedule of Assessments .......................................................................................28
Table 7
-1:Approximate Volume of Blood to Be Drawn from Each Subject .........................68
Table 8-1: Adverse Event Relatedness ....................................................................................70
Table 9
-1: Percentage of Responders for All Available Data (ie, Non- missing Data) b y 
Strata ......................................................................................................................79
Table 9
-2:Pharmacokinetic Parameters ................................ ................................ ..................82
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 16of 98
LIST OF FIGURES
Figure 1: Study  Design Flow Chart ................................ ................................ .......................35
LIST OF APPENDICES
Appendix 1 Protocol History ..........................................................................................93
Appendix 2 Scales and Assessments ...............................................................................94
Appendix 3 Dysphagia Sy mptom Questionnaire ePRO for EoE ....................................95
Appendix 4
Patient Global I mpression of Severity.........................................................96
Appendix 5 Biosciences Generic Clinical Protocol Insert ..............................................97
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 17of 98
ABBREVIATIONS
ACTH adrenocorticotropic hormone
AE adverse event
ANCOVA analysis of covariance
Auc tau area under the curve for the defined interval between doses
β-hCG beta-human chorionic gonadotropin
BID twice dail y
BMD bone mineral densit y
CFR Code of Federal Regulations
CI confidence interval
Cmax m
aximum concentration occurring at t max
CRA clinical research associate
CRF case report form
CRO contract research organization
CYP450 3A4 cytochrome P450 3A4
DSG1 desmoglein 1
DSQ Dysphagia Symptom Questionnaire
DXA (DEXA) dual-energy  X -ray absorptiometry
EC ethics committee
EGD esophagogastroduodenoscopy
EIS external independent statistical
EMA European Medicines Agency
EoE eosinophilic esophagitis
EoE-QoL-A  Adult Eosinophilic Esop hagitis Qualit y of Life
ePRO electronic patient- reported outcome
EQ-5D- 3L EuroQol -5 Dimensions 3- level
EQ-5D EuroQol
EQ-5D-Y EuroQol 5 Dimensions Youth
EREFS EoE Endoscopic Reference Score
ET early termination
EU European Union
FAS full analy sis se t
FDA Food and Drug Administration
GCP Good Clinical Practice
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 18of 98
HIPAA Health Insurance Portability  and Accountability  Act
HPF high-powered field
HRQoL health
-related quality  of life
hs at bedtime
ICH International Conference on Harmonisation
IRB Institutional Review Board
ITT intent -to-treat
IWRS interactive w eb-based response s ystem
Med ID medication information
MedDRA Medical Dictionary  for Regulatory  Activities
MI multiple imputation
OBS oral budesonide suspension
pc after meal
s
PedsQL -EoE Pediatric Quality  of Life Inventory  –EoE
PGA Physician Global 
Assessment
PGI-S Patient Global I mpression of Severity
PP per- protocol
PPI proton pump inhibitor
PT preferred term
PVRM Pharmacovigilance and Risk Management
qAM every  morning
SAE serio us adverse event
SAP statistical analy sis plan
SAS®statistical analy sis sy stem
SOC system organ class
TEAE treatment -emergent adverse event
tmaxtime of maximum observed concentration sampled during a dosing 
interval
UK United Kingdom
US United Sta tes
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 19of 98
STUDY SYNOPSIS
Protocol num ber:  SHP621 -301 Drug: SHP621, oral budesonide s uspension (OBS )
Title of the study: Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 
55Years of Age, Inclusive ) with Eosinophilic Esophagitis: A Phase 3 Randomized, Double -blind, 
Placebo -controlled Study
Number of subjects (total and for each treatm ent arm):
Approximately 300subjects will be enrolled into the placebo lead-in period to allow for 228subjects 
(approximately 152and 7 6 per OBS and placeb o treatment group , respectively )to be randomized into 
the double- blind treatment period.
Investigator(s):   Multicenter study
Site(s) and Region(s): 
Approximately 60sites in North America
Study period (planned):
Oct 2015 to July 2018Clinical phase: 3
Objectives
Co-primary:
To demonstrate in a placebo -controlled trial that:
OBS induces a histologic response (eosinophilic count ≤6/high-powered field [HPF] ) in 
adolescent and adult subjects with eosinophilic esophagitis (EoE) over a 12-week course of 
therapy .
OBS reduces dysphagia, as measured by the Dysphagia Symptom Questionnaire (DSQ), by at 
least 30% from baseline in adolescent and adult subjects with EoE over a 12-week course of 
therapy .
Key Secondary:
OBS reduces dysphagia, as measured by the DSQ s core from baseline to the final treatment period 
evaluation (Visit 4). 
Secondary:
To assess the response of endoscopically identified esophageal features to OBS as compared to 
placebo as measured by the EoE Endoscopic Reference Score (EREFS) 
To explore o ther responding criteria based on histology and DSQ
To assess the impact of OBS on pain, as measured by the DSQ pain score
To evaluate the safety and tolerability of OBS over a 12-week course of therapy
To obtain 
OBS pharmacokinetic data in adult subjects with EoE
Exploratory:

Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 20of 98
Rationale:
Currently there is no approved medication for the treatment of EoE. This study is being conducted in 
order to provide safety and efficacy data demonstrating histologic response (as measured by 
eosinophilic count ≤6/HPF)and improvement in dysphagia symptoms (as measured by the DSQ) 
following 12 weeks of treatment with OBS in adolescent and adult subjec ts with EoE. 
Investigational product, dose, and m ode of administration
OBS will be administered in 10mL at a concentration of 0.2 mg/mL (2mg dose), twice daily (in the 
morning [qAM] after meal s [breakfast, pc] and at bedtime [hs]) .The 0.2 m g/mL conce ntration of OBS 
and dosing regimens were selected for use in this Phase 3 study based on the results of Study MPI 
101-06, a Phase 2 study in 93 adolescents and adult subjects with EoE and symptoms of dysphagia. 
Subjects were treated in Study MPI 101-06 with 2mg OBS twice daily to investigate the c o-prim ary 
endpoints of histologic response (defined as ≤6eosinophils/ HPF) and reduction in DSQ score from 
baseline to Week 12 of treatment . For the current study, the investigational product will be supplied in 
amber glass, multi -dose bottles with child -resistant caps and refrigerated through outthe study (in the 
clinic and subject’s home). Each bottle will contain approximately 210mL of suspension with a 
budesonide concentration of 0.2 mg/mL, or 0.00 mg/mL (matching placebo). 
After the screening period, eligible subjects will enter a 4 -week single -blind placebo l ead-in period and
will receive 10 mL of OBS placebo twice daily (qAM, pc, and hs). At the end of the placebo lead-in
period, eligible subjects will ente r a 12 -week double -blind treatment period ( baseline visit , Visit 1) and 
will be randomized to 1 of 2 treatment groups in a 2:1 ratio (approximately 152and 7 6 subjects for 
OBS and placebo twice daily treatment groups, respectively). Subjects will receive oral administration 
of 10 mL of 2mg investigational product twice daily (qAM, pc,and hs; 4 mg/day total), with no 
ingestion of food or liquids permitted for 30 minutes after study drug administration:
Placebo twice daily group :  placebo qAM (pc) and hs
OBS twice daily group: OBS 10 mL of 0.2 mg/mL (2mg total) qAM ( pc)and hs
The total daily dose of budesonide will be 0 mg for each subject in the placebo group and 4mg for 
each subject in the OBS treatment group (Table 1). 
Table 1 : Total Daily Dose of OBS
Dose GroupOBS 
Concentration
(mg/mL)Volume 
per DoseMorning Dose 
(qAM, pc)Evening 
Dose (hs)Total 
Dose/Day
(mg/day)
Placebo 0.0 10 mL 0.0 mg 0.0 mg 0.0
OBS 0.2 10 mL 2.0 mg 2.0 mg 4.0
Abbreviations: hs=at bedtime; OBS=oral budesonide suspension; pc=after meal s; qAM=every 
morning
At the end of the 12-week double- blind treatment period (Visit 4), subjects who complete the study 
will have the opportunity to enroll in the treatment extension study. These subjects will continue on the 
blinded assigned treatment for 2-4 weeks as part of the screening prior to enrolling into the treatment 
extension study. 
Methodology:
This is a Phase 3, randomized, double- blind, multicenter, parallel -group, placebo -controlled study to 
evaluate the efficacy, safety, and tolerability of twice daily administration of OBS (qAM, pc,and hs) 
in adolescents and adults aged 11 -55 years, inclusive, with EoE and dysphagia. 
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 21of 98
This study will comprise 3 periods: a 3-to 6-week screening period , 4-week single -blind placebo 
lead-inperiod , and 12 -week double -blind treatment period (Figure 1). Approximately 300subjects will 
be enrolled into the placebo lead-inperiod to allow for approximately 228subjects to be randomized 
in a 2:1 ratio (approximately 152and 7 6 per OBS and placebo treatment group, respectively ) into the 
double- blind treatment period . The randomization will be performed centrally and stratified by age 
group (2 strata total: <18 years or ≥18 years) and diet restriction for EoE or other health -related 
conditions (no diet restriction or any diet restriction). The stratification by age will ensure a minimum 
of 40 subjects in the pediatric group (11-17 years, inclusive). The stratification by age and diet will 
ensure balance between treatment groups for the respective stratif ication factors.
Subjects who sign informed consent (or assent as applicable for subjects <18years) will be screened 
(Visit -1 ). Subjects who meet eligibility criteria at the screening visit (Visit -1) and at the placebo 
lead-invisit (Visit 0) will enter the 4 -week placebo lead -inperiod to assess their ability to comply with 
twicedaily medication administration and assess whether there is a placebo response. Upon 
completion of the placebo lead -inperiod, subjects will return for the baseline visit (Visi t 1) to confirm 
eligibility. Eligible subjects will be randomized 2:1 into the double- blind treatment period and will be 
evaluated for efficacy and safety at Weeks 8, 12, and 16(Visits 2-4).Subjects who fail to meet all
eligibility criteria at Visits -1, 0, or 1will be considered screen failures. Subjects cannot be rescreened 
once it is confirmed they do not meet inclusion/exclusion criteria unless the screen failure was due to a 
concomitant medication that can be discontinued prior to rescreening; those subjects may be 
rescreened. Other reasons for rescreening (ie, reasons unrelated to inclusion/exclusion criteria) must be 
discussed prospectively with the medical monitor . Subjects who discontinue will not be replaced.
Subjects will be required to visit t he site up to 6 times over up to a 22-week period. A safety follow -up 
phone call will occur 4 weeks following the last dose of investigational product for subjects who 
discontinue prem aturely during the double -blind treatment period or who do not enroll in the treatment 
extension study .
Figure 1: Study Design Flow Chart
Abbreviations: BID=twice daily; EGD= esophagogastroduodenoscopy ; ET=early termination; 
OBS=oral budesonide suspension
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 22of 98
Inclusion and exclusion criteria:
Inclusion Criteria:
The subject will not be considered eligible forthe study without meeting all of the following criteria 
(including test results):
1.Subject is able to provide written inform ed consent (subject, parent or legal guardian and, as 
appropriate, subject assent) to participate in the study before completing any study-related 
procedures. 
2.Subject is male or female aged 11-55 years, inclusive ,at time of consent. 
3.Subject has histologic evidence of EoE with a peak eosinophil count of ≥15/HPF, from 2 
of3 
(proximal, mid -,and/or distal) levels of the esophagus at the s creening endoscopy .
4.Subject has a history of clinical symptoms of esophageal dysfunction (eg, eating problems, 
abdominal pain, heartburn, dysphagia, vomiting, food impaction, weight loss) intermittently or 
continuously at screening (Visit -1).
5.Subject must have experienced dysphagia (response of “yes” to question 2 on DSQ) on a 
minimum of 4 days and completed the DSQ on ≥70% of days inany 2consecutive weeks of the 
screening period and in the 2 weeks prior to the baseline visit (Visit 1).
6.Subject must not have proton pump inhibitor (PPI)–responsive EoE based on esophageal biopsies 
performed after the patient has been on at least 8 weeks of high-dose PPI therapy (high -dose 
therapy refers to the total daily dose, which may have been administered as a once -or twice daily 
dosing regim en). This may occur at the time of the qualifying esophagogastroduodenoscopy 
(EGD ; in which case the same PPI regimen must be continued) ,or this may have been done 
previously (in which case PPI therapy may have been stopped if there was no response to therapy 
based on esophageal biopsy results). If PPI responsiveness was excluded by a previous EGD and 
biopsy, thehistorical EGD and biopsy must have been performed after the patient had been on a 
minimum of 6 weeks of high -dose PPI therapy .
7.Subject w ill be on a stable (no changes) diet ≥3 m onths prior to the screening visit (Visit -1).
8.Subject is willing and able to continue any dietary therapy, environmental therapy, and/or medical 
regimens (including gastric acid suppression; see exclusions below ) in effect at the screening visit 
(Visit -1).There should be no change to these regimens during study participation.
9.All female subjects must have a negative serum pregnancy test (beta-human chorionic 
gonadotropin [β-hCG]) prior to enrol lment into the study . Females of childbearing potential must 
agree to continue acceptable birth control measures (eg, abstinence, stable oral contraceptives ,or 
double- barrier methods) throughout study participation.
10.Subject is willing and has an understanding and ab ility to fully comply with study procedures and 
restrictions defined in this protocol.
Exclusion Criteria:
Subjects are excluded from the study if any of the following exclusion criteria are met:
1.Subject has any condition or abnormality (including laborato ry abnorm alities), current or past, 
that, in the opinion of the principal investigator or medical monitor , would comprom ise the safety 
of the subject or interfere with or complicate the assessment of signs or symptoms of EoE. Such 
conditions may include psychiatric problems; neurologic deficits or disease; developmental delay; 
cardiovascular, metabolic, or pulmonary disease; or previous gastroesophageal surgery . These 
should be discussed with the medical monitor .
2.Subject has used immunomodulatory therapy within 8 weeks prior to the qualifying EGD or 
betw een the qualifying EGD and baseline visit ( Visit 1)or anticipates using immunomodulatory 
therapy during the treatment period (except for any ongoing regimen of allergy shots). Use of 
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 23of 98
long-acting immunomodula tory therapy (eg, Rituxan) within 3 months of the qualifying EGD 
should be review ed with the medical monitor .
3.Subject has been using swallowed topical corticosteroid for EoE or systemic corticosteroid for any 
condition within the 4 weeks prior to the quali fying EGD, betw een the qualifying EGD and 
baseline visit ( Visit 1),or anticipates use during the treatment period ; any temporary use (≤7days) 
or initiation of new steroid treatment during the study should be documented and discussed with 
the medical moni torprospectively but cannot occur within 4 w eeks of the final EGD . 
4.Subject has been on inhaled steroids and not on stable treatment for ≥3 months prior to screening 
visit (Visit -1).Subjects on inhaled steroids need to stay on stable treatment during study 
participation. Subject has been on intranasal steroids and has not been on stable treatment for a 
minimum of 4 weeks prior to the qualifying EGD. After the qualifying EGD, subjects with 
seasonal allergic rhinitis may resume (or discontinue) intranasal corticosteroids based on the 
subject's usual treatment regimen for allergy season.
5.Subject has initiated, discontinued, or changed dosage regimen of PPIs, H2 antagonists, antacids, 
or leukotriene inhibitors for any condition (such as gastroesophageal reflu x disease asthma or 
allergic rhinitis) within the 4 weeks prior to the qualifying EGD, between the qualifying EGD and 
baseline visit ( Visit 1), or anticipates changes in theuse of such medications during the treatm ent 
period .  
6.Subject has been using cytochrome P450 3A4 inhibitors (eg,ketoconazole, grapefruit juice) 
within the 2 weeks prior to the baseline visit ( Visit 1)or within 5 half-lives (whichever is greater)
or anticipates using such medications during the treatment period .  
7.Subject has an appea rance on qualifying EGD of an esophageal stricture (high-grade), as defined 
by the presence of a lesion that does not allow passage of a diagnostic adult upper endoscope (eg, 
with an insertion tube diameter of >9 mm). 
8.Subject is on a pure liquid diet or the 6-food elimination diet .
9.Subject has had an esophageal dilation within the 3 months prior to screening (Visit -1).
10.Subject has presence of esophageal varices at the screening endoscop y.
11.Subject has any current disease of the gastrointestinal tract, aside from EoE, including 
eosinophilic gastritis, enteritis, colitis, or proctitis ; inflammatory bow el disease ; or celiac disease. 
12.Subject has other diseases causing or associated with EoE, including hypereosinophilic syndrome, 
collagen vascular disease, vasc ulitis, achalasia, or parasitic infection.
13.Subject has current evidence of oropharyngeal or esophageal candidiasis.
14.Subject has acute or chronic viral infection or immunodeficiency condition, including 
tuberculosis, fungal, bacterial, viral/parasite infect ion, ocular herpes simplex, herpes esophagitis, 
or chicken pox/measles .
15.Subject has upper gastrointestinal bleeding within 4 weeks prior to the screening visit (Visit -1) or 
betw een the screening visit and baseline visit ( Visit 1).
16.Subject has evidence of active infection with Helicobacter pylori.
17.Subject has evidence of unstable asthma within 4 weeks prior to the screening visit (Visit -1) and 
betw een the screening visit and baseline visit (Visit 1).
18.Subject is female and pregnant or nursing.
19.Subject has ahistory of intolerance, hypersensitivity, or idiosyncratic reaction to budesonide (or 
any other corticosteroids) or to any other ingredients of the investigational product .
20.Subject has taken part in aninterventional study related to EoE within 6 months prior to the 
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 24of 98
screening visit (Visit -1), or any investigational study within 30 days prior to the screening visit 
(Visit -1).
21.Subject has a history or high risk of noncompliance with treatment or regular clinic visits.
22.Subject has previously completed, discontinued, or withdrawn from this study.
23.Subject has participated in a previous clinical study involving OBS (SHP621).
24.Subject anticipates using sucralfate during the study.
Maximum duration of subject involvem ent in the study:
 Planned duration of screenin g period : 3-6 weeks
 Planned duration of placebo l ead-in period: 4 w eeks
 Planned duration of treatment period : 12 w eeks
 Planned duration of safety follow -up p eriod: 4 weeks
Endpoints and statistical analysis:
Subject Populations
 The safety setwill include all subjects who receive at least 1 dose of any double -blind 
investigational product . 
 The intent -to-treat (ITT) set will include all randomized subjects. Subjects will be analyzed 
according to their assigned treatment, regardless of the treatment actuall y received.
 The full analysis set (FAS) will include all randomized subjects who received at least 1 dose of a 
double- blind investigational product and have both an evaluable post-baseline biopsy in the 
treatment period (ie, peak eosinophil count is report ed for at least 2 esophageal levels) and a 
post-baseline DSQ score .
 The per-protocol (PP) setwill include all subjects in the FAS excluding subjects with protocol 
violat ions. The PP set will be identified prior to unblinding the treatment assignments by ateam 
consisting of, at a minimum, a physician and a statistician from Shire. 
 The pharm acokinetic setwill include all subjects in the safety set for whom the primar y 
pharmacokinetic data areconsidered sufficient and interpretable.
Prim ary Efficacy Endpo ints
The co -primary efficacy endpoints are the following :
 Histologic respon se, defined as a peak eosinophil count of ≤6/HPF across all available 
esophageal levels at the final treatment period evaluation (Visit 4 )
 Dysphagia symptom response, defined as ≥30% reduction in the DSQ combined score (questions 
2+3) from baseline to the final treatment period evaluation (Visit 4 )
Key Secondary Efficacy Endpoint
 Change in DSQ combined score (
questions 2 +3) from baseline to the final treatment period 
evaluation ( Visit 4)
Secondary Efficacy Endpoints 
 Change in total endoscopy score, as measured by the EREFS classification, from baseline to the 
final treatment period evaluation (Visit 4)
 Peak eosinophil count <15/HPF across all available esophagus levels at the final t reatment period 
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 25of 98
evaluation (Visit 4)
 Peak eosinophil count ≤1/HPF across all available esophagus levels at the final treatment period 
evaluation (Visit 4)
 Change from baseline in the peak eosinophil count to the final treatment period evaluation 
(Visit 4) for each available esophageal level (proximal, mid -, and distal)
 Change from baseline in the histopathologic epithelial features combined total score (grade and 
stage) to the final treatment period evaluation (Visit 4)
 Dysphagia symptom response (binary response) , defined as a ≥50% reduction in the DSQ 
combined score (questions 2+3), from baseline to the final treatment period evaluation (Visit 4 )
 Change from baseline in the DSQ combined score (questions 2+3) over time including 
post-baseline visits
 Cumulative distribution function curves for the change and the percent change in the DSQ score 
from baseline to the final treatment period evaluation (Visit 4)
 Overall binary response I, defined as a reduction in the DSQ score of ≥30% from baseline to the 
final treatment period evalu ation (Visit 4) and a peak eosinophil count of ≤6/HPF across all 
esophageal levels at the final treatment period evaluation (Visit 4)
 Overall binary response II, defined as a reduction in the DSQ score of ≥50% from  baseline to the 
final treatment period evaluation (Visit 4) and a peak eosinophil count of ≤6/HPF across all 
esophageal levels at the final treatment period evaluation (Visit 4)
 Change in the DSQ + pain score (questions 2 +3+4) from baseline to the final treatment period 
evaluation (Visit 4)
 Chan ge in the DSQ pain score ( question 4) from  baseline to the final treatment period evaluation 
(Visit 4)
Exploratory Efficacy Endpoint 
Safety Endpoints 
Safety param eters will include monitoring of AEs, physical examinations, stadiometry, vital signs
(temperature, systolic and diastolic blood pressure, pulse, and respiratory rate), weight and height 
assessments, dual-energy X-ray absorptiometry (DXA) scans for bone mineral densi ty (BMD )and 
body composition measurements (for adolescents aged 11 -17 years, inclusive) , clinical laboratory tests 
(hematology, chemistry, urinalysis; serum pregnancy test, if appropriate ), and adrenocorticotropic 
horm one (ACTH) stimulation tests. To acco unt for the effects of puberty in adolescent subjects (11 -17 
years , inclusive ), BMD z-scores will be adjusted for height z -scores using the Bone Mineral Density in 
Childhood Study calculator (http://www.bmdcspublic.com).
Health Econom ics and Outcom es Resea rch Endpoints 
 Change in Adult Eosinophilic Esophagitis Quality of Life (EoE -QoL- A) score from baseline to 
the final treatment period evaluation (Visit 4)
 Change in EuroQol (EQ-5D; EuroQol -5 Dimensions 3-level [EQ-5D-3L] or EuroQol -5 
Dimensions Youth [EQ-5D-Y], according to subject’s age)score from baseline to the final 
treatment period evaluation (Visit 4)
 Change in Pediatric Quality of Life Inventory –EoE (PedsQL -EoE) score from baseline to the 
final treatment period evaluation (Visit 4)

Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 26of 98
Pharm acokinet ic Endpoints 
Pharm acokinetic param eters will be determined from the plasma concentration -time data for 
budesonide by non-compartmental analysis. The pharmacokinetic param eters will include, but not be 
limited to:
AUC tau Area under the curve for the defin ed interval betw een doses
Cmax Maximum concentration occurring at t max
tmax Time of maximum observed concentration sampled during a dosing 
interval
Statistical Methodology for Prim ary Efficacy Endpoint 
The co-primary efficacy endpoints will be analyzed based on the ITT set. Each of the co-primar y 
efficacy endpoint sis a binary response (ie,responders vs non-responders); the endpoint will be 
analyzed using the Cochran -Mantel- Haenszel (CMH) test adjusting for age group (either <18 years or 
≥18 years) anddiet restriction for EoE or other health -related conditions (no diet restriction or any diet 
restriction) . The adjusted odds ratio of being a responder on each of the co-primary endpoints for the 
OBS 2 mg twice daily group vsplacebo group and associated 95% confidence interval (CI)will be 
provided . Subjects who withdraw without providing efficacy data at the final treatment period 
evaluation ( Visit 4, Week 16) will be classified as non -responders in the primary efficacy analysis.
Additionally, the propo rtion of responders based on each of the co-prim ary endpoints for each 
treatment group will be summarized and their respective 95% CI will be reported. The difference in 
the proportion of responders betw een the 2 treatment groups and the corresponding 95% CI will also 
be summarized.
The follow ing sensitivity and supportive analyses will be perform ed for the co -prim ary to evaluate the 
robustness of the results from the primary analysis methods: 
Each of the co-prim ary efficacy endpoints will be analyzed using a logistic regression with the 
effects of treatment group, age group (either <18 years or ≥18 years) and diet restriction for EoE 
or other health -related conditions (no diet restriction or any diet restriction). The odds ratio of 
being a responder on each of the co-prim ary endpoints for the OBS 2 mg twice daily group vs 
placebo group and associated 95% confidence interval (CI) will be estimated from the final 
model. Subjects who withdraw  without providing efficacy data at the final treatment period 
evalua tion (Visit 4, Week 16) will be classified as non -responders in the primary efficacy analysis.
 Analyses will be repeated using the FAS and the PP set.
 Analyses will be repeated by  considering subjects who withdraw  without providing efficacy data 
at the fin al treatment period evaluation (Visit 4) w ill be classified as responders.
Statistical Methodology for Key Secondary Efficacy Endpoint
The key secondary efficacy endpoint is defined as the change in the DSQ combined score 
(questions 2+3) from baseline to the final treatment period evaluation (Visit 4). The change from 
baseline DSQ score at the final treatment period evaluation (Visit 4) will be analyzed using an analysis 
of covariance (ANCOVA) model with treatment group and age group as factors and the baseline DSQ 
score as a continuous covariate.
Statistical Methodology for Secondary Efficacy Endpoints
Secondary subjective efficacy endpoints that are defined as:
 Binary response endpoints will be analyzed using the same logistic model as the co-primar y 
efficacy endpoints .
Shire CONFIDENT IAL 17December 2015
Protocol SHP621 -301 Amendment 1 Page 27of 98
 Continuous endpoints will be analy zed as a change from baseline using an ANCOVA model that 
includes treatment group and age group as factors and baseline score as a continuous covariate .
The analyses for all secondary efficacy endpoints (inc luding the key secondary efficacy endpoint) will 
be carried out using 2-sided tests at the 5% level of significance. For each of the secondary efficac y 
endpoints, the treatment difference , corresponding 95% CIfor the difference, and treatment 
comparison p -value for testing the null hypothesis of zero treatment effect based on the final statistical 
model (ie, either logistic regression model or ANCOVA model) will be provided.
Statistical Methodology for Safety Endpoints 
All safety measures, including AEs, physical examination, stadiometry, vital signs (temperature, 
systolic and diastolic blood pressure, pulse, and respiratory rate), w eight and height assessments, DXA 
scans for BMD and body composition measurements (for adolescents aged 11-17 years, inclusiv e), 
clinical 
laboratory results (hematology, chemistry, urinalysis; serum pregnancy test, if appropriate), 
and ACTH stimulation will be descriptively summarized by treatment group at baseline and for each 
post-baseline visit.
The number and percent of subjects with TEAEs will be presented. TEAEs are defined as AEs that 
start or deteriorate on or after the date of the first dose of investigational product and no later than 
3days following the last dose of investigational product. However, for any subjects w ho die during the 
study (ie, the date of death is betw een the date of first dose of investigational product and the date of 
study discontinuation entered by the site, inclusive), all AEs (including those resulting in death) that 
occur during the study willbe considered as TEAEs irrespective of the last dose and will be included 
in the TEAE summaries. 
Statistical Methodology for Pharm acokinetic Endpoint(s) 
Summary statistics (number of observations, mean, standard deviation, coefficient of variation, 
medi an, maximum, minimum, and geometric mean) will be determined for all pharmacokinetic 
parameters by overall and by week. Plasma concentrations at each nominal sampling time will also be 
summarized using descriptive statistics .
Sample Size Justification
Based on at least a 30-percentage -point reduction in DSQ score, there is an expected difference 
betw een treatment response proportions of 69% and 45% in the OBS 2mg twice daily (qAM, pc, and 
hs) a
nd placebo groups, respectively. Atotal of 228subjects (152subjects random ized to OBS and 
76subjects randomized to placebo) are required to achieve 90% power at the significance level of 
0.0499 ( 2-sided) using a 2-group chi-square test with unequal allocation 2:1 to treatment groups (OBS 
2mg twice daily and place bo). With the specified number of subjects per treatment group, the study 
will be powered at 99% assuming histological response proportions of 40% and 3% in the OBS 2mg 
twice daily and placebo groups, respectively. The overall study power for the co-prim ary endpoi nts 
will be at least 85%. There fore, approximately 228 (approximately 152:76OBS and placebo subjects, 
respectively ) will be randomized 
to the study to allow for a loss of approximately 5% of subjects due 
to dropouts or invalid data.   Expected res ponse and dropout rates are based on observation in the Phase 
2 study (MPI 101 -06).
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 28of 98
STUDY SCHEDULE(S)
Table 1-1: Schedule of Assessments
ProceduresScreeningPlacebo 
Lead -in Treatm ent PhaseSafety 
Follow -up 
Telephone 
Contactp
Visit -1 Visit 0Randomization 
Baseline/Visit 1Visit 2 Visit 3 Visit 4 
or ETo Visit 5
Week -6 0 4 8 12 16 20
Window ≤6 weeks -- ±3 days ±3 days ±3 days ±3 days ±3 days
Informed consent/assent X
Medical history review X
Inclusion/exclusion criteria review X X X
Vital signsa; heightband w eight 
assessmentX X X X X X
EGD w ith endoscopy score (EREFS) and 
biopsyc X X
DSQ training and issue of handset X
Retrieval of DSQ handset X
DSQ completion Once daily completion
DSQ compliance assessment X X X X X
EQ-5DdX X
PedsQL -EoE (subjects 11 -17 years of 
age, inclusive)X X
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 29of 98
Table 1-1:Schedule of Assessments
ProceduresScreeningPlacebo 
Lead -in Treatm ent PhaseSafety 
Follow -up 
Telephone 
Contactp
Visit -1 Visit 0Randomization 
Baseline/Visit 1Visit 2 Visit 3 Visit 4 
or ETo Visit 5
Week -6 0 4 8 12 16 20
Window ≤6 weeks -- ±3 days ±3 days ±3 days ±3 days ±3 days
EoE-QoL- A (subjects ≥18 years of age) X X
PGI-S X X X X
Physical examination X X X X X X
Tanner Staging AssessmenteX X
Clinical laboratory testsfX X X X X X
UrinalysisgX X X X X X
Pregnancy testhX X X X X X
Morning cortisol (tar get 6:00 -9:00 AM) X X X X
ACTH stimulation testing X X
Blood pharmacokinetic sampling 
(subjects ≥18years of age)i X X
DXA Scan 
(subjects 11 -17years of age, inclusive)j X X
RandomizationkX
Investigational product supplied X X X X Xl
Investigational product administrationmTwice-daily administration of investigational product
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 30of 98
Table 1-1:Schedule of Assessments
ProceduresScreeningPlacebo 
Lead -in Treatm ent PhaseSafety 
Follow -up 
Telephone 
Contactp
Visit -1 Visit 0Randomization 
Baseline/Visit 1Visit 2 Visit 3 Visit 4 
or ETo Visit 5
Week -6 0 4 8 12 16 20
Window ≤6 weeks -- ±3 days ±3 days ±3 days ±3 days ±3 days
Investigational product compliance 
assessmentX X X X
Concomitant medications and procedures 
recorded X X X X X X X
Revie w of adverse even tsnX X X X X X
Abbreviations: ACTH=adrenocorticotropic hormone; DSQ=Dysphagia Symptom Questionnaire; DXA=dual -energy X-ray absorptiometry; 
EGD=esophagogastroduodenoscopy; EoE-QoL- A=Ad ult Eosinophilic Esophagitis Quality of Life; EQ-5D=EuroQol; EQ-5D-3L=EuroQol -5 Dim ension 3-level; EQ-
5D-Y=EuroQol -5 Dimensions Youth; EREFS=EoE Endoscopic Reference Score; hs=at bedtime; IWRS=interactive web-based response system; PedsQL -
EoE=Pediatric Quality of Life Inventory – EoE; pc=after meals; PGI -S=Patient Global Imp ression of Severity; qAM=every morning
aVital signs will be assessed after the subject has been in a supine position for at least 5 minutes immediately prior to the assessment and will include blood 
pressure (systolic and diastolic), heart rate, respiration s, and temperature.
bHeight to be collected at screening visit (Visit -1) and Visit 4 for all subjects. Stadiometers are required for subjects 11 -17 years of age, inclusive, and w ill be used 
at Visit - 1 and 4.
cPre-treatment endoscopy will be performed durin g the screening period (at least 2 weeks prior to placebo lead-in visit [Visit 0] to allow  adequate time for 
processing and central review). Endoscopy should include esophageal (proximal, mid-, and/or distal), gastric, and duodenal biopsies. Final treatmen t evaluation 
EGD must include esophageal biopsies; gastric and duodenal biopsies may be done at the discretion of the investigator. Final treatment evaluation EGD should 
occur at or w ithin (±) 7 days of the scheduled visit.  
dSubjects 11 -17 years of age, i nclusive, will complete t he EQ -5D-Y; subjects ≥18 years of age will complete the EQ -5D-3L. 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 31of 98
eTanner staging assessments will be performed for all subjects aged ≥11 years until investigator confirms subject is post pube rty.
fClinical laboratory tests will include the following: alkal ine phosphatase, aspartate aminotransferase, alanine aminotransferase, total bilirubin, total protein, 
albumin, glucose, blood urea nitrogen, creatinine, sodium, potassium, chloride, calcium, carbon dioxide, hemoglobin, hematocr it, mean corpuscular hemoglo bin, 
mean corpuscular hemoglobin concentration, mean corpuscular volume, erythrocyte count, leukocyte count, neutrophils, lymphocy tes, monocytes, eosinophils, 
basophils, and platelet count. All subjects must fast overnight prior to collection.
gUrinalysis p aram eters will include glucose, protein, specific gravity, pH, nitrite, bilirubin, ketones, hemoglobin, urobilinogen, and leu kocyte esterase.
hThe serum pregnancy test will be performed for all female subjects at the screening visit (Visit -1) and final treatment evaluation (Visit 4). Urine pregnancy tests 
will be performed at all other visits.
iBlood sam ples for pharmacokinetic analysis will be taken from adult subjects (aged ≥18 years). Subjects who do not participate in pharm acokinetic sampling will 
not be discontinued from the study and lack of participation will not be a considered protocol deviation. Blood samp les for pharmacokinetic analysis will be 
obtained at the Week 8 or Week 12 visit at the following time points: pre -dose and at 0.5, 1, 2, 3, 4, 6, 8, and 12 hours post -dose. 
jThe baseline DXA scan may be performed any time during the plac ebo lead -in period after the subject has met all screening criteria and prior to blinded- treatment 
randomization. Baseline and post-treatment DXA scans should be performed using the same machine and software. Post-treatment DXA scan should occur at or 
within (±) 7 days of the scheduled visit.
kRandomization will occur via IWRS at the baseline visit (Visit 1) once the subject’s eligibility for study entry is confirmed . 
lInvestigational product will be dispensed at Visit 4 to subjects who consent to enroll in the treatment extension study.
mSubjects will receive oral administration of 10 mL of investigational product twice daily  (qAM, pc, and hs), with no ingestio n of food or liquids permitted for 
30minutes after study drug administration.
nAE assessments at each visit and physical examination must include specific assessments for signs of glucocorticoid excess (eg, moon facies, acne, hirsutism, 
mood swings, insomnia, and depression).
oIf subject discontinues study prematurely, the evaluations listed for Visit 4 a re to be performed as completely as possible.
pFor subjects who withdraw from the study or do not continue into treatment extension study, a safety follow -up contact by phone will be performed 4 weeks 
following the last dose of investigational product.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 32of 98
1. BACK GROUND INFORMATION
1.1 Indication and Current Treatment Options 
Eosinophilic esophagitis (EoE) is defined as “a chronic, immune/antigen -mediated esophageal 
disease characterized clinically  by symptoms related to esophageal dysfunction and 
histologically  by eosinophil- predominant inflammation” (Liacouras et al., 2011). Clinical 
symptoms of EoE often vary by age: Infants and toddlers present with feeding difficulties; 
school -aged children are more likely  to present with vomiting or pain; and adolescents and 
adults present with dysphagia and food impaction. When these symptoms are present, the 
diagnosis is confirmed by  finding eosinophilic inflammation of ≥15 eosinophils/high
-power ed
field (HPF) on at least 1 esophagea l biopsy  and when other causes such as proton pump 
inhibitor (PPI)-responsive esophageal eosinophilia are excluded ( Dellon et al., 2014a ; Furuta 
et al., 2007 ).The s tandards of care are diet therapies and off -lab el use of glucocorticosteroids.
Esophageal dilation is used to temporarily  relieve symptoms but does not address underl ying 
inflammation. Given the clinical outcomes associated with EoE, including severe dysphagia, 
esophageal stricture, food impaction, and esophageal perforation (Hirano and Aceves , 2014;
Liacouras e
t al., 2011 ) and the fact that there are currentl y no FDA -approved treatments, there 
is a clear unmet medical need for a novel treatment for this disease.  
1.2 Product Background and Clinical Information
Oral budesonide suspension (OBS) consists of budesonide formulated in a viscous suspension 
that is designed to inc rease the residence time of budesonide on the surface of the esophagus 
after swallowing compared to a non-viscous suspension . Shire is developing OBS as a 
first-line therap y for EoE in adolescents and adults.
The nonclinical pharmacology , pharmacokinetics , and toxicity  and the clinical pharmacology , 
pharmacokinetics, and safety  of budesonide are well studied because budesonide is present in 
several US FDA -approved drug products. Budesonide is currently marketed for the 
management of Crohn’s disease, for as thma maintenance, for the treatment of allergic rhinitis, 
and for induction of remission in patients with active, mild to moderate ulcerative colitis. 
Budesonide has strong glucocorticoid receptor affinity  and is subject to considerable first pass 
metaboli sm by the liver with a short half-life. These attributes permit budesonide to act 
rapidly  and locall y in the gut mucosa for treatment of inflammatory  disorders such as Crohn’s 
disease and ulcerative colitis. Once absorbed into the systemic circulation, budesonide is 
rapidly  metabolized in the liver and inactivated ( FDA ,
2011).
The efficacy  of OBS for the treatment of EoE has been demonstrated in 
two Phase 2 studies in 
the OBS clinical development program. Studies MPI 101-01 and MPI 101- 06 evaluated the 
efficacy  of OBS in the treatment of EoE in children and adolescents aged 2-18 years and in 
adolescents and adults aged 11-40 years, respectively , by measuring histological response 
(defined as mean peak eosinophil count ≤6/HPF after treatment). Study  MPI 101 -06 also 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 33of 98
evaluated symptom response as measured by the Dysphagia Symptom Questionnaire (DSQ). 
The DSQ contains 4 questions related to consumption of solid food, the presence of d ysphagia 
and its severity , as well as pain. The DSQ score is calculated only from responses to the
questions related to dysphagia ,and this clinical outcome assessment was considered to be fit 
for purpose as a result of the MPI 101-06 study . Results from Study  MPI 101-01 
demonstrated a statistically  significant histologic response (eosinophil count ≤6/HPF) and 
remission (eosinophil count ≤1/HPF) in the medium -dose (1.4-2.0mg daily) and high-dose 
(2.8-4.0mg daily ) OBS groups compared to placebo following 12 weeks of treatment. 
In Study MPI101-06, a significant treatment effect for OBS vs placebo was shown for both 
the co-primary  efficacy endpoints of histologic response and change from baseline in 
dysphagia symptoms. Following 12weeks of twice daily  treatment (once in the morning after 
meals[qAM, pc] and at bedtime [hs]), OBS -treated subjects demonstrated a highl y consistent 
reduction from baseline values for cellular (mean peak eosinophil count and histopathology  
features), organ (endoscopy  score) ,and holistic measures (Phy sician Global Assessment 
[PGA] and DSQ scores); these results were independent of the type of rater/reviewer (central 
pathologist, phy sician at the study  site, or subject). 
Alway s refer to the latest version of the SHP621 investigator’s brochure for the overall 
risk/b enefit assessment and the most accurate and current information regarding the drug 
metabolism, pharmacokinetics, efficacy ,and safety of SHP621. 
2. STUDY OBJECTIVES AND PURPOSE
2.1 Rationale for the Study
Currently  there is no approved medication for the treatme nt of EoE. This study  is being 
conducted in order to provide safet y and efficacy  data demonstrating histologic response (as 
measured by eosinophilic count ≤6/HPF ) and improvement in dysphagia symptoms (as 
measured by the DSQ) following 12 weeks of treatment with OBS in adolescent and adult 
subjects with EoE .
2.2
Study Objectives
2.2.1 Primary Objectives
The co -primary  objectives of the study  areto demonstrate in a placebo- controlled trial that:
OBS induces a histologic response (eosinophilic count ≤6/HPF) in adolesc ent and adult 
subjects with EoE over a 12- week course of therapy .
OBS reduces dysphagia, as measured by the DSQ ,by at least 30% from baseline in 
adolescent and adult subjects with EoE over a 12-week course of therap y .
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 34of 98
2.2.2 Secondary Objectives
The key seconda ry objective of this study  is:
OBS reduces dysphagia, as measured by the DSQ score from baseline to the final 
treatment period evaluation (Visit 4). 
Additional secondary  objectives of the study  are:
To assess the response of endoscopicall y identified esophageal features to OBS as 
compared to placebo as measured b y the 
EoE Endoscopic Reference Score (EREFS) 
To explore other responding criteria based on histology  and DSQ
To assess the impact of OBS on pain, as measured by  the DSQ pain score
To evaluate the safet y and tolerability  of OBS over a 12- week course of therapy  
To obtain OBS pharmacokinetic data in adult subjects with EoE
2.2.3 Exploratory Objective
Theexploratory  objective of this study  is:
3. STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 3, randomized, multicenter, double -blind, parallel
-group, placebo- controlled 
study  to evaluate the efficacy  and safet y of OBS treatment administered twice daily  (qAM, 
pc, and hs) for 12weeks. The study  will be conducted in adolescents and adults, aged 
11-55years, inclusive, with EoE and dy sphagia . 
Approximately  300 subjects will be enrolled in the placebo lead-inperiod to allow for 
appro ximately  228 subjects to be randomized into the double -blind treatment period . A 
minimum of 40 randomized subjects will be aged 11-17 years, inclusive . Subjects will be 
randomized 2:1 (approximately  152and 76per OBS and placebo treatment group, 
respectiv ely) to rec eive either OBS 2 mg twice daily  (qAM, pc, and hs) or placebo twice dail y 
(qAM, pc, and hs) .  
This study  will consist of 3 periods: a 3-to 6-week screening period , 4-week single -blind 
placebo lead -inperiod, and a 12-week double -blind treatment period (see Figure 1).

Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 35of 98
Figure 1:Study Design Flow Chart
Abbreviations: BID=twice daily; EGD= esophagogastroduodenoscopy ; ET=end of treatment; OBS=oral 
budesonide suspension
The upper limit of 55 years, inclusive ,was selected for this study  population based on the low 
prevalence of EoE in older patients ( Dellon et al ., 2014a ) and the fact that the ty pe of EoE that 
develops in older patients is not amenable to anti-inflammatory  treatment alone ( Dellon et al.,
2014b). A natural history  study demonstrated that for every  decade of life, the odds of 
developing the fibrostenotic phenoty pe of EoE more than doubles (Dellon et al., 2014b). By 
age 55, fibrostenotic EoE occurs in approximately  80% 
of patients. Fibrostenotic disease is 
treated with dilatation and is not amenable to anti-inflammatory  treatment alone. Therefore, 
budesonide is not expe cted to be an effective treatment for the majority of patients above 
age55.
Subjects will be required to visit the site up to 6 times over up to a 22-week period. Following 
completion of the screening and placebo lead-invisits, subjects will be evaluated for 
eligibility  and 
safet y at Week 4 (Visit 1). Subjects who are eligible and randomized will be 
evaluated for efficacy  and safet y at Weeks 8,12, and 16 (Visits 2-4) and additionally  for 
safet y at follow -
up at Week 20(Visit 5; telephone contact ). Subjec ts who fail to meet all 
eligibility  criteria at Visits -1, 0 ,or 1 will be considered screen failures. Subjects cannot be 
rescreened once it is confirmed they  do not meet inclusion/exclusion criteria unless the screen 
failure was due to a concomitant medication that can be discontinued prior to rescreening; 
those subjects may be rescreened. Other reasons for rescreening (ie, reasons unrelated to 
inclusion/exclusion criteria) must be discussed prospectivel y with the medical monitor . 
Subjects who discontinue will not be replaced. 
The screening period will start when subjects sign informed consent (or assent as applicable 
for subjects <18yearsof age; screening visit [Visit - 1]) and will be approximately  3- 6weeks 
in duration. During the screening period , allsubjects will receive an upper endoscop y with 
histologic analysis of biopsy  specimens to confirm the diagnosis of EoE (eosinophil count of 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 36of 98
≥15/HPF from 2 of 3[proximal, mid-,and/or distal] levels of the esophagus ). In addition, 
subjects must complete the DSQ daily  during the screening period (3-6 weeks) and have at 
least 4 reported days with symptoms of dysphagia and completed the DSQ on ≥70% of days 
in any 2consecutive weeks. At the screening visit (Visit -1), subjects who are on a PPI must 
remain on the same dose of the PPI throughout the study ; if they are not taking a PPI, they 
must remain off of a PPI for the remain der of the study . After the screening period, eligible 
subjects will enter a 4-week single -blind placebo lead-inperiod and will receive 10mL of 
OBS placebo twice daily  (in the morning after meal s/breakfast [qAM, pc] and at bedtime 
[hs]). The placebo lead-inperiod will enable assessment of the subject’s ability  to comply 
with twice daily medication administration and assess whether the subject experiences a 
placebo response. 
At the end of the placebo lead-inperiod, subjects will return for the baseline visit (Visit 1) to 
confirm eligibility . Subjects who continue to meet all eligibility  criteria (those with at least 
4reported dysphagia days and who completed the DSQ on ≥70% of days in the 2 weeks prior 
to randomization per daily  DSQ completion) will be randomized to receive either OBS or 
placebo during the 12 -
week double -blind treatment period. 
OBS will be administered in 10 mL at a concentration of 0.2 mg/mL (2mg dose), twice daily . 
The 0.2 mg/mL concentration of OBS and dosing regimens were selected for use in this 
Phase 3 study  based on the results of Study MPI  101-06, a Phase 2 study  in 93adolescent and 
adult subject s with EoE and symptoms of dysphagia . Subjects were treated in 
Study MPI 101
-06 with 2mg OBS twice daily to investigate theco-primar y endpoints of 
histologic response (defined as ≤6 eosinophils/HPF) and reduction in DSQ score from 
baseline to Week 12 of treatment .For the current study , the investigational product will be 
supplied in amber glass, multi- dose bottles with child- resistant caps and refrigerated 
through out the study  (in the clinic and subject’s home) . Each bottle will contain 
approximately 210mL of suspension with a budesonide concentration of 0.2 mg/mL, or 0.00 
mg/mL  (matching placebo).
At the end of the 12-week double -blind treatment period (Visit 4, Week 16), subjects who 
complete the study  will have the opportunity  to enroll in the treatment extension study . These 
subjects will continue on the blinded assigned treatment for 2 -4 weeks as part of the screening 
prior to enrolling into the treatment extension study . Subjects who do not enroll in the 
treatment extension study  or who discontinue at any time during the SHP621 -
301(Induction) 
study  will receive a follow -up phone call4weeks post last dose of investigational product
(Visit 5) .
3.2 Duration and Study Completion Definition
The subject’s maximum duration of participation is expected to be approximately  26 weeks, 
depending on the 3- to 6-week screening period.
The study  will be completed in approximately 32months
.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 37of 98
The Study Completion Date is defined as the date the final subject, across all sites, completes 
their final protocol -defined assessment. Please note that this includes the follow -up visit or 
contact, whichever is later. The Study  Completion Date is used to asce rtain timing for study 
results posting and reporting.
A completer is a subject who completes all procedures and assessments up to and including  
Visit 4(Week 16), inclusive of the final treatment evaluation EGD .Subjects who do not 
enroll in the treatment extension study  or who discontinue prematurel y at any time during the 
SHP621-301 (Induction) study  will receive a follow - up phone call4weeks post last dose of 
the investigational product to which they were randomized .
3.3 Sites and Regions
Approximately  60 s ites in North America will participate.
4. STUDY POPULATION
Each subject must participate in the informed consent process and provide written informed 
consent/assent before any procedures specified in the protocol are performed.
4.1 Inclusion Criteria
The subject will not be considered eligible for the study  without meeting all of the following 
criteria (including test results) :
1.Subject is able to provide written informed consent (subject, parent or legal guardian ,and, 
as appropriate, subject assent) to participa te in the study  before completing any 
study -related procedures.
2.Subject is male or female aged 11-55 years, inclusive ,at time of consent. 
3.
Subject has histologic evidence of EoE with a peak eosinophil count of ≥15/HPF, from 2 
of 3 (proximal, mid - ,and/or distal) levels of the esophagus at the screening endoscopy .
4. Subject has a history  of clinical symptoms of esophageal dysfunction (eg, eating 
problems, abdominal pain, heartburn, dysphagia, vomiting, food impacti on, weight loss) 
intermittently  or continuously  at screening (Visit -1).
5. Subject must have experienced dysphagia (response of “yes” to question 2 on DSQ) on a 
minimum of 4days and completed the DSQ on ≥70% of days inany 2 consecutive weeks 
of the screening period and in the last 2 weeks prior to the baseline visit (Visit 1). 
6. Subject must not have PPI-responsive EoE based on esophageal biopsies performed after 
the patient has been on at least 8 weeks of high-dose PPI therapy  (high-dose therapy  refers 
to the total daily  dose, which may  have been administered as a once -or twice daily dosing 
regimen). This may occur at the time of the qualify ing EGD (in which case the same PPI 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 38of 98
regimen must be continued) ,or this may have been done previousl y (in which case PPI 
therap y may have been stopped if there was no response to therapy  based on esophageal 
biopsy  results). If PPI responsiveness was excluded by a previous EGD and biopsy , the
historical EGD and biopsy  must have been performed after the patient had been on a 
minimum of 6 weeks of high -dose PPI therapy .
7. Subject will be on a stable (no changes) diet ≥3 months prior to the screening visit
(Visit -1).
8.
Subject is willing and able to continue any dietary  therap y, environmental therapy , and/or 
medical regimens (including gastric acid suppression; see exclusions below) in effect at 
the screening visit (Visit-1).There should be no change to these regimens during study  
participation.
9. All female subjects must have a negative serum pregnancy  test (beta-human chorionic 
gonadotropin [β-hCG]) prior to enrol lment into the study . Females of childbearing 
potential must agree to continue acceptable birth control measures (eg, abstinence, stable 
oral contraceptives, or double -barrier methods) throughout stud y participation.
10. Subject is willing and has an understanding and ability  to fully  comply  with study  
procedures a nd restrictions defined in this protocol.
4.2 Exclusion Criteria
Subjects are excluded from the study  if an y of the following exclusion criteria are met : 
1. Subject has any condition or abnormality  (including laboratory  abnormalities), current or 
past, that, in the opinion of the principal investigator or medical monitor , would 
compromise the safety  of the subject or interfere with or complicate the assessment of 
signs or symptoms of EoE. Such conditions may  include psy chiatric problems; neurologic 
deficits or disease; developmental delay ; cardiovascular, metabolic, or pulmonary  disease; 
or previous gastroesophageal surgery . 
These should be discussed with the medical 
monitor .
2. Subject has used immunomodulatory  therap y within 8 weeks prior to the qualify ing EGD 
or between the qualify ing EGD and baseline visit (Visit 1)or anticipates using
immunomodulatory  therapy  during the treatment period (except for any ongoing 
regimen 
of allergy  shots). Use of long-acting immunomodulatory  therap y (eg, Rituxan) within 
3months of the qualify ing EGD should be reviewed with the medical monitor .
3. Subject has been using swallowed topical corticosteroid for EoE or systemic 
corticosteroid for any condition within the 4 weeks prior to the qualify ing EGD, between 
the qualify ing EGD and baseline visit (Visit 1),or anticipates use during the treatment 
period
; any  temporary  use(≤7 day s)or initiation of new steroid treatment during the study 
should be documented and discussed with the medical monitor prospectively  but cannot 
occur within 4 weeks of the final EGD . 
4. Subject has been on inhaled steroids andhas not been on stable treatment for ≥3 months 
prior to screening visit (Visit -1).Subjects on inhaled steroids need to stay on a stable 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 39of 98
treatment during study  participation. Subject has been on intranasal steroids and has not 
been on stable treatment for a minimum of 4 weeks prior to the qualify ing EGD. After the 
qualify ing EGD, subjects with seasonal allergic rhinitis may resume (or discontinue) 
intranasal corticosteroids based on the subje ct's usual treatment regimen for allergy  
season.
5. Subject has initiated, discontinued, or changed dosage regimen of PPIs, H2 antagonists, 
antacids, orleukotriene inhibitors for any condition (such as gastroesophageal reflux 
disease, asthma or allergic rhinitis) within the 4 weeks prior to the qualify ing EGD, 
between the qualify ing esophagogastroduodenoscopy  (EGD )and baseline visit (Visit 1), 
or anticipates changes in the use of such medications during the treatment period .  
6.
Subject has been using cytochro me P450 3A4 (CYP450 3A4) inhibitors (eg,
ketoconazole, grapefruit juice) within the 2weeks prior to the baseline visit (Visit 1)or 
within 5 half-lives (whichever is greater) or anticipates using such medications during the 
treatment period .  
7.
Subject has an appearance on qualify ing EGD of an esophageal stricture (high -grade), as 
defined by the presence of a lesion that does not allow passage of a diagnostic adult upper 
endoscope (eg, with an insertion tube diameter of >9 mm). 
8.Subject ison a pure liquid diet or the 6-food elimination diet .
9. Subject has had an esophageal dilation within the 3 months prior to screening (Visit -1).
10.Subject has presence of esophageal varices at the screening endoscopy .
11.
Subject has any current disease of the gastrointestinal tract, aside from EoE, including 
eosinophilic gastritis, enteritis, colitis, or proctitis; inflammatory  bowel disease ; or celiac 
disease. 
12. Subject has other diseases causing or associated with EoE, including hypereosinophilic 
syndrome, collagen vascular dise ase, vasculitis, achalasia, or parasitic infection.
13.Subject has current evidence of oropharyngeal or esophageal candidiasis.
14. Subject has acute or chronic viral infection or immunodeficiency  condition, including 
tuberculosis, fungal, bacterial, viral/parasi te infection, ocular herpes simplex, herpes 
esophagitis, or chicken pox/measles .
15. Subject has upper gastrointestinal bleeding within 4 weeks prior to the screening visit
(Visit -1) or between the screening visit and baseline visit (Visit 1).
16.Subject has evi dence of active infection with Helicobacter pylori.
17. Subject has evidence of unstable asthma within 4 weeks prior to the screening visit
(Visit -1) and between the screening visit and baseline visit (Visit 1).
18.
Subject is female and pregnant or nursing.
19.Subject has a history  of intolerance, hypersensitivity , or idiosy ncratic reaction to 
budesonide (or any other corticosteroids) or to any other ingredients of the investigational 
product .
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 40of 98
20. Subject has taken part in an interventional study  related to EoE within 6months prior to 
the screening visit (Visit -1), or any investigational study  within 30days prior to the 
screening visit (Visit -
1).
21.Subject has a history  or high risk of noncompliance with treatment or regular clinic visits.
22.Subject has previously  comple ted, discontinued, or withdrawn from this study .
23. Subject has participated in a previous clinical study involving OBS (SHP621).
24.Subject anticipates using sucralfate during the study.
4.3 Restrictions
Subjects must adhere to the following restrictions for the du ration of the study :
No change in exercise (other than seasonal changes in sports or activities). Intense 
exercise should be avoided unless part of an established exercise routine. 
No change in diet ( liquid diet for 3 day s or less is acceptable) .
Short course of systemic steroids (≤7 days) are permitted to treat, for example, 
exacerbation of asthma but cannot be used 4 weeks prior to the final EGD .
Stable treatment with intranasal or inhaled corticosteroids. For subjects with perennial 
allergic rhinitis and stable asthma, the topical corticosteroid must be maintained at the 
same dose throughout the study . For subjects with seasonal allergic rhinitis, it is 
permissible after the qualify ing EGD to resume (or discontinue) intranasal corticosteroids 
based on the subject's usual treatment regimen for allergy  season. All topical 
corticosteroid dosing changes, including those for seasonal allergic rhinitis, should be 
avoided within 4 weeks prior to the Week 16 EGD. Subjects who require a change in 
inhaled corticost eroid treatment for an asthma exacerbation should be discussed with the 
medical monitor.
No change in PPI use
No use of CYP450 3A4 inhibitors
No use of sucralfate during the stud y as this may interfere with the adherence of OBS
An esophageal dilatation during the trial (Dilatation is considered a treatment failure ,and 
the subject should be withdrawn from the study .)
4.4 Reproductive Potential
4.4.1 Female Contraception
All females must have a negative pregnancy  test at the screening visit (Visit -1), placebo 
lead-invisit (Visit 0),baseline visit (Visit 1), and Visits 1-4.A serum pregnancy  test will be 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 41of 98
performed at the screening visit (Visit -1)and final treatment evaluation (Visit 4). Urine 
pregnancy  tests will be performed at all other visits.   
Female subjects should be either:
Pre-
menarchal and Tanner Stage 1, or
Post-menopausal (24 consecutive months of spontaneous amenorrhea and age 51 yearsor 
older ).
Be surgicall y sterile (having undergone one of the following surgical acts:  hysterectom y, 
bilateral tubal ligation, bilateral oophorectomy  or bilateral salpingectomy ) and at least 
6weeks post -sterilization, or
Females of child- bearing potential must agree to abstain from sexual activity  that could 
result in pregnancy  or agree to use acceptable methods of contr aception throughout the 
study  period and for 30 day s following the last dose of investigational product.
Acceptable methods of contraception are:
 Intrauterine devices plus condoms
 Double- barrier methods (eg,condoms and diaphragms with spermicidal gel or 
foam)
 Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), 
stabilized for at least 30 days prior to the screening visit (Visit -1), plus condoms .If 
hormonal contraceptives are used, they should be administered according to the 
package insert. Note: If subjects become sexually  active during the study , they should 
use one of the other acceptable methods noted above in addition to the hormonal 
contraceptive until it has been stabilized for 30 days.
4.5 Discontinuation of Subjects
A subject may withdraw from the study  at any time for any reason without prejudice to their 
future medical care by the physician or at the institution. The investigator or sponsor may 
withdraw the subject at any time (eg,in the interest of subject safet y).The invest igator is 
encouraged to discuss withdrawal of a subject from investigational product with the medical 
monitor when possible.
If investigational product is discontinued, leading to subject discontinuation from the study , 
regardless of the reason, the evalua tions listed for Visit 4are to be perfor med as completel y as 
possible. If investigational product is discontinued due to an AE, the subject may remain on 
study  to allow for completion of study  procedures. 
Whenever possible, all discontinued subjects should also undergo the protocol -specified 
follow -up. Comments (spontaneous or elicited) or complaints made by the subject must be 
recorded in the source documents. The reason for termination, date of stopping investigational 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 42of 98
product, and total amount of inves tigational product taken must be recorded in the case report 
form ( CRF )and source documents.
Subjects who discontinue will not be replaced. 
4.5.1 Subject Withdrawal Criteria
Medically  important events that in the opinion of the investigator or medical monitor would 
compromise the subject’s ability  to safel y continue in the study , including but not limited to 
an esophageal stricture requiring dilation and/or worsening signs and symptoms of EoE (eg, 
weight loss or increased dysphagia), would be considered a treatment failure and result in 
withdrawal of the subject from the study .
4.5.2 Reasons for Discontinuation
The reason for withdrawal must be determined by the investigator and recorded in the 
subject’s medical record and on the CRF. If a subject is withdrawn for more than 1reason, 
each reason should be documented in the source document and the most clinically  relevant 
reason should be entered on the CRF.
Reasons for discontinuation include but are not limited to:
 Completed
 Death
 AE
 Non-compliance with study  drug
 Non-compliance with study  procedure
 Withdrawal by  subject
 Withdrawal by  parent/guardian
 Physician decision
 Study  terminated by  sponsor
 Site terminated by  sponsor
 Lost to follow -up
 Pregnancy
 Trial screen failure
 Protocol deviation
 Other 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 43of 98
4.5.3 Subjects “Lost to Follow- up” P rior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact any subject lost to follow -up 
at any  time point prior to the last scheduled contact (offic e visit or telephone contact). At least 
1of these documented attempts must include a written communication sent to the subject’s 
last known address via courier or mail (with an acknowledgement of receipt request) asking 
that they return to the site for final safet y evaluations and return any unused investigational 
product.
4.5.4 Safety -related Stopping Rules
An urgent safet y review will be conducted within 7 days by the sponsor if one or more of the 
following criteria are met:
Death that is considered related to the study  drug
Two SAEs of similar type (defined as same or similar Medical Dictionary  for Regulatory 
Activities [ MedDRA ]higher level group code) and considered related to the study  drug
The urgent review will be performed by  a sponsor safet y review group, which will include the 
study  Pharmacovigilance and Risk Management (PVRM) physician and the PVRM 
Therapeutic Area Head. The PVRM Therapeutic Area Head, not the PVRM physician 
involved in the study , may be unblinded as part of this urgent safet y review, if required. 
Following the sponsor’s review of safet y data, one of th e following actions will be taken with 
respect to stud y status:
Continue study  with protocol unchanged
Continue study  with modifications to the protocol
Terminate stud y
Subject safet y will be monitored 
on a continuous basis during this study  until the last subject 
completes his or her last scheduled stud y visit/assessment. 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 44of 98
5. PRIOR AND CONCOMITAN T TREATMENT
All non-study  treatment (including but not limited to herbal treatments, vitamins, behavioral 
treatment, and non-pharmacological treatment, such as psychotherapy , as appropriate)
received within 3months prior to the screening visit (Visit
-1) (or pharmacokinetic equivalent 
of 5half-lives, whichever is longer) and through the final study  contact (including 
protocol -defined follow -up period) must be recor ded on the appropriate CRF page.
5.1 Prior Treatment
Prior treatment includes all treatment , including but not limited to herbal treatments, vitamins, 
and non-pharmacological treatment such as psychotherap y ,as appropriate ,received within 
3months of the screening visit (Visit -1). Prior treatment information must be recorded on the 
appropriate CRF page.
5.2 Concomitant Treatment 
Concomitant treatment refers to all treatment taken between the dates of the first dose of 
investigational product and the end of the follow -up period, inclusive. Concomitant treatment 
information must be recorded on the appropriate CRF page.
The investigator may prescribe additional medications during the study , as long as the 
prescribed medication is not prohibited by the protocol. In the event of an emergency , any 
needed medications may be prescribed without prior approval, but the medical monitor must 
be notified of the use of any  prohibited medications immediately  thereafter.
5.2.1 Permitted Treatment
The following medications are allowed during the course of the study  if the subject has been 
on a stable dosing regimen (ie, same dose and frequency  in the previous 4 weeks prior to the 
endoscop yrequired for entrance to this study) and will continue this dosing regimen 
throughout study  partici pation. The investigator must contact the medical monitor
to discuss 
any changes to concomitant steroid regimens or for any medications not listed here that could 
impact the outcome of the study .
1.Inhaled or intranasal steroids for conditions other than EoE ; subject must be on stable 
treatment for ≥3months prior to screening visit (Visit -1), except for seasonal allergic 
rhinitis, see Section 4.3.
2.PPIs
3.H2 antagonists
4.Antacids
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 45of 98
5.Antihistamines or antileukotrienes
6.Maintenance immunotherap y (allergy  shots)
Influenza and other routine required vaccinations are allowed during the study .
5.2.2 Prohibited Treatment
The following medications and treatments are prohibited throughout the course of the study 
and prior to treatment, as specified:
1.Immunomodulatory  therapy  within 8 weeks prior to the qualify ing EGD or between the 
qualify ing EGD and baseline visit (Visit 1)or anticipated use of immunomodulatory  
therap y during the treatment period (except for any ongoing regimen of allergy  shots). 
Use of long-acting immunomodulatory  therap y (eg, Rituxan) within 3 months of the 
qualify ing EGD should be reviewed with the medical monitor .
2.Swallowed topical corticosteroid for EoE or systemic corticosteroid for any condition 
within the 4 weeks prior to the qualify
ing EGD, between the qualify ingEGD and baseline 
visit (Visit 1)or anticipated use during the treatment period ; any temporary  use (≤7days) 
or initiation of new steroid treatment during study  should be documented and discussed 
with the medical monitor prospectivel y but cannot occur within the 4 weeks of the final 
EGD .
3.Inhaled steroids if initiated or changed in dose <3 months prior to screening visit
(Visit -1).  (Seasonal nasal corticosteroid use for seasonal allergic rhinitis is 
permitted; changes within 4 weeks of scheduled EGD should be avoided).
4.Initiation or change in dosing frequency  ofPPIs, H2 antagonists, antacids, or leukot riene 
inhibitors for any condition (such as gastroesophageal reflux disease, asthma ,or allergic 
rhinitis) within the 4 weeks prior to the qualify ing EGD, between the qualify ing EGD and 
baseline visit 1, or anticipated changes in the use of such medications during the treatment 
period.
5.CYP450 3A4 inhibitors (eg ,ketoconazole, grapefruit juice) within the 2 weeks prior to the 
baseline visit (Visit 1) or within 5 half-lives (whichever is greater) or anticipated use of 
such medications during the treatment period. For an expanded list of CYP3A inhibitors, 
investigators should refer to the 2012 FDA Draft Guidance on Drug Interactions (FDA 
Guidance 2012) and use their clinical judgment with respect to specific medications.
6.
Esophageal dilation within the 3 months prior to screening (Visit -1)
7.Investigational study  treatment within 6months prior to the screening visit (Visit -1)
8.Sucralfate use during the treatment period
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 46of 98
6. INVESTIGATIONAL PROD UCT
6.1 Identity of Investigational Product
The test product is OBS (oral budes onide suspension , 0.2 mg/mL) ,which will be provided in
multi- dose amber glass bottles, each containing approximately 210mL.Additional 
information is provided in the current SHP621 investigator’s brochure.
The reference/comparator product is placebo, which will be provided inamber glass bottle
form with the same volume .
6.1.1 Blinding the Treatment Assignment
Investigational product will be supplied in amber glass, multi- dose bottles with child- resistant 
caps and refrigerated through outthe study  (in the clinic and subject’s home) .Each bottle 
contains approximately 210mL of suspension with a budesonide concentration of 0.2 mg/mL .
Inactive ingredients in OBS include dextrose, disodium edetate, citric acid, sodium citrate, 
potassium sorbate, polysorbate 80, glycerin, sodium benzoate, cherry  flavor, Magnasweet 
110, acesulfame potassium, and water .
The placebo solution will also be supplied in amber glass multi- dose bottles with 
child- resistant caps. Placebo consists of all components of the investigational produ ct solution 
with the exception of budesonide.
6.2 Administration of Investigational Product(s)
All investigational product and supplies (eg, dosing spoons ) will be provided by Shire or its 
designee. At each visit, subjects will be supplied with enough investi gational product to last 
until the subsequent visit. The first dose of investigational product (placebo) for each subject 
will be administered in the clinic at the placebo lead-invisit (Visit 0).  The subject will 
continue with the e
vening dosing regimen at home. 
OBS and placebo will besupplied in amber glass bottles and must be shaken well prior to 
administration. OBS and placebo should be refrigerated at 2-8ºC (36-46ºF) throughout the 
study  (in the clinic and subject’s home). The appropriate dose will be dispensed using the 
graduated dosing spoon provided. For subjects who are minors (<18 years), a parent/guardian 
will be responsible for ensuring that the subject stake their investigational product 
appropriatel y. 
Subjects will be instructed not to eat or drink for 30 minutes after taking the investigational 
product . Activities such as brushing teeth or rinsing the mouth should also be avoided during 
this time interval. After 30 minutes, subjects will be instructed torinse with water and spit, 
particula rlyafter the bedtime dose.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 47of 98
Please refer to the Investigational Product Administration Manual for additional details.
6.2.1 Interactive Response Technology for Investigational Product Management
An interactive web-based response system(IWRS ) will be used for screening and enrolling 
subjects, recording subject visits, randomization, investigational product supply  dispensation 
and management, inventory  management and supply  ordering, investigational product 
expiration tracking and management, return of investigat ional product, and emergency 
unmasking. Please refer to the Study  Manual for additional details regarding the IWRS .
The investigator or designee will access the IWRS at the screening visit (Visit -1) to record 
subject -
specific information (ie, unique subjectnumber, date of birth, etc.). Subjects will be 
entered as screen failures or as entering the placebo lead-inperiod. Subjects cannot be 
rescreened once it is confirmed they  do not meet inclusion/exclusion criteria unless the screen 
failure was due to aconcomitant medication that can be discontinued prior to rescreening; 
those subjects may be rescreened. Other reasons for rescreening (ie, reasons unrelated to 
inclusion/exclusion criteria) must be discussed prospectivel y with the medical monitor . For 
subjects who enter the placebo lead-inperiod, IWRSwill provide the assignment of placebo 
lead-in period medication to dispense. 
At the baseline visit (Visit 1), the investigator or designee will again access the IWRS to 
either document a screen failure or,if the subject has met all entry  criteria, to 
randomize the 
subject.  Sites will enter eligibility  criteria information prior to randomization. For 
randomized subjects, the I WRS will provide a medication identification (Med ID) number (ie, 
kit number to dispense for treatment).  
The IWRS will also be used for creating, tracking, and confirm ing inve stigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be 
provided to the site and site personnel will receive training.
The IWRS provider will provide a user manual and training to each site, with detailed 
instructions on use of the I WRS.
6.2.2 Allocation of Subjects to Treatment 
This study  consists of a single -blind lead-in period followed by a double -blind 
placebo- controlled study period. The actual treatment given to individual subjects during the 
double -blind period is determined by  a randomization schedule.
Subject numbers are assigned to all subjects as they consent to take part in the study . Within 
each site (num bered uniquely  within a protocol), the subject number is assigned to subjects 
according to the sequence of presentation for study participation.  
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 48of 98
The randomization number represents a unique number corresponding to investigational 
product allocated to the subject once eligibility  has been determined following the placebo 
lead-inperiod .  
Individual subject treatment is automatically  assigned by  the I WRS .
Subjects will be randomized after confirmation of study  eligibility  in a ratio of 2:1 via a 
computer -
generated randomization schedule to receive OBS 2mg twice daily  (qAM, pc, and 
hs) or placebo. The randomization will be performed centrally  and stratified by age group 
(2strata total: <18 years or≥18 years) and diet restriction for EoE or other health- related 
conditions (no diet restriction orany diet restriction) . The stratification by age will ensure a 
minimum of 40subjects in the pediatric group (11-17 years, inclusive ). The stratification by 
age and diet restriction will ensure balance between treatment groups for the respective 
stratification factors. Fixed block randomization will be used to ensure that approximately  
equal numbers of patients are assigned each treatment within strata.  
 
6.2.3 Dosing
During the 4-week single -blind placebo lead-inperiod, all subjects will receive 10 mL of 
placebo twice daily (qAM, pc, and hs). During the 12-week double -blind treatment period, 
oral administration of 10 mL of investigational product will occur twice daily (qAM, pc, and 
hs), with no ingestion of food or liquids permitted for 30minutes after study  drug 
administration. Subjects randomized to OBS will receive 10 mL of 0.2 mg/mL  of OBS (2mg) 
twice dail yfor a total daily  dose of 4mg.  
Investigational product doses that are required to be administered at the clinic include the first 
dose of placebo administered at the placebo lead-invisit (Visit 0),the first dose of 
randomized invest igational product (OBS or placebo) administered at the baseline visit
(Visit
1)and all morning doses of investigational product administered at Visits 2-4.Subjects 
will Subjects will be required to eat breakfast at the clinic prior to self-administering these 
doses. Subjects canself-administer all other doses of placebo andinvestigational product at 
home . 
During the visit where the pharmacokinetic blood samples are collected (Visit 2 or Visit 3), 
subjects will be required to eat a moderate -fat breakfas t on-site and will be instructed to take 
their morning dose at a set time to establish the schedule for post -dose sample collection .
6.2.4 Unblinding the Treatment Assignment
The treatment assignment must not be broken during the study  except in emergency  situations 
where the identification of the investigational product is required for further treatment of the 

Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 49of 98
subject. The investigator should contact the medical monitor and the sponsor as soon as 
possible after the i nvestigator has been unblinded.
In the even t that the treatment assignment is broken, the date, the signature of the person who 
broke the code, and the reason for breaking the code are recorded in the IWRS and the source 
documents. Upon breaking the blind, the subject is withdrawn from the study  but should be 
followed up for safet y purposes. Any code breaks that occur must be reported 
to the contract 
research organization (CRO )and sponsor .Code break information is held by the 
pharmacist/designated person at the site and by the CRO medical monitor for the study  or 
designee.
There will be a provision for unblinding to ensure adequate treatment of the subject in the 
case of an emergency .
6.3 Labeling, Packaging, Storage, and Handling
6.3.1 Labeling
Labels containing study  information and pack identification are applied to the investigational 
product(s) container. 
All investigational product is labeled with a minimum of the protocol number, Med ID, 
dosage form (including product name and quantity  in pack), directions for use, storage 
conditions, expiry  date (if applicable), batch number and/or packaging reference, the 
statements “For clinical trial use only”and/or “CAUTION: New Drug -Limited by Federal 
(or US) Law to Investigational Use ,” “Keep out of reach of children ,”and the sponsor’s name 
and address. Any additional labeling requirements for participating countries and/or 
controlled substances will also be included on the label.
Space is allocated on the label so that the site representative can record subject information. 
Additional labels (eg,those used when dispensing marketed product) may, on a case-by-case 
basis, be applied to the investigational product in order to satisfy  local or institutional 
requirements, but must not:
 Contradict the clinical study  label .
 Obscure the clinical study label .
 Identify the study  subject by  name.
Additional labels may  not be added without the sponsor’s prior full agreement.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 50of 98
6.3.2 Packaging
Investigational product is packaged in the following labeled containers:
The sponsor will supply  the following medication to the study  sites in a blinded manner: OBS 
0.2 mg/mL or placebo in an 8-ounce amber glass bottle for multiple use. Three bottles will be 
packaged in an appropriately  labeled carton.
Changes to sponsor -supplied packaging prior to dosing may not occur without full agree ment 
in advance b y the sponsor.
6.3.3 Storage
The investigator has overall responsibility  for ensuring that investigational product is stored in 
a secure, limited -access location. Limited responsibility  may be delegated to the pharmacy  or 
member of the stud y tea m, but this delegation must be documented.  
OBS and placebo must be stored at 2 -
8ºC (36- 46ºF), protected from light.
Investigational products are distributed by the pharmacy  or nomin ated member of the study 
team. The pharmacist/nominated team member will enter the unique subject identifier on the 
investigational product bottle/carton labels as they are distributed.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage locatio n to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study  and that 
records are maintained; the temperature should be monitored continuously  by using either an 
in-house system, a mechanical recording device such as a calibrated chart recorder, or by 
manual means, such that both minimum and maximum thermometric values over a specific 
time period can be recorded and retrieved as required. Such a device (ie,certified min/max 
thermometer) would require manual resetting upon each recording. The sponsor must be 
notified immediately  upon discovery  of any excursion from the established range.  
Temperature excur sions will require site investigatio n as to cause and remediation. The 
sponsor will determine the ultimate impact of excursions on the investigational product and 
will provide supportive documentation as necessary .Under no circumstances should the 
product be dispensed to subjects until the impact has been determined and the product is 
deemed appropriate for use by  the sponsor.
The sponsor should be notified immediately  if there are any  changes to the storage area of the 
investigational product that could affect the integrit y of the product(s), eg,fumigation of a 
storage room.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 51of 98
6.3.4 Special Handling
The investigational product should be stored under refrigeration at 2 -8°C/36 -46°F at all times .
The investigational product should be protected from light and shaken well immediately  prior 
to each dose .
6.4 Drug Accountability
Investigators will be provided with sufficient amounts of the investigational product to carry 
out this protocol for the agreed-upon number of subjects. The investigator or designee will 
acknowledge receipt of the investigational product, documenting shipment content and 
condition. Accurate records of all investigational product dispensed, used, returned, and/or 
destroy ed must be maintained as detailed further in this section.
The investigator has overall responsibility  for administering/disp ensing investigational 
product. Where permissible, tasks may  be delegated to a qualified designee ( eg,a pharmacist) 
who is adequatel y trained in the protocol and who works under the direct supervision of the 
inves tigator. This delegation must be documented in the applicable study  delegation of 
authority form.
The investigator or his/her designee (as documented by the investigator in the applicable 
study  delegation of authority  form) will dispense the investigationa l product only to subjects 
included in this study  following the procedures set out in the study  protocol. Each subject will 
be given onl y the investigational product carry inghis/her treatment assignment. All dispensed 
medication will be documented on the CRFs and/or other investigational product record. The 
investigator is responsible for assuring the retrieval of all study  supplies from subjects. The 
investigator or his/her designee will enter the unique subject identifier and initials on the 
investigatio nal product kit labels as they  are assigned and dispensed.
No investigational product stock or returned inventory  from a Shire -sponsored study  may be 
removed from the site where originally  shipped without prior knowled ge and consent by the 
sponsor. If such transfer is authorized by the sponsor, all applicable local, state, and national 
laws must be adhered to for the transfer.
The sponsor or its representatives must be permitted access to review the supplies storage and 
distribution procedures and records provided that the blind of the study  is not compromised.
At the end of the study , or as instructed by the sponsor, all unused stock , subject -returned 
investigational product, and empty /used investigational product packaging are to be sent to a 
nominated contractor on behalf of the sponsor. Investigational product being returned to the 
sponsor’s designated contractors must be counted and verified by clinical site personnel and 
the sponsor (or designated CRO). For unused supplies where the original supplied 
tamper -evident feature is verified as intact, the tamper -evident feature must not be broken ,
and the labeled amount is to be documented in lieu of counting. Shipment return forms, when 
used, must be signed prior to shipment from the site. Validated electroni c return systems (ie,
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 52of 98
IWRS ) do not require a shipment form. Returned investigational product must be packed in a 
tamper -evident manne r to ensure product integrity . Contact the sponsor for authorization to 
return any investigatio nal product prior to shipment. Shipment of all returned investigational 
product must comply  with local, state, and national laws.
Based on entries in the site drug accountability  forms, it must be possible to reconcile 
investigational products delivere d with those used and returned. All investigational products 
must be accounted for and all discrepancies investigated and documented to the sponsor’s 
satisfaction.
6.5 Subject Compliance
Compliance with investigational product will be assessed at each st udy visit. Subjects must be 
instructed to bring their unused investigational product and empty /used investigational 
product packaging to every  visit. Drug accountability  must be assessed at the 
container/packaging level for unused investigational product that is contained within the 
original tamper -evident sealed container ( eg,bottles) or at the individual count level for 
opened containers/packaging. The pharmacist/nominated person will record details on the 
drug accountability  form.
Visit to visit compliance of investigational product dosing willbe assessed by site personnel.
Site personnel must review the returned investigational product to assess compliance at every  
visit prior to dispensing addit ional investigational product. Any discrepancies should be 
reconciled with the subject immediat ely. Subjects who do not return their used and unused 
investigational product should be reminded to bring all used and unused investigational 
product at their next visit.
Subjects who have taken 70-130% of the investigational product will be assessed as being 
compliant with the study  protocol. Compliance will be assessed at each treatment visit. 
7. STUDY PROCEDURES
7.1 Study Schedule
The detailed study  procedures/assessments to be performed throughout the study  are outlined 
in the Schedule of Assessments (see Table 1-1) and must be referred to in conjunction with 
the instructions provided in this section. 
Prior to performing any study -related procedures (including those related to screening), the 
investigator or his/her designee must obtain written informed consent from the subjec t (as per 
local requirements). There must be documentation of consent (as per local requirements) 
indicating that the subject is aware of the investigational nature of the study  and the required 
procedures and restrictions, prior to perf orming any  study -related procedures.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 53of 98
7.1.1 Screening Period (Week s -6to 0)
The screening period starts when subjects sign informed consent. The screening period
will 
comprise 3-6 weeks, during which all procedures listed for the screening visit (Visit - 1) in 
Table 1-1shall be completed. The screening period will allow for the determination of 
eligibility  of each subject’s inclusion into the study .A subject should not be instructed to 
discontinue use of any medication or treatment to participate in this study  until infor med 
consent has been obtained. Subjects should not stop permitted medications or treatments that 
are effective and well tolerated to participate in this study (see Section 5.2.1 ).
Screening assessments may take place 
across several days to allow an appropriate time frame 
in which to complete all procedures and confirm study  eligibility . 
After the screening period, subjects who meet eligibility  criteria at the end of the screening 
visit (Visit -1) will enter the 4-week single -blind, placebo lead- in period. The placebo lead-in
period should not commence until all screening assessments required to confirm initial 
eligibility  have been completed. If the subject does not meet eligibility  criteria following 
completion of screening assessments, the inves tigator or designee will document the subject 
as a screen failure in the IWRS.
A screen failure is a subject who has given informed consent and failed to meet the inclusion 
criteria and/or met at least 1 of the exclusion criteria and has not been randomize d or 
administered randomized investigational product. Screen failures can occur at the screening , 
placebo lead-in,or baseline visits. Subjects cannot be rescreened once it is confirmed they do 
not meet inclusion/exclusion criteria unless the screen failur e was due to a concomitant 
medication that can be discontinued prior to rescreening; those subjects may be rescreened. 
Other reasons for rescreening (ie, reasons unrelated to inclusion/exclusion criteria) must be 
discussed prospectivel y with the medical mo nitor .
7.1.1.1 Screening Visit (Visit -1) 
The screening visit (Visit -1) assessments and procedures , beginning with informed consent, 
will be performed as outlined in Table 1-1.
The following procedures should be performed first:
Obtain subject c onsent (or assent as applicable for subjects <18 y ears).
Review eligibility  criteria.
Review medical history .
Record vital signs (including blood pressure [systolic and diastolic], heart rate, 
respirations, and temperature), height, and weight.   Perform stadiometry  in subjects aged 
11-17 years, inclusive.
Review current use of concomitant medications, including medications taken and 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 54of 98
procedures completed within 3months prior to the biopsy  required for entrance to this 
study . Note: Subjects who are on a PPI must remain on the same dose of the PPI 
throughout the study , and if they are not taking a PPI, they must remain off of a PPI for 
the remainder of the study .
Clinical chemistry , hematology , and urinal ysis laboratory  tests will be performed on all 
subjects; all subjects must fast overnight prior to collection.
The following order is recommended for the remaining procedures that will be performed at 
this visit or within the 6 -week screening period :
Dispense the DSQ electronic patient -reported outcome (ePRO )device for nightl y 
completion and train the subject on its use. In order to qualify  for study entry , subjects 
must have experienced dysphagia (response of “yes” to question 2 on DSQ) on a
minimum of 4daysand completed the DSQ on ≥70% of days in any 2consecutive weeks 
of the screening period.
Perform a physical examination on all subjects. Adolescents (subjects ≤17 years) will also 
undergo Tanner S taging Assessment .
Serum pregnancy  test will be performed on all female subjects. 
Perform EGD and biops y; both must be performed within the 6 weeks prior to the Placebo 
Lead -in Visit either at the investigative site or by a referring physician. Biopsy  specimens 
must be available to be sent to the central patholo gy lab at least 2 weeks prior to the 
Placebo Lead -in Visit to allow sufficient time for processing and central review and 
determination of eligibility .
7.1.2 Placebo Lead -in Period (Week s 0to 4)
The placebo lead-inperiod will comprise 4 weeks, during which allprocedures listed for the 
placebo visit (Visit 0) in Table 1-1 shall be completed .
During the 4-week single -blind placebo lead-in, all eligible subjects will self-administer 
10mL of placebo twice daily  (qAM, pc, and hs ). 
At the end of the placebo lead-inperiod, eligible subjects (those with at least 4 reported 
dysphagia days and completion of DSQ on ≥70% of days in the 2 weeks prior to baseline  
[Visit 1]) will be randomized and enter the 12-week double -blind treatment period (baseline 
visit).Subjects must be administrated placebo during the placebo lead-in period for 4weeks
(±3days) prior to Visit 1 (baseline) to be eligible for randomization into the 12-week double -
blind treatment period .
7.1.2.1 Placebo Lead -in Visit (Visit 
0) 
The placebo lead-in visit (Visit 0) assessments and proce dures will be performed as outlined 
in Table 1
-1. 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 55of 98
The following procedures should be performed first:
Reassess eligibility  according to the inclusion/exclusion criteria and medical history .
Record vital signs (including blood pressure [systolic and diastolic], heart rate, 
respirations, and temperatur e) and weight.
Perform AE assessments.
Review concomitant medications and procedures.
Clinical chemistry , hematology , and urinal ysis laboratory  tests; all subjects must fast 
overnight prior to collection.
The following order is recommended for the remainin g procedures that will be performed at 
this visit:
Review DSQ dy sphagia episodes and compliance; re -dispense DSQ device to subject with 
instruction to continue completion of the DSQ nightly .
Perform a ph ysical examination and assess any  changes since screening.
Urine pregnancy  test for female subjects.  
Perform dual-energy  X-ray absorptiometry  (DXA )scan for bone mineral density  (BMD )
and body  composition in subjects aged 11-17 years , inclusive ; the DXA scan may be 
performed any time during the placebo lead-inperiod, after the subject has met all 
screening criteria and prior to blinded- treatment randomization. Baseline and post-
treatment DXA scans should be performed using the same machine and software.
Dispense placebo study  medication and review administ
ration instructions. Subjects will 
self-administer the first dose of placebo in the clinic after eating breakfast. Site personnel 
will record the date and time of the first placebo dose in the source documents. Beginning 
on the evening of Visit 0, the subject will take their second dose at home and continue 
with the twice dail y (qAM, pc, and hs) dosing regimen.
7.1.3 Double -blind Treatment Period (Visits 1-4): Weeks 4, 8, 12, and 1 6(or Early 
Termination )
The double -blind treatment period will comprise 12weeks, during which all assessments and 
procedures listed for Visits 1 -
4in Table 1-1 shall be completed.
During this period, a3-day visit window will bepermitted , unless otherwise specified .Visit 
windows are calculated based upon the date of the placebo lead -invisit (Visit 0).
Subjects who continue to meet all eligibility  criteria will be randomized 
2:1 to receive either 
OBS twice daily (qAM, pc, 
and hs) or placebo twice daily (qAM, pc, and hs). The 
investigator or assigned site staff will access the IWRS torandomize the subject and dispense 
the investigational product. Subjects who fail to meet eligibility  criteria at the baseline visit
(Visit 1) will be documented as screen failures in the I WRS.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 56of 98
Subjects who complete the 12-week double -blind treatment period will have the opportunity  
to enroll in the treatment extension study . These subjects will continue on the blinded 
assigned treatment for 2-4 weeks as part of the screening prior to enrolling into the treatment 
extension study . Subjects who do not enroll in the treatment extension study  or who 
discontinue prematurely  at any time during the SHP621 -301 (Induction) study  will receive a 
follow -up phone call 4 -weeks post last dose of investigational product.
7.1.3.1 Baseline Visit (Visit 
1): Week 4
Subjects will retur n to the site for the baseline visit (Visit 1) to confirm eligibility . The 
baseline visit (Visit 
1) assessments and procedures will be performed as outlined in Table 1-1.
The following procedures should be performed first:
Reassess eligibility  according to the inclusion/exclusion criteria and medical history .
Record vital signs (including blood pressure [systolic and diastolic], heart rate, 
respirations, and temperature) and weight.
Perform AE assessments, including specific assessments for signs of glucoc orticoid 
excess. Any  AE that occurs during this visit will be recorded in the CRF and considered a 
TEAE.
Review concomitant medications and procedures.
Clinical chemistry , hematology , and urinal ysis laboratory  tests; all subjects must fast 
overnight prior to collection.
Morning cortisol (performed between 6:00 and 9:00 AM). Subjects should be instructed 
not to take the morning dose of investigational product until after the morning cortisol test 
has been performed. 
Administer adrenocorticotropic hormone (ACTH) stimulation testing; the typeof 
synthetic and route of administration will be per local lab discretion . Additional cortisol 
samples will be drawn at 30 and 60 minutes following stimulation testing.
The following order is recommended for the remainin g procedures that will be performed at 
this visit:
Review study  medication dosing compliance.
Review DSQ dy sphagia episodes and compliance; re -dispense DSQ device to subject with 
instruction to continue completion of the DSQ nightly .
Administer health- related quality -of-life(HRQoL) assessments including the EuroQol 
(EQ-5D
), Pediatric Quality  of Life Inventory –EoE (PedsQL -EoE), and Adult 
Eosinophilic Esophagitis Quality  of Life ( EoE-QoL-A)as age-appropriate.
Administer PGI -S of disease assessment. 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 57of 98
Perfo rm a ph ysical examination and assess any  changes since screening.
Re-administer urine pregnancy  test for female subjects.  
Dispense investigational product (OBS or placebo) according to IWRS randomization and 
review administration instructions. Subjects will self-administer the first dose of 
investigational product in the clinic during this visit after breakfast . Site personnel will 
record the date and time of the first randomized dose in the source documents. Beginning 
on the evening of Visit 1, the subje ct will take their first dose at home and continue with 
the twice daily (morning and evening) dosing regimen. For subjects who are minors (<18 
years), a parent/guardian will be responsible for ensuring subject takes their 
investigational product appropriat ely.
Following all blood draws, subjects can eat breakfast and take their morning dose of 
investigational product.
7.1.3.2 Visit s 2and 3(Weeks 8and 12)
Subjects will return to the site for Visit 2(Week 8) and Visit 3(Week 12). Assessments at 
these visits will be performed as outlined in Table 1 -
1.
The following procedures should be performed first:
Record vital signs (including blood pressure [systolic and diastolic], heart rate, 
respirations, and temperature) and weight.
Perform AE assessments, including specific assessments for signs of glucocorticoid 
excess. Any  AE that occurs during this visit will be recorded in the CRF and considered a 
TEAE.
Review concomitant medications and procedures.
Clinical chemistry , hematology , and urinal ysis laboratory  tests; allsubjects must fast 
overnight prior to collection.
Morning cortisol (performed between 6:00 and 9:00 AM). Subjects should be instructed 
not to take the morning dose of study  medication until after the morning cortisol test has 
been performed. 
Collect blood samples for pharmacokinetic analy sis for adult subjects. Subjects will be 
instructed to take their morning dose at a set time to establish the schedule for post-dose 
sample collection.
The following order is recommended for the remaining procedures that will be performed at 
this visit:
Review DSQ dy sphagia episodes and compliance; re -dispense DSQ device to subject with 
instruction to continue completion of the DSQ nightly .
Administer PGI -S assessment. 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 58of 98
Perform a ph ysical examination and assess any  changes since s creening.
Re-administer urine pregnancy  test for female subjects.  
Dispense investigational product (OBS or placebo) and review investigational product 
dosing compliance.
Following all blood draws, subjects can eat breakfast and take their morning dose of 
investigational product.
7.1.3.3 Visit 4 (Week 1 6)
Subjects will return to the site for Visit 4(Week 16). Assessments at this visit will be 
performed as outlined in Table 1-1.
The following order is recommended for the procedures that will be performed a t this visit:
Record vital signs (including blood pressure [systolic and diastolic], heart rate, 
respirations, and temperature), height, and weight. Perform stadiometry  in subjects aged 
11-17 years, inclusive.
Perform AE assessments, including specific assessments for signs of glucocorticoid 
excess. Any  AE that occurs during this visit will be recorded in the CRF and considered a 
TEAE.
Review concomitant medications and procedures.
Clinical chemistry , hematology , and urinal ysis laboratory  tests; all subject s must fast 
overnight prior to collection.
Morning cortisol (performed between 6:00 and 9:00 AM). Subjects should be instructed 
not to take the morning dose of investigational product until after the morning cortisol test 
has been performed. 
Administer adrenocorticotropic hormone (ACTH) stimulation testing; the typeof 
synthetic and route of administration will be per local lab discretion. Additional cortisol 
samples will be drawn at 30 and 60 minutes following stimulation testing. 
Retrieve DS Qhandset an d review D SQcompliance .
Administer HRQoL  assessments including the EQ-5D, PedsQL -EoE, and EoE-QoL-
Aas 
age-appropriate.
Administer PGI -S assessment. 
Perform a physical examination and assess any changes since screening .Adolescents 
(subjects ≤17 y ears) will also undergo Tanner Staging Assessment.
Re-administer serum pregnancy  test for female subjects.  
Perform DXA scan for BMD and body  composition in subjects aged 11-17 years , 
inclusive . DXA scan should be completed at or within (±)7days of this visit. Baseline 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 59of 98
and post-treatment DXA scans should be performed using the same machine and software.
Perform EGD and biopsy .EGD should be completed at or within (±) 7 days of the 
scheduled visit.
For eligible subjects continu ing into the treatment extension study , obtain informed 
consent for the treatment extension study , dispense investigational product (OBS or 
placebo) according to IWRS randomization and review investigational product dosing 
compliance.
Following all blood draws, subjects can eat breakfast and take their morning dose of 
investigational product if they  are continuing in the treatment extension study .
7.1.4 Follow -up Period
The follow -up period for this protocol is 4 weeks from the last dose of investigational 
produc t. Subjects who do not enroll in the treatment extension study  or who discontinue 
prematurel y at any time during the study  will receive a follow -up 4 phone call at Visit 5 
(Week 20) to query  for SAEs, AEs, and concomitant treatments (Section 7.1.4.1 ).
7.1.4.1 Safety Follow -up Contact (Visit 5): Week 20
Assessments at this 
time, as outlined in Table 1-1, will include the following:
Review concomitant medications and procedures .
Perform AE assessments, including specific assessments for signs of glucocorticoid 
excess. Any  AE that occurs during this visit will be recorded in the CRF and considered a 
TEAE; all AEs and SAEs that are not resolved at the time of this contact will be followed 
to closure .
7.1.5 Additional Care of Subjects a fter the Study
No after care is planned for this study for those 
subjects who do not enroll in the treatment 
extension study .
7.2 Study Evaluations and Procedures
The full title and details about who completes the scales used in this study  is included in 
Appendix 1 .
All assessments listed below will be performed by the subject and/or a qualified/trained site 
staff as indicated in the assessment description. For subject -completed assessments, trained 
site staff should not assist the subject in completing assessments in such a manner that it 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 60of 98
would influence their responses. Site staff should review the completed assessment to ensure 
completeness.
If an answer is marked in error, the subject may  correct it by  drawing a single line through the 
error and initialing and dating the change; however, correction s can only  be made to scales by  
the subject during a study  visit and changes must not be made to subject -completed scales 
after the visit has been completed. Assessments are to be performed according to the schedule 
shown in Table 1-1.
7.2.1 Efficacy
7.2.1.1 Esophagogas troduodenoscopy with Esophageal Biopsy and Histopathologic 
Evaluation
The EGD with endoscopy  score and biopsy  will be performed during the study  as outlined in 
Table 1-1. 
An EGD with esophageal, gastric and duodenal biopsies will be required for study 
participation; the peak eosinophil count per HPF from each esophageal level will be used as a 
primary  measure of efficacy . The qualify ing/baseline EGD with biopsies must be performed 
bya physician at the investigative sitewithin the 6weeks prior to placebo lead-invisit 
(Visit
1).Biops y specimens must be available to be sent to the central pathology  lab by at 
least 2weeks prior to the placebo lead-invisit to allow sufficient time for processing and 
central review and determination of eligibility .
Multipl e specimens (at least 2 biopsies from each of 3 levels , 
6 specimens total) will be 
obtained from the proximal (3 cm below the cricophary ngeus muscle), mid-esophagus (mid -
point between the cricophary ngeus muscle and the gastroesophageal junction), and dista l 
(3cm above the gastroesophageal junction) .Biopsy  tissue will be placed in 3 separate vials 
(1vial for each of the levels) and sent to the central pathology  laboratory for processing of 
tissue into slides . Acentral pathologist will determine histologi c eligibility  for study  entry. 
Peak eosinophil counts of ≥15/HPF in specimens from 2 or more levels of the esophagus will 
be a requirement for study  entry, as determ ined by a central pathologist. Eosinophil counts, 
histopathologic features, and gross endoscopic findings will be evalu ated and scored for each 
EGD. Eight histopathologic epithelial features (basal layer hyperplasia, eosinophil density , 
eosinophil microabscesses, eosinophil surface layering , dilated intercellular spaces, surface 
epithelial alteration, dyskeratotic epithelial cells, lamina propria fibrosis ) will be scored 
ona 
4-point scale (0=normal, 3=worst) for both the severity  of the abnormality (ie,grade) and the 
amount of tissue affected by  the abnormality  (ie, stage) . 
Endoscopic findings with separate evaluations of the proxim
al and distal esophagus will be 
recorded with respect to 5 categories by the endoscopist : 1) exudates or plaques (grade 0–2); 
2) fixed esophageal rings (grade 0–3); 3) edema (grade 0–2); 4) furrows (grade 0–2); and 5) 
strictures (grade 0–1). An endoscop y score for each category  will be calculated and summed 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 61of 98
for each anatomic location (proximal and distal). The maximum endoscopy score is 10 points 
for each location, and a Total Endoscopy  Score is the sum of the scores for the proximal and 
distal locations.
In addition, the general appearance of the stomach and duodenum will be assessed by the 
endoscopist. Biopsies will be taken from the stomach and duodenum for the screening EGD 
as follows: gastric body (greater curvature): 2 specimens, gastric antrum: 2 specimens, and 
duodenum (third part or distal): 2 specimens. Biopsies from the stomach should be submitted 
in one vial; biopsies from the duodenum should be submitted in a separate vial to the central 
pathology  laboratory  for processing of tissue into slides. If the pre-treatment biopsy  identifies 
eosinophilia in the stomach and/or duodenum, the subject will be excluded from the study . 
At the Week 16visit (Visit 4) or at early  termination (ET) , and EGD with esophageal biopsies 
(at least 2biopsies from each of 3 levels [proximal, mid- , and distal] )is required. Endoscopic 
findings will be recorded by the endoscopist.  Biopsies will be sent to the central laboratory 
for processing . A central pathologist will evaluate the slides. Gastric and duodenal biopsies 
may be repeated at the discretion of the investigator , but are not required .
7.2.1.2 Dysphagia Symptom Questionnaire
Subjects’ dy sphagia s ymptoms will be evaluated using a DSQ ePRO device ( Appendix 3 ). 
The questionnaire will be completed by subjects daily  for a minimum of 3weeks during the 
screening period , during the 4-week placebo lead -inperiod , and during the 12 -week treatment 
period. Each evening before bedtime, subjects will be asked to indicate if they experience d 
dysphagia symptoms (eg, food passing slowly  or food sticking) during that day. Subject must 
have experienced dysphagia (response of “yes” to question 2 on DSQ) on a minimum of 
4days total and completed the DSQ on ≥70% of days in any 2 consecutive weeks of the 
screening period and in the 2 weeks prior to the baseline visit (Visit 1).Subjects must fill out 
the DSQ at least 5or more 
daysduring a given week in order to be compliant.
Visit to visit compliance of DSQ completion will also be assessed by sitepersonnel. Protocol 
deviations will be documented for subjects who fail to complete the DSQ for 3 or more days 
in a given week.
Calculations will be performed on daily  ePRO entries during a 2-week interval prior to each 
study  visit during the treatment period
s. The DSQ score for the co-primary  endpoint and 
secondary  endpoints will be calculated by  summing the scores of responses to questions 2 and 
3 only . Questions 1 and 4 will be excluded from the DSQ score:
DSQ score =   (Sum of points from questions 2+3 in the daily  DSQ)×14
Number of diaries reported with non -missing data
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 62of 98
The DSQ + pain score for the secondary  endpoints will be calculated by summing the scores 
of responses to questions 2, 3, and 4. Question 1 will be excluded from the DSQ + pain score.
DSQ + pain score =(Sum of points from questions 2+3+4 in the dail y DSQ)×14
Number of diaries reported with non -missing data
The DSQ pain score for the secondary  endpoint will be calculated by summing the scores of 
responses to Question 4 only .
DSQ pain 
score =(Sum of points from question 4 in the daily  DSQ)×14
Number of diaries reported with non -missing data
7.2.2 Safety
The name and address of each third- party  vendor (eg,clinical laboratory) used in this study 
will be maintained in the investigator’s and sp onsor’s files.
7.2.2.1 Medical and Medication History
Medical History
The investigator must record all clinicall y or medically  relevant information regardless of 
how much time has elapsed since the date of any diagnosis. Medical history  will be classified 
as EoE or non-EoE by the investigator. The EoE medical history  must include any prior 
history  of esophageal strictures and esophageal dilations.
Medication History
Refer to Section 5.1for full details on collection of prior treatment.
Prior treatment information ,including any prior treatments for EoE (eg, dietary , medication, 
or other) ,must be recorde d on the appropriate CRF page.
7.2.2.2 Physical Examination (Including Height and Weight)
Abnormalities identified at the screening visit (Visit -1) will be documented in the subject’s 
source documents and on the medical history  CRF. Changes after the screening visit (Visit -
1) 
will be captured as AEs on the AE CRF page, as deemed b y the investigator.
Physical examination assessments at each visit should also include specifi c assessments for 
signs of glucocorticoid excess (eg, moon faces, acne, hirsutism, mood swings, insomnia, and 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 63of 98
depression). Physical examination at the screening visit (Visit -1) will also include Tanner 
Staging Assessments 
for subjects < 18 years of age.
Height will be collected at the screening visit (Visit -1) and Visit 4 for all subjects. 
Stadiomet ers will be used to measure height at Visit -1 and Visit 4 forsubjects aged 
11-17 years, inclusive . Statural height will be measured by trained site staff using a stabilized 
stadiometer. The same stadiometer should be used for the baseline and post treatment 
measurements. Standard measuring procedures should be followed (eg, removal of socks, 
shoes ,and hats). The stadiometer must be calibrated at least once daily, and as feasible,
within 4hours of measurement . All measurements should be recorded to the nearest 10thof a 
centimeter (1mm) .  Please refer to the study  manual for additional details.
7.2.2.3 Adverse Event Collection
At each study  visit, subjects will be questioned in a general way to ascertain if AEs have 
occurred 
since the previous visit (eg,“Have you had any health problems since your last 
visit?”). AEs are collected from the time informed consent is signed. (Please refer to 
Section 8.)
AE assessments ateach visit should also include specific assessments for signs of 
glucocorticoid excess 
(eg, moon facies, acne, hirsutism, mood swings, insomnia, and 
depression).
7.2.2.4 Vital Signs
Vital signs will be conducted after the subject has been supine for at least 5 minutes 
immediately  prior to the assessment and will include blood pressure (systolic and diastolic), 
heart rate, respirations, and temperature . Blood pressure should be determined by cuff (using 
the same method, the same arm, and in the same position throug hout the study ). Any 
clinically  significant deviations from baseline (Visit 1) vital signs that are deemed clinicall y 
significant in the opinion of the investigator areto be recorded as an AE.
7.2.2.5 Clinical Laboratory Evaluations
All clinical laboratory  assayswill be performed according to the laboratory ’s normal 
procedures. All s
ubjects must fast overnight prior to collection of c linical laboratory  tests.
Reference ranges are to be supplied by the laboratory  and will be used to assess the clinical 
laboratory  data for clinical significance and out-of- range pathological changes. The 
investigator should assess out-of- range clinical laboratory  values for clinical significance, 
indicating if the value(s) is/are not clinically  signific ant or clinicall y significant. Abnormal 
clinical laboratory  values, which are unexpected or not explained by the subject’s clinical 
condition, may , at the discretion of the investigator or sponsor, be repeated as soon as possible 
until confirmed, explained, or resolved.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 64of 98
The following cl inical laboratory  assessments will be performed: 
Biochemistry
alkaline phosphatase 
aspartate aminotransferase
alanine aminotransferase
total bilirubin
total protein
albumin
glucose blood urea nitrogen 
creatinine
sodium 
potassium 
chloride 
calcium
carbon dioxide
Hematology
hemoglobin 
hematocrit 
mean corpuscular hemoglobin
mean corpuscular hemoglobin concentration
mean corpuscular volume
erythrocyte count
leukocyte countneutrophils
lymphocytes
monocytes
eosinophils
basophils
platelet count
Urinalysis
glucose
protein
specific gravity
pH
nitritebilirubin
ketones
hemoglobin
urobilinogen
leukocyte esterase
Other tests
serum pregnancy
urine pregnancymorning cortisol (6:00- 9:00 AMcollection)
ACTH stimulation testing
ACTH stimulation testing will be performed by measuring the levels of cortisol in the blood 
following the injection of a synthetic form of ACTH. The typeof synthetic and route of 
administration will beperlocal lab discretion. Blood samples will be collected just prior to 
andapproximately  30 and 60 minutes following the injection. 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 65of 98
In the event of clinically significant abnormal laboratory  test results, follow -up laboratory 
tests may be conducted. All subjects with an abnormal ACTH stimulation test or urinary  or 
serum glucos e level must be followed closely  until resolution. For subjects who discontinue 
from the treatment period at any time and have an abnormal ACTH stimulation test at the 
early termination visit, subjects will be scheduled for repeat testing approximately  6 w eeks 
post last dose of investigational product to ensure that ACTH levels have normalized.  Any 
clinically  significant abnormalities noted in the laboratory  tests will be discussed with the 
medical monitor .
7.2.2.6 Pregnancy Test 
A serum β-hCG pregnancy  test is performed on all female subjects at the screening visit
(Visit -1) and the final treatment evaluation visit (Visit 4 )or ETvisit. A urine pregnancy  test 
is performed on all female subjects at the placebo lead-invisit (Visit 0), baseline visit (Visit 
1), Visit 2, and Visit 3or if pregnancy  is suspected.
7.2.2.7 Dual -energy X -ray Absorptiometry for Bone Mineral Density
DXA (also referred to as DEXA
) scans for determination of BMD and body  composition will 
be performed in subject saged 1 1-17 y ears, inclusive, as outlined in Table 1-1.
The sites for DXA measurement will be the lumber spine (L1-L4 preferred) and total body 
less head (Bachrach, 2011; Gordon, 2008 ; International Society  for Clinical Densitometry , 
2013). The same DXA machine and software should be used for the baseline and 
post-treatment scans. The DXA manufacturer, model ,and software version sho
uld be 
recorded in the CRF.
7.2.3 Other Assessments
7.2.3.1 Health -related Quality -of-life Assessment
EuroQol -5 Dimension s 3-level Questionnaire 
The EuroQol -5D Dimensions 3-level (EQ -5D-3L ; for subjects ≥18 years) and the EuroQol -5 
Dimensions Youth (EQ-5D-Y ; for subjects 11-17 yearsof age, inclusive ) will be performed 
during the stud y as outlined in Table 
1-1.
The EQ -5D-3 L is a standardized measure of health status for use in adult populatio ns that was 
developed by the EuroQol Group in order to provide a simple, generic measure of health for 
clinical and economic appraisal ( EuroQol Group, 1990). The EQ- 5D-3 L provides a simple 
descriptive profile anda single index value for health status that can be used in the clinical 
and economic evaluation of healthcare as well as in population hea lth survey s. It consists of a 
5-item descriptive system that measures 5dimensions of health, including mobility , self -care, 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 66of 98
usual activities, pain/discomfort, and anxiety /depression. Each dimension is represented by a 
single item with 3levels of responses. The EQ-5D-3L will be completed by the subject. The 
EQ-5D-3 L should take the subject a fewminutes to complete.
TheEQ-5D- Y is a self -report version of the EQ -5D that was developed by  the EuroQol Group 
for use in younger populations (Wille et al., 2010). The EQ-5D-Yprovides a simple 
descriptive profile and a single index value for health status that can be used in the clinical 
and economic evaluation of healthcare as well a s in population health survey s.It consists of a 
5-item descriptive system that measures 5 dimensions of health, including mobility , looking 
after myself, 
doing usual activities, having pain or discomfort, and feeling worried, sad,or 
unhappy . Each dimension 
is represented by a single item with 3 levels of responses. The 
EQ-5D-Y w ill be completed by  the subject and should take a few minutes to complete .
Pediatric Quality of Life – EoE Questionnaire
The PedsQL -EoE questionnaire will be completed bysubjects 11-17 years of age, inclusive,
and their parent or legal guardian, as outlined in Table 
1-1.
The PedsQL -EoE is a modular , disease -specific instrument designe d to measure HRQoL in 
children and adolescents (2-18 years of age) with EoE (Franciosi , 2013; PROQOLID ). The
PedsQL -EoE module consists of
35 items for children and teenagers encompassing the 
following 7 scales: 1)Symptoms I (6 items; chest/throat/stomach pain and nausea/vomiting), 
2) Symptoms II (4items; trouble swallowing), 3) Treatment (5 items; treatment barriers), 4) 
Worry  (6 items; worries about treatment and disease), 5)Communication (5 items; 
communication with others about EoE), 6) Food and Eating (4 items; food and eating allergies 
and limitations), and7) Food Feelings (3 items; emotions associated with food allergies). The 
PedsQL -EoE should take the subject and parent approximately  10minutes to complete.
Adult Eosinophilic Esophagitis Quality of Life Questionnaire
The EoE -QoL-A will be performed in subjects 
≥18 y ears of age as outlined in Table 1-1.
The EoE- QoL-A is a disease -specific measure of HRQoL in adult patients (≥18 yearsof age)
with EoE (Taft et 
al.,2011 ). The EoE-QoL- A consists of a 30-item test with 5subscales: 
eating/diet impact, social impact, emotional impact, diseas e anxiety ,and choking anxiet y. The 
EoE-QoL-A will be completed by the subject and sho
uld take the subject approximately  15
minutes to complete.
7.2.3.2 Severity of Disease Assessments
Patient Global Impression of Severity 
The PGI -S will be performed in all subjects as outlined in Table 
1-1.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 67of 98
The PGI-S is a global index (Appendix 4) that canbe used to rate the severity  of a specific 
condition -in this case, dysphagia in EoE. Subjects will be asked to rate the severity  of their
dysphagia 
over the last 7 days using a 5- point scale .
7.2.4 Clinical Ph armacology Assessments
Blood samples will be collected from adult subjects (≥18 yearsof age) as outlined in Table 
1-1to measure plasma concentrations of budesonide. Subjects who do not participate in 
pharmacokinetic sampling will not be discontinued from the study ,and lack of participation 
will not be a considered protocol deviation. 
Actual pharmacokinetic blood sample collection times vstime of dosing will be monitored. 
The sponsor’s expectation is that the investigator will ensure that every  effort will be made to 
collect all pharmacokinetic 
blood samples at the precise protocol scheduled time. 
Pharmacokinetic blood collection must not deviate from the nominal collection time set forth 
in the protocol by more than ± 5 minutes forsamples drawn within 4hours post-dose or by 
more than ± 15 minutes for samples drawn after 4 hours post-dose. Samples drawn outside 
these parameters will be considered a protocol deviation.
Blood samples (4mL) for pharmacokinetic anal ysis will be drawn by  direct venipuncture into 
K2EDTA tubes, capped and mixed by  inversion (×3), and chilled immediately  on crushed ice. 
The actual blood collection time will be recorded in the subject’s source documents and on 
the appropriate CRF page (24 -hour format). After apply ing a tournique t, venous blood will be 
drawn with a disposable needle. If a catheter is used, the first milliliter of blood on each 
sampling occasion will be discarded. Saline can be used to keep catheters patent .
Within 15minutes following each sample collection, the blood tubes will be centrifuged at 
approximately  
1500 g (15minutes, 4°C). The separated plasma will be decanted into 
appropriatel y labeled primary  and backup polypropylene tubes via a plastic pipette. All 
samples will be stored nominally  at -20°C, and the freezer temperature will be controlled, 
monitored, and recorded during the storage period until the samples are shipped to the 
designated bioanal ytical laboratory  for analy sis.
For additional information detailing sample handling, storage
,and shipment, see Appendix 5 .
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 68of 98
7.2.5 Volume of Blood to Be Drawn f rom Each Subject
Table 7-1: Approximate Volume of Blood to B e Drawn from Each Subject
AssessmentSample Volume 
(mL)Number of 
SamplesApproxim ate Total 
Volume (mL)
Pharm acokinetic samplesa5 9 45
Safety Biochemistry and -hCGb6 6 36
ACTH 2 4 8
Cortisol 2 4 8
Hem atology 2 6 12
Total mL 109
Abbreviations: ACTH=adrenocorticotropic hormone; β -hCG=beta- human chorionic gonadotropin
aIf a catheter is used, the f irst mL is to be discarded; then take 4 mL into appropriate tube for pharmacokinetic 
sample.  A total of 5 mL of blood drawn has been used in determination of sample volume.
b-hCG testing is for females only.
During this study , it is expected that approx imately  109 mLof blood will be drawn from all 
subjects, regardless of sex.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of 
blood to be drawn may vary according to the 
instructions provided by the manufacturer or 
laboratory  for an individual assessment; however, the total volume drawn over the course of 
the study  should be approximately  109 mL. When more than 1 blood assessment is to be done 
at the time point/period, if they require the same type of tube, the assessme nts may be 
combined.  
8. ADVERSE AND SERIOUS 
ADVERSE EVENTS ASSES SMENT
8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events
An AEis any untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this 
treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory  finding), symptom, or disease temporally  associated with the use of a 
medici nal (investigational) product, whether or not related to the medicinal (investigational) 
product (ICH Guidance E2A 1995).  
All AEs are collected from the time the informed consent is signed until the defined follow- up 
period stated in Section 7.1.4. This includes events occurring during the screening phase of 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 69of 98
the study , regardless of whether or not investigat ional product is administered. Where 
possible, a diagnosis rather than a list of symptoms should be recorded. If a diagnosis has not 
been made, then each symptom should be listed individually .All AEs should be captured on 
the appropriate AE pages in the CRF and in source documents. In addition to untoward AEs, 
unexpected benefits outside the investigational product indication should also be captured on
the AE CRF.
All AEs must be followed to closure (the subject’s health has returned to his/her baseline 
status or all variables have returned to normal), regardless of whether the subject is sti ll 
participating in the study. Closure indicates that an outcome is reached, stabilization achieved 
(the investigator does not expect any further improvement or worsening of the event), or the 
event is otherwise explained. When appropriate, medical tests and examinations are 
performed so that resolution of event(s) c an be documented.
8.1.1 Severity Categorization
The severity  of AEs must be recorded during the course of the event including the start and 
stop dat es for each change in severity .An event that changes in severit y shou ld be captured as 
a new event. Worsening of pre -treatment events, after initiation of investigational product, 
must be recorded as new AEs (for example, if a subject experiences mild intermittent 
dyspepsia prior to dosing of investigational product, but the dyspepsia becomes severe and 
more frequent after first dose of investigational product has been administered, a new AE of 
severe d yspepsia [with the appropriate date of onset] is recorded on the appropriate CRF).
The medical assessment of severit y is determined by using the following definitions:
Mild: A type of AE that is usually  transient and may require only minimal treatment 
or therapeutic intervention. The event does not generall y interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention.  
The event interferes with usual activities of dail y living, causing discomfort but 
poses no significant or permanent risk of harm to the research subject.
Severe: A type of AE that interrupts usual activities of daily  living, or significantly  
affects clinical status, or may require intensive therapeutic intervention.
8.1.2 Relationship Categorization
A physician/investigator must make the assessment of relationship to invest igational product 
for each AE. The investigator should decide whether, in his or her medical judgment, there is 
a reasonable possibility  that the event may  have been caused by  the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related .”Other wise, if there is any valid reason, even if undetermined or untested, for 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 70of 98
suspecting a possible cause -and-effect relationship between the investigational product and 
the occurrence of the AE, then the AE should be considered “related ”based on the definiti ons 
in Table 8-1. The causality  assessment must be documented in the source document.
Table 8-1: Adverse Event Relatedness
Term Relationship Definition
Not Related Unrelated to study drug.
Possibly RelatedA clinical event or laboratory abnormality with a reasonable time sequence to 
administration of study drug, but which could also be explained by concurrent 
disease or other drugs or chemicals.
Probably RelatedA clinical event or laboratory abnormality with a reasonable time sequence to 
administration of study drug, unlikely to be attributable to concurrent disease or 
other drugs and chemicals and which follows a clinically reasonable response on 
de-challenge.  The association of the clinical event or laboratory abnormality must 
also have some biologic plausibility, at least on theoretical grounds.
Definitely RelatedThe event follows a reasonable temporal sequence from administration of the study 
drug, follows a known or suspected response pattern to the study drug, is confirmed 
by improvement upon stopping the study drug (de-challenge), and reappears upon 
repeated exposure (re-challenge).  Note that this is not to be construed as requiring 
re-exposure of the patient to study drug; however, the determ ination of definitely 
related can only be used when recurrence of event is observed.
8.1.3 Outcome Categorization
The outcome of AEs must be recorded during the course of the study  on the CRF. Outcomes 
are as follows:
 Fatal
 Not Recovered/Not Resolved
 Recovered/Resolved
 Recovered/Resolved With Sequelae
 Recovering/Resolving
 Unknown
8.1.4 Symptoms of the Disease u nder Study
Symptoms of the disease under study  should not be classed as AEs as long as they are within 
the normal day-to-day fluctuation or expected progression ofthe disease and are part of the 
efficacy  data to be collected in the study ; however, significant worsening of the symptoms 
should be recorded as an AE.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 71of 98
8.1.5 Clinical Laboratory and Other Safety Evaluations
A change in the value of a clinical laboratory  or vital sign assessment can represent an AE if 
the change is clinically  relevant or if, during treatment with the investigational product, a shift 
of a parameter is observed from a normal value to an abnormal value, or a further worsenin g 
of an already  abnormal value. When evaluating such changes, the extent of deviation from the 
reference range, the duration until return to the reference range, either while continuing 
treatment or after the end of treatment with the investigational product, and the range of 
variation of the respective parameter within its reference range, must be taken into 
consideration.
If, at the end of the treatment phase, there are abnormal clinical laboratory or vital sign values 
which were not present at the pre-treatment value observed closest to the start of study  
treatment, further investigations should be performed until the values return to within the 
reference range or until a plausible explanation (eg,concomitant disease) is found for the 
abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory or vital sign parameter is clinicall y 
significant and therefore represents an AE.
8.1.6 Pregnancy
All pregnancies are to be reported from the time informed consent is signed until the defined 
follow -up period stated in Section 7.1.4.
Any report of pregnancy  for any female study  participant must be reported within 24 hours to 
the Shire Global PVRM Department using the Shire Investigational and Marke ted Products 
Pregnancy  Report Form. A copy  of the Shire Investigational and Marketed Products 
Pregnancy  Report Form (and any applicable follow -
up reports) must also be sent to the 
CRO/Shire medical monitor using the details specified in the emergency  contact information 
section of the protocol. The pregnant female study  participant must be withdrawn from the 
study .
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infant. It is the responsibility  of the investigator to obtain this information 
within 30 calendar days after the initial notification and approximately  30 calendar days 
postpartum.
Pregnancy  complications such as spontaneous abortion/miscarriage or congenital abnormalit y 
are considered SAEs and must be reported using the Shire Clinical Study  Adverse Event 
Form for SAEs and Non-serious AEs as Required by Protocol . Note: An elective abortion is 
not considered an SAE.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 72of 98
In addition to the above, if the investigator determines that the pregnancy  meets serious 
criteria, it must be reported as an SAE using the Shire Clinical Study  Adverse Event Form for 
SAEs and Non-serious AEs as Required by Protocol as well as the Shire Investigational and 
Marketed Products Pregnancy  Report Form. The test date of the first positive serum/urine 
-HCG test or ultrasound result will determine the pregnancy  onset date.
8.1.7 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the 
sponsor according to th e SAE reporting procedure whether or not they  result in an AE/SAE as 
described in Section 8.2. Note: The 24 -hour reporting requirement for SAEs does not apply  to 
reports of abuse, misuse, overdose, or medication errors unless
 these result in an SAE. 
The c ategories below are not mutually  exclusive; the event can meet more than 1 category .
 Abuse –Persistent or sporadic intentional intake of investigational product when used 
for a non-medical purpose (eg,to alter one’s state of consciousness or get high) ina 
manner that may  be detrimental to the individual and/or society
 Misuse –Intentional use of investigational product other than as directed or indicated at 
any dose (Note: this includes a situation where the investigational product is not used as 
directe d at the dose prescribed by  the protocol)
 Overdose –Intentional or unintentional intake of a dose of an investigational product 
exceeding a pre -specified total daily  dose of 4 mg of the product.
 Medication Error –An error made in prescribing, dispensing,
administration, and/or 
use of an investigational product. For studies, medication errors are reportable to the 
sponsor only  as defined below.
Cases of subjects missing doses of the investigational product are not considered reportable as 
medication errors.
Medication errors should be collected/reported for all products under investigation.
The administration and/or use of the unassigned treatment is/are alway s reportable as a 
medication error.
The administration and/or use of an expired investigational product should be considered as a 
reportable medication error.
All investigational product provided to pediatric subjects should be supervised by the 
parent/legall yauthorized representative/caregiver.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 73of 98
8.2 Serious Adverse Event Procedures
8.2.1 Reference Safety Inform ation
The reference for safet y information for this study  is the investigator brochure ,which the 
sponsor has provided under separate cover to all investigators.
8.2.2 Reporting Procedures
All initial and follow -up SAE reports must be reported by the investigato r to the Shire Global 
PVRM Department andthe CRO medical monitor within 24 hours of thefirst awareness of 
the event. Note: The 24-hour reporting requirement for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors (see Section 8.1.7) unless they result in an SAE.
The investigator must complete, sign, and date the Shire Clinical Study  Adverse Event Form 
for SAEs and Non-serious AEs as Required by Protocol and verify  the accuracy  of the 
information recorded on the form with the corresponding source documents (Note: Source 
documents are not to be sent unless requested) and fax or e
-mail the form to the Shire Global 
PVRM Department. A copy  of the Shire Clinical Study  Adverse Event Form for SAEs and 
Non-serious AEs as Required by  Protocol (and any applicable follow -up reports ) must also be 
sent to the CRO medical monitor using the details specified in the emergency  contact 
information section of the protocol.
8.2.3 Serious Adverse Event Definition
A Serious Adverse Event (SAE) is any untowa rd medical occurrence (whether considered to 
be related to investigational product or not) that at any  dose:
 Results in death
 Is life-threatening. Note: The term “life-threatening ”in the definition of “serious” refers 
to an event in which the subject was at risk of death at the time of the event; it does not 
refer to an event which hy pothetically  might have caused death if it was more severe.
 Requires inpatient hospitalization or prolongati on of existing hospitalization. Note: 
Hospitalizations, which are the result of elective or previousl y scheduled surgery  for 
pre-existing conditions, which have not worsened after initiation of treatment, should 
not be classified as SAEs. For example, an admission for a previously scheduled ventral 
hernia repair would not be classified as an SAE; however, complication(s) resulting 
from a hospitalization for an elective or previously  scheduled surgery that meet(s) 
serious criteria must be reported as SAE(s).
 Results in persistent or significant disability /incapacity
 Is a co ngenital abnormality /birth defect
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 74of 98
 Is animportant medical event. Note: Important medical events that may not result in 
death, be life-threatening, or require hospitalization may be considered an SAE when, 
based upon appropriate medical judgment, they may jeopardize the subject and may 
require medical or surgical intervention to prevent 1 of the outcomes listed in this 
definition. Examples of such medical events include allergic bronchospasm requiring 
intensive treatment in an emergency  room or at home; blood dyscrasias or convulsions 
that do not result in inpatient hospitalization; or the development of drug dependency  or 
drug abuse.  
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study ) are collected from the time the s ubject signs the 
informed consent until the defined follow -up period stated in Section 7.1.4 and must be 
reported to the Shire Global PVRM Department andthe medical monitor within 24 hours of 
the first awareness of the event. 
In addition, any SAE(s) considered “related” to the investigational product and discovered by 
the investigator at any interval after the study  has completed must be reported to the Shire 
Global PVRM Department within 24 hours of the first awareness of the event.
8.2.5 Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The 
resolution date is the date the event no longer meets serious criteria, the date the symptoms 
resolve, or the event is considered chronic. Inthe case of hospitalizations, the hospital 
admission and discharge dates are considered the onset and resolution dates, respectivel y.
In addition, any signs or symptoms experienced by the subject after signing the informed 
consent form, leading up to the onset date of the SAE, or following the resolution date of the 
SAE must be recorded as an AE, if appropriate.
8.2.6 Fatal Outcome
Any SAE that results in the subject’s death (ie,the SAE was noted as the primary  cause of 
death) must have “fatal”checked as an outcome with the date of death recorded as the 
resolution date. For all other events ongoing at the time of death that did not contribute to the 
subject’s death, the outcome should be considered as not resolved, without a resolution date 
recorded.
For any SAE that results in the subject’s death or any ongoing events at the time of death, the 
action taken with the investigational product should be recorded as “dose not changed” or 
“not applicable” (if the subject never received investigational product).
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 75of 98
8.2.7 Regula tory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting
The sponsor and the clinical CRO areresponsible for notify ing the relevant regulatory 
authorities/US central Institutional Review Boards ( IRBs)of related, unexpected SAEs.
In addition ,the sponsor and the clinical CRO areresponsible for notify ing active sites of all 
related, unexpected SAEs occurring during all interventional studies across theSHP621
program.  
The investigator is responsible for notify ing the local IRB, loca l ethics committee ( EC), or the 
relevant local regulatory  authority  of all SAEs that occur at his or her site as required.
9. DATA MANAGEMENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information requi red by the 
protocol on the CRF. A study  monitor will visit each site in accordance with the monitoring 
plan and review the CRF data against the source data for completeness and accuracy .  
Discrepancies between source data and data entered on the CRF will be address ed by 
qualified site personnel. When a data discrepancy warrants correction, the correction will be 
mad
e by authorized site personnel. Data collection procedures will be discussed with the site 
at the site initiation visit and/or at the investigat or’s meeting. Once a subject is randomized, it 
is expected that site personnel will complete the CRF entry  within approximately  3 business 
days of the subject’s visit.
9.2 Clinical Data Management
Data are to be entered into a clinical database as specified intheCRO’s data management 
plan. Quality  control and data validation procedures are applied to ensure the validity  and 
accuracy  of the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using compu terized and manual procedures. Data queries requiring clarification 
are to be communicated to the site for resolution. Only  authorized personnel will make 
corrections to the clinical database, and all corrections are documented in an auditable 
manner.
9.3 Data Handling Considerations
Data that may potentially  unblind the treatment assignment ( ie,investigational product serum 
concentrations, treatment allocation, and investigational product preparation/accountability  
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 76of 98
data) will be handled with specia l care during the data cleaning and review process. These 
data will be handled in such a way that, prior to unblinding, any data that may unblind study 
team personnel will be presented as blinded information or otherw ise will not be made 
available. If applicable, unblinded data may be made available to quality  assurance 
representatives for the purposes of conducting independent drug audits. 
9.4 Statistical Analysis Process
The study  will be analy zed by the sponsor or its agent. All statistical analyses will be
performed using SAS®(SAS I nstitute, Cary , NC, USA) version 9.1 or higher.
The statistical analysis plan (SAP)will provide the statistical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to betaken for 
summarizing other study information such as subject disposition, demographics and baseline 
characteristics, investigational product exposure, and prior and concomitant medications. The 
SAP will also include a description of how missing, unused and spurious data will be 
addressed.
In addition to a final SAP for the final analysis, a separate interim SAP for the interim 
analysis will be finalized prior to unblinding and performing the analysis. The SAP for the 
final analy sis will be finalized prior to final database lock and performing analysis (ie, 
unblinding )to preserve the integrity  of the statistical a nalysis and study  conclusions. 
9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee
A planned interim analysis for each of the co-primary  endpoints will take place after 50% of 
all randomized subjects have either completed the study  or prematurely  withdraw nfrom the 
study , whichever comes first. The purpose of the unblinded interim analy sis is to reassess the 
appropriateness ofassumptions used for each of co-primary  efficacy  endpoints when the 
study  was designed. The reassessment of the sample size will utilize the conditional power 
approach under certain conditions that do not inflate the type I error (Mehta and Pocock ,
2011 ). The planned interim analy sis will be conducted by an external independent statistical 
(EIS) group; the individuals involved in the day-to-day conduct of the trial will not be 
involved in the interim analysis or have access to the results of the interim analysis. The 
Sponsor will only be notified by the EIS group if any recommendation of increasing the 
sample size is needed from the conditional power ; this will be detailed in the pre-specified 
interim SAP including a potential maximum sample size to be increased if deemed necessary . 
A very minimal fraction of alpha (0.0001) will be spent at the interim analy sis as the trial will 
not stop due to the interim results. The final analysis will use 4.99% for each of the 
co-primary  endpoints in order to preserve an overall ty pe I error at 5% level.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 77of 98
9.6 Sample Size Calculation and Power Considerations
Based on at least a 30-percentage -point reduction in DSQ score, there is an expected 
difference between treatment response propor tions of 69% and 45% in the OBS 2mg twice 
daily  (qAM, pc, and hs) and placebo groups, respectivel y. A total of 228 subjects 
(152subjects randomized to OBS and 76subjects randomized to placebo) arerequired to 
achieve 90% power at the significance level of 0.0499 
(2-sided) using a 2-group chi-square 
test with unequal allocation 2:1 to treatment groups (OBS 2 mg twice daily  and placebo). 
With the specified number of subjects per treatment group, the study  will be powered at 99% 
assuming histological respon se proportions of 40% and 3% in the OBS 2 mg twice dailyand 
placebo groups, respectively . The overall study  power for the co-primary  endpoints will be at 
least 85%. Therefore, approximately  228 ( approximately  152:76OBS and placebo subjects, 
respectivel y)will be randomized to the study  to allow for a loss of approximately  5% 
of 
subjects due to dropouts or invalid data. Expected response and dropout rates are based on 
observation from the Phase 2 study  (MPI 101- 06).
9.7 Study Population
The safety setwill inc lude all subjects who receive at least 1 dose of any double -blind 
investigational product. 
The intent -to-treat (ITT) set will include all randomized subjects. Subjects will be analy zed 
according to their assigned treatment, regardless of the treatment act ually received.
The full analysis set (FAS) will include all randomized subjects who received at least 1 dose 
of a double -blind investigational product and have both an evaluable post-baseline biops y in 
the treatment period ( ie, peak eosinophil count is re ported for at least 2 esophageal levels) and 
a post -baseline DSQ score.
The per-protocol (PP) set will include all subjects in the FAS excluding subjects with 
protocol violations. The PP set will be identified prior to unblinding the treatment 
assignments by  a team consisting of, at a minimum, a phy sician and a statistician from Shire. 
The pharmacokinetic setwill include all subjects in the safet y set for whom the primary 
pharmacokinetic data are considered sufficient and interpretable.
9.8 Efficacy Analyses
The primary , key secondary ,and secondary  efficacy  analyses will be performed on the ITT
set and presented b y treatment group.
Data collected at the baseline visit (Visit 1) will be used as the baseline for all efficacy  
analyses.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 78of 98
9.8.1 Primary Efficacy Endpoints
The co-primary  efficacy  endpoint s are the following:
Histologic response, defined as a peak eosinophil count of ≤6/HPF across all available 
esophageal levels at the final treatment period evaluation ( Visit 4)
Dysphagia symptom response, defined as ≥30% reduction in the DSQ combined score 
(questions 2+3) 
from baseline to the final treatment period evaluation ( Visit 4)
The co-primary  efficacy  endpoints will be analy zed based on the ITT set. Each of the 
co-primary  efficacy  endpoints is a binary  response (ie,responders vs non-responders); the 
endpoint will be analyzed using the Cochran- Mantel -Haenszel (CMH) test adjusting for age 
group (either <18years or ≥18years) and diet restriction for EoE or other health- related 
conditions (no diet restriction or any diet restriction) . The adjusted odds ratio of being a 
responder on each of the co -primary  endpoints for the OBS 2 mg twice daily  group v splacebo
group and associated 95% confidence interval (CI)will be provided. Subjects who withdraw 
without providing efficacy  data at the final treatment period evaluation (Visit 4, Week 16) 
will be classified as non -responders in the primary  efficacy  anal ysis.
Additionally , the proportion of responders based on each of the co -primary  endpoints for each 
treatment group will be summarized ,and their respective 95% CI will be reported. The 
difference in the proportion of responders between the 2 treatment groups and the 
corresponding 95% CI will also be summarized.
The following sensitivity  and supportive analyses will be performed for the co-primary  to 
evaluate the robustness of the results from the primary  anal ysis methods: 
Each of the co-primary  efficacy  endpoints will be analyzed using a logist ic regression 
with the effects of treatment group, age group (either <18 years or ≥18 years) and diet 
restriction for EoE or other health-related conditions (no diet restriction or any diet 
restriction). The odds ratio of being a responder on each of the co-primary  endpoints 
for the OBS 2 mg twice daily  group vs placebo group and associated 95% confidence 
interval (CI) will be estimated from the 
final model. Subjects who withdraw without 
providing efficacy  data at the final treatment period evaluation (Visit 4, Week 16) will 
be classified as non -responders in the primary  efficacy  anal ysis.
Analy ses will be repeated using the FAS and the PP set.
Analy ses will be repeated by considering subjects who withdraw without providing 
efficacy  data at the final treatme nt period evaluation (Visit 4) and will be classified as 
responders.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 79of 98
9.8.1.1 Missing Data Imputation
Method 1: Distribution -based Imputation
The subjects with missing co -primary  efficacy  endpoints will be assigned randomly  according 
to the distribution of responde rs with available data for each of the co-primary  endpoints (ie, 
those with non- missing data) across the 2 treatment groups by  strata (see Table 9 - 1). 
Table 9-1: Percentage of Responders for All Available Dat a (ie, Non-missing D ata) by 
Strata
Strata No Yes
<18 years X0% X1%
≥18 years Y0% Y1%
For instance, if there are N subjects with missing data in strata 1 (age <18 years), then 
X0%*N subjects will be randomly  assigned as non-responders and X1%*N subje cts will be 
randomly  assigned as responders.
Conversel y, if there are M subjects with missing data in strata 2 (age ≥18 years), the Y0%*M 
subjects will be randomly  assigned as non-responders and Y1%*N subjects will be randomly 
assigned as responders.
Metho d 2: Multiple Imputations
Multiple imputation (MI) methods will utilize the SAS procedures PROC MI and PROC 
MIANALYZE. The MI procedure will involve fitting a logistic regression model with the 
binary  outcome (responders vs non-responders) as the dependent variable and the age group 
and the treatment group as the independent variables. The MI procedure will generate 
10version datasets with binary  outcome imputed from the subjects with complete data. Once 
the missing values are imputed and each dataset is created, the results will be appropriatel y 
pooled across the multiply  imputed estimated regression coefficients and their standard errors 
using PROC MI ANALYZE.
Other sensitivity  analy ses will be explored , and details will be provided in the SAP.
9.8.2 Secondary E fficacy Endpoints
9.8.2.1 Key Secondary Efficacy Endpoint
The key secondary  efficacy  endpoint is defined as the change in DSQ combined score 
(questions 2+3) from baseline to the final treatment period evaluation (Visit 4). The change 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 80of 98
from baseline DSQ score at thefinal treatment period evaluation (Visit 4) will be analyzed 
using an analysis of covariance (ANCOVA) model with treatment group and age group as 
factors and the baseline DSQ score as a continuous covariate.
The additional secondary efficacy  endpoints are the following:
Change in total endoscopy  score, as measured by the EREFS classification, from baseline 
to the final treatment period evaluation (Visit 4)
Peak eosinophil count <15/HPF across all available esophagus levels at the final treatment 
period eva luation (Visit 4)
Peak eosinophil count ≤1/HPF across 
all available esophagus levels at the final treatment 
period evaluation (Visit 4)
Change from baseline in the peak eosinophil count to the final treatment period evaluation 
(Visit 4) for each available esophageal level (proximal, mid-, and distal)
Change from baseline in the histopathologic epithelial features combined total score 
(grade and stage) to the final treatment period evaluation (Visit 4)
Dysphagia sy mptom response (binary  response), defined as a  ≥50% reduction in the DSQ 
combined score (questions 2+3), from baseline to the final treatment period evaluation 
(Visit 4)
Change from baseline in the DSQ combined score (questions 2+3) over time including 
post baseline visits
Cumulative distribution f unction curves for the change and the percent change in the DSQ 
score from baseline to the final treatment period evaluation (Visit 4)
Overall binary  response I, defined as a reduction in the DSQ score of ≥30% from baseline 
to the final treatment period evaluation (Visit 4) and a peak eosinophil count of ≤6/HPF 
across all esophageal levels at the final treatment period evaluation (Visit 4)
Overall binary  response II, defined as a reduction in the DSQ score of ≥50% from 
baseline to the final treatment period evaluation (Visit 4) and a peak eosinophil count of 
≤6/HPF across all esophageal levels at the final treatment period evaluation (Visit 4)
Change in the DSQ + pain score (questions 2+3+4) from baseline to the final treatment 
period evaluation (Visit 4)
Change in the DSQ pain score (question 4) from baseline to the final treatment period 
evaluation (Visit 4)
The binary  response endpoints will be analyzed using the same logistic model as the 
co-primary  efficacy  endpoints.
Continuous endpoints will be analyzed as a change from baseline using an ANCOVA model 
that includes treatment group and age group as factor sand baseline score as a covariate.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 81of 98
The analyses for all secondary  efficacy  endpoints (including the key secondary  efficacy  
endpoint) will be carried out using 2-sided tests at the 5% level of significance. For each of 
the secondary  efficacy  endpoints, the treatment difference , 
corresponding 95% CIfor the 
difference, and treatment comparison p-value for testing the null hypothesis of zero treatment 
effec t based on the final statistical model (ie, either logistic regression model or ANCOVA 
model) will be provided.
9.8.3 Exploratory Efficacy Endpoint
The exploratory  endpoint that will be explored isthe following:
9.9 Safety Analyses
Safety  data will be presented for the safet y set by treatment group.
The safety  data collected at the baseline visit (Visit 1) or the last preceding visit if not 
collected at Visit 1will be used as the basel
ine value for safet y analyses.
TEAEs are defined as AEs that start or deteriorate on or after the first dose of investigational 
product (Visit 1) and no later than 3 days following the last dose of investigational product.
However, for any subjects who dieduring the study  (ie, the date of death is between the date 
of first dose of investigational product and the date of study  discontinuation entered by the 
site, inclusive), all AEs (including those resulting in death) that occur during the study  will be 
considered as TEAEs irrespective of the last dose and will be included in the TEAE 
summaries.
AEs will be coded using MedDRA . The number of events, incidence, and percentage of 
TEAEs will be calculated overall by system organ class (SOC ), preferre d term (PT), and 
treatment group. TEAEs will be further summarized by severit y and relationsh ip to 
investigational product. AEs related to investigational product, AEs leading to withdrawal, 
SAEs, and deaths will be similarly  summarized/listed.
Safety  parameters will include monitoring of AEs, physical examinations, stadiometry , vital 
signs (temperature, systolic and diastolic blood pressure, pulse, and respiratory  rate), weight 
and height assessments, DXA scans for BMD and body  composition measurements (for 
adolescents aged 11-17 years, inclusive), clinical laboratory  tests (hematology , chemistry , 
urinaly sis; serum pregnancy  test, if appropriat e), and ACTH stimulation tests. To account for 
the effects of pubert yin adolescent subjects (11-
17 yearsof age, inclusive ), BMD z-scores 
will be adjusted for height z-scores using the Bone Mineral Densit y in Childhood Study  
calculator (http://www.bmdcspublic.com) .Safety  parameters will be descriptivel y 
summarized by  treatment group at baseline and for each post- baseline visit.

Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 82of 98
9.10 Other Analyses
9.10.1 Health -related Quality -of-life Analyses
The health economic s and outcomes research endpoints that will be explored are the 
following:
EoE-QoL-A Questionnaire ( Taft et al. , 2011)
EQ-5D (EQ -
5D-3L or EQ-5D-Y, according to subject’s age)
PedsQL -EoE
The sub-modules of the EoE-QoL-A and PedsQL -EoE will be assessed in addition to the 
overall score with a focus on emotional and physical elements. For all HRQoL  analyses, 
change from baseline to the final treatment period evaluation (Visit 4) will be assessed.
9.10.2 Pharmacokinetic Analyses
Pharmacokinetic parameters will be determined from the plasma concentration -time data for 
budesonide b y non -compartmental anal ysis.  
The pharmacokinetic endpoints will include but not be limited to those listed in Table 9-2.
Table 9-2: Pharmacokinetic Parameters
Param eter Defin ition
AUC 0-tau Area under the curve for the defined interval betw een doses
Cmax Maximum concentration o ccurring at t max
tmax Time of maximum observed concentration sampled during a dosing interval
Summary  statistics (number of observations, mean, standard deviation, coefficient of 
variation, median, maximum, minimum, and geometric mean) will be determine d for all 
pharmacokinetic parameters by overall and by week. Plasma concentrations at each nominal 
sampling time will also be summarized using descriptive statistics.
10. SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements.  
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 83of 98
The name and address of each third- party vendor (eg,CRO) used in this study  will be 
maintained in the investigator’s and sponsor’s fi les, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.1 Good Clinical Practice Compliance
The study  sponsor and any third party to whom aspects of the study  management or 
monitoring have been delegated will undertake their assigned roles for this study  in 
complian ce with all applicable industry  regulations, ICH GCP Guideline E6 (1996), EU 
Directive 2001/20/EC, as well as all applicable national and local laws and regulations.
Visits to sites are conducted by representatives of the study  sponsor and/or the company 
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and CRFs in accordance with current GCP and the respective local and 
(inter)national governme nt regulations and guidelines. Records and data may additionally  be 
reviewed b y auditors or by  regulatory  authorities.
The sponsor ensures that local regulatory  authority  requirements are met before the start of 
the study . The sponsor (or a nominated designee) is responsible for the preparation, 
submission, andconfirmation of receipt of any regulatory  authorit y approvals required prior 
to release of investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry Guidelines. If appropriate, a copy  of the indemnity  document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that suitable clinical study  insurance coverage is in 
place p rior to the start 
of the study .An insurance certificate is supplied to the CRO as necessary .
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on applicable websites.
Information included in clinical study  registries may include participating investigators’ 
names and contact information.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 84of 98
10.1.4 Submission of Summary of Clinical Study Report to Competent Authorities of 
Member States Concerned and Ethics Committees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of 
the member state(s) concerned as required by regulatory  requirement(s) and to comply  with 
the community  guideline on GCP. This requirement will be fulfilled within 6 months of the 
end of the study  completion date for pediatric studies and within 1 year for non-pediatric 
studies as per guidance.
10.1.5
Study Suspension, Termination, and Completion
The sponsor may suspend or terminate the study , or part of the study, at any time for any 
reason. If the study  issuspended or terminated, the sponsor will ensure that applicable sites, 
regulatory  agencies and IRBs/EC s are notified as appropriate. Additionally , the 
discontinuation of a registered clinical study ,which has been posted to a designated public 
website , will be updated accordingl y.
10.2 Investigator’s Responsibilities
10.2.1 Good Clinical Practice Compliance
The investigator must undertake to perform the study  in accordance with ICH GCP Guideline 
E6 (1996), EU Directive 2001/20/EC, and applicable regulatory  requiremen ts and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriatel y trained 
resources are available at the site prior to commitment to participate in this study . The 
investigator should also be able to estimate or demonstrate a potential for recruiting the 
required number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriatel y qualified persons to whom the 
investigator has delegated significant study -related tasks, and shall, upon request of the 
sponsor, provide documented evidence of any licenses and certifications necessary  to 
demonstrate such qualification. Curriculum vitae for investigators and sub-invest igators are 
provided to the study  sponsor (or designee) before starting the study .
If a potential research subject has a primary  care physician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
Acoordinating principal investigator is appointed to review the final clinical study  report for 
multicenter studies. Agreement with the 
final clinical study  report is documented by the 
signed and dated signature of the principal investigator (single -site study) or coordinating 
principal investigator (multicenter study ), in compliance with Directive 2001/83/EC as 
amended b y Directive 2003/63/EC and I CH Guidance E3 ( 1995). 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 85of 98
10.2.2 Protocol Adherence and Investigator Agreement
The investigator and any co-investigator s must adhere to the protoc ol as detailed in this 
document. The investigator is responsible for enrolling only those subjects who have met 
protocol eligibility  criteria. Investigators arerequired to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly 
inform the sponsor and the IRB/EC and provide them with a detailed written explanation. The 
investigator will also return all investigational product, containers, and other study  materials 
to the sponsor. Upon study  completion, the investigator will provide the sponsor, IRB/EC, 
and regulatory  agenc y with final reports and summaries as required by (inter)national 
regulations.
Communication with local I RBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may be done by the sponsor, applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investiga tor according to national provisions 
and will be documented in the investigator agreement.
10.2.3 Documentation and Retention of Records
10.2.3.1 Case Report Forms
Electronic CRFs are supplied by the CRO and should be handled in accordance with 
instructions from the spons or.
The investigator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded onto CRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Cas e report forms must be 
completed b y the investigator or designee as stated in the site delegation log.
All data from the investigator will have separate source documentation; no data will be 
recorded directly  onto the CRF.   
All data sent to the sponsor mu st be endorsed b y the investigator.
The data from the central pathologist will be recorded directl y onto paper CRFs.  
The clinical research associate ( CRA )/study  monitor will verify  the contents against the 
source data per the monitoring plan. If the data are unclear or contradictory , queries are sent 
for corrections or verification of data.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 86of 98
10.2.3.2 Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include but are not limited to
subject’s medical file,original clinical laboratory  reports, and histology  and pathology 
reports.
All key  data must be recorded in the subject’s medical records.
The investigator must permit 
authorized representatives of the sponsor ; the respective 
national, local , or foreign regulatory  authorities ; the IRB/EC ; and auditors to inspect facilities 
and have direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC ,or regulatory  inspectors) may check the CRF 
entrie s against the source documents. The consent form includes a statement by which the 
subject agrees to the monitor/auditor from the sponsor or its representatives, national or local 
regulatory  authorities, or the IRB/EC, having access to so urce data ( eg,subject’s medical file, 
appointment books, original laboratory
 reports, X -rays,etc.).
These records must be made available within reasonable times for inspection and duplication, 
if required, by a  properly  authorized representative of any regulatory  agency  (eg,the US 
FDA, EMA, UK Medicines and Healthcare products Regulatory  Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
10.2.3.3 Audit/Inspection
To ensure compliance with relevant regulations, data generated by this study  must be 
available for inspection upon request by  representatives of, for example, the US FDA (as well 
as other US national and local regulatory  authorities), the EMA , the Medicines and Healthcare 
products Regulatory  Agency , other regulatory  authorities, the sponsor or its representatives, 
and the IRB/EC for each site.
10.2.3.4 Financial Disclosure
The investigator is required to disclose any financial arrangement during the study and for 
1year after, whereb y the outcome of the study could be influenced by the value of the 
compensation for conducting the study , or other payments the investiga tor received from the 
sponsor. The following information is collected: any  significant payments from the sponsor or 
subsidiaries such as a grant to fund ongoing research, compensation in the form of equipment,
retainer for ongoing consultation ,or honoraria; any proprietary  interest in investigational 
product; any significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 
2(b) ( 1998).
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 87of 98
10.3 Ethical Considerations
10.3.1 Informed Consent
It is the responsibility  of the investigator to obtain written informed consent (or assent as 
applicable for subjects <18yearsof age) from all study subjects prior to any study -related 
procedures includ ing screening assessments. All consent documentation must be in 
accordance with applicable regulations and GCP. Each subject or the subject’s legally
authorized representative, as applicable, is requested to sign and date the subject ’sinformed 
consent form or a certified translation ,if applicable, after the subject has received and read (or 
been read) the written subject information and received an explanation of what the study 
involves, including but not limited to the objectives, potential benefits and risk, 
inconveniences, and the subject’ s rights 
and responsibilities. A copy  of the informed consent 
documentation (ie,a complete set of subject information sheets and fully  executed signature 
pages) must be given to the subject or the subject’s legall y authorized representative, as 
applicable. This document may require transl ation into the local language. Signed consent 
forms must remain in each subject’s study  file and must be available for verifica tion at any 
time.
Within the source documents, site personnel should document instruction of and 
understanding by the parent/legally authorized representative/caregiver of the safe, 
responsible storage and administration of investigational product to the s tudy subject.
The principal investigator provides the sponsor with a copy  of the consent form consent (or 
assent as applicable for subjects <18yearsof age)that was reviewed by the IRB/EC and 
received their favorable opinion/approval. A copy  of the IRB’s/EC’s written favorable 
opinion/approval of these documents must be provided to the sponsor, prior to the start of the 
study  unless it is agreed to and documented (abiding by regulatory  guidelines and national 
provisions) prior to study  start that another party  (ie,sponsor or coordinating principal 
investigator) is responsible for this action. Additionally , if the IRB/EC requires modification 
of the sample subject information and consent document provided by the sponsor, the 
documentation supporting this r equirement must be provided to the sponsor.
10.3.2 Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility  of the investigator to submit this protocol, the 
informed consent document (approved by the sponsor or their desig nee), relevant supporting 
information ,and all types of subject recruitment information to the IRB/EC for review, and 
all must be approved prior to site initiation .
For sites within the EU, the applicant for an EC opinion can be the sponsor or the investig ator 
or,for multicenter studies ,the coordinating principal investigator or sponsor, according to 
national provisions.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 88of 98
Responsibility  for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any 
revisions of all informed consent (or assent as applicable for subjects <18yearsof age) 
documents and amendments to the protocol unless there is a subject safet y issue.
Investigational product supplies will not be released until the CRO has received written 
IRB/EC approval of and copies of revised documents.
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of 
the progress of the study  and of any changes made to the protocol, but in any case at least 
once a year; for sites within the EU, this can be done by  the sponsor or the investigator or ,for 
multicenter studies ,the coordinating principal investigator, according to national provisions. 
The investigator must also keep the local IRB/EC informed of any serious and significant 
AEs.
10.4 Privacy and Confidentiality
All US-based sites and laboratories or entities providing support for this study , must, where 
applicable, compl y with HIPAA of 1996. A site that is not a covered entity  asdefined by 
HIPAA must provide documentation of this fact to the CRO/sponsor .
The confidentialit y of records that may be able to identify  subjects will be protected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consen ted to take part in the study , the sponsor and/or its representatives 
reviews their medical records and data collected during the study .These records and data 
may, in addition, be reviewed by others including the following: independent auditors who 
valida te the data on behalf of the sponsor; third parties with whom the sponsor may develop, 
register, or market SHP621 ; national or local regulatory  authorities; and the IRBs/ECs which 
gave approval for the study  to proceed. The sponsor and/or its representatives accessing the 
records and data will take all reasonable precautions in accordance with applicable laws, 
regulations, and guidelines to maintain the confidentiality  of subjects’ identities.
Subjects are assigned a unique identify ing number; however, their initials and date of birth 
may also be collected and used to assist the sponsor to verify  the accuracy  of the data (eg,to 
confirm that laboratory  results have been assigned to the correct subject).
The results of studies –containing subjects’ unique identify ing number, relevant medical 
records, and possibly  initials and dat es of birth –will be recorded. They  may  be transferred to 
and used in other countries which may not afford the same level of protection that applies 
within the countries where this study is conducted. The purpose sof any such transfer would 
include support ingregulatory  submissions, conduct ingnew data analyses to publish or 
present the stud y results, or answer ingquestions asked by  regulatory  or health authorities.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 89of 98
10.5 Study Results/Publ ication Policy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timel y manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionall y, Shire adheres to external guidelines 
(eg,Good Publication Practices 2) when forming a publication steering committee, which is 
done for large, multicenter Phase 2-4 and certain other studies as determined by Shire. The 
purpose of the publication steeri ng committee is to act as a non -commercial body  that advises 
or decides on dissemination of scientific study  data in accordance with the scope of this 
policy .
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information.
The review is aimed at protecting the sponsor’s proprietary  information existing either at the 
commencement of the study or generated during the study .To the extent permitted by the 
publisher and copyright law, the principal investigator will own (or share with other authors) 
the copyright on his/her publications. To the extent that the principal investigator has such 
sole, joint or shared rights, the principal investigator grants the sponsor a perpetual, 
irrevocable, ro yalty
-free license to make and distribute copies of such publications.
The term “publication” refers to any public disclosure including original research articles, 
review articles, oral presentations , abstracts and posters at medical congresses, journal 
supplements, letters to the editor, invited lectures, opinion pieces, book chapters, electronic 
postings on medical/scientific websites, or other disclosure of the study results, in printed, 
electronic , oral ,or other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any background information provided by the sponsor that is necessary  to 
include in any  publication of study  results, or necessary  for other scholars to verify  such study 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential information shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 daysto 
allow for filing of a patent application.
If the study  is part of a multicenter study , the first publication of the study  results shall be 
made by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter 
publication of the com piled and anal yzed study results. If such a multicenter publication is not 
submitted to a journal for publication by the sponsor within an 18-month period after 
conclusion, abandonment, or termination of the study  at all sites, or after the sponsor confirm s 
there shall be no multicenter study  publication of the study  results, an investigator may 
individually  publish the study  results from the specific site inaccordance with this section. 
The investigator must, however, acknowledge in the publication the li
mitations of the 
single -site data being presented.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 90of 98
Unless otherwise required by the journal in which the publication appears, or the forum in 
which it is made, authorship will comply  with the International Committee of Medical Journal 
Editors current standards. Participation as an investigator does not confer any rights to 
authorship of publications.
11. REFERENCES
Bachrach LK, Sills IN, Section on Endocrinology . Clinical report—Bone densitometry  in 
children and adolescents. Pediatrics 2011;127:189
-194.
Bone Mineral Density  in Childhood Study  (BMDCS) calculator . Available at:
http://www.bmdcspublic.com. Accessed August 5, 2015. 
Dellon ES, Jensen ET, Martin CF, et al. Prevalence of eosinophilic esophagitis in the United 
States. Clin Gastroenterol Hepatol 2014a ;12(4):589 -96.
Dellon ES, Kim HP, Sperry  SL, et al. A phenoty pic analysis shows that eosinophilic 
esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc 2014b;79(4):577-85.
EuroQol Group. EuroQol--a new facility  for the measurement of heal th-related qualit y of life. 
Health Policy  1990;16(3):199 -208.
Food and Drug Administration. Uceris pharmacology  review. NDA 203- 634. 2011.
Franciosi JP, Hommel KA, Bendo CB. PedsQL  eosinophilic esophagitis module: feasibility , 
reliability , and validity . J Pediatr Gastroenterol Nutr 2013;57(1):57-66.
Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: 
a systematic review and consensus recommendations for diagnosis and treatment. 
Gastroenterology  2007;133(4):1342-63.
Gordon CM, Bachrach LK, Carpenter TO, et al. Duel energy  X-ray absorptiometry 
interpretation and reporting in children and adolescents: The 2007 ISCD pediatric official 
positions. J Clin Densitometry 2008;11:43 -58.
Hirano I, Aceves S. Clinical Implications and Pathogenesis of Esophageal Remodeling in 
Eosinophilic Esophagitis. Gastro Clin North Am 2014;43(2):297 -316.
International Societ y for Clinical Densitometry . 2013 Official Positions—Adult & Pediatric. 
2014:1 -20.
Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus 
recommendations for children and adults. J Allergy  Clin I mmunol 2011;128 (1):3-20. 
Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: a 
practical guide with examples. Stat Med 2011;30(28):3267-84.
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 91of 98
Patient- Reported Outcome and Quality  of Life Instruments Database (PROQOLID). 
Available at: http://www.proqolid.org . Accessed August 24, 2015. 
Taft TH, Kern E, Kwiatek MA. The adult eosinophilic oesophagitis quality  of life 
quest ionnaire: a new measure of health -related quality  of life. Aliment Pharmacol Ther 
2011t;34(7):790-8.
Wille N, Badia X, Bonsel G, et al. Development of the EQ-
5D-Y: a child- friendl y version of 
the EQ -5D. Qual L ife Res 2010;19(6):875-86. 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 92of 98
12. APPENDICES
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 93of 98
Appendix 1 Protoco l History 
Document Date Global/Country/Site Specific
Protocol Amendment 1 16Dec 2015 Global
Original Protocol 31 Aug 2015 Global
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 94of 98
Appendix 2 Scales and Assessments
The following scales/assessments will be utilized in this study :
Full Title of Scale/Assessment Completed By
DSQ Subject
EQ-5D-3L (for subjects ≥18 years)
EQ-5D-Y (for subjects 11 -17 years of age, inclusive)Subject
PedsQL -EoE (subjects 11 -17 years of age, inclusive ) Subject and parent or legal 
guardian
EoE-QoL- A (subjects ≥18 years of age) Subject
PGI-S Subject
Tanner Staging Assessment (for subjects 11 -17 years of age, inclusive) Site
EREFS Site
Abbreviations: DSQ=Dysphagia Symptom Questionnaire; EoE -QoL- A=Adult Eosinophilic Esophagitis Quality 
of Life; EQ -5D=EuroQol; EREFS=EoE Endoscopic Reference Score; PedsQL -EoE= Pediatric Quality of Life 
Inventory –EoE; PGI -S=Patient Global Impression of Severity
A separate master file containing each scale/assessment listed above will be provided to the 
site. Updates to scales/assessments during the study  (if applicable) will be documented in the 
table above ,and a new master file containing the revised scale/assessment will be provided to 
the site. 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 95of 98
Appendix 3 Dysphagia Symptom Questionnaire ePRO for EoE

Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 96of 98
Appendix 4 Patient Global Impression of Severity
How would you rate the overall severity  of your dysphagia (difficult y swallowing) over the 
past 7 days?
Rating Description
0 No dysphagia
1 Mild dysphagia
2 Moderate dysphagia
3 Severe dysphagia
4 Very  severe dysphagia
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 97of 98
Appendix 5 Biosciences Generic Clinical Protocol Insert
Blood Sample Collection
Blood samples will be collected at the times specified inTable 1-1to measure plasma 
concentrations of budesonide . Potential metabolites may  also be determined as appropriate.
Blood samples 4 mLfor pharmacokinetic analysis will be drawn by in-dwelling cathe ters or 
direct venipuncture into K2EDTA tubes, capped and mixed by inversion (x3),and chilled 
immediately  on 
crushed ice. The actual time that the sample was obtained will be recorded in 
the subject’s source document and on the appropriate CRF page. After apply ing a tourniquet, 
venous blood will be drawn with a disposable needle. If a catheter is used, the first milliliter 
of blood on each sampling occasion will be discarded. Saline can be used to keep catheters 
patent.
1.1 Blood/Plasma Sample Handling
Samples should be kept on crushed ice until plasma is separated as soon as possible after 
collection within <15minutes, unless advised otherwise by refrigerated centrifugation (4C, 
1500 rpm 15 minutes). The separated plasma will be decanted into appropriatel y labeled 
polypropylene tubes via a plastic pipette. All samples will be stored at approximately  
-20C 
or colder and the freezer temperature will be controlled, monitored, and recorded during the 
storage period until they are transferred in the frozen state t
o a designated bioanal ytical 
contract laboratory . Samples will remain frozen at -20C or colder until analy sis.
Plasma sample tubes for bioanaly sis 
must be freezer -safe and identified with freezer -safe 
labels provided b y the central laboratory . The labels will contain the following information:
 Study  number
 Subject identifier (randomization number)
 Matrix identifier (plasma)
 Visit
 Nominal time
1.2 Shipment of Plasma Samples
Plasma samples should be double -bagged to contain leaks and packed with a sufficient 
quantity  of dry  ice to ensure that they  remain frozen for at least 72 hours to allow for delay s in 
shipment. All applicable shipping regulations must be followed. Shipments should be 
scheduled so that no samples arrive on the weekend and should be shipped Monday  to
Wednesday  only . 
Shire CONFIDENT IAL 17Dec 2015
Protocol SHP621 -301 Amendment 1 Page 98of 98
Plasma samples, along with the corresponding documentation, will be shipped to:
PPD
2 Tesseneer Drive
Highland Heights, KY 41076, USA
Email:
Phone:   or , 
Fax:  
Plasma samples will be stored nominally  at -20C prior to and after analysis at Covance until 
their disposal is authorized by  Shire.
1.3 Assay Methodology
Drug analysis will be performed at Covance under the guidance of the NCE group atShire. 
Plasma sample analy sis will be performed according to the bioanaly tical study  plans prepared 
for the stud y. 
Plasma samples will be analyzed at Covance for budesonide using the most current validated 
bioanaly tical method. 
In addition, selected plasma sampl es may be used to investigate incurred sample 
reproducibility  (full details will be described in the bioanal ytical study  plan). The presence of 
other metabolites or artifacts may  be monitored or quantified as appropriate.
Raw data will be stored in the archives at Covance .

PROTOCOL: SHP621 -301
TITLE: Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects 
(11 to 55 Years of Age, Inclusive) with Eosinophilic Esophagitis: 
A Phase 3 Randomized, Double- blind, Placebo -controlled Study
DRUG: SHP621, oral budesonide suspension (OBS)
IND: 103,173
EUDRACT NO.: Non-EUDRACT
SPONSOR: Shire ViroPharma, Incorporated (Shire) 
300 Shire Way , Lexington, MA 02421 USA
PROTOCOL 
HISTORY:Original Protocol: 31 Aug 2015
Protocol Amendm ent 1: 17 Dec 2015
Protocol Amendment 2: 26 Jan 2018
This document contains confidential and proprietary information of Shire and is disclosed pursuant to confidentiality 
and nondisclosure obligations. This information should be used solely for the purposes for which it was provided 
and should not be copied, shared w ith, or disclosed to any third party without the express written consent of Shire.

Shire CONFI DENTIAL Page 2
Protocol Am endment 2
SHP621 -301 26 Jan 2018
PROTOCOL  SIGNA TURE P AGE

Shire CONFI DENTIAL Page 3
Protocol Am endment 2
SHP621 -301 26 Jan 2018
SUMMAR Y OF CHANGES F ROM PREVIOUS VERSION
The SHP621-301 protocol is amended to address the following items:
Increase the number of enrolled subjects to allow an adequate number of subjects to 
enroll in the treatment extension study  (SHP621
-302).
Admini strative changes issued since Protocol Amendment 1.
Additional edits, as capture d in the below table, were made to Protocol Amendment 2 to 
improve the clarit y of the protocol and/or correct minor inconsistencies. Note that correction of 
typos and grammatical errors are not captured in the below table.
New text indicated in bold; delet ed text indicated in strikethrough.
Protocol Am endments
Summary of Change(s) Since Last Version of Approved Protocol
Amendment Number 1 Amendment Date
26Jan 2018Global Amendment
Description of Change Section(s) Affected by Change
Revised text to reflect increased enrollment of subjects in this study 
(from 300 to 420) to allow  an adequate number of subjects to enroll in 
the treatment extension study. Updated number of subjects to be 
randomized (from 152 to 204 for OBS; from 76 to 102 for placebo) to 
reflect increase enrollment of subjects in this study.Study Synopsis : Number of subjects
Section 3.1: Study Design and Flow  
Chart
Approximately 6070sites in North America Study Synopsis : Sites and Region(s)
Section 3.3; Sites and Regions
Oct 2015 to July 2018 Nov 2018 Study Synopsis : Study Period 
(Planned)
14. Subject has a potentially serious acute or chronic viral 
infection or immunodeficiency condition, including tuberculosis, 
fungal, bacterial, viral/parasite infection, ocular herpes simplex, herpes 
esophagitis, or chicken pox/measles.Study Synopsis :Exclusion Criteria;
Section 4.2: Excl usion Criteria
20. Subject has taken part and received intervention in an
interventional study related toEoE (except for an interventional 
study for a topical swallowed steroid) within 6 months prior to the 
screening visit (Visit -1), or any investigatio nal study within 30 days 
prior to the screening visit (Visit -1).An investigational topical 
swallowed steroid must have been discontinued at least 30 days 
prior to the screening visit (Visit -1).Study Synopsis : Exclusion Criteria;
Section 4.2: Exclusion Criteria
Pharm acokinetic param eters will be determined from the plasma 
concentration -time data for budesonide by non- compartmental 
analysis .for subjects who provide sufficient numbers of intensive 
PK samples . For all subjects who provide PK samples (ie, limited 
or intensive samples) population PK analysis will be conducted.
A report for the population PK analysis will be provided Study Synopsis : Endpoints and 
Statistical Analysis; Pharmacokinetic 
Endpoints
Section 9.10.2 : Pharmacokinetic 
Analysis
Section 9.10.2 : Pharmacokinetic 
Shire CONFI DENTIAL Page 4
Protocol Am endment 2
SHP621 -301 26 Jan 2018
separately from  the clinical study report (CSR). Analysis 
Height measurements for adolescent subjects 11-17 years of age, 
inclusive, should be measured in triplicate.Table 1 - 1;Schedule of Assessments , 
footnote b
Section 7.2.2.2 ; Physical Examination 
(Including Height and Weight)
Weight measurements for adolescent subjects (11-17 years, 
inclusive) should be measured in duplicate.Table 1 -1;Sched ule of Assessments , 
footnote c
Section 7.2.2.2 ; Physical Examination 
(Including Height and Weight)
DSQ assessment includes completion of reports on DSQ handset 
(ie, eligibility reports and visit confirm ations). Table 1 -1;Schedule of Assessments , 
footnot e e
Blood samples for pharmacokinetic analysis willcanbe obtained at the
one time on any day starting 7 days after Visit 1 (Week 8 or 5) and 
through Visit 4 (Week 12 visit 16). PK samples should be drawn, 
ideally, at pre-dose, 0.5 and 1 hour post-dose, and at the follow ing
additional post-dose time points: pre-dose and at 0.5, 1 , if feasible (2, 
3, 4, 6, 8, and 12 hours post- dose).Table 1 -1, Schedule of Assessments , 
footnote k
Section 7.1.3.2 ; Visits 2 and 3 
(Weeks 8 and 12)
Section 7.1.3.3 ; Visit 4 (W eek 16)
Subjects cannot be rescreened once it is confirm ed they do not meet 
inclusion/exclusion criteria unless the screen failure was due to a 
temporary condition or incom plete information at the time of 
consent (Visit -1) that would make rescreening at a later date 
appropriate (eg, concomitant medication that can be discontinued 
prior to rescreening; those subjects may be rescreened . Other, review 
of subject medical records provides new inform ation with respect 
to the date of a prior esophageal dilation or diet change, or subject 
has a minor illness such as an upper respiratory or urinary tract 
infection). All reasons for rescreening (ie, reasons unrelated to 
inclusion/exclusion criteria) must be discussed and approved
prospectively with the medical monitor. Subjects who discontinue will 
not be replaced.Section 3.1: Study Design and Flow  
Chart
Section 7.1.1 ; Screening Period 
(Weeks -6 to 0)
Abstinence
Surgically sterile m ale partner
Stable oral contraceptivesSection 4.4.1 ; Female Contraception
Medicall y important events that in the opinion of the investigator or 
medical monitor would compromise the subject’s ability to safely 
continue in the study, including but not limited to severe signs and 
symptoms of EoE, such as an esophageal stricture requiring dilation 
and/or worsening signs and symptoms of EoE (eg, weight loss or 
increased due to severe dysphagia ), and/or upper GI bleed would be 
considered a treatment failure and result in withdrawal of the subject 
from the study.Section 4.5.1 ; Subject Withdraw al 
Criteria
6.Maintenance immunotherapy (allergy shots or sublingual 
immunotherapy )Section 5.2.1 ; Permitted Treatment
During the visit day where the pharmacokinetic blood samples are 
collected (Visit 2 or Visit 3), subjects will be required to eat a 
moderate -fat breakfast on -siteSection 6.2.3 ; Dosing
Revie wConfirm DSQ dysphagia episodes and compliance by 
completing baseline screening eligibility report on DSQ 
device;Section 7.1.2.1 ; Placebo Lead -in Visit 
(Visit 0)
Section 7.1.3.1 ; Baseline Visit 
Shire CONFI DENTIAL Page 5
Protocol Am endment 2
SHP621 -301 26 Jan 2018
(Visit1)
Revie w DSQ dysphagia episodes compliance and complete 
visit confirm ation on the DSQ device ;Section 7.1.3.2 ; Visits 2 and 3 (Weeks 
8 and 12)
Section 7.1.3.3 ; Visit 4 (Week 16)
If an esophageal dilatation is performed at Visit 4 
(treatm ent failure), subjects will not be eligible to 
participate in the treatm ent extension study.
Follow ing all safety blood draws, subjects can eat breakfast and take 
their morning dose of investigational product if they are continuing in 
the treatment extension study or staying in clinic for PK sampling (to 
be perform ed as described in Section 7.1.3.2 above).Section 7.1.3.3 ; Visit 4 (Week 16)
Subjects must fill out the DSQ at least 54 or more days during a given 
week in order to be compliant.
Protocol deviations will be documented for subjects who fail to 
complete the DSQ for 34 or more days in a given week.Section 7.2.1.2 ; Dysphagia Symptom 
Questionnaire
The original protocol noted that a total of 228 subjects (152 subjects 
randomized to OBS and 76 subjects randomiz ed to placebo) are 
required to achieve 90% power at the significance level of 0.0499 (2-
sided)…
The overall study power for the co-prim ary endpoints will was 
estim ated to be at least 85%. Therefore, approximately 228 
(approximately 152:76 OBS and placebo subjects, respectively) will 
were to be randomized tointhe study to allow for a loss of 
approximately 5% of subjects due to dropouts or invalid data.
In this protocol amendment, in order to ensure that a sufficient 
number of subjects will complete this study and enroll in the 
treatm ent extension study, up to approximately 420 subjects will 
be enrolled in the placebo lead-in period to allow for 
approximately 306 subjects to be random ized into the double blind 
period of this study (approximately 204:102 OBS and placebo 
subjects, respectively). With a total of 306 random ized subjects in 
this study, using the same assumptions for the co-prim ary 
endpoints and the dropout rate, the overall study power for the co -
primary endpoints is estimated to be at least 95%.
Rationale: The sample size is increa sed to ensure that a sufficient 
number of subjects complete this study and enroll in the treatment 
extension study (SHP621 -302). Approximately 200 subjects (65%) 
who are random ized in the SHP621 -301 study are estimated to 
complete the SHP621 -301 study and enroll in the treatment extension 
study.Section 9.6; Sample Size and Pow er 
Considerations
Added text to clarify the retention period for laboratory samples (blood 
and urine).Section 10.2.3.2 ; Recording, Access, 
and Retention of Source Data and 
Study Documents
See Appendix 1 for protocol history , including all amendments.
Shire CONFI DENTIAL Page 6
Protocol Am endment 2
SHP621 -301 26 Jan 2018
EMERGENCY CONTACT IN FORMATION
In the event of an SAE, the investigator must fax or e-mail the Shire Clinical Study  Adverse 
Event Form for Serious Adverse Events (SAEs) and Non-serious AEs as Required by Protocol 
within 24 hours to the Shire Global Drug Safety  Department. Applicable fax numbers and e -mail 
address can be found on the form (sent under separate cover). A copy  of the Shire Clinical Study
Adverse Event Form for SAEs and Non-serious AEs as Required by Protocol must also be sent 
to the CRO medical monitor by  fax or e -mail using the details below.
, MD
Email:
Fax: 7
For protocol -or safety- related issues during normal business hours (8am to 5 pm Eastern 
Standard Time) ,the investigator must contact the CRO medical monitor:
, MD
Phone: 
Mobile: 
Email: 
Fax:
For protocol -or safety -related issues outside of normal business hours , the investigator 
must contact the CRO medical monitor:
, MD
Mobile:
Email:

Shire CONFI DENTIAL Page 7
Protocol Am endment 2
SHP621 -301 26 Jan 2018
PRODUCT QUALITY COMP LAINTS
Investigators are required to report investigationa l product quality  complaints to Shire within 
24hours. This includes any instances wherein the qualit y or performance of a Shire product 
(marketed or investigational) does not meet expectations (eg, inadequate or faulty  closure, 
product contamination) or that the product did not meet the specifications defined in the 
application for the product (eg, wrong product such that the label and contents are different 
products). For instructions on reporting AEs related to product complaints, see Section 8.
Please u
se the information below as applicable to report the Product Quality Complaint:
Origin of Product Quality Complaint E-mail Address
North and South America
European Union and Rest of World
Telephone numbers (provided for r eference if needed):
Shire, Lexington, MA (USA)
or 

Shire CONFI DENTIAL Page 8
Protocol Am endment 2
SHP621 -301 26 Jan 2018
TABLE OF CONTENTS
PROTOCOL  SIGNATURE P AGE .................................................................................................2
SUMMARY OF CHANGES F ROM PREVIOUS VERSI ON........................................................3
EMERGENCY CONTACT I NFORMATION ................................................................................6
PRODUCT QUALITY COMP LAINTS ..........................................................................................7
TABLE OF CONTENTS .................................................................................................................8
LIST OF TABLES .........................................................................................................................12
LIST OF FIGURES .......................................................................................................................12
ABBREVIAT IONS .......................................................................................................................13
STUDY SYNOPSI S
......................................................................................................................15
STUDY SCHEDULE(S) ...............................................................................................................24
1.BACKGROUND INFORMATI ON.......................................................................................28
1.1 Indication and Current Treatment Options ...............................................................28
1.2 Product Background and Clinical I nformation ........................................................28
2.STUDY OBJECTIVES AND PURPOSE ..............................................................................30
2.1 Rationale for the Study .............................................................................................30
2.2 Study  Objectives ......................................................................................................30
2.2.1 Primary  Objectives .................................................................................................30
2.2.2 Secondary  Objectives .............................................................................................30
2.2.3 Exploratory  Objective ............................................................................................30
3.STUDY DESIGN ...................................................................................................................31
3.1 Study  Design and Flow Chart ..................................................................................31
3.2 Duration and Study  Completion Definition .............................................................33
3.3 Sites and Regions .....................................................................................................33
4.STUDY POPUL ATION.........................................................................................................34
4.1 Inclusion Criteria
......................................................................................................34
4.2 Exclusion Criteria .....................................................................................................35
4.3 Restrictions ................................ ................................ ................................ ............... 36
4.4 Reproductive Potential ................................ ................................ ............................. 37
4.4.1 Female Contraception ................................ ................................ ............................ 37
4.5 Discontinuation of Subjects .....................................................................................38
4.5.1
Subject Withdrawal Criteria ................................ ................................ .................. 38
4.5.2 Reasons for Discontinuation ................................ ................................ .................. 38
4.5.3 Subjects “L ost to Follow -up” Prior to Last Scheduled Visit ................................ .39
4.5.4 Safety -related Stopping Rules................................................................................39
5.PRIOR AND CONCOMITAN T TREATMENT ...................................................................41
5.1 Prior Treatment ........................................................................................................41
Shire CONFI DENTIAL Page 9
Protocol Am endment 2
SHP621 -301 26 Jan 2018
5.2 Concomitant Treatment ............................................................................................41
5.2.1 Permitted Treatment ...............................................................................................41
5.2.2 Prohibited Treatment .............................................................................................42
6.INVESTIGAT IONAL PROD UCT ........................................................................................43
6.1 Identity  of Investigational Product ...........................................................................43
6.1.1 Blinding the Treatment Assignment ......................................................................43
6.2 Administration of I nvestigational Product(s) ...........................................................43
6.2.1 Interactive Response Technology  for Investigational Product Management ........44
6.2.2 Allocation of Subjects to Treatment ......................................................................44
6.2.3 Dosing ....................................................................................................................45
6.2.4 Unblinding the Treatment Assignment ..................................................................45
6.3
Labeling, Packaging, Storage, and Handling ...........................................................46
6.3.1 Labeling .................................................................................................................46
6.3.2 Packaging ...............................................................................................................46
6.3.3 Storage ................................ ................................ ................................ ................... 46
6.3.4 Special Handling ....................................................................................................47
6.4 Drug Accountability .................................................................................................47
6.5 Subject Compliance ..................................................................................................48
7.
STUDY PROCEDURES........................................................................................................50
7.1 Study  Schedule .........................................................................................................50
7.1.1 Screening Period (Weeks -6 to 0) ..........................................................................50
7.1.2 Placebo Lead -in Period (Weeks 0 to 4) .................................................................51
7.1.3
Double- blind Treatment Period (Visits 1 -4): Weeks 4, 8, 12, and 16 (or 
Early Termination) .................................................................................................53
7.1.4 Follow -up Period ...................................................................................................56
7.1.5 Additional Care of Subjects after the Stud y
..........................................................57
7.2 Study  Evaluations and Procedures
...........................................................................57
7.2.1 Efficacy ................................ ................................ ................................ .................. 57
7.2.2 Safety ................................ ................................ ................................ ..................... 59
7.2.3 Other Assessments ................................ ................................ ................................ .62
7.2.4 Clinical Pharmaco logy Assessments .....................................................................64
7.2.5 Volume of Blood to Be Drawn from Each Subject ................................ ............... 65
8.ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT ....................................66
8.1
Definition of Adverse Events, Period of Observation, Recording of Adverse 
Events .......................................................................................................................66
8.1.1 Severity  Categorization ..........................................................................................66
8.1.2 Relation
ship Categorization ................................ ................................ ................... 67
8.1.3 Outcome Categorization ................................ ................................ ........................ 67
Shire CONFI DENTIAL Page 10
Protocol Am endment 2
SHP621 -301 26 Jan 2018
8.1.4 Symptoms of the Disease under Study ..................................................................68
8.1.5 Clinical L aboratory  and Other Safet y Evaluations ................................................68
8.1.6 Pregnancy ...............................................................................................................68
8.1.7 Abuse, Misuse, Overdose, and Medication Error ..................................................69
8.2 Serious Adverse Event Procedures ..........................................................................70
8.2.1 Reference Safet y Information ................................................................................70
8.2.2 Reporting Procedures .............................................................................................70
8.2.3 Serious Adverse Event Definition .........................................................................70
8.2.4 Serious Adverse Event Collection Time Frame .....................................................71
8.2.5
Serious Adverse Event Onset and R esolution Dates .............................................71
8.2.6 Fatal Outcome ........................................................................................................71
8.2.7 Regulatory  Agency , Institutional Review Board, Ethics Committee, and Site 
Reporting................................................................................................................71
9.DATA MANAGEMENT AND STATISTICAL METHODS
...............................................73
9.1 Data Collection .........................................................................................................73
9.2 Clinical Data Management .......................................................................................73
9.3
Data Handling Considerations..................................................................................73
9.4 Statistical Analy
sis Process ......................................................................................73
9.5 Planned Interim Anal ysis, Adaptive Design, and Data Moni toring Committee
......74
9.6
Sample Size Calculation and Power Considerations................................................74
9.7 Study  Population ......................................................................................................75
9.8 Efficacy  
Anal yses.....................................................................................................75
9.8.1 Primary  Efficacy  Endpoints ...................................................................................75
9.8.2 Secondary  Efficacy  Endpoints ...............................................................................77
9.8.3 Explora tory Efficacy  Endpoint ..............................................................................78
9.9 Safety  Anal yses........................................................................................................78
9.10 Other Anal yses.........................................................................................................79
9.10.1 Health
-related Quality -of-life Anal yses................................ ................................ .79
9.10.2 Pharmacokinetic Analy ses................................ ................................ ..................... 79
10.SPONSOR’S AND I NVEST IGATOR’S RESPONSIBILIT IES................................ ........... 81
10.1 Sponsor’s Responsibilities .......................................................................................81
10.1.1 Good Clinical Practice Compliance ................................ ................................ .......81
10.1.2 Indemnity /Liability  and Insurance ................................ ................................ ......... 81
10.1.3 Public Posting of Study  Information ................................ ................................ ......81
10.1.4 Submission of Summary  of Clinical Study  Report to Competent Authorities 
of Member States Concerned and Ethics Committees ...........................................82
10.1.5 Study  Suspension, Termination, and Completion
..................................................82
10.2 Investigator’s Responsibilities ................................ ................................ ................. 82
Shire CONFI DENTIAL Page 11
Protocol Am endment 2
SHP621 -301 26 Jan 2018
10.2.1 Good Clinical Pra ctice Compliance .......................................................................82
10.2.2 Protocol Adherence and Investigator Agreement ..................................................83
10.2.3 Documentation and Retention of Records .............................................................83
10.3 Ethical Considerations ..............................................................................................85
10.3.1 Informed Consent ...................................................................................................85
10.3.2 Institutional Review Board or Ethics Committee ..................................................85
10.4 Privacy  and Confidentiality ......................................................................................86
10.5 Study  Results/Publication Policy .............................................................................87
11.REFERENCES .......................................................................................................................89
12.APPENDI CES ........................................................................................................................91
Appendix 1
Protocol History .....................................................................................92
Appendix 2 Scales and Assessments .........................................................................93
Appendix 3 Dysphagia Sy mptom Questionnaire ePRO for EoE ...............................94
Appendix 4
Patient Global I mpression of Severity ...................................................95
Appendix 5 Biosciences Generic Clinical Protocol Insert .........................................96
Shire CONFI DENTIAL Page 12
Protocol Am endment 2
SHP621 -301 26 Jan 2018
LIST OF TABLES
Table 1-1: Schedule of Assessments .......................................................................................24
Table 7
-1: Approximate Volume of Blood to Be Drawn from Each Subje ct.........................65
Table 8-1: Adverse Event Relatedness ....................................................................................67
Table 9
-1: Percentage of Responders for All Available Data (ie, Non- missing Data) b y 
Strata ......................................................................................................................76
Table 9
-2:Pharmacokinetic Parameters ..................................................................................80
LIST OF FIGURES
Figure 1: Study  Design Flow Chart .......................................................................................31
Shire CONFI DENTIAL Page 13
Protocol Am endment 2
SHP621 -301 26 Jan 2018
ABBREVIATIONS 
ACTH adrenocorticotropic hormone
AE adverse event
ANCOVA analysis of covariance
Auc tau area under the curve for the defined interval between doses
β-hCG beta-human chorionic gonadotropin
BMD bone mineral densit y
CFR Code of Federal Regulations
CI confidence interval
Cmax maximum concentration occurring at t max
CRA clinical research associate
CRF case report form
CRO contract research organizat ion
CYP450 3A4 cytochrome P450 3A4
DSQ Dysphagia Sy mptom Questionnaire
DXA (DEXA) dual-energy  X-ray absorptiometry
EC ethics committee
EGD esophagogastroduodenoscopy
EIS external independent statistical
EMA European Medicines Agency
EoE eosinophili c esophagitis
EoE-QoL-A Adult Eosinophilic Esophagitis Qualit y of Life
ePRO electronic patient- reported outcome
EQ-5D- 3L EuroQol -5 Dimensions 3 -level
EQ-5D EuroQol
EQ-5D-Y EuroQol 5 Dimensions Youth
EREFS EoE Endoscopic Reference Score
ET early termination
EU European Union
FAS full analy sis set
FDA Food and Drug Administration
GCP Good Clinical Practice
GDS Global Drug Safet y
HIPAA Health Insurance Portability  and Accountability  Act
Shire CONFI DENTIAL Page 14
Protocol Am endment 2
SHP621 -301 26 Jan 2018
HPF high-powered field
HRQoL health- related quality  of lif e
hs at bedtime
ICH International Conference on Harmonisation
IRB Institutional Review Board
ITT intent -to-treat
IWRS interactive web -based response sy stem
Med ID medication identification
MedDRA Medical Dictionary  for Regulatory  Activities
MI multiple imputation
OBS oral budesonide suspension
pc after meals
PedsQL -EoE Pediatric Quality  of Life Inventory  –EoE
PGI-
S Patient Global I mpression of Severity
PP per-protocol
PPI proton pump inhibitor
PT preferred term
qAM every morning
SAE serious adverse event
SAP statistical analy sis plan
SAS®statistical analy sis sy stem
SOC system organ class
TEAE treatment emergent adverse event
tmaxtime of maximum observed concentration sampled during a dosing 
interval
UK United Kingdom
US United Stat es
Shire CONFI DENTIAL Page 15
Protocol Am endment 2
SHP621 -301 26 Jan 2018
STUDY SYNOPSIS
Protocol num ber: SHP621 -301 Drug: SHP621, oral budesonide suspension (OBS)
Title of the study: Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 
55Years of Age, Inclusive) with Eosinophilic Esophagitis: A Phase 3 Randomized, Double -blind, 
Placebo -controlled Study
Number of subjects (total and for each treatm ent arm):
Approximately up to approximately 420 subjects will be enrolled into the placebo lead-in period to 
allow  for approximately 306subjects (approximat ely 204 and 102 per OBS and placebo treatment 
group, respectively) to be randomized into the double -blind treatment period.
Investigator(s): Multicenter study
Site(s) and Region(s): 
Approximately 70 sites in North America
Study period (planned):
Oct 20 15 to Nov 2018Clinical phase: 3
Objectives
Co-prim ary: 
To demonstrate in a placebo -controlled trial that:
OBS induces a histologic response (eosinophilic count ≤6/high -powered field [HPF]) in 
adolescent and adult subjects with eosinophilic esophagitis (EoE) over a 12-week course of 
therapy.
OBS reduces dysphagia, as measured by the Dysphagia Symptom Questionna ire (DSQ), by at 
least 30% from baseline in adolescent and adult subjects with EoE over a 12-week course of 
therapy.
Key Secondary:
OBS reduces dysphagia, as measured by the DSQ score from baseline to the final treatment period 
evaluation (Visit 4). 
Secon dary:
To assess the response of endoscopically identified esophageal features to OBS as compared to 
placebo as measured by the EoE Endoscopic Reference Score (EREFS) 
To explore other responding criteria based on histology and DSQ
To assess the impact of O BS on pain, as measured by the DSQ pain score
To evaluate the safety and tolerability of OBS over a 12 -week course of therapy
To obtain OBS pharmacokinetic data in adult subjects w ith EoE
Exploratory:
 

Shire CONFI DENTIAL Page 16
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Rationale:
Currently there is no approved medication for the treatment of EoE. This study is being conducted in 
order to provide safety and efficacy data demonstrating histologic respons e (as measured by 
eosinophilic count ≤6/HPF ) and improvement in dysphagia symptoms (as measured by the DSQ) 
following 12 weeks of treatment with OBS in adolescent and adult subjects with EoE. 
Investigational product, dose, and m ode of administration
OBS will be administered in 10 mL at a concentration of 0.2 mg/mL (2mg dose), twice daily (every 
morning [qAM] after meals [breakfast, pc] and at bedtime [hs]). The 0.2 mg/mL concentration of OBS 
and dosing regimens were selected for use in this Phase 3 study based on the results of Study MPI 
101-06, a Phase 2 study in 93 adolescents and adult subjects with EoE and symptoms of dysphagia. 
Subjects were treated in Study MPI 101-06 with 2mg OBS twice daily to investigate the co-prim ary 
endpoints of histologic response (defined as ≤6eosinophils/HPF) and reduction in DSQ score from 
baseline to Week 12 of treatment. For the current study, the investigational product will be supplied in 
amber glass, multi -dose bottles with child -resistant caps and refrigerated throughout the study (in the 
clinic and subject’s home). Each bottle will contain approximately 210mL of suspension with a 
budesonide concentration of 0.2 mg/mL, or 0.00 mg/mL (matching placebo). 
After the screening period, eligible subjects w ill enter a 4 -
week single -blind placebo lead -in period and 
will receive 10 mL of OBS placebo twice daily (qAM, pc, and hs). At the end of the placebo lead-in 
period, eligible subjects will enter a 12 -week double -blind treatment period (baseline visit, Visit 1) and 
will be randomized to 1 of 2 treatment groups in a 2:1 ratio (approximately 152 and 76 subjects for 
OBS and placebo tw ice daily treatment groups, respectively). Subjects will receive oral administration 
of 10 mL of 2mg investigational product twice daily (qAM, pc, and hs; 4 mg/day total), with no 
ingestion of food or liquids permitted for 30 minutes after study drug administration:
Placebo tw ice daily group: placebo qAM (pc) and hs
OBS tw ice daily group: OBS 10 mL of 0.2 mg/mL (2 mg total) qAM (pc) and hs
The total daily dose of budesonide will be 0 mg for each subject in the placebo group and 4mg for 
each subject in the OBS treatment group (Table 1). 
Table 1: Total Daily Dose of OBS
Dose GroupOBS 
Concentration
(mg/mL)Volume 
per DoseMorning Dose 
(qAM, pc)Evening 
Dose (hs)Total 
Dose/Day
(mg/day)
Placebo 0.0 10 mL 0.0 mg 0.0 mg 0.0
OBS 0.2 10 mL 2.0 mg 2.0 mg 4.0
hs=at bedtime; OBS=oral budesonide suspension; pc=after meals; qAM=every morning
At the end of the 12-week double -blind treatment period (Visi t 4), subjects who complete the study 
will have the opportunity to enroll in the treatment extension study. These subjects will continue on the 
blinded assigned treatment for 2-4 weeks as part of the screening prior to enrolling into the treatment 
extensio n study. 
Methodology:
This is a Phase 3, randomized, double- blind, multicenter, parallel -group, placebo -controlled study to 
evaluate the efficacy, safety, and tolerability of twice daily administration of OBS (qAM, pc, and hs) 
in adolescents and adults a ged 11 -55 years, inclusive, with EoE and dysphagia. 
This study will comprise 3 periods: a 3-to 6-week screening period, 4-week single -blind placebo 
lead-in period, and 12-week double -blind treatment period (Figure 1). The original protocol (dated 
31Aug 2015) planned for a pproximately 300 subjects tobe enrolled into the placebo lead- in period to 
Shire CONFI DENTIAL Page 17
Protocol Am endment 2
SHP621 -301 26 Jan 2018
allow  for approximately 228 subjects to be randomized in a 2:1 ratio (approximately 152 and 76 per 
OBS and placebo treatment group, respectively) into the double- blind treatment period. Under this 
protocol amendment, up to 420 subjects will be enrolled in the double- blind period to allow  for 
approximately 306 subjects to be randomized 2:1 in the double blind period (approximately 204 and 
102 per OBS and placebo group, respectively), in order to provide for at least 200 subjects who 
complete this study and enroll in the successive treatment extension study (SHP621 -302). The 
randomization will be performed centrally and stratified by age group (2 strata total: <18 years or 
≥18years) and diet restriction for EoE or other health -related conditions (no diet restriction or any diet 
restriction). The stratification by age will ensure a minimum of 40 subjects in the pediatric group 
(11-17 years, inclusive). The stratificat ion by age and diet will ensure balance between treatment 
groups for the respective stratification factors.
Subjects who sign informed consent (or assent as applicable for subjects <18years) will be screened 
(Visit - 1). Subjects who meet eligibility criteria at the screening visit (Visit -1) and at the placebo 
lead-in visit (Visit 0) will enter the 4 -week placebo lead -in period to assess their ability to comply with 
twice daily medication administration and assess whether there is a placebo response. Upon 
completion of the placebo lead -in period, subjects will return for the baseline visit (Visit 1) to confirm 
eligibility. Eligible subjects will be randomized 2:1 into the double- blind treatment period and will be 
evaluated for efficacy and safety at Weeks 8, 12, and 16 (Visits 2-4). Subjects who fail to meet all 
eligibility criteria at Visits -1, 0, or 1 will be considered screen failures. Subjects cannot be rescreened 
once it is confirmed they do not meet inclusion/exclusion criteria unless the screen failu re was due to a 
temporary condition or incomplete information at the time of consent (Visit -1) that would make 
rescreening at a later date appropriate (eg, concomitant medication that can be discontinued prior to 
rescreening , review of subject medical records provides new information with respect to the date of a 
prior esophageal dilation of diet change, or subject has a minor illness such as an upper respiratory or 
urinary tract infection). Allreasons for rescreening (ie, reasons unrelated to inclusion/e xclusion 
criteria) must be discussed and approved prospectively with the medical monitor. Subjects who 
discontinue will not be replaced.
Subjects will be required to visit the site up to 6 times over up to a 22 -week period. A safety follow -up 
phone call will occur 4 weeks following the last dose of investigational product for subjects who 
discontinue prematurely during the double -blind treatment period or who do not enroll in the treatment 
extension study.
Figure 1: Study Design Flow Chart
BID=tw ice daily ; EGD= esophagogastroduodenoscopy ; ET=early termination; OBS=oral budesonide 
suspension
Inclusion and exclusion criteria:
Inclusion Criteria: 
Shire CONFI DENTIAL Page 18
Protocol Am endment 2
SHP621 -301 26 Jan 2018
The subject will not be considered eligible for the study without meeting all of the following criteria 
(includin g test results):
1.Subject is able to provide written inform ed consent (subject, parent or legal guardian and, as 
appropriate, subject assent) to participate in the study before completing any study-related 
procedures. 
2.Subject is male or female aged 11 -55 years, inclusive, at time of consent. 
3.Subject has histologic evidence of EoE with a peak eosinophil count of ≥15/HPF, from 2 of 3 
(proximal, mid -, and/or distal) levels of the esophagus at the screening endoscopy.
4.Subject has a history of clinical symptoms of esophageal dysfunction (eg, eating problems, 
abdominal pain, heartburn, dysphagia, vomiting, food impaction, weight loss) intermittently or 
continuously at screening (Visit -1).
5.Subject must have experienced dysphagia (response of “yes” to question 2 on DSQ) on a 
minimum of 4 days and completed the DSQ on ≥70% of days in any 2 consecutive weeks of the 
screening period and in the 2 weeks prior to the baseline visit (Visit 1).
6.Subject must not have proton pump inhibitor (PPI) –responsive EoE based on esophageal biopsies 
performed after the patient has been on at least 8 weeks of high-dose PPI therapy (high -dose 
therapy refers to the total daily dose, which may have been administered as a once -or twice daily 
dosing regim en). This may occur at the time of the qualifying esophagogastroduodenosco py 
(EGD; in which case the same PPI regimen must be continued), or this may have been done 
previously (in which case PPI therapy may have been stopped if there was no response to therapy 
based on esophageal biopsy results). If PPI responsiveness was exclud ed by a previous EGD and 
biopsy, the historical EGD and biopsy must have been performed after the patient had been on a 
minimum of 6 weeks of high -dose PPI therapy.
7.Subject w ill be on a stable (no changes) diet ≥3 m onths prior to the screening visit (Visit -1).
8.Subject is willing and able to continue any dietary therapy, environmental therapy, and/or medical 
regimens (including gastric acid suppression; see exclusions below) in effect at the screening visit 
(Visit -1). There should be no change to these reg imens during study participation.
9.All female subjects must have a negative serum pregnancy test (beta -human chorionic 
gonadotropin [β-hCG]) prior to enrollment into the study. Females of childbearing potential must 
agree to continue acceptable birth control measures (eg, abstinence, stable oral contraceptives, or 
double- barrier methods) throughout study participation.
10.Subject is willing and has an understanding and ability to fully comply with study procedures and 
restrictions defined in this protocol.
Exclusion Criteria:
Subjects are exclu ded from the study if any of the following exclusion criteria are met:
1.Subject has any condition or abnormality (including laboratory abnorm alities), current or past, 
that, in the opinion of the principal investigator or medical monitor, would comprom ise the safety 
of the subject or interfere with or complicate the assessment of signs or symptoms of EoE. Such 
conditions may include psychiatric problems; neurologic deficits or disease; developmental delay; 
cardiovascular, metabolic, or pulmonary disease; or previous gastroesophageal surgery. These 
should be discussed with the medical monitor.
2.Subject has used immunomodulatory therapy within 8 weeks prior to the qualifying EGD or 
betw een the qualifying EGD and baseline visit (Visit 1) or anticipates using immu nomodulatory 
therapy during the treatment period (except for any ongoing regimen of allergy shots). Use of 
long-acting immunomodulatory therapy (eg, Rituxan) within 3 months of the qualifying EGD 
should be review ed with the medical monitor.
3.Subject has bee n using swallowed topical corticosteroid for EoE or systemic corticosteroid for any 
Shire CONFI DENTIAL Page 19
Protocol Am endment 2
SHP621 -301 26 Jan 2018
condition within the 4 weeks prior to the qualifying EGD, betw een the qualifying EGD and 
baseline visit (Visit 1), or anticipates use during the treatment period; any tempo rary use ( ≤7days) 
or initiation of new steroid treatment during the study should be documented and discussed with 
the medical monitor prospectively but cannot occur within 4 w eeks of the final EGD. 
4.Subject has been on inhaled steroids and not on stable treatment for ≥3 months prior to screening 
visit (Visit -1). Subjects on inhaled steroids need to stay on stable treatment during study 
participation. Subject has been on intranasal steroids and has not been on stable treatment for a 
minimum of 4 weeks prior to the qualifying EGD. After the qualifying EGD, subjects with 
seasonal allergic rhinitis may resume (or discontinue) intranasal corticosteroids based on the 
subject's usual treatment regimen for allergy season.
5.Subject has initiated, discontinued, or changed dosage regimen of PPIs, H2 antagonists, antacids, 
or leukotriene inhibitors for any condition (such as gastroesophageal reflux disease asthma or 
allergic rhinitis) within the 4 weeks prior to the qualifying EGD, between the qualifying EGD and 
baselin e visit (Visit 1), or anticipates changes in the use of such medications during the treatm ent 
period.
6.Subject has been using cytochrom e P450 3A4 inhibitors (eg, ketoconazole, grapefruit juice) 
within the 2weeks prior to the baseline visit (Visit 1) or within 5 half-lives (whichever is greater) 
or anticipates using such medications during the treatment period.
7.Subject has an appearance on qualifying EGD of an esophageal stricture (high -grade), as defined 
by the presence of a lesion that does not allow pas sage of a diagnostic adult upper endoscope (eg, 
with an insertion tube diameter of >9 mm). 
8.Subject is on a pure liquid diet or the 6 -food elimination diet.
9.Subject has had an esophageal dilation within the 3 months prior to screening (Visit -1).
10.Subject h as presence of esophageal varices at the screening endoscopy.
11.Subject has any current disease of the gastrointestinal tract, aside from EoE, including 
eosinophilic gastritis, enteritis, colitis, or proctitis; inflammatory bow el disease; or celiac disease. 
12.Subject has other diseases causing or associated with EoE, including hypereosinophilic syndrome, 
collagen vascular disease, vasculitis, achalasia, or parasitic infection.
13.Subject has current evidence of oropharyngeal or esophageal candidiasis.
14.Subject hasa potentially serious acute or chronic viral infection or immunodeficiency condition, 
including tuberculosis, fungal, bacterial, viral/parasite infection, ocular herpes simplex, herpes 
esophagitis, or chicken pox/measles.
15.Subject has upper gastrointestinal bleeding within 4 weeks prior to the screening visit (Visit -1) or 
betw een the screening visit and baseline visit (Visit 1).
16.Subject has evidence of active infection with Helicobacter pylori.
17.Subject has evidence of unstable asthma within 4 weeks prior to the screening visit (Visit -1) and 
betw een the screening visit and baseline visit (Visit 1).
18.Subject is female and pregnant or nursing.
19.Subject has a history of intolerance, hypersensitivity, or idiosyncratic reaction to budesonide (or 
any other corticos teroids) or to any other ingredients of the investigational product.
20.Subject has taken part and received intervention in an interventional study related to EoE (except 
for an interventional study for a topical swallowed steroid) within 6 months prior to the screening 
visit (Visit -1), or any investigational study within 30 days prior to the screening visit (Visit -1). 
An investigational topical swallow ed steroid must have been discontinued at least 30 days prior to 
the screening visit (Visit -1).
Shire CONFI DENTIAL Page 20
Protocol Am endment 2
SHP621 -301 26 Jan 2018
21.Subject ha s a history or high risk of noncompliance with treatment or regular clinic visits.
22.Subject has previously completed, discontinued, or withdrawn from this study.
23.Subject has participated in a previous clinical study involving OBS (SHP621).
24.Subject anticipat es using sucralfate during the study.
Maximum duration of subject involvem ent in the study:
 Planned duration of screening period: 3 -6 weeks
 Planned duration of placebo lead -in period: 4 w eeks
 Planned duration of treatment period: 12 w eeks
 Planned duration of safety follow -up period: 4 w eeks
Endpoints and statistical analysis:
Subject Populations
 The safety setwill include all subjects who receive at least 1 dose of any double -blind 
investigational product. 
 The intent -to-treat (ITT) set will include all randomized subjects. Subjects will be analyzed 
according to their assigned treatment, regardless of the treatment actually received.
 The full analysis set (FAS) will include all randomized subjects who received at least 1 dose of a 
double- blind investigati onal product and have both an evaluable post-baseline biopsy in the 
treatment period (ie, peak eosinophil count is reported for at least 2 esophageal levels) and a 
post-baseline DSQ score.
 The per-protocol (PP) setwill include all subjects in the FAS excluding subjects with protocol 
violations. The PP set will be identified prior to unblinding the treatment assignments by a team 
consisting of, at a minimum, a physician and a statistician from Shire. 
 The pharm acokinetic setwill include all subjects in the safety set for whom the primar y 
pharmacokinetic data are considered sufficient and interpretable.
Prim ary Efficacy Endpoints
The co-primary efficacy endpoints are the following:
 Histologic response, defined as a peak eosinophil count of ≤6/HPF across all available 
esophageal levels at the final treatment period evaluation (Visit 4)
 Dysphagia symptom response, defined as ≥30% reduction in the DSQ com bined score (questions 
2+3) from baseline to the final treatment period evaluation (Visit 4)
Key Secondary Ef ficacy Endpoint
 Change in DSQ combined score (questions 2+3) from baseline to the final treatment period 
evaluation (Visit 4)
Secondary Efficacy Endpoints 
 Change in total endoscopy score, as measured by the EREFS classification, from baseline to the 
final treatment period evaluation (Visit 4)
 Peak eosinophil count <15/HPF across all available esophagus levels at the final treatment period 
evaluation (Visit 4)
 Peak eosinophil count ≤1/HPF across all available esophagus levels at the final treatment period 
evaluation (Visit 4)
Shire CONFI DENTIAL Page 21
Protocol Am endment 2
SHP621 -301 26 Jan 2018
 Change from baseline in the peak eosinophil count to the final treatment period evaluation 
(Visit 4) for each available esophageal level ( proximal, mid -, and distal)
 Change from baseline in the histopathologic epithelial features combined total score (grade and 
stage) to the final treatment period evaluation (Visit 4)
 Dysphagia symptom response (binary response), defined as a≥50% reduction in the DSQ 
combined score (questions 2+3), from baseline to the final treatment period evaluation (Visit 4)
 Change from baseline in the DSQ combined score (questions 2+3) over time including 
post-baseline visits
 Cumulative distribution function curves for the change and the percent change in the DSQ score 
from baseline to the final treatment period evaluation (Visit 4)
 Overall binary response I, defined as a reduction in the DSQ score of ≥30% from baseline to the 
final treatment period evaluation (Visit 4) and a peak eosinophil count of ≤6/HPF across all 
esophageal levels at the final treatment period evaluation (Visit 4 )
 Overall binary response II, defined as a reduction in the DSQ score of ≥50% from  baseline to the 
final treatment period evaluation (Visit 4) and a peak eosinophil count of ≤6/HPF across all 
esophageal levels at the final treatment period evaluation (Visi t 4)
 Change in the DSQ + pain score (questions 2 +3+4) from baseline to the final treatment period 
evaluation (Visit 4)
 Change in the DSQ pain score (question 4) from  baseline to the final treatment period evaluation 
(Visit 4)
Exploratory Efficacy Endpoint
Safety Endpoints 
Safety param eters will include monitoring of adverse events ( AEs) , physical examinations, 
stadiometry, vital signs (temperature, systolic and diastolic blood pressure, pulse, and respiratory rate), 
weight and height assessments, dual-energy X-ray absorptiometry (DXA) scans for bone mineral 
density (BMD) and body composition measurements (for adolescents aged 11-17 years, inclusive), 
clinical laboratory tests (hematology, chemistry, urinalysis; serum pregnancy test, if appropriate), and 
adrenocorticotropic horm one (ACTH) stimulation tests. To account for the effects of puberty in 
adolescent subjects (11-17 years, inclusive), BMD z
-scores will be adjusted for height z-scores using 
the Bone Mineral Density in Childhood Study calculator (BMDCS 2015)
(http://www.bmdcspublic.com).
Health Econom ics and Outcom es Research Endpoints 
 Change in Adult Eosinophilic Esophagitis Quality of Life (EoE -QoL
-A) score from baseline to 
the final treatment period evaluation (Visit 4) 
 Change in EuroQol (EQ-5D; EuroQol -5 Dimensions 3-level [EQ-5D-3L] or EuroQol -5 
Dimensions Youth [EQ-5D-Y], according to subject’s age) score from baseline to the final 
treatment period evaluation (Visit 4)
 Change in Pediatric Quality of Life Inventory –EoE (PedsQL -EoE) score from baseline to the 
final treatment period evaluation (Visit 4)
Pharm acokinetic Endpoints 
Pharm acokinetic param eters will be determined from the plasma concentration -time data for 
budesonide by non -compartmental analysis for subjects who provide sufficient number sof intensive 

Shire CONFI DENTIAL Page 22
Protocol Am endment 2
SHP621 -301 26 Jan 2018
PK sam ples. For all subjects who provide PK samples (ie, limited or intensive samples) population PK 
analysis will be conducted . The pharmacokinetic parameters will include, but not be limited to:
AUC tau Area under the curve for the defined interval betw een doses
Cmax Maximum concentration occurring at t max
tmax Time of maximum observed concentration sampled durin g a dosing 
interval
Statistical Methodology for Prim ary Efficacy Endpoint 
The co-primary efficacy endpoints will be analyzed based on the ITT set. Each of the co-primar y
efficacy endpoints is a binary response (ie, responders vs non-responders); the endp oint will be 
analyzed using the Cochran -Mantel- Haenszel (CMH) test adjusting for age group (either <18 years or 
≥18 y ears) and diet restriction for EoE or other health -related conditions (no diet restriction or any diet 
restriction) . The adjusted odds ratio of being a responder on each of the co-primary endpoints for the 
OBS 2 mg twice daily group vs placebo group and associated 95% confidence interval (CI) will be 
provided. Subjects who withdraw without providing efficacy data at the final treatment perio d 
evaluation (Visit 4, Week 16) will be classified as non -responders in the primary efficacy analysis.
Additionally, the proportion of responders based on each of the co-prim aryendpoints for each 
treatment group will be summarized and their respective 95% CI will be reported. The difference in 
the proportion of responders betw een the 2 treatment groups and the corresponding 95% CI will also 
be summarized.
The follow ing sensitivity and supportive analyses will be perform ed for the co-prim aryto evaluate the
robustness of the results from the primary analysis methods: 
Each of the co-prim aryefficacy endpoints will be analyzed using a logistic regression with the 
effects of treatment group, age group (either <18 years or ≥18 years) and diet restriction for EoE 
or other health -related conditions (no diet restriction or any diet restriction). The odds ratio of 
being a responder on each of the co-prim aryendpoints for the OBS 2 mg twice daily group vs 
placebo group and associated 95% CI will be estimated from thefinal model. Subjects who 
withdraw without providing efficacy data at the final treatment period evaluation (Visit 4, Week 
16) w ill be classified as non -responders in the primary efficacy analysis.
 Analyses will be repeated using the FAS and the PP set.
 Analyses will be repeated by  considering subjects who withdraw  without providing efficacy data 
at the final treatment period evaluation (Visit 4) w ill be classified as responders.
Statistical Methodology for Key Secondary Efficacy Endpoint
The key secondary efficacy endpoint is defined as the change in the DSQ combined score 
(questions 2+3) from baseline to the final treatment period evaluation (Visit 4). The change from 
baseline DSQ score at the final treatment period evaluation (Visit 4) will be analyzed u sing an analysis 
of covariance (ANCOVA) model with treatment group and age group as factors and the baseline DSQ 
score as a continuous covariate.
Statistical Methodology for Secondary Efficacy Endpoints
Secondary subjective efficacy endpoints that are defi ned as:
 Binary response endpoints will be analyzed using the same logistic model as the co-primar y
efficacy endpoints.
 Continuous endpoints will be analy zed as a change from baseline using an ANCOVA model that 
includes treatment group and age group as factors and baseline score as a continuous covariate.
The analyses for all secondary efficacy endpoints (including the key secondary efficacy endpoint) will 
be carried out using 2-sided tests at the 5% level of significance. For each of the secondary efficac y 
Shire CONFI DENTIAL Page 23
Protocol Am endment 2
SHP621 -301 26 Jan 2018
endpoints, the treatment difference, corresponding 95% CI for the difference, and treatment 
comparison p -value for testing the null hypothesis of zero treatment effect based on the final statistical 
model (ie, either logistic regression model or ANCOVA mod el) w ill be provided.
Statistical Methodology for Safety Endpoints 
All safety measures, including AEs, physical examination, stadiometry, vital signs (temperature, 
systolic and diastolic blood pressure, pulse, and respiratory rate), w eight and height asse ssments, DXA 
scans for BMD and body composition measurements (for adolescents aged 11-17 years, inclusive), 
clinical 
laboratory results (hematology, chemistry, urinalysis; serum pregnancy test, if appropriate), 
and ACTH stimulation will be descriptively summarized by treatment group at baseline and for each 
postbaseline visit.
The number and percent of subjects with treatment emergent adverse event s (TEAEs )will be 
presented. TEAEs are defined as AEs that start or deteriorate on or after the date of the first dose of 
investigational product and no later than 3days following the last dose of investigational product. 
How ever, for any subjects who die during the study (ie, the date of death is betw een the date of first 
dose of investigational product and the date of study discontinuation entered by the site, inclusive), all 
AEs (including those resulting in death) that occur during the study will be considered as TEAEs 
irrespective of the last dose and w ill be included in the TEAE summaries.
Statistical Methodo logy for Pharm acokinetic Endpoint(s) 
Summary statistics (number of observations, mean, standard deviation, coefficient of variation, 
median, maximum, minimum, and geometric mean) will be determined for all pharmacokinetic 
parameters by overall and by week . Plasma concentrations at each nominal sampling time will also be 
summarized using descriptive statistics.
Sample Size Justification
Based on at least a 30-percentage -point reduction in DSQ score, there is an expected difference 
betw een treatment response proportions of 69% and 45% in the OBS 2mg twice daily (qAM, pc, and 
hs) and placebo groups, respectively. The original protocol noted that atotal of 228 subjects 
(152 subjects randomized to OBS and 76 subjects randomized to placebo) are required to achi eve 90% 
power at the significance level of 0.0499 (2-sided) using a 2
-group chi-square test with unequal 
allocation 2:1 to treatment groups (OBS 2mg twice daily and placebo). With the specified number of 
subjects per treatment group, the study will be powered at 99% assuming histological response 
proportions of 40% and 3% in the OBS 2 mg twice daily and placebo groups, respectively. The overall 
study power for the co-prim aryendpoints was estimated to be at least 85%. Therefore, approximately 
228 (approxim ately 152:76 OBS and placebo subjects, respectively) were tobe randomized inthe 
study to allow for a loss of approximately 5% of subjects due to dropouts or invalid data. Expected 
response and dropout rates are based on observation in the Phase 2 study ( MPI 101 -06).
In this protocol amendment, in order to ensure that a sufficient number of subjects will complete this 
study and enroll in the treatment extension study, up to approximately 420 subjects will be enrolled in 
the placebo lead-in period to allow  for approximately 306 subjects to be randomized into the double 
blind period of this study (approxim ately 204:102 OBS and placebo subjects, respectively). With a 
total of 306 randomized subjects in this study, using the same assum ptions for the co-prim ary
endpoints and the dropout rate, the overall study power for the co-primary endpoints is estimated to be 
at least 95%.
Shire CONFIDENTIAL Page 24
Protocol Am endment 2
SHP621 -301 26 Jan 2018
STUDY SCHEDULE(S)
Table 1-1:Schedule of Assessments
ProceduresScreeningPlacebo 
Lead -
in Treatm ent PhaseSafety 
Follow -up 
Telephone 
Contactr
Visit -1 Visit 0Randomization 
Baseline/Visit 
1Visit 2 Visit 3 Visit 4 
or ETqVisit 5
Week -6 0 4 8 12 16 20
Window ≤6 weeks -- ±3 days ±3 days ±3 days ±3 days ±3 days
Informed consent/assent X
Medical history review X
Inclusion/exclusion criteria review X X X
Vital signsa; heightband w eightc
assessmentX X X X X X
EGD w ith endoscopy score (EREFS)
and biopsyd X X
DSQ training and issue of handset X
Retrieval of DSQ handset X
DSQ completion Once daily completion
DSQ compliance assessmenteX X X X X
EQ-5DfX X
PedsQL -EoE (subjects 11 -17 years of 
age, inclusive)X X
EoE-QoL- A (subjects ≥18 years of age) X X
PGI-S X X X X
Physical examination X X X X X X
Tanner Staging AssessmentgX X
Shire CONFIDENTIAL Page 25
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Table 1-1: Schedule of Assessments
ProceduresScreeningPlacebo 
Lead -
in Treatm ent PhaseSafety 
Follow -up 
Telephone 
Contactr
Visit -1 Visit 0Randomization 
Baseline/Visit 
1Visit 2 Visit 3 Visit 4 
or ETqVisit 5
Week -6 0 4 8 12 16 20
Window ≤6 weeks -- ±3 days ±3 days ±3 days ±3 days ±3 days
Clinical laboratory testshX X X X X X
UrinalysisiX X X X X X
Pregnancy testjX X X X X X
Morning cortisol (tar get 6:00 -9:00 AM) X X X X
ACTH stimulation testing X X
Blood pharmacokinetic sampling 
(subjects ≥18years of age)k X X X
DXA Scan 
(subjects 11 -17years of age, inclusive)l X X
RandomizationmX
Investigational product supplied X X X X Xl
Investigational product administrationoTwice-daily administration of investigational product
Investigational product compliance 
assessmentX X X X
Concomitant medications and 
procedures recorded X X X X X X X
Revie w of adverse eventspX X X X X X
Shire CONFIDENTIAL Page 26
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Table 1-1: Schedule of Assessments
ProceduresScreeningPlacebo 
Lead -
in Treatm ent PhaseSafety 
Follow -up 
Telephone 
Contactr
Visit -1 Visit 0Randomization 
Baseline/Visit 
1Visit 2 Visit 3 Visit 4 
or ETqVisit 5
Week -6 0 4 8 12 16 20
Window ≤6 weeks -- ±3 days ±3 days ±3 days ±3 days ±3 days
ACTH=adrenocorticotropic hormone; DSQ=Dysphagia Symptom Questionnaire; DXA=dual- energy X -ray absorptiometry; 
EGD=esophagogastroduodenoscopy; EoE -QoL- A=Ad ult Eosinophilic Esophagitis Quality of Life; EQ -5D=EuroQol; EQ -5D-
3L=EuroQol -5 Dime nsion 3 -level; EQ -5D-Y=EuroQol -5 Dimensions Youth; EREFS=EoE Endoscopic Reference Score; hs=at 
bedtime; IWRS=interactive web -based response system; PedsQL -EoE=Pediatric Quality of Life Inventory – EoE; pc=after meals; 
PGI- S=Patient Global Impression of Severity; qAM=every morning
aVital signs will be assessed after the subject has been in a supine position for at least 5 minutes immediately prior to the 
assessment and will include blood pressure (systolic and diastolic), heart rate, respirations, and tempera ture.
bHeight to be collected at screening visit (Visit -1) and Visit 4 for all subjects. Stadiometers are required for subjects 11 -17 years of 
age, inclusive, and w ill be used at Visit - 1 and 4. Height measurements for adolescent subjects (11 -17 years of a ge, inclusive) 
should be measured in triplicate.
cWeight measurements for adolescent subjects (11 -17 years, inclusive) should be measured in duplicate.
dPretreatment endoscopy will be performed during the screening period (at least 2 weeks prior to placebo lead-in visit [Visit 0] to 
allow  adequate time for processing and central review). Endoscopy should include esophageal (proximal, mid-, and/or distal), 
gastric, and duodenal biopsies. Final treatment evaluation EGD must include esophageal biopsies; gastric and duodenal biopsies 
may be done at the discretion of the investigator. Final treatm ent evaluation EGD should occur at or within (±) 7 days of the
scheduled visit. 
eDSQ assessment includes completion of reports on DSQ handset (ie, eligibility reports and visit confirmations).
fSubjects 11 -17 years of age, inclusive, will complete the EQ- 5D-Y; subjects ≥18 years of age will complete the EQ -5D-3L.
gTanner staging assessments will be performed for all subjects aged ≥11 years until investigator confirms subject is post -puberty.
hClinical laboratory tests will include the following: alkaline phosphatase, aspartate aminotransferase, alanine aminotransfer ase, 
total bilirubin, total protein, albumin, glucose, blood urea nitrogen, creatinine, sodium, potassium, chlorid e, calcium, carbon 
dioxide, hemoglobin, hematocrit, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, mean corpuscular 
volume, erythrocyte count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and platel et count. All 
Shire CONFIDENTIAL Page 27
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Table 1-1: Schedule of Assessments
ProceduresScreeningPlacebo 
Lead -
in Treatm ent PhaseSafety 
Follow -up 
Telephone 
Contactr
Visit -1 Visit 0Randomization 
Baseline/Visit 
1Visit 2 Visit 3 Visit 4 
or ETqVisit 5
Week -6 0 4 8 12 16 20
Window ≤6 weeks -- ±3 days ±3 days ±3 days ±3 days ±3 days
subjects must fast overnight prior to collection.
iUrinalysis parameters will include glucose, protein, specific gravity, pH, nitrite, bilirubin, ketones, hemoglobin, urobilino gen, and 
leukocyte esterase.
jThe serum pregnancy test will be perfo rmed for all female subjects at the screening visit (Visit -1) and final treatment evaluation 
(Visit 4). Urine pregnancy tests will be performed at all other visits.
kBlood samples for pharmacokinetic analysis will be taken from adult subjec ts (aged ≥18 y ears). Subjects who do not participate in 
pharmacokinetic sampling will not be discontinued from the study and lack of participation will not be a considered protocol 
deviation. Blood samples for pharmacokinetic analysis can be obtained one t ime on any day  starting 7 days after Visit 1 (Week 5) 
and through Visit 4 (Week 16). PK samples should be draw n, ideally, at pre -dose, 0.5 and 1 hour post -dose, and at additional post -
dose time points, if feasible (2, 3, 4, 6, 8, and 12 hours post -dose).
lThe baseline DXA scan may be performed any time during the placebo lead-in period after the subject has met all screening 
criteria and prior to blinded -treatm ent randomization. Baseline and post-treatment DXA scans should be performed using the 
same machine and software. Post -treatment DXA scan should occur at or w ithin (±) 7 days of the scheduled visit.
mRandomization will occur via IWRS at the baseline visit (Visit 1) once the subject’s eligibility for study entry is confirmed . 
nInvestigational product will be dispensed at Visit 4 to subjects who consent to enroll in the treatment extension study.
oSubjects will receive oral administration of 10 mL of investigational product twice daily (qAM, pc, and hs), with no ingestio n of 
food or liquids permitted for 30 minutes after study drug administration.
pAE assessments at each visit and physical examination must include specific assessments for signs of glucocorticoid excess (eg, 
moon facies, acne, hirsutism, mood swings, insomnia, and depression).
qIf subject discon tinues study prematurely, the evaluations listed for Visit 4 are to be performed as completely as possible.
rFor subjects who withdraw from the study or do not continue into treatment extension study, a safety follow -up contact by  phone 
will be performed 4 weeks follow ing the last dose of investigational product.
Shire CONFIDENTIAL Page 28
Protocol Am endment 2
SHP621 -301 26 Jan 2018
1. BACKGROUND INFORMATI ON
1.1 Indication and Current Treatment Options 
Eosinophilic esophagitis (EoE) is defined as “a chronic, immune/antigen -mediated esophageal 
disease characterized clinically  by symptoms related to esophageal dy sfunction and 
histologically  by eosinophil- predominant inflammation” ( Liacouras et al., 2011 ). Clinical 
symptoms of EoE often vary  by age: Infants and toddlers present with feeding difficulties; 
school -aged children are more likely  to present with vomiting or pain; and adolescents and adults 
present with d ysphagia and food impaction. When these sy mptoms are present, the diagnosis is 
confirmed b y finding eosinophilic inflammation of ≥15 eosinophils/high- powered field (HPF) on 
at least 1 esophageal biopsy  and when other causes such as proton pump inhibitor (PPI )-
responsive esophageal eosinophilia are excluded ( Dellon et al., 2014a ;Furuta et al., 2007). The 
standards of care are diet therapies and off- label use o f glucocorticosteroids. Esophageal dilation 
is used to temporarily  relieve sy mptoms but does not address underl ying inflammation. Given 
the clinical outcomes associated with EoE, including severe d ysphagia, esophageal stricture, 
food impaction, and esophag eal perforation ( Hirano and Aceves, 2014; Liacouras et al., 2011 ) 
and the fact that there are currentl y no FDA -approved treatments, there is a clear unmet medical 
need for a novel treatment for this disease.
1.2 Product Background and Clinical Information
Oral budesonide suspension (OBS) consists of budesonide formulated in a viscous suspension 
that is designed to increase the residence time of budesonide on the surface of the esophagus 
after swallowing compared to a non -viscous suspension. Shire is developing OBS as a first- line 
therap y for EoE in adolescents and adults. 
The nonclinical pharmacology , pharmacokinetics, and toxicity  and the clinical pharmacology , 
pharmacokinetics, and safety  of budesonide are well studied because budesonide is present in 
several US FDA -approved drug products . Budesonide is currentl y marketed for the management 
of Crohn’s disease, for asthma maintenance, for the treatment of allergic rhinitis, and for 
induction of remission in patients with active, mild to moderate ulcerative colitis. Budesonide 
has strong glu cocorticoid receptor affinity and is subject to considerable first pass metabolism by  
the liver with a short half -life. These attributes permit budesonide to act rapidly  and locally  in the 
gut mucosa for treatment of inflammatory  disorders such as Crohn’s disease and ulcerative 
colitis. Once absorbed into the sy stemic circulation, budesonide is rapidly  metabolized in the 
liver and inactivated ( FDA, 2011 ).
The efficacy  of OBS for the treatment of EoE has been demonstra ted in two Phase 2 studies in 
the OBS clinical development program. Studies MPI  101- 01 and MPI  101-06 evaluated the 
efficacy  of OBS in the treatment of EoE in children and adolescents aged 2 -18 years and in 
adolescents and adults aged 11
-40 years, respecti vely, by measuring histological response 
(defined as mean peak eosinophil count ≤6/HPF after treatment). Stud y MPI 101 -06 also 
evaluated s ymptom response as measured by  the Dy sphagia S ymptom Questionnaire (DSQ). The 
DSQ contains 4 questions related to consumption of solid food, the presence of d ysphagia and its 
severit y, as well as pa in. The DSQ score is calculated only  from responses to the questions 
Shire CONFIDENTIAL Page 29
Protocol Am endment 2
SHP621 -301 26 Jan 2018
related to d ysphagia, and this clinical outcome assessment was considered to be fit for purpose as 
a result of the MPI 101 -06 study . Results from Study  MPI 101 -01 demonstrated a statistic ally 
significant histologic response (eosinophil count ≤6/HPF) and remission (eosinophil count 
≤1/HPF) in the medium -dose (1.4 -2.0mg daily) and high -dose (2.8-4.0 mg daily ) OBS groups 
compared to placebo following 12 weeks of treatment. 
In Stud y MP I 101 -06, a significant treatment effect for OBS vs placebo was shown for both the 
co-primary efficacy  endpoints of histologic response and change from baseline in dy sphagia 
symptoms. Following 12 weeks of twice daily treatment ( every morning after meals [qAM, pc] 
and at bedtime [hs]), OBS -treated subjects demonstrated a highl y consistent reduction from 
baseline values for cellular (mean peak eosinophil count and histopathology features), organ 
(endoscop y score), and holistic measures (Physician Global Assessment and DSQ scores); these 
results were independent of the ty pe of rater/reviewer (central pathologist, phy sician at the study  
site, or subject). 
Alway s refer to the latest version of the SHP621 investigator’s brochure for the overall 
risk/benefit assessment and the most accurate and c urrent information regarding the drug 
metabolism, pharmacokinetics, efficacy , and safety  of SHP621. 
Shire CONFIDENTIAL Page 30
Protocol Am endment 2
SHP621 -301 26 Jan 2018
2. STUDY OBJECTIVES AND PURPOSE
2.1 Rationale for the Study
Currently  there is no approved medication for the treatment of EoE. This study  is being 
conducted in o rder to provide safet y and efficacy data demonstrating histologic response (as 
measured b y eosinophilic count ≤6/HPF) and improvement in dy sphagia s ymptoms (as measured 
by the DSQ) following 12 weeks of treatment with OBS in adolescent and adult subjects with 
EoE.
2.2 Study Objectives
2.2.1 Primary Objectives
The co-primary objectives of the study  are to demonstrate in a placebo -controlled trial that:
OBS induces a histologic response (eosinophilic count ≤6/HPF) in adolescent and adult 
subjects with EoE over a 12- week course of therapy . 
OBS reduces dysphagia, as measured by the DSQ, by at least 30% from baseline in 
adolescent and adult subjects with EoE over a 12 -week course of therap y.
2.2.2 Secondary Objectives
The key  secondary  objective of this study  is:
OBS reduces dysphagia, as measured by the DSQ score from baseline to the final treatment 
period evaluation (Visit 4). 
Additional secondary  objectives of the study  are:
To assess the response of endoscopicall y identified esophageal features to OBS as compared 
to placebo as measured by the EoE Endoscopic Reference Score (EREFS) 
To explore other responding criteria based on histology  and DSQ
To assess the impact of OBS on pain, as measured by  the DSQ pain score
To evaluate the safet y and tolerability  of OBS over a 12-week course of therapy  
To obtain OBS pharmacokinetic data in adult subjects with EoE
2.2.3 Exploratory Objective
The exploratory  objective of this study  is:

Shire CONFIDENTIAL Page 31
Protocol Am endment 2
SHP621 -301 26 Jan 2018
3. STUDY DESIGN
3.1 Study Design and Flow Chart
This is a Phase 3, randomized, multicenter, double -blind, parallel -group, placebo -controlled 
study  to evaluate the efficacy  and safety  of OBS treatment administered twice dail y (qAM, pc, 
and hs) for 1 2weeks. The study  will be conducted in adolescents and adults, aged 11-55 years, 
inclusive, with EoE and dy sphagia. 
The original protocol (dated 31 Aug 2015) planned for approximately  300 subjects to be enrolled 
in the placebo lead -in period to allow for approximately  228 subjects to be randomized into the 
double -blind treatment period. Under this protocol amendment, up to approximately  420 subjects 
will be enrolled in the placebo lead -in period to allow for approximately  306 subjects to be 
randomized int o the double blind period, in order to provide for at least 200 subjects who 
complete this study  and enroll in the successive treatment extension study  (SHP621 -302). A 
minimum of 40 randomized subjects will be aged 11 -17 years, inclusive. Subjects will be 
randomized 2:1 (approximately  204 and 102 per OBS and placebo treatment group, respectivel y) 
to receive either OBS 2 mg twice daily  (qAM, pc, and hs) or placebo twice daily  (qAM, pc, and 
hs).
This study  will consist of 3 periods: a 3- to 6-week screening p eriod, 4- week single -blind 
placebo lead -in period, and a 12- week double -blind treatment period (see Figure 1 ). 
Figure 1:Study Design Flow Chart
BID=tw ice daily; EGD=esophagogastroduodenoscopy ; ET=end of treatment; OBS=oral bude sonide suspension
The upper limit of 55 y ears, inclusive, was selected for this study  population based on the low 
prevalence of EoE in older patients ( Dellon et al., 2014a ) and the fact that the ty pe of EoE that 
develops in older patients is not amenable to anti- inflammatory  treatment alone ( Dellon et al., 
2014b). A natural history study  demonstrated that for every  decade of life, the odds of 
Shire CONFIDENTIAL Page 32
Protocol Am endment 2
SHP621 -301 26 Jan 2018
developing the fibrostenotic phenoty pe of EoE more than doubles ( Dellon et al., 2014b ). By  age 
55, fibrostenotic EoE occurs in approximately  80% of patients. Fibrostenotic disease is treated 
with dilatation and is not amenable to anti -inflammatory  treatment alone. Therefore, budesonide 
is not exp ected to be an effective treatment for the majority  of patients above age 55.
Subjects will be required to visit the site up to 6 times over up to a 22 -week period. Following 
completion of the screening and placebo lead -in visits, subjects will be evaluate d for eligibility  
and safet y at Week 4 (Visit 1). Subjects who are eligible and randomized will be evaluated for 
efficacy  and safet y at Weeks 8, 12, and 16 (Visits 2-4) and additionall y for safet y at follow -up at 
Week 20 (Visit 5; telephone contact). Subje cts who fail to meet all eligibility  criteria at Visits -
1, 
0, or 1 will be considered screen failures. Subjects cannot be rescreened once it is confirmed they  
do not meet inclusion/exclusion criteria unless the screen failure was due to a temporary  
condit ion or incomplete information at the time of consent (Visit - 1) that would make 
rescreening at a later date appropriate (eg, concomitant medication that can be discontinued prior 
to rescreening, review of subject medical records provides new information wi th respect to the 
date of a prior esophageal dilation or diet change, or subject has a minor illness such as an upper 
respiratory  or urinary  tract infection). All reasons for rescreening (ie, reasons unrelated to 
inclusion/exclusion criteria) must be discu ssed and approved prospectivel y with the medical 
monitor. Subjects who discontinue will not be replaced. 
The screening period will start when subjects sign informed consent (or assent as applicable for 
subjects <18 years of age; screening visit [Visit -1]) and will be approximately 3 -6weeks in 
duration. During the screening period, all subjects will receive an upper endoscopy  with 
histologic anal ysis of biopsy  specimens to confirm the diagnosis of EoE ( eosinophil count of 
≥15/HPF from 2 of 3 [proximal, mid -, and/or distal] levels of the esophagus ). In addition, 
subjects must complete the DSQ daily  during the screening period (3 -6 weeks) and have at least 
4 reported day s with sy mptoms of dy sphagia and completed the DSQ on ≥70% of day s in an y 2 
consecutive w eeks. At the screening visit (Visit -1), subjects who are on a PPI  must remain on 
the same dose of the PPI throughout the stud y; if they  are not taking a PPI , they  must remain off 
of a PPI  for the remainder of the study . After the screening period, eligibl e subjects will enter a 
4-week single - blind placebo lead-in period and will receive 10 mL of OBS placebo twice dail y 
(every morning after meals/breakfast [qAM, pc] and at bedtime [hs]). The placebo lead -in period 
will enable assessment of the subject’s abi lity to comply  with twice dail y medication 
administration and assess whether the subject experiences a placebo response. 
At the end of the placebo lead -in period, subjects will return for the baseline visit (Visit 1) to 
confirm eligibility . Subjects who c ontinue to meet all eligibility  criteria (those with at least 4 
reported d ysphagia day s and who completed the DSQ on ≥70% of day s in the 2 weeks prior to 
randomization per daily  DSQ completion) will be randomized to receive either OBS or placebo 
during the 12-week double -blind treatment period. 
OBS will be administered in 10 mL  at a concentration of 0.2 mg/mL  (2mg dose), twice daily . 
The 0.2 mg/mL concentration of OBS and dosing regimens were selected for use in this Phase 3 
study  based on the results of Study  MPI  101-06, a Phase 2 study  in 93 adolescent and adult 
subjects with EoE and symptoms of dy sphagia. Subjects were treated in Study MPI 101-06 with 
Shire CONFIDENTIAL Page 33
Protocol Am endment 2
SHP621 -301 26 Jan 2018
2mg OBS twice dail y to investigate the co -primary  endpoints of histologic response (defined as 
≤6 eosi nophils/HPF) and reduction in DSQ score from baseline to Week 12 of treatment. For the 
current stud y, the investigational product will be supplied in amber glass, multidose bottles with 
child- resistant caps and refrigerated throughout the study  (in the cli nic and subject’s home). Each 
bottle will contain approximately 210mL of suspension with a budesonide concentration of 0.2 
mg/mL , or 0.00 mg/mL  (matching placebo).
At the end of the 12 -week double -blind treatment period (Visit 4, Week 16), subjects who 
complete the study  will have the opportunit y to enroll in the treatment extension study . These 
subjects will continue on the blinded assigned treatment for 2 -4 weeks as part of the screening 
prior to enrolling into the treatment extension study . Subjects who do not enroll in the treatment 
extension study  or who discontinue at any  time during the SHP621 -301 (Induction) study  will 
receive a follow -up phone call 4 weeks post last dose of investigational product (Visit 5).
3.2 Duration and Study Completion Definition
The subject’s maximum duration of participation is expected to be approximately  26 weeks, 
depending on the 3- to 6-week screening period.
The study  will be completed in approximately  32months.
The Study  Completion Date is defined as the date the final s ubject, across all sites, completes 
their final protocol -defined assessment. Please note that this includes the follow -up visit or 
contact, whichever is later. The Study  Completion Date is used to ascertain timing for study  
results posting and reporting.
A completer is a subject who completes all procedures and assessments up to and including Visit 
4 (Week 16), inclusive of the final treatment evaluation esophagogastroduodenoscop y (EGD ) . 
Subjects who do not enroll in the treatment extension study  or who dis continue prematurel y at 
any time during the SHP621- 301 (Induction) study  will receive a follow -up phone call 4 weeks 
post last dose of the investigational product to which they  were randomized.
3.3 Sites and Regions
Approximately  70 sites in North America will participate.
Shire CONFIDENTIAL Page 34
Protocol Am endment 2
SHP621 -301 26 Jan 2018
4. STUDY POPULATION
Each subject must participate in the informed consent process and provide written informed 
consent/assent before any procedures specified in the protocol are performed.
4.1 Inclusion Criteria
The subject will not be considered el igible for the study  without meeting all of the following 
criteria (including test results):
1.Subject is able to provide written informed consent (subject, parent or legal guardian, and, as 
appropriate, subject assent) to participate in the study  before completing any study -related 
procedures.
2.Subject is male or female aged 11 -55 years, inclusive, at time of consent. 
3.Subject has histologic evidence of EoE with a peak eosinophil count of ≥15/HPF, from 2 of 3 
(proximal, mid -, and/or distal) levels of the esophagus at the screening endoscopy.
4. Subject has a history  of clinical symptoms of esophageal dysfunction (eg, eating problems, 
abdominal pain, heartburn, dysphagi a, vomiting, food impaction, weight loss) intermittentl y 
or continuously  at screening (Visit -1).
5. Subject must have experienced dysphagia (response of “yes” to question 2 on DSQ) on a 
minimum of 4days and completed the DSQ on ≥70% of days in any 2 consecutive weeks of 
the screening period and in the last 2 weeks prior to the baseline visit (Visit 1).
6. Subject must not have PPI-responsive EoE based on esophageal biopsies performed after the 
patient has been on at least 8 weeks of high -dose PPI  therapy  (high-dose therapy  refers to the 
total daily  dose, which may  have been administered as a once or twice daily dosing regimen). 
This may  occur at the time of the qualify ing EGD (in which case the same PPI  regimen must 
be continued), or this may have been done previously  (in which case PPI therap y may have 
been stopped if there was no response to therapy  based on esophageal biopsy  results). If PPI 
responsiveness was excluded by a previous EGD and biopsy , the historical EGD and biops y 
must have been performed after the patient had been on a minimum of 6 weeks of high-dose 
PPI therap y.
7. Subject will be on a stable (no changes) diet ≥3 months prior to the screening visit 
(Visit - 1).
8. Subject is willing and able to continue any dietary  therap y, environmental therapy , and/or 
medical regimens (including gastric acid suppression; see exclusion s below) in effect at the 
screening visit (Visit -1). There should be no change to these regimens during study  
participation.
9.All female subjects must have a negative serum pregnancy  test (beta -human chorionic 
gonadotropin [β-hCG]) prior to enrollment into the study . Females of childbearing potential 
must agree to continue acceptable birth control measures (eg, abstinence, stable oral 
contraceptives, or double -barrier methods) throughout study  participation.
Shire CONFIDENTIAL Page 35
Protocol Am endment 2
SHP621 -301 26 Jan 2018
10.Subject is willing and has an understanding and a bility  to fully  comply  with study  procedures 
and restrictions defined in this protocol.
4.2 Exclusion Criteria
Subjects are excluded from the study  if an y of the follow ing exclusion criteria are met:
1. Subject has any condition or abnormality  (including laboratory  abnormalities), current or 
past, that, in the opinion of the principal investigator or medical monitor, would compromise 
the safet y of the subject or interfere with or complicate the assessment of signs or symptoms 
of EoE. Such conditions may include psychiatric problems; neurologic deficits or disease; 
developmental delay ; cardiovascular, metabolic, or pulmonary  disease; or previous 
gastroesophageal surgery. These should be discussed with the medical monitor.
2. Subject has used immunomodulatory  therap y within 8 weeks prior to the qualify ing EGD or 
between the qualify ing EGD and baseline visit (Visit 1) or anticipates using 
immunomodulatory  therapy  during the treatment period (except for any ongoing regimen of 
allergy  shots). Use of long-acting immunomodula tory therap y (eg, Rituxan) within 3months 
of the qualify ing EGD should be reviewed with the medical monitor.
3. Subject has been using swallowed topical corticosteroid for EoE or systemic corticosteroid 
for any condition within the 4 weeks prior to the quali fying EGD, between the qualify ing 
EGD and baseline visit (Visit 1), or anticipates use during the treatment period; any 
temporary  use (≤7 days) or initiation of new steroid treatment during the study  should be 
documented and discussed with the medical moni tor prospectively  but cannot occur within 4 
weeks of the final EGD. 
4.Subject has been on inhaled steroids and has not been on stable treatment for ≥3 months prior 
to screening visit (Visit -1). Subjects on inhaled steroids need to stay on a stable treatment 
during study  participation. Subject has been on intranasal steroids and has not been on stable 
treatment for a minimum of 4 weeks prior to the qualify ing EGD. After the qualify ing EGD, 
subjects with seasonal allergic rhinitis may resume (or discontinue) intranasal corticosteroids 
based on the subject's usual treatment regimen for allergy  season.
5. Subject has initiated, discontinued, or changed dosage regimen of PPIs, H2 antagonists, 
antacids, or leukotriene inhibitors for any  condition (such as gastroesophageal reflux disease, 
asthma or allergic rhinitis) within the 4 weeks prior to the qualify ing EGD, between the 
qualify ing EGD and baseline visit (Visit 1), or anticipates changes in the use of such 
medications during the treatment period.
6. Subject has been using cytochrome P450 3A4 (CYP450 3A4) inhibitors (eg, ketoconazole, 
grapefruit juice) within the 2 weeks prior to the baseline visit (Visit 1) or within 5 half-lives 
(whichever is greater) or anticipates using such medications during the treatment period .
7. Subject has an appearance on qualify ing EGD of an esophageal stricture (high -grade), as 
defined by the presence of a lesion that does not allow passage of a diagnostic adult upper 
endoscope (eg, with an insertion tube diameter of >9 mm). 
8.Subject is on a pure liquid diet or the 6 -food elimination diet.
Shire CONFIDENTIAL Page 36
Protocol Am endment 2
SHP621 -301 26 Jan 2018
9. Subject has had an esophageal dilation within the 3 months prior to screening (Visit - 1).
10.Subject has presence of esophageal varices at the screening endoscop y.
11. Subject has any current disease of the gastr ointestinal tract, aside from EoE, including  
eosinophilic gastritis, enteritis, colitis, or proctitis; inflammatory  bowel disease; or celiac 
disease. 
12. Subject has other diseases causing or associated with EoE, including hypereosinophilic 
syndrome, collagen vascular disease, vasculitis, achalasia, or parasitic infection.
13.Subject has current evidence of oropharyngeal or esophageal candidiasis.
14. Subject has a potentially  serious acute or chronic viral infection or immunodeficiency  
condition, including tuberculosis, fungal, bacterial, viral/parasite infection, ocular herpes 
simplex, herpes esophagitis, or chicken pox/measles.
15.Subject has upper gastrointestinal bleeding within 4 weeks prior to the screening visit (Visit -
1) or between the screening visit and baseline visit (Visit 1).
16.Subject has evidence of active infection with Helicobacter pylori.
17. Subject has evidence of unstable asthma within 4 weeks prior to the screening visit (Visit - 1) 
and between the screening visit and baseline visit (Visit 1).
18.Subject is female and pregnant or nursing.
19. Subject has a history  of intolerance, hypersensitivity , or idiosy ncratic reaction to budesonide 
(or an y other corticosteroids) or to an y other ingredients of the investigational product.
20. Subject has taken part and received intervention in an interventional study  related to EoE 
(except for an interventional study  for a topical swallowed steroid) within 6months prior to 
the screening visit (Visit -1), or any investigational study  within 30days prior to the 
screening visit (Visit -1). An investigational topical swallowed steroid must have been 
discontinued at least 30 day s prior to the screening visit (Visit -1).
21.Subject has a history  or high risk of noncompliance with treatment or regular clinic visits.
22.Subject has previously  completed, discontinued, or withdrawn from this study .
23. Subject has participated in a previous clinical study involving OBS (SHP621).
24.Subject anticipates using sucralfate during the study.
4.3 Restrictions
Subjects must adhere to the following restrictions for the duration of the study :
No change in exercise (other than seasonal changes in sports or activities). Intense exercise 
should be avoided unless part of an established exercise routine. 
No change in diet (liquid diet for 3 day s or less is acceptable).
Short course of systemic steroids (≤7 days) are permitted to treat, for example, exacerbation 
of asthma but cannot be used 4 weeks prior to the final EGD.
Shire CONFIDENTIAL Page 37
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Stable treatment with intranasal or inhaled corticosteroids. For subjects with perennial 
allergic rhini tis and stable asthma, the topical corticosteroid must be maintained at the same 
dose throughout the study . For subjects with seasonal allergic rhinitis, it is permissible after 
the qualify ing EGD to resume (or discontinue) intranasal corticosteroids based on the 
subject's usual treatment regimen for allergy  season. All topical corticosteroid dosing 
changes, including those for seasonal allergic rhinitis, should be avoided within 4 weeks 
prior to the Week 16 EGD. Subjects who require a change in inhaled cor ticosteroid treatment 
for an asthma exacerbation should be discussed with the medical monitor.
No change in PPI use
No use of CYP450 3A4 inhibitors
No use of sucralfate during the stud y as this may interfere with the adherence of OBS
An esophageal dilatati on during the trial (Dilatation is considered a treatment failure, and the 
subject should be withdrawn from the stud y)
4.4 Reproductive Potential
4.4.1 Female Contraception
All females must have a negative pregnancy  test at the screening visit (Visit -1), placebo le ad-in 
visit (Visit 0), baseline visit (Visit 1), and Visits 1 -4. A serum pregnancy  test will be performed 
at the screening visit (Visit - 1) and final treatment evaluation (Visit 4). Urine pregnancy  tests 
will be performed at all other visits.
Female subje cts should be either:
Premenarchal and Tanner Stage 1, or
Post-menopausal (24 consecutive months of spontaneous amenorrhea and age 51 years or 
older).
Be surgically  sterile (having undergone one of the following surgical acts: hysterectomy , 
bilateral tubal ligation, bilateral oophorectomy or bilateral salpingectomy ) and at least 
6weeks post -sterilization, or
Females of child- bearing potential must agree to abstain from sexual activity  that could result 
in pregnancy  or agree to use acceptable methods of contraception throughout the study 
period and for 30 day s following the last dose of investigational product.
Acceptable methods of contraception are:
 Abstinence
 Surgicall y sterile male partner
 Stable oral contraceptives
 Intrauterine devices plus condoms
Shire CONFIDENTIAL Page 38
Protocol Am endment 2
SHP621 -301 26 Jan 2018
 Doub le-barrier methods (eg, condoms and diaphragms with spermicidal gel or 
foam)
 Hormonal contraceptives (oral, depot, patch, injectable, or vaginal ring), 
stabilized for at least 30 day s prior to the screening visit (Visit -1), plus condoms. 
If hormonal contr aceptives are used, they should be administered according to the 
package insert. Note: If subjects become sexually  active during the study , they 
should use one of the other acceptable methods noted above in addition to the 
hormonal contraceptive until it h as been stabilized for 30 days.
4.5 Discontinuation of Subjects
A subject may  withdraw from the study  at any  time for an y reason without prejudice to their 
future medical care b y the physician or at the institution. The investigator or sponsor may  
withdraw the subject at any  time (eg, in the interest of subject safet y). The investigator is 
encouraged to discuss withdrawal of a subject from investigational product with the medical 
monitor when possible.
If investigational product is discontinued, leading to subj ect discontinuation from the study , 
regardless of the reason, the evaluations listed for Visit 4 are to be performed as completel y as 
possible. I f investigational product is discontinued due to an adverse event ( AE), the subject may  
remain on study  to allo w for completion of study  procedures.
Whenever possible, all discontinued subjects should also undergo the protocol -specified follow -
up. Comments (spontaneous or elicited) or complaints made by  the subject must be recorded in 
the source documents. The reason for termination, date of stopping investigational product, and 
total amount of investigational product taken must be recorded in the case report form (CRF) and 
source documents.
Subjects who discontinue will not be replaced. 
4.5.1 Subject Withdrawal Criteria
Medically  important events that in the opinion of the investigator or medical monitor would 
compromise the subject’s ability  to safel y continue in the study , including but not limited to 
severe signs and s ymptoms of EoE, such as an esophageal stricture requiring dilation, weight 
loss due to severe d ysphagia, and/or upper GI bleed would be considered a treatment failure and 
result in withdrawal of the subject from the stud y.
4.5.2 Reasons for Discontinuation
The reason for withdrawal must be determined b y the inv estigator and recorded in the subject’s 
medical record and on the CRF. If a subject is withdrawn for more than 1 reason, each reason 
should be documented in the source document and the most clinically  relevant reason should be 
entered on the CRF.
Reasons f or discontinuation include but are not limited to:
Shire CONFIDENTIAL Page 39
Protocol Am endment 2
SHP621 -301 26 Jan 2018
 Completed
 Death
 AE
 Noncompliance with study  drug
 Noncompliance with study  procedure
 Withdrawal by  subject
 Withdrawal by  parent/guardian
 Physician decision
 Study  terminated by  sponsor
 Site terminated by  sponsor
 Lost to follow -up
 Pregnancy
 Trial screen failure
 Protocol deviation
 Other 
4.5.3 Subjects “Lost to Follow-up” Prior to Last Scheduled Visit
A minimum of 3 documented attempts must be made to contact an y subject lost to follow -up at 
any time point prior to t he last scheduled contact (office visit or telephone contact). At least 1 of 
these documented attempts must include a written communication sent to the subject’s last 
known address via courier or mail (with an acknowledgement of receipt request) asking that they  
return to the site for final safet y evaluations and return any unused investigational product.
4.5.4 Safety -related Stopping Rules
An urgent safety review will be conducted within 7 days b y the sponsor if one or more of the 
following criteria are met:
Death that is considered related to the study  drug
Two serious adverse events (SAEs )of similar type (defined as same or similar Medical 
Dictionary  for Regulatory  Activities [MedDRA] higher level group code) and considered 
related to the stud y drug
The urgent review will be performed by  a sponsor safet y review group, which will include the 
study  Global Drug Safety  (GDS) physician and the GDS Therapeutic Area Head. The GDS
Therapeutic Area Head, not the GDS physician involved in the study , may  be unblinded as part 
of this urgent safet y review, if required. Following the sponsor’s review of safet y data, one of the 
following actions will be taken with respect to study status:
Shire CONFIDENTIAL Page 40
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Continue study  with protocol unchanged
Continue study  with modifications to the protocol
Terminate stud y
Subject safet y will be monitored on a continuous basis during this study  until the last subject 
completes his or her last sc heduled stud y visit/assessment.
Shire CONFIDENTIAL Page 41
Protocol Am endment 2
SHP621 -301 26 Jan 2018
5. PRIOR AND CONCOMITAN T TREATMENT
All non- study  treatment (including but not limited t o herbal treatments, vitamins, behavioral 
treatment, and nonpharmacological treatment, such as psy chotherapy , as appropriate) received 
within 3 months prior to the screening visit (Visit -1) (or pharmacokinetic equivalent of 5 half-
lives, whichever is long er) and through the final study  contact (including protocol -defined 
follow -up period) must be recorded on the appropriate CRF page.
5.1 Prior Treatment
Prior treatment includes all treatment, including but not limited to herbal treatments, vitamins, 
and nonpha rmacological treatment such as ps ychotherapy , as appropriate, received within 
3 months of the screening visit (Visit - 1). Prior treatment information must be recorded on the 
appropriate CRF page.
5.2 Concomitant Treatment 
Concomitant treatment refers to all t reatment taken between the dates of the first dose of 
investigational product and the end of the follow -up period, inclusive. Concomitant treatment 
information must be recorded on the appropriate CRF page.
The investigator may  prescribe additional medicati ons during the stud y, as long as the prescribed 
medication is not prohibited by  the protocol. In the event of an emergency , any  needed 
medications may  be prescribed without prior approval, but the medical monitor must be notified 
of the use of an y prohibit ed medications immediately  thereafter.
5.2.1 Permitted Treatment
The following medications are allowed during the course of the stud y if the subject has been on a 
stable dosing regimen (ie, same dose and frequency in the previous 4 weeks prior to the 
endoscop y required for entrance to this study ) and will continue this dosing regimen throughout 
study  participation. The investigator must contact the medical monitor to discuss any  changes to 
concomitant steroid regimens or for an y medications not listed here that could impact the 
outcome of the stud y.
1.Inhaled or intranasal steroids for conditions other than EoE; subject must be on stable 
treatment for ≥3months prior to screening visit (Visit -1), except for seasonal allergic 
rhinitis, see Section 4.3.
2.PPIs
3.H2 antagonists
4.Antacids
5.
Antihistamines or anti- leukotrienes
6.Maintenance immunotherap y (allergy  shots or sublingual immunotherapy )
Shire CONFIDENTIAL Page 42
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Influenza and other routine required vaccinations are allowed during the study .
5.2.2 Prohibited Treatment
The following medications and treatments are prohibited throughout the course of the stud y and 
prior to treatment, as specified:
1.Immunomodulatory  therapy  within 8 weeks prior to the qualify ing EGD or between the 
qualify ing EGD and baseline visit (Visit 1) or anticipated use of immunomodulatory  therap y 
during the treatment period (except for any ongoing regimen of allergy  shots). Use of long-
acting immunomodulatory  therap y (eg, Rituxan) within 3 months of the qualify ing EGD 
should be reviewed with the medical monitor. 
2.Swallowed topical corticosteroid for EoE or systemic cortic osteroid for any condition within 
the 4 weeks prior to the qualify ing EGD, between the qualify ing EGD and baseline visit 
(Visit 1) or anticipated use during the treatment period; anytemporary use (≤7days) or 
initiation of new steroid treatment during study  should be documented and discussed with the 
medical monitor prospectively  but cannot occur within the 4 weeks of the final EGD.
3.Inhaled steroids if initiated or changed in dose <3months prior to screening visit 
(Visit
-1).(Seasonal nasal corticosteroid use for seasonal allergic rhinitis is permitted; 
changes within 4 weeks of scheduled EGD should be avoided).
4.Initiation or change in dosing frequency  of PPIs, H2 antagonists, antacids, or leukotriene 
inhibitors for any condition (such as gastroesophageal reflux disease, asthma, or allergic 
rhinitis) within the 4 weeks prior to the qualify ing EGD, between the qualify ing EGD and 
baseline visit 1, or anticipated changes in the use of such medications during the treatment 
period.
5.CYP450 3A4 inhibitors (eg, ketoconazole, grapefruit juice) within the 2 weeks prior to the 
baseline visit (Visit 1) or within 5 half-lives (whichever is greater) or anticipated use of such 
medications during the treatment period. For an expanded list of CYP3A inhibitors, 
investigators should refer to the 2012 FDA Draft Guidance on Drug Interactions (FDA 
Guidance 2012) and use their clinical judgment with respect to specific medications.
6.Esophageal dilation within the 3 months prior to screening (Visit -1)
7.Investigational study  treatment within 6 months prior to the screening visit (Visit -1)
8.Sucralfate use during the treatment period
Shire CONFIDENTIAL Page 43
Protocol Am endment 2
SHP621 -301 26 Jan 2018
6. INVESTIGATIONAL PRODUCT
6.1 Identity of Investigational Product
The test product is OBS (oral budesonide suspension, 0.2 mg/mL), which will be provided in 
multi- dose amber glass bottles, each containing approximately 210mL. Additional information 
is provided in the current SHP621 investigator’s brochure.
The reference/comparator product is placebo, which will be provided in amber glass bottle form 
with the same volume.
6.1.1 Blinding the Treatment Assignment
Investigational product will be supplied in amber glass, multi- dose bottles with child- resistant 
caps and refrigerated throughout the stu dy (in the clinic and subject’s home). Each bottle 
contains approximately 210mL of suspension with a budesonide concentration of 0.2 mg/mL . 
Inactive ingredients in OBS include dextrose, disodium edetate, citric acid, sodium citrate, 
potassium sorbate, pol ysorbate 80, gl ycerin, sodium benzoate, cherry flavor, Magnasweet 110, 
acesulfame potassium, and water.
The placebo solution will also be supplied in amber glass multi -dose bottles with child -resistant 
caps. Placebo consists of all components of the investigational product solution with the 
exception of budesonide.
6.2
Administration of Investigational Product(s) 
All investigational product and supplies (eg, dosing spoons) will be provided by  Shire or its 
designee. At each visit, subjects will be supplied with enough investigational product to last until 
the subsequent visit. The first dose of investigational product (placebo) for each subject will be 
administered in the clinic at the placebo lead -in visit (Visit 0). The subject will continue with the 
evening dosing regimen at home.
OBS and placebo will be supplied in amber glass bottles and must be shaken well prior to 
administration. OBS and placebo should be refrigerated at 2-8ºC (36- 46ºF) throughout the stud y 
(in the clinic and subject’s home). The appropria te dose will be dispensed using the graduated 
dosing spoon provided. For subjects who are minors (<18 years), a parent/guardian will be 
responsible for ensuring that the subjects take their investi gational product appropriatel y.
Subjects will be instructed not to eat or drink for 30 minutes after taking the investigational 
product. Activities such as brushing teeth or rinsing the mouth should also be avoided during this 
time interval. After 30 minutes, subjects will be instructed to rinse with water and spi t, 
particularl y after the bedtime dose.
Please refer to the Investigational Product Administration Manual for additional details.
Shire CONFIDENTIAL Page 44
Protocol Am endment 2
SHP621 -301 26 Jan 2018
6.2.1 Interactive Response Technology for Investigational Product Management 
An interactive web -based response s ystem (IWRS) will be used for screening and enrolling 
subjects, recording subject visits, randomization, investigational product supply  dispensation and 
management, inventory  management and suppl y ordering, investigational product expiration 
tracking and management, return o f investigational product, and emergency unmasking. Please 
refer to the Study  Manual for additional details regarding the I WRS. 
The investigator or designee will access the IWRS at the screening visit (Visit - 1) to record 
subject -specific information (ie,unique subject number, date of birth, etc.). Subjects will be 
entered as screen failures or as entering the placebo lead -in period. Subjects cannot be rescreened 
once it is confirmed they do not meet inclusion/exclusion criteria unless the screen failure was 
due to a concomitant medication that can be discontinued prior to rescreening; those subjects 
may be rescreened. Other reasons for rescreening (ie, reasons unrelated to inclusion/exclusion 
criteria) must be discussed prospectively  with the medical moni tor. For subjects who enter the 
placebo lead-in period, IWRS will provide the assignment of placebo lead-in period medication 
to dispense. 
At the baseline visit (Visit 1), the investigator or designee will again access the IWRS to either 
document a screen failure or, if the subject has met all entry  criteria, to randomize the subject.
Sites will enter eligibility  criteria information prior to randomization. For randomized subjects, 
the IWRS will provide a medication identification (Med ID) number (ie, kit number to dispense 
for treatment).
The I WRS will also be used for creating, tracking, and confirming investigational product 
shipments. A user manual with specific functions and instructions for the IWRS will be provided 
to the site and site personnel wil l receive training.
The I WRS provider will provide a user manual and training to each site, with detailed 
instructions on use of the I WRS.
6.2.2 Allocation of Subjects to Treatment 
This study  consists of a single- blind lead -in period followed by  a double -blind placebo-
controlled study  period. The actual treatment given to individual subjects during the double -blind 
period is determined b y a randomization schedule.
Subject numbers are assigned to all subjects as they consent to take part in the study . Within each
site (numbered uniquel y within a protocol), the subject number is assigned to subjects according 
to the sequence of presentation for study  participation.
The randomization number represents a unique number corresponding to investigational product 
allocate d to the subject once eligibility  has been determined following the placebo lead -in period.
Individual subject treatment is automatically  assigned by  the I WRS.
Shire CONFIDENTIAL Page 45
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Subjects will be randomized after confirmation of study  eligibility  in a ratio of 2:1 via a 
computer -generated randomization schedule to receive OBS 2 mg twice daily  (qAM, pc, and hs) 
or placebo. The randomization will be performed centrall y and stratified by age group (2 strata 
total: <18 y ears or ≥18 years) and diet restriction for EoE or other health-related conditions (no 
diet restriction or an y diet restriction). The stratification by age will ensure a minimum of 
40subjects in the pediatric group (11 -17 years, inclusive). The stratification by  age and diet 
restriction will ensure balance betwee n treatment groups for the respective stratification factors. 
Fixed block randomization will be used to ensure that approximately  equal numbers of patients 
are assigned each treatment within strata.  
6.2.3 Dosing
During the 4- week single -blind placebo lead -in period, all subjects will receive 10 mL  of placebo 
twice dail y (qAM, pc, and hs). During the 12 -week double -blind treatment peri od, oral 
administration of 10 mL  of investigational product will occur twice dail y (qAM, pc, and hs), 
with no ingestion of food or liquids permitted for 30 minutes after stud y drug administration. 
Subjects randomized to OBS will receive 10 mL of 0.2 mg/mL of OBS (2 mg) twice dail y for a 
total daily  dose of 4 mg.
Investigational product doses that are required to be administered at the clinic include the first 
dose of placebo administered at the placebo lead -in visit (Visit 0), the first dose of randomized 
investigational product (OBS or placebo) administered at the baseline visit (Visit 1) and all 
morning doses of investigational product administered at Visits 2 -4. Subjects will be required to 
eat breakfast at the clinic prior to self- administering these doses. Subjects can self-administer all 
other doses of placebo and investigational product at home.
During the day  where the pharmacokinetic blood samples are collected, subjects will be required 
to eat a moderate -fat breakfast onsite and will be instructed t o take their morning dose at a set 
time to establish the schedule for post-dose sample collection.
6.2.4 Unblinding the Treatment Assignment
The treatment assignment must not be broken during the stud y except in emergency situations 
where the identification of the investigational product is required for further treatment of the 
subject. The investigator should contact the medical monitor and the sponsor as soon as possible 
after the investigator has been unblinded. 
In the event that the treatment assignment is broken, the date, the signature of the person who 
broke the code, and the reason for breaking the code are recorded in the IWRS and the source 
documents. Upon breaking the blind, the subject is withdrawn from the study ,but should be 
followed up for safet ypurposes. Any  code breaks that occur must be reported to the contract 
research organization (CRO) and sponsor. Code- break information is held by  the 
pharmacist/designated person at the site and b y the CRO medical monitor for the study or 
designee.

Shire CONFIDENTIAL Page 46
Protocol Am endment 2
SHP621 -301 26 Jan 2018
There w ill be a provision for unblinding to ensure adequate treatment of the subject in the case of 
an emergency .
6.3 Labeling, Packaging, Storage, and Handling
6.3.1 Labeling 
Labels containing study  information and pack identification are applied to the invest igational 
product(s) container.
All investigational product is labeled with a minimum of the protocol number, Med ID, dosage 
form (including product name and quantit y in pack), directions for use, storage conditions, 
expiry  date (if applicable), batch number and/or packaging reference, the statements “For clinical 
trial use only ” and/or “CAUTION: New Drug -Limited by  Federal (or US) Law to 
Investigational Use,” “Keep out of reach of children,” and the sponsor’s name and address. An y 
additional labeling requirements for participating countries and/or controlled substances will also 
be included on the label.
Space is allocated on the label so that the site representative can record subject information. 
Additional labels (eg, those used when dispensing marketed product ) may , on a case- by-case 
basis, be applied to the investigational product in order to satisfy  local or institutional 
requirements, but must not:
 Contradict the clinical study  label.
 Obscure the clinical study label.
 Identify  the study  subject by  name.
Additional labels may  not be added without the sponsor’s prior full agreement.
6.3.2 Packaging
Investigational product is packaged in the following labeled containers:
The sponsor will supply  the following medication to the study  sites in a blinded manner: OBS 
0.2 mg/mL  or placebo in an 8 - ounce amber glass bottle for multiple use. Three bottles will be 
packaged in an appropriately  labeled carton.
Changes to sponsor -supplied packaging prior to dosing may  not occur without full agreement in 
advance b y the sponsor.
6.3.3 Storage
The investigator has overall responsibility  for ensuring that investigational product is stored in a 
secure, limited -access location. L imited responsibility  may  be delegated to the pharmacy  or 
member of the stud y team, but this delegation must be docu mented.
Shire CONFIDENTIAL Page 47
Protocol Am endment 2
SHP621 -301 26 Jan 2018
OBS and placebo must be stored at 2 -8ºC (36- 46ºF), protected from light.
Investigational products are distributed b y the pharmacy or nominated member of the stud y 
team. The pharmacist/nominated team member will enter the unique subject identifier o n the 
investigational product bottle/carton labels as they are distributed.
Investigational product must be stored in accordance with labeled storage conditions. 
Temperature monitoring is required at the storage location to ensure that the investigational 
product is maintained within an established temperature range. The investigator is responsible 
for ensuring that the temperature is monitored throughout the duration of the study and that 
records are maintained; the temperature should be monitored continuo usly by using either an in -
house sy stem, a mechanical recording device such as a calibrated chart recorder, or by  manual 
means, such that both minimum and maximum thermometric values over a specific time period 
can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) 
would require manual resetting upon each recording. The sponsor must be notified immediately  
upon discovery  of any  excursion from the established range. Temperature excursions will require 
site investigation as to cause and remediation. The sponsor will determine the ultimate impact of 
excursions on the investigational product and will provide supportive documentation as 
necessary . Under no circumstances should the product be dispensed to subjects until the im pact 
has been determined and the product is deemed appropriate for use b y the sponsor.
The sponsor should be notified immediately  if there are an y changes to the storage area of the 
investigational product that could affect the integrity  of the product(s), eg, fumigation of a 
storage room.
6.3.4 Special Handling
The investigational product should be stored under refrigeration at 2 -8°C/36 -46°F at all times. 
The investigational product should be protected from light and shaken well immediately  prior to 
each dose.
6.4 D rug Accountability
Investigators will be provided with sufficient amounts of the investigational product to carry  out 
this protocol for the agreed- upon number of subjects. The investigator or designee will 
acknowledge receipt of the investigational product, documenting shipment content and 
condition. Accurate records of all investigational product dispensed, used, returned, and/or 
destroy ed must be maintained as detailed further in this section.
The investigator has overall responsibility  for administering/ dispensing investigational product. 
Where permissible, tasks may  be delegated to a qualified designee (eg, a pharmacist) who is 
adequatel y trained in the protocol and who works under the direct supervision of the investigator. 
This delegation must be documented in the applicable study  delegation of authority  form.
The investigator or his/her designee (as documented by  the investigator in the applicable study  
delegation of authorit y form) will dispense the investigational product only to subjects included 
Shire CONFIDENTIAL Page 48
Protocol Am endment 2
SHP621 -301 26 Jan 2018
inthis study  following the procedures set out in the study  protocol. Each subject will be given 
only the investigational product carry ing his/her treatment assignment. All dispensed medication 
will be documented on the CRFs and/or other investigational prod uct record. The investigator is 
responsible for assuring the retrieval of all stud y supplies from subjects. The investigator or 
his/her designee will enter the unique subject identifier and initials on the investigational product 
kit labels as they  are assigned and dispensed.
No investigational product stock or returned inventory  from a Shire -sponsored study  may  be 
removed from the site where originall y shipped without prior knowledge and consent b y the 
sponsor. If such transfer is authorized by  the sponsor , all applicable local, state, and national 
laws must be adhered to for the transfer.
The sponsor or its representatives must be permitted access to review the supplies storage and 
distribution procedures and records provided that the blind of the study  isnot compromised.
At the end of the stud y, or as instructed b y the sponsor, all unused stock , subject -returned 
investigational product, and empty /used investigational product packaging are to be sent to a 
nominated contractor on behalf of the sponsor. Inve stigational product being returned to the 
sponsor’s designated contractors must be counted and verified b y clinical site personnel and the 
sponsor (or designated CRO). For unused supplies where the original supplied tamper -evident 
feature is verified as in tact, the tamper -evident feature must not be broken, and the labeled 
amount is to be documented in lieu of counting. Shipment return forms, when used, must be 
signed prior to shipment from the site. Validated electronic return s ystems (ie, I WRS) do not 
require a shipment form. Returned investigational product must be packed in a tamper -evident 
manner to ensure product integrit y. Contact the sponsor for authorization to return an y 
investigational product prior to shipment. Shipment of all returned investigat ional product must 
comply  with local, state, and national laws.
Based on entries in the site drug accountability  forms, it must be possible to reconcile 
investigational products delivered with those used and returned. All investigational products 
must be a ccounted for and all discrepancies investigated and documented to the sponsor’s 
satisfaction.
6.5
Subject Compliance
Compliance with investigational product will be assessed at each study  visit. Subjects must be 
instructed to bring their unused investigational product and empt y/used investigational product 
packaging to every visit. Drug accountability  must be assessed at the container/packaging level 
for unused investigational product that is contained within the original tamper -evident sealed 
container (eg, bo ttles) or at the individual count level for opened containers/packaging. The 
pharmacist/nominated person will record details on the drug accountability  form.
Visit to visit compliance of investigational product dosing will be assessed by  site personnel. Si te 
personnel must review the returned investigational product to assess compliance at every visit 
prior to dispensing additional investigational product. Any  discrepancies should be reconciled 
Shire CONFIDENTIAL Page 49
Protocol Am endment 2
SHP621 -301 26 Jan 2018
with the subject immediately . Subjects who do not return their used and unused investigational 
product should be reminded to bring all used and unused investigational product at their next 
visit. 
Subjects who have taken 70 -130% of the investigational product will be assessed as being 
compliant with the study
 protocol . Compliance will be assessed at each treatment visit. 
Shire CONFIDENTIAL Page 50
Protocol Am endment 2
SHP621 -301 26 Jan 2018
7. STUDY PROCEDURES
7.1 Study Schedule
The detailed stud y procedures/assessments to be performed throughout the study are outlined in 
the Schedule of Assessments (see Table 1 -1) and must be referred to in co njunction with the 
instructions provided in this section. 
Prior to performing an y study-related procedures (including those related to screening), the 
investigator or his/her designee must obtain written informed consent from the subject (as per 
local req
uirements). There must be documentation of consent (as per local requirements) 
indicating that the subject is aware of the investigational nature of the study and the required 
procedures and restrictions, prior to performing any  study -related procedures.
7.1.1 S creening Period (Weeks -6 to 0)
The screening period starts when subjects sign informed consent. The screening period will 
comprise 3- 6 weeks, during which all procedures listed for the screening visit (Visit -1) in Table 
1-1shall be completed. The screen ing period will allow for the determination of eligibility  of 
each subject’s inclusion into the study . A subject should not be instructed to discontinue use of 
any medication or treatment to participate in this study  until informed consent has been obtaine d. 
Subjects should not stop permitted medications or treatments that are effective and well tolerated 
to participate in this study  (see Section 5.2.1).
Screening assessments may  take place across several day s to allow an appropriate time frame in 
which to complete all procedures and confirm study  eligibility .
After the screening period, subjects who meet eligibility  criteria at the end of the screening visit 
(Visit 
-1) will enter the 4 -week single -blind, placebo lead- in period. The placebo lead -in period 
should not commence until all screening assessments required to confirm initial eligibility  have 
been completed. If the subject does not meet eligibility  criteria following completion of 
screening assessments, the investigator or designee will document the s ubject as a screen failure 
in the I WRS.
A screen failure is a subject who has given informed consent and failed to meet the inclusion 
criteria and/or met at least 1 of the exclusion criteria and has not been randomized or 
administered randomized investigational product. Screen failures can occur at the screening, 
placebo lead -in, or baseline visits. Subjects cannot be rescreened once it is confirmed they  do not 
meet inclusion/exclusion criteria unless the screen failure was due to temporary  condition or 
incomplete information at the time of consent (Visit - 1) that would make rescreening at a later 
date appropriate (eg, a concomitant medication that can be discontinued prior to rescreening, 
review of subject medical records provides new information with respect to the date of a prior 
esophageal dilation or diet change, or subject has a minor illness such as an upper respiratory  or 
urinary  tract infection). All reasons for rescreening (ie, reasons unrelated to inclusion/exclusion 
criteria) must be discussed and approved prospectively  with the medical monitor.
Shire CONFIDENTIAL Page 51
Protocol Am endment 2
SHP621 -301 26 Jan 2018
7.1.1.1 Screening Visit (Visit -1) 
The screening visit (Visit - 1) assessments and procedures, beginning with informed consent, will 
be performed as outlined in Table 1-1.
The following procedures should be perform ed first:
Obtain subject consent (or assent as applicable for subjects <18 years).
Review eligibility  criteria.
Review medical history .
Record vital signs (including blood pressure [systolic and diastolic], heart rate, respirations, 
and temperature), heigh t, and weight. Perform stadiometry  in subjects aged 11-17 years, 
inclusive.
Review current use of concomitant medications, including medications taken and procedures 
completed within 3months prior to the biopsy  required for entrance to this study . Note: 
Subjects who are on a PPI must remain on the same dose of the PPI throughout the study, 
and if they  are not taking a PPI , they  must remain off of a PPI for the remainder of the stud y.
Clinical chemistry , hematology , and urinal ysis laboratory  tests will be performed on all 
subjects; all subjects must fast overnight prior to collection.
The following order is recommended for the remaining procedures that will be performed at this 
visit or within the 6 -week screening period:
Dispense the DSQ 
electronic patient -reported outcome (ePRO) device for nightly  completion 
and train the subject on its use. In order to qualify  for study  entry, subjects must have 
experienced dysphagia (response of “yes” to question 2 on DSQ) on a minimum of 4days 
and completed the DSQ on ≥ 70% of days in any 2  consecutive weeks of the screening 
period. 
Perform a physical examination on all subjects. Adolescents (subjects ≤17 years) will also 
undergo Tanner Staging Assessment.
Serum pregnancy  test will be pe rformed on all female subjects.
Perform EGD and biopsy ; both must be performed within the 6 weeks prior to the Placebo 
Lead -in Visit either at the investigative site or by a  referring physician. Biops y specimens 
must be available to be sent to the central pathology  lab at least 2 weeks prior to the Placebo 
Lead -in Visit to allow sufficient time for processing and central review and determination of 
eligibility .
7.1.2 Placebo Lead -in Period (Weeks 0 to 4)
The placebo lead -in period will comprise 4 weeks, during which all procedures listed for the 
placebo visit (Visit 0) in Table 1-1 shall be completed.
Shire CONFIDENTIAL Page 52
Protocol Am endment 2
SHP621 -301 26 Jan 2018
During the 4- week single -blind placebo lead -in, all eligible subjects will self -administer 10 mL 
of placebo twice dail y (qAM, pc, and hs). 
At the end of the placebo lead -in period, eligible subjects (those with at least 4 reported 
dysphagia da ys and completion of DSQ on ≥70% of day s in the 2 weeks prior to baseline [Visit 
1]) will be randomized and enter the 12 -week double -blind treatment period (baseline visit). 
Subjects must be administrated placebo during the placebo lead -in period for 4 weeks (±3 days) 
prior to Visit 1 (baseline) to be eligible for randomization into the 12 -week double -blind 
treatment period.
7.1.2.1 Placebo Lead -in Visit (Visit 0) 
The placebo lead -in visit (Visit 0) assessments and procedures will be performed as outlined in 
Table 1-1. 
The following procedures should be performed first:
Reassess eligibility  according to the inclusion/exclusion criteria and medical history .
Record vital signs (including blood pressure [systolic and diastolic], heart 
rate, respirations, 
and temperat ure) and weight.
Perform AE assessments.
Review concomitant medications and procedures.
Clinical chemistry , hematology , and urinal ysis laboratory  tests; all subjects must fast 
overnight prior to collection.
The following order is recommended for the remain ing procedures that will be performed at this 
visit:
Confirm DSQ dysphagia episodes and compliance by completing screening eligibility  report 
on DSQ device; re-dispense DSQ device to subject with instruction to continue completion 
of the DSQ nightl y.
Perfo rm a ph ysical examination and assess any  changes since screening.
Urine pregnancy  test for female subjects.
Perform dual-energy  X-ray absorptiometry  (DXA) scan for bone mineral density  (BMD) and 
body  composition in subjects aged 11-17 years, inclusive; the DXA scan may be performed 
any time during the placebo lead -in period, after the subject has met all screening criteria and 
prior to blinded- treatment randomization. Baseline and post-treatment DXA scans should be 
performed using the same machine and soft ware.
Dispense placebo stud y medication and review administration instructions. Subjects will self -
administer the first dose of placebo in the clinic after eating breakfast. Site personnel will 
record the date and time of the first placebo dose in the source documents. Beginning on the 
evening of Visit 0, the subject 
will take their second dose at home and continue with the 
twice dail y (qAM, pc, and hs) dosing regimen.
Shire CONFIDENTIAL Page 53
Protocol Am endment 2
SHP621 -301 26 Jan 2018
7.1.3 Double -blind Treatment Period (Visits 1 -4): Weeks 4, 8, 12, and 16 (or Early 
Termination)
The double -blind treatment period will comprise 12 weeks, during which all assessments and 
procedures listed for Visits 1 -4 in Table 1-1 shall be completed.
During this period, a 3-day visit window will be permitted, unless otherwise specified. Visit 
windows are calculated based upon the date of the placebo lead- in visit (Visit 0).
Subjects who continue to meet all eligibility  criteria will be randomized 2:1 to receive either 
OBS twice daily  (qAM, pc, and hs) or placebo twice dail y (qAM, pc, and hs). The 
investigator or 
assigned site staff will access the I WRS to randomize the subject and dispense the investigational 
product. Subjects who fail to meet eligibility criteria at the baseline visit (Visit 1) will be 
documented as screen failures in the I WRS.
Subjects who complete the 12 -week double -blind treatment period will have the opportunity  to 
enroll in the treatment extension study . These subjects will continue on the blinded assigned 
treatment for 2 -4 weeks as part of the screening prior to enrolling int o the treatment extension 
study . Subjects who do not enroll in the treatment extension study  or who discontinue 
prematurel y at an y time during the SHP621 -301 (Induction) study  will receive a follow -up phone 
call 4-weeks post last dose of investigational pr oduct.
7.1.3.1 Baseline Visit (Visit 1): Week 4
Subjects will return to the site for the baseline visit (Visit 1) to confirm eligibility . The baseline 
visit (Visit 1) assessments and procedures will be performed as outlined in Table 1-1.
The following procedures should be performed first:
Reassess eligibility  according to the inclusion/exclusion criteria and medical history .
Record vital signs (including blood pressure [systolic and diastolic], heart 
rate, respiration s, 
and temperature) and weight.
Perform AE assessments, including specific assessments for signs of glucocorticoid excess. 
Any AE that occurs during this visit will be recorded in the CRF and considered a treatment 
emergent adverse event (TEAE).
Review concomitant medications and procedures.
Clinical chemistry , hematology , and urinal ysis laboratory  tests; all subjects must fast 
overnight prior to collection.
Morning cortisol (performed between 6:00 and 9:00 AM). Subjects should be instructed not 
to take the morning dose of investigational product until after the morning cortisol test has 
been performed. 
Administer adrenocorticotropic hormone (ACTH) stimulation testing; the type of synthetic 
and route of administration will be per local lab discretion. Additional cortisol samples will 
Shire CONFIDENTIAL Page 54
Protocol Am endment 2
SHP621 -301 26 Jan 2018
be drawn at 30 and 6 0minutes following stimulation testing.
The following order is recommended for the remaining procedures that will be performed at this 
visit:
Review study  medication dosing compliance.
Confirm DSQ dysphagia episodes and compliance by completing baseline eligibility  report 
on DSQ device; re-dispense DSQ device to subject with instruction to continue completion 
of the DSQ nightl y.
Administer health- related quality  oflife (HRQoL) assessments including the EuroQol (EQ-
5D), Pediatric Quality  of Life Inventory  –EoE (PedsQL -EoE), and Adult Eosinophilic 
Esophagitis Qualit y of Life (EoE -QoL-A) as age -appropriate.
Administer PGI -S of disease assessment. 
Perform a ph ysical examination and assess any  changes since screening.
Re-administer urine pregnancy  test for fe male subjects.
Dispense investigational product (OBS or placebo) according to IWRS randomization and 
review administration instructions. Subjects will self-administer the first dose of 
investigational product in the clinic during this visit after breakfas t. Site personnel will record 
the date and time of the first randomized dose in the source documents. Beginning on the 
evening of Visit 1, the subject will take their first dose at home and continue with the twice 
daily  (morning and evening) dosing regimen . For subjects who are minors (<18 years), a 
parent/guardian will be responsible for ensuring subject takes their investigational product 
appropriatel y.
Following all blood draws, subjects can eat breakfast and take their morning dose of 
investigational pr oduct.
7.1.3.2 Visits 2 and 3 (Weeks 8 and 12)
Subjects will return to the site for Visit 2 (Week 8) and Visit 3 (Week 12). Assessments at these 
visits will be performed as outlined in Table 1-1.
The following procedures should be performed first:
Record vital signs (including blood pressure [systolic and diastolic], heart rate, respirations, 
and temperature) and weight.
Perform AE assessments, including specific assessments for signs of glucocorticoid excess. 
Any AE that occurs during this visit will be recorded i n the CRF and considered a TEAE.
Review concomitant medications and procedures.
Clinical chemistry , hematology , and urinal ysis laboratory  tests; all subjects must fast 
overnight prior to collection.
Morning cortisol (performed between 6:00 and 9:00 AM). Subjects should be instructed not 
Shire CONFIDENTIAL Page 55
Protocol Am endment 2
SHP621 -301 26 Jan 2018
to take the morning dose of study  medication until after the morning cortisol test has been 
performed. 
Collect blood samples for pharmacokinetic analy sis for adult subjects. Samples may be 
obtained one time on any day betwe en 7 days after Visit 1 (Week 5) and through Visit 4 
(Week 16). PK samples should be drawn, ideally , at pre-dose, 0.5 and 1 hours post-dose and 
at additional time points ,if feasible (2, 3, 4, 6, 8, and 12 hours post-dose). Subjects will be 
instructed to take their morning dose at a set time to establish the schedule forpost-dose 
sample collection.
The following order is recommended for the remaining procedures that will be performed at this 
visit:
Review DSQ compliance and complete visit confirmation on the DSQ device; re-dispense 
DSQ device to subject with instruction to continue completion of the DSQ nightly .
Administer PGI -S assessment. 
Perform a ph ysical examination and assess any  changes since screening.
Re-administer urine pregnancy  test for female subjects.
Dispense investigational product (OBS or placebo) and review investigational product dosing 
compliance.
Following all blood draws, subjects can eat breakfast and take their morning dose of 
investigational product.
7.1.3.3 Visit 4 (Week 16)
Subjects will return to the site for Visit 4 (Week 16). Assessments at this visit will be performed 
as outlined in Table 1-1.
The following order is recommended for the procedures that will be performed at this visit:
Record vital signs (including blood pressure [systolic and diastolic], heart rate, respirations, 
and temperature), height, and weight. Perform stadiometry  in subjects aged 11-17 years, 
inclusive.
Perform AE assessments, including specific assessments for signs of glucocorticoid excess. 
Any AE that occurs du ring this visit will be recorded in the CRF and considered a TEAE.
Review concomitant medications and procedures.
Clinical chemistry , hematology , and urinal ysis laboratory  tests; all subjects must fast 
overnight prior to collection.
Morning cortisol (performed between 6:00 and 9:00 AM). Subjects should be instructed not 
to take the morning dose of investigational product until after the morning cortisol test has 
been performed.
Administer ACTH stimulation testing; the type of synthetic and route of administ ration will 
Shire CONFIDENTIAL Page 56
Protocol Am endment 2
SHP621 -301 26 Jan 2018
be per local lab discretion. Additional cortisol samples will be drawn at 30 and 60minutes
following stimulation testing.
Collect blood samples for pharmacokinetic analy sis for adult subjects. Samples may be 
obtained one time on any day betwee n 7 days after Visit 1 (Week 5) andthrough Visit 4 
(Week 16). PK samples should be drawn, ideally , at pre-dose, 0.5 and 1 hours post-dose and 
at additional time points , if feasible (2, 3, 4, 6, 8, and 12 hours post- dose).
Retrieve DSQ handset, review DSQ compliance, and complete visit confirmation on DSQ 
device .
Administer HRQoL  assessments including the EQ-5D, PedsQL -EoE, and EoE-QoL-A as 
age-appropriate.
Administer PGI -S assessment. 
Perform a physical examination and assess any changes since screening. Adolescents 
(subjects ≤17 y ears) will also undergo Tanner Staging Assessment.
Re-administer serum pregnancy  test for female subjects.
Perform DXA scan for BMD and body  composition in subjects aged 11-17 years, inclusive. 
DXA scan should be completed at or within (±)7days of this visit. Baseline and post-
treatment DXA scans should be performed using the same machine and software.
Perform EGD and biopsy . EGD should be completed at or within (±) 7 day s of the scheduled 
visit. If an esophageal dilatation is performed at Visit 4 (treatment failure), subjects will not 
be eligible to participate in the treatment extension study .
For eligible subjects continuing into the treatment extension study , obtain informed 
consent 
for the treatment extension study , dispense investigational product (OBS or placebo) 
according to IWRS randomization and review investigational product dosing compliance.
Following all safet y blood draws, subjects can eat breakfast and take their morning dose of 
investigational product if they  are continui ng in the treatment extension study  or stay ing in clinic 
for PK sampling (to be performed as described in Section 7.1.3.2 above) .
7.1.4 Follow -up Period
The follow -
up period for this protocol is 4 weeks from the last dose of investigational product. 
Subjects who do not enroll in the treatment extension study  or who discontinue prematurel y at 
any time during the study will receive a follow -up 4 phone call at Visit 5 (Week 20) to query for 
SAEs, AEs, and concomitant treatments (Section 7.1.4.1).
7.1.4.1 Safety Follow -up Co ntact (Visit 5): Week 20
Assessments at this time, as outlined in Table 1
-1, will include the following:
Review concomitant medications and procedures.
Perform AE assessments, including specific assessments for signs of glucocorticoid excess. 
Any AE that o ccurs during this visit will be recorded in the CRF and considered a TEAE; all 
Shire CONFIDENTIAL Page 57
Protocol Am endment 2
SHP621 -301 26 Jan 2018
AEs and SAEs that are not resolved at the time of this contact will be followed to closure.
7.1.5 Additional Care of Subjects after the Study
No after care is planned for this study  for those subjects who do not enroll in the treatment 
extension study .
7.2 Study Evaluations and Procedures
The full title and details about who completes the scales used in this study  is included in 
Appendix 1 .
All assessments listed below will be performed b ythe subject and/or a qualified/trained site staff 
as indicated in the assessment description. For subject-completed assessments, trained site staff 
should not assist the subject in completing assessments in such a manner that it would influence 
their responses. Site staff should review the completed assessment to ensure completeness.
If an answer is marked in error, the subject may  correct it b y drawing a single line through the 
error and initialing and dating the change; however, corrections can onl y be m ade to scales b y 
the subject during a study  visit and changes must not be made to subject- completed scales after 
the visit has been completed. Assessments are to be performed according to the schedule shown 
in Table 1-1.
7.2.1 Efficacy
7.2.1.1 Esophagogastroduodenoscopy with Esophageal Biopsy and 
Histopathologic Evaluation
The EGD with endoscopy  score and biops y will be performed during the study  as outlined in 
Table 1-1. 
An EGD with esophageal, gastric and duodenal biopsies will be required for study  participation; 
thepeak eosinophil count per HPF from each esophageal level will be used as a primary  measure 
of efficacy . The qualify ing/baseline EGD with biopsies must be performed by  a ph ysician at the 
investigative site within the 6 weeks prior to placebo lead -in visit (Visit 1). Biopsy  specimens 
must be available to be sent to the central pathology  lab b y at least 2 weeks prior to the placebo 
lead-in visit to allow sufficient time for processing and central review and determination of 
eligibility .
Multiple specimens (at least 2 biopsies from each of 3 levels, 6 specimens total) will be obtained 
from the proximal (3 cm below the cricophary ngeus muscle), mid -esophagus (midpoint between 
the cricophary ngeus muscle and the gastroesophageal junction), and distal (3 cm above th e 
gastroesophageal junction). Biops y tissue will be placed in 3 separate vials (1 vial for each of the 
levels) and sent to the central pathology  laboratory  for processing of tissue into slides. A central 
pathologist will determine histologic eligibility  for study  entry . Peak eosinophil counts of 
≥15/HPF in specimens from 2 or more levels of the esophagus will be a requirement for stud y 
entry , as determined by  a central pathologist. Eosinophil counts, histopathologic features, and 
Shire CONFIDENTIAL Page 58
Protocol Am endment 2
SHP621 -301 26 Jan 2018
gross endoscopic findings will be evaluated and scored for each EGD. Eight histopathologic 
epithelial features (basal lay er hy perplasia, eosinophil density , eosinophil micro -abscesses, 
eosinophil surface lay ering, dilated intercellular spaces, surface epithelial alteration, dy skerat otic 
epithelial cells, lamina propria fibrosis) will be scored on a 4 -
point scale (0=normal, 3=worst) for 
both the severity of the abnormality (ie, grade) and the amount of tissue affected b y the 
abnormality  (ie, stage). 
Endoscopic findings with separate evaluations of the proximal and distal esophagus will be 
recorded with respect to 5 categories b y the endoscopist: 1) exudates or plaques (grade 0 –2); 2) 
fixed esophageal rings (grade 0 –3); 3) edema (grade 0–2); 4) furrows (grade 0–2); and 5) 
strictures (g rade 0 –1). An endoscopy  score for each category  will be calculated and summed for 
each anatomic location (proximal and distal). The maximum endoscopy  score is 10 points for 
each location, and a Total Endoscopy  Score is the sum of the scores for the proxima l and distal 
locations.
In addition, the general appearance of the stomach and duodenum will be assessed by  the 
endoscopist. Biopsies will be taken from the stomach and duodenum for the screening EGD as 
follows: gastric bod y (greater curvature): 2 specimen s, gastric antrum: 2 specimens, and 
duodenum (third part or distal): 2 specimens. Biopsies from the stomach should be submitted in 
one vial; biopsies from the duodenum should be submitted in a separate vial to the central 
pathology  laboratory  for processin g of tissue into slides. I f the pre -treatment biopsy  identifies 
eosinophilia in the stomach and/or duodenum, the subject will be excluded from the study . 
At the Week 16 visit (Visit 4) or at earl y termination (ET), and EGD with esophageal biopsies (at 
least 2biopsies from each of 3 levels [proximal, mid -, and distal]) is required. Endoscopic 
findings will be recorded by  the endoscopist. Biopsies will be sent to the central laboratory  for 
processing. A central pathologist will evaluate the slides. Gastric and duodenal biopsies may  be 
repeated at the discretion of the investigator, but are not required.
7.2.1.2 Dysphagia Symptom Questionnaire
Subjects’ dy sphagia s ymptoms will be evaluated using a DSQ ePRO device ( Appendix 3 ). 
The questionnaire will be completed b y subjects daily for a minimum of 3 weeks during the 
screening period, during the 4- week placebo lead - in period, and during the 12 -week treatment 
period. Each evening before bedtime, subjects will be asked to ind icate if they  experienced 
dysphagia sy mptoms (eg, food passing slowl y or food sticking) during that day. Subject must 
have experienced d ysphagia (response of “y es” to question 2 on DSQ) on a minimum of 4 days 
total and completed the DSQ on ≥70% of day s in any 2consecutive weeks of the screening 
period and in the 2 weeks prior to the baseline visit (Visit 1). Subjects must fill out the DSQ at 
least 4 or more day s during a given week in order to be compliant.
Visit to visit compliance of DSQ completion will also be assessed b y site personnel. Protocol 
deviations will be documented for subjects who fail to complete the DSQ for 4 or more day s in a 
given week.
Shire CONFIDENTIAL Page 59
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Calculations will be performed on daily  ePRO entries during a 2- week interval prior to each 
study  visit during the treatment periods. The DSQ score for the co-primary endpoint and 
secondary  endpoints will be calculated by  summing the scores of responses to questions 2 and 3 
only. Questions 1 and 4 will be excluded from the DSQ score:
DSQ score= (Sum of poi nts from questions 2+3 in the daily  DSQ)×14
Number of diaries reported with non -missing data
The DSQ + pain score for the secondary  endpoints will be calculated b y summing the scores of 
responses to questions 2, 3, and 4. Question 1 will be excluded from the DSQ + pain score.
DSQ + pain score= (Sum of points from questions 2+3+4 in the dail y DSQ)×14
Number of diaries reported with non -missing data
The DSQ pain score for the secondary  endpoint will be calculated b y summing the scores of 
responses to Que stion 4 only .
DSQ pain score=(Sum of points from question 4 in the daily  DSQ)×14
Number of diaries reported with non -missing data
7.2.2 Safety
The name and address of each third -party vendor (eg, clinical laboratory ) used in this study  will 
be maintained in th e investigator’s and sponsor’s files.
7.2.2.1 Medical and Medication History
Medical History
The investigator must record all clinically  or medically  relevant information regardless of how 
much time has elapsed since the date of an y diagnosis. Medical history will be classified as EoE 
or non- EoE by the investigator. The EoE medical history must include an y prior history  of 
esophageal strictures and esophageal dilations.
Medication History
Refer to Section 5.1for full details on collection of prior treatment.
Prior treatment information, including any prior treatments for EoE (eg, dietary, medication, or 
other), must be recorded on the appropriate CRF page.
Shire CONFIDENTIAL Page 60
Protocol Am endment 2
SHP621 -301 26 Jan 2018
7.2.2.2 Physical Examination (Including Height and Weight)
Abnormalities identified at the screening visit (Visit - 1) will be documented in the subject’s 
source documents and on the medical history  CRF. Changes after the screening visit (Visit -1) 
will be captured as AEs on the AE CRF page, as deemed b y the investigator.
Physical examination assessments at each visit should also include specific assessments for signs 
of glucocorticoid excess (eg, moon faces, acne, hirsutism, mood swings, insomnia, and 
depression). Ph ysical examination at the screening visit (Visit -1) will also include Tanner 
Staging Assessments for subjec ts <18 years of age until investigator confirms subject is post -
puberty . 
Height will be collected at the screening visit (Visit -1) and Visit 4 for all subjects. Stadiometers 
will be used to measure height at Visit -1 and Visit 4 for subjects aged 11 -17years, inclusive. 
Statural height will be measured b y trained site staff using a stabilized stadiometer. The same 
stadiometer should be used for the baseline and post-treatment measurements. Standard 
measuring procedures should be followed (eg, removal of s ocks, shoes, and hats). The 
stadiometer must be calibrated at least once dail y, and as feasible, within 4hours of 
measurement. All measurements should be recorded to the nearest 10thof a centimeter (1 mm) ;
measurements for adolescent subjects (11-17 years of age, inclusive ), should be measured in 
triplicate
.Please refer to the study  manual for additional details.
Weight measurements for adolescent subjects (11 -17 years, inclusive) should be measured in 
duplicate.
7.2.2.3 Adverse Event Collection
At each stud y visit, subjects will be questioned in a general way  to ascertain if AEs have 
occurred since the previous visit (eg, “Have you had an y health problems since your last visit?”). 
AEs are collected from the time informed consent is signed. (Please refer to Secti on8, Adverse 
and Serious Adverse Events Assessment.)
AE assessments at each visit should also include specific assessments for signs of glucocorticoid 
excess (eg, moon facies, acne, hirsutism, mood swings, insomnia, and depression).
7.2.2.4 Vital Signs
Vital sign
s will be conducted after the subject has been supine for at least 5 minutes immediately  
prior to the assessment and will include blood pressure (s ystolic and diastolic), heart rate, 
respirations, and temperature. Blood pressure should be determined b y cuff (using the same 
method, the same arm, and in the same position throughout the study ). Any  clinically  significant 
deviations from baseline (Visit 1) vital signs that are deemed clinicall y significant in the opinion 
of the investigator areto be recorded a s an AE.
Shire CONFIDENTIAL Page 61
Protocol Am endment 2
SHP621 -301 26 Jan 2018
7.2.2.5 Clinical Laboratory Evaluations
All clinical laboratory  assay s will be performed according to the laboratory ’s normal procedures. 
All subjects must fast overnight prior to collection of clinical laboratory  tests.
Reference ranges are to be supplie d by the laboratory  and will be used to assess the clinical 
laboratory  data for clinical significance and out-of-range pathological changes. The investigator 
should assess out -
of-range clinical laboratory  values for clinical significance, indicating if the
value(s) is/are not clinically  significant or clinically  significant. Abnormal clinical laboratory  
values, which are unexpected or not explained by  the subject’s clinical condition, may , at the 
discretion of the investigator or sponsor, be repeated as soo n as possible until confirmed, 
explained, or resolved.
The following clinical laboratory  assessments will be performed: 
Biochemistry
alkaline phosphatase
aspartate aminotransferase
alanine aminotransferase
total bilirubin
total protein
albumin
glucoseblood urea nitrogen
creatinine
sodium
potassium
chloride
calcium
carbon dioxide
Hematology
hemoglobin
hematocrit
mean corpuscular hemoglobin
mean corpuscular hemoglobin concentration
mean corpuscular volume
erythrocyte count
leukocyte countneutrophils
lymphocytes
monocytes
eosinophils
basophils
platelet count
Urinalysis
glucose
protein
specific gravity
pH
nitritebilirubin
ketones
hemoglobin
urobilinogen
leukocyte esterase
Shire CONFIDENTIAL Page 62
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Other tests
serum pregnancy
urine pregnancymorning cortisol (6:00- 9:00 A M collection)
ACTH stimulation testing
ACTH stimulation testing will be performed b y measuring the levels of cortisol in the blood 
following the injection of a sy nthetic form of ACTH. The ty pe of s ynthetic and route of 
administration will be per local la b discretion. Blood samples will be collected just prior to and 
approximately  30 and 60 minutes following the injection. 
In the event of clinically  significant abnormal laboratory  test results, follow- up laboratory  tests 
may be conducted. All subjects wit h an abnormal ACTH stimulation test or urinary  or serum 
glucose level must be followed closel y until resolution. For subjects who discontinue from the 
treatment period at an y time and have an abnormal ACTH stimulation test at the ETvisit, 
subjects will be scheduled for repeat testing approximately  6 weeks post last dose of 
investigational product to ensure that ACTH levels have normalized. Any clinically  significant 
abnormalities noted in the laboratory  tests will be discussed with the medical monitor.
7.2.2.6 Pregnancy Test 
A serum β -hCG pregnancy  test is performed on all female subjects at the screening visit (Visit -
1) and the final treatment evaluation visit (Visit 4) or ET visit. A urine pregnancy  test is 
performed on all female subjects at the placebo lead -in visit (Visit 0), baseline visit 
(Visit 1), Visit 2, and Visit 3 or if pregnancy  is suspected.
7.2.2.7 Dual -energy X -ray Absorptiometry for Bone Mineral Density
Dual -energy  X-ray absorptiometry (also referred to as DEXA) scans for determination of BMD 
and body  composition will be performed in subjects aged 11 -17 years, inclusive, as outlined in 
Table 1-1.
The sites for DXA measurement will be the lumber spine (L1 -L4 preferred) and total body  less 
head ( Bachrach and Sills, 2011 ; Gordon et al., 2008 ; ISCD, 2014). The same DXA machine and 
software should be used for the baseline and post -treatment scans. The DXA manufacturer, 
model, and software version should be recorde d in the CRF.
7.2.3 Other Assessments
7.2.3.1 Health -related Quality -of-life Assessment
EuroQol -5 Dimensions 3 -level Questionnaire 
The EuroQol -5 Dimensions 3 -level (EQ -
5D-3L; for subjects ≥18 y ears) and the EuroQol -5 
Dimensions Youth (EQ -5D- Y; for subjects 11- 17 years of age, inclusive) will be performed 
during the stud y as outlined in Table 1
-1.
Shire CONFIDENTIAL Page 63
Protocol Am endment 2
SHP621 -301 26 Jan 2018
The EQ -5D- 3L is a standardized measure of health status for use in adult populations that was 
developed b y the EuroQol Group in order to provide a simple, generic measure of he alth for 
clinical and economic appraisal ( EuroQol, 1990 ). The EQ -5D- 3L provides a simple descriptive 
profile and a single index value for health status that can be used in the clinical and economic 
evaluation of healthcare as well as in population health survey s. It consists of a 5 -item 
descriptive s ystem that measures 5 dimensions of health, including mobility, self- care, usual 
activities, pain/di scomfort, and anxiety /depression. Each dimension is represented by  a single 
item with 3 levels of responses. The EQ -5D-3L will be completed by  the subject. The EQ- 5D-3L 
should take the subject a few minutes to complete.
The EQ -5D- Y is a self -report version of the EQ -5D that was developed by  the EuroQol Group 
for use in younger populations ( Wille et al., 2010 ). The EQ -5D-Y provides a simple descripti ve 
profile and a single index value for health status that can be used in the clinical and economic 
evaluation of healthcare as well as in population health survey s. It consists of a 5 -item 
descriptive s ystem that measures 5 dimensions of health, including mobility , looking after 
myself, doing usual activities, having pain or discomfort, and feeling worried, sad, or unhapp y. 
Each dimension is represented by  a single item with 3 levels of responses. The EQ
-5D- Y will be 
completed b y the subject and should tak e a few minutes to complete.
Pediatric Quality of Life –EoE Questionnaire
The PedsQL -EoE questionnaire will be completed by  subjects 11 -17 years of age, inclusive, and 
their parent or legal guardian, as outlined in Table 1 -1.
The PedsQL -EoE is a modular, disease -specific instrument designed to measure HRQoL in 
children and adolescents (2 -18 years of age) with EoE ( Franciosi et al., 2013
;PROQOLID, 
2015). The PedsQL - EoE module consists of 35 items for children and teenagers encompassing 
the following 7 scales: 1) Symptoms I (6 items; chest/throat/stomach pain and nausea/vomiting ), 
2) Sy mptoms II (4 items; trouble swallowing), 3) Treatment (5 items; treatment barriers), 4) 
Worry  (6 items; worries about treatment and disease), 5) Communication (5 items; 
communication with others about EoE), 6) Food and Eating (4 items; food and eat ing allergies 
and limitations), and 7) Food Feelings (3 items; emotions associated with food allergies). The 
PedsQL -EoE should take the subject and parent approximately  10minutes to complete. 
Adult Eosinophilic Esophagitis Quality of Life Questionnaire 
The EoE -QoL-A will be performed in subjects ≥18 y ears of age as outlined in Table 1-1.
The EoE -QoL-A is a disease -specific measure of HRQoL
 in adult patients ( ≥18 y ears of age) 
with EoE ( Taft et al., 2011). The EoE -QoL-A consists of a 30 -item test with 5 subscales: 
eating/diet impact, social impact, emotional impact, disease anxiety , and choking anxiety
. The 
EoE-QoL-A will be completed by  the subject and should take the subject approximately  
15 minutes to complete.
Shire CONFIDENTIAL Page 64
Protocol Am endment 2
SHP621 -301 26 Jan 2018
7.2.3.2 Severity of Disease Assessments
Patient Global Impression of Severity 
The PGI -S will be performed in all subjects as outlined in Table 1-1.
The PGI -S is a global index ( Appendix 4 ) that c an be used to rate the severity of a specific 
condition -in this case, dysphagia in EoE. Subjects will be asked to rate the severit y of their 
dysphagia over the last 7 days using a 5- point scale.
7.2.4 Clinical Pharmacology Assessments
Blood samples will be col lected f rom adult subjects ( ≥18 y ears of age) as outlined in Table 1-1
to measure plasma concentrations of budesonide. Subjects who do not participate in 
pharmacokinetic sampling will not be discontinued from the study , and lack of participation will 
not be a cons idered protocol deviation. 
Actual pharmacokinetic blood sample collection times vs time of dosing will be monitored. The 
sponsor’s expectation is that the investigator will ensure that every  effort will be made to collect 
all pharmacokinetic blood samples at the precise protocol scheduled time. Pharmacokinetic 
blood collection must not deviate from the nominal collection time set forth in the protocol by 
more than ± 5 minutes for samples drawn within 4 hours post -dose or b y more than ± 15 minutes 
for sampl es drawn after 4 hours post -dose. Samples drawn outside these parameters will be 
considered a protocol deviation.
Blood samples (4 mL) for pharmacokinetic anal ysis will be drawn b y direct venipuncture into 
K2EDTA tubes, capped and mixed by  inversion (×3), 
and chilled immediately  on crushed ice. 
The actual blood collection time will be recorded in the subject’s source documents and on the 
appropriate CRF page (24 -hour format). After apply ing a tourniquet, venous blood will be drawn 
with a disposable needle. If a catheter is used, the first milliliter of blood on each sampling 
occasion will be discarded. Saline can be used to keep catheters patent.
Within 15 minutes following each sample collection, the blood tubes will be centrifuged at 
approximately  1500 g (15minutes, 4°C). The separated plasma will be decanted into 
appropriatel y labeled primary and backup polypropylene tubes via a plastic pipette. All samples 
will be stored nominally  at -20°C, and the freezer temperature will be controlled, monitored, and 
recorded during the storage period until the samples are shipped to the designated bioanal ytical 
laboratory  for anal ysis.
For additional information detailing sample handling, storage, and shipment, see Appendix 5 .
Shire CONFIDENTIAL Page 65
Protocol Am endment 2
SHP621 -301 26 Jan 2018
7.2.5 Volume of Blood to Be Drawn from Each Subj ect
Table 7-1: Approximate Volume of Blood to Be Drawn from Each Subject
AssessmentSample Volume 
(mL)Number of 
SamplesApproxim ate Total 
Volume (mL)
Pharm acokinetic samplesa5 9 45
Safety Biochemistry and -hCGb6 6 36
ACTH 2 4 8
Cortisol 2 4 8
Hem atology 2 6 12
Total mL 109
ACTH=adrenocorticotropic hormone; β -hCG=beta -human chorionic gonadotropin
aIf a catheter is used, the first mL is to be discarded; then take 4 mL into appropriate tube for pha rmacokinetic 
sample. A total of 5 mL of blood draw n has been used in determination of sample volume.
b-hCG testing is for females only.
During this stud y, it is expected that approximately 109 mL of blood will be drawn from all 
subjects, regardless of se x.
Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood 
to be drawn may  vary  according to the instructions provided by  the manufacturer or laboratory  
for an individual assessment; however, the total volume drawn ove r the course of the stud y 
should be approximately  109 mL. When more than 1 blood assessment is to be done at the time 
point/period, if they  require the same type of tube, the assessments may  be combined.
Shire CONFIDENTIAL Page 66
Protocol Am endment 2
SHP621 -301 26 Jan 2018
8. ADVERSE AND SERIOUS ADVERSE EVENTS ASSES SMENT
8.1 Defini tion of Adverse Events, Period of Observation, Recording of Adverse Events
An AEis any  untoward medical occurrence in a clinical investigation subject administered a 
pharmaceutical product and that does not necessarily have a causal relationship with this
treatment. An AE can therefore be an y unfavorable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (inv estigational) product (ICH 
Guidance E2A 1995).
All AEs are collected from the time the informed consent is signed until the defined follow -up 
period stated in Section 7.1.4 . This includes events occurring during the screening phase of the 
study , regardless of whether or not investigational product is administered. Where possible, a 
diagnosis rather than a list of sy mptoms should be recorded. If a diagnosis has not been made, 
then each s ymptom should be listed individually . All AEs should be captured on the appropriate 
AE pages in the CRF and in source documents. In addition to untoward AEs, unexpected 
benefits outside the investigational product indication should also be captured on the AE CRF.
All AEs must be followed to closure (the subject’s health has returned to his/her baseline status 
or all variables have returned to normal), regardless of whether the subject is still participating in 
the study . Closure indicates that an outcome is reached, stabilization achieved (the investigator 
does not expect any further improvement or worsening of the event), or the event is otherwise 
explained. When appropriate, medical tests and examinations are performed so that resolution of 
event(s) can be documented.
8.1.1 Severity Categorization
The severit y of AEs must be record ed during the course of the event including the start and stop 
dates for each change in severity. An event that changes in severity should be captured as a new 
event. Worsening of pretreatment events, after initiation of investigational product, must be 
recorded as new AEs (for example, if a subject experiences mild intermittent dy spepsia prior to 
dosing of investigational product, but the dy spepsia becomes severe and more frequent after first 
dose of investigational product has been administered, a new AE of severe dy spepsia [with the 
appropriate date of onset] is recorded on the appropriate CRF).
The medical assessment of severit y is determined by using the following definitions:
Mild: A type of AE that is usually  transient and may require only minimal treatment or 
therapeutic intervention. The event does not generall y interfere with usual 
activities of daily  living.
Moderate: A type of AE that is usually  alleviated with specific therapeutic intervention. The 
event interferes with usual activities of daily  living, causing discomfort but poses 
no significant or permanent risk of harm to the research subject.
Shire CONFIDENTIAL Page 67
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Severe: A type of AE that interrupts usual activities of daily  living, or significantly affects 
clinical status, or may  require intensive therapeutic int ervention.
8.1.2 Relationship Categorization
A phy sician/investigator must make the assessment of relationship to investigational product for 
each AE. The investigator should decide whether, in his or her medical judgment, there is a 
reasonable possibility  that the event may  have been caused b y the investigational product. If 
there is no valid reason for suggesting a relationship, then the AE should be classified as “not 
related.” Otherwise, if there is an y valid reason, even if undetermined or untested, for susp ecting 
a possible cause -and-effect relationship between the investigational product and the occurrence 
of the AE, then the AE should be considered “related” based on the definitions in Table 8-1. The 
causality  assessment must be documented in the source do cument.
Table 8-1: Adverse Event Relatedness
Term Relationship Definition
Not Related Unrelated to study drug.
Possibly RelatedA clinical event or laboratory abnormality with a reasonable time sequence to 
administration of study drug, but which could also be explained by  concurrent disease 
or other drugs or chemicals.
Probably RelatedA clinical event or laboratory abnormality with a reasonable time sequence to 
administration of study drug, unlikely to be attributable to concurrent disease or other 
drugs and chemicals and which follows a clinically reasonable response on de -
challenge. The association of the clinical event or laboratory abnorm ality must also 
have some biologic plausibility, at least on theor etical grounds.
Definitely RelatedThe event follows a reasonable temporal sequence from administration of the study 
drug, follows a known or suspected response pattern to the study drug, is confirmed 
by improvement upon stopping the study drug (dechallen ge), and reappears upon 
repeated exposure (rechallenge). Note that this is not to be construed as requiring re-
exposure of the patient to study drug; however, the determination of definitely related 
can only be used when recurrence of event is observed.
8.1.3 Outcome Categorization
The outcome of AEs must be recorded during the course of the stud y on the CRF. Outcomes are 
as follows:
 Fatal
 Not Recovered/Not Resolved
 Recovered/Resolved
 Recovered/Resolved With Sequelae
 Recovering/Resolving
 Unknown
Shire CONFIDENTIAL Page 68
Protocol Am endment 2
SHP621 -301 26 Jan 2018
8.1.4 Symptoms of th e Disease under Study
Symptoms of the disease under study  should not be classed as AEs as long as they  are within the 
normal day -to-day fluctuation or expected progression of the disease and are part of the efficacy  
data to be collected in the study ; howev er, significant worsening of the s ymptoms should be 
recorded as an AE.
8.1.5 Clinical Laboratory and Other Safety Evaluations
A change in the value of a clinical laboratory  or vital sign assessment can represent an AE if the 
change is clinicall y relevant or if, during treatment with the investigational product, a shift of a 
parameter is observed from a normal value to an abnormal value, or a further worsening of an 
alread y abnormal value. When evaluating such changes, the extent of deviation from the 
reference ra nge, the duration until return to the reference range, either while continuing treatment 
or after the end of treatment with the investigational product, and the range of variation of the 
respective parameter within its reference range, must be taken into c onsideration.
If, at the end of the treatment phase, there are abnormal clinical laboratory  or vital sign values 
which were not present at the pretreatment value observed closest to the start of study  treatment, 
further investigations should be performed u ntil the values return to within the reference range or 
until a plausible explanation (eg, concomitant disease) is found for the abnormal values.
The investigator should decide, based on the above criteria and the clinical condition of a 
subject, whether a change in a clinical laboratory  or vital sign parameter is clinically  significant 
and therefore represents an AE.
8.1.6 Pregnancy
All pregnancies are to be reported from the time informed consent is signed until the defined 
follow -up period stated in Section 7.1.4.
Any report of pregnancy  for any  female study  participant must be reported within 24 hours to the 
Shire Global GDS Department using the Shire Investigational and Marketed Products Pregnancy  
Report Form. A cop y of the Shire Investigational and Marketed Products Pregnancy  Report 
Form (and an y applicable follow -
up reports) must also be sent to the CRO/Shire medical monitor 
using the details specified in the emergency  contact information section of the protocol. The 
pregnant female stud y participant must b e withdrawn from the stud y.
Every  effort should be made to gather information regarding the pregnancy  outcome and 
condition of the infant. It is the responsibility  of the investigator to obtain this information within 
30 calendar day s after the initial not ification and approximately  30 calendar day s postpartum.
Pregnancy  complications such as spontaneous abortion/miscarriage or congenital abnormality  
are considered SAEs and must be reported using the Shire Clinical Study  Adverse Event Form 
for SAEs and Non -serious AEs as Required by  Protocol. Note: An elective abortion is not 
considered an SAE.
Shire CONFIDENTIAL Page 69
Protocol Am endment 2
SHP621 -301 26 Jan 2018
In addition to the above, if the investigator determines that the pregnancy  meets serious criteria, 
it must be reported as an SAE using the Shire Clinical Study  Adver se Event Form for SAEs and 
Non-serious AEs as Required by Protocol as well as the Shire Investigational and Marketed 
Products Pregnancy  Report Form. The test date of the first positive serum/urine -HCG test or 
ultrasound result will determine the pregnanc y onset date.
8.1.7 Abuse, Misuse, Overdose, and Medication Error
Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor 
according to the SAE reporting procedure whether or not they  result in an AE/SAE as described 
in Sec tion 8.2. Note: The 24 -hour reporting requirement for SAEs does not apply  to reports of 
abuse, misuse, overdose, or medication errors unless these result in an SAE.
The categories below are not mutually  exclusive; the event can meet more than 1 category .
 Abuse –
Persistent or sporadic intentional intake of investigational product when used for a 
non-medical purpose (eg, to alter one’s state of consciousness or get high) in a manner that 
may be detrimental to the individual and/or society
 Misuse –Intentiona l use of investigational product other than as directed or indicated at 
any dose (Note: this includes a situation where the investigational product is not used as 
directed at the dose prescribed by  the protocol)
 Overdose –Intentional or unintentional intake of a dose of an investigational product 
exceeding a pre -specified total daily  dose of 4 mg of the product.
 Medication Error –An error made in prescribing, dispensing, administration, and/or use 
of an investigational product. For studies, medication err
ors are reportable to the sponsor 
only as defined below.
Cases of subjects missing doses of the investigational product are not considered reportable as 
medication errors.
Medication errors should be collected/reported for all products under investigation.
The administration and/or use of the unassigned treatment is/are alway s reportable as a 
medication error.
The administration and/or use of an expired investigational product should be considered as a 
reportable medication error.
All investigational produc t provided to pediatric subjects should be supervised by  the 
parent/legall y autho rized representative/caregiver.
Shire CONFIDENTIAL Page 70
Protocol Am endment 2
SHP621 -301 26 Jan 2018
8.2 Serious Adverse Event Procedures
8.2.1 Reference Safety Information
The reference for safet y information for this study  is the investigator brochure, which the 
sponsor has provided under separate cover to all investigators.
8.2.2 Reporting Procedures
All initial and follow -up SAE reports must be reported by  the investigator to the Shire Global 
GDS Department andthe CRO medical monitor within 24 hours of the first awareness of the 
event. Note: The 24 -hour reporting requirement for SAEs does not apply to reports of abuse, 
misuse, overdose, or medication errors (see Section 8.1.7) unless they  result in an SAE.
The investigator must complete, sign, and date the Shire Clinical Study  Adverse Event Form for 
SAEs and Non
-serious AEs as Required b y Protocol and verify the accuracy of the information 
recorded on the form with the corresponding source documents (Note: Source documents are not 
to be sent unless requested) and fax or e -mail the form to the Shire Global GDS Department. A 
copy  of the Shire Clinical Study  Adverse Event Form for SAEs and Non- serious AEs as 
Required b y Protocol (and any applicable follow -up reports) must also be sent to the CRO 
medical monitor using the details specified in the emergency  contact information section of the 
protocol.
8.2.3 Serious Adverse Event Definition
A SAE is any  untoward medical occurrence (whether considered to be related to investigational 
product or not) that at any dose:
 Results in death
 Is life-threatening. Note: The term 
“life-threatening” in the definition of “serious” refers to 
an event in which the subject was at risk of death at the time of the event; it does not refer 
to an event which h ypothetically might have caused d eath if it was more severe.
 Requires inpatient hospitalization or prolongation of existing hospitalization. Note: 
Hospitalizations, which are the result of elective or previously  scheduled surgery  for 
preexisting conditions, which have not worsened after i nitiation of treatment, should not be 
classified as SAEs. For example, an admission for a previousl y scheduled ventral hernia 
repair would not be classified as an SAE; however, complication(s) resulting from a 
hospitalization for an elective or previously  scheduled surgery  that meet(s) serious criteria 
must be reported as SAE(s).
 Results in persistent or significant disability /incapacity
 Is a congenital abnormality /birth defect
 Is an important medical event. Note: Important medical events that may  not resul t in death, 
be life-threatening, or require hospitalization may  be considered an SAE when, based upon 
appropriate medical judgment, they  may  jeopardize the subject and may  require medical or 
surgical intervention to prevent 1 of the outcomes listed in thisdefinition. Examples of 
Shire CONFIDENTIAL Page 71
Protocol Am endment 2
SHP621 -301 26 Jan 2018
such medical events include allergic bronchospasm requiring intensive treatment in an 
emergency  room or at home; blood dy scrasias or convulsions that do not result in inpatient 
hospitalization; or the development of drug dependency or drug abuse.
8.2.4 Serious Adverse Event Collection Time Frame
All SAEs (regardless of relationship to study ) are collected from the time the subject signs the 
informed consent until the defined follow- up period stated in Section 7.1.4 and must be reported 
tothe Shire G DSDepartment andthe medical monitor within 24 hours of th e first awareness of 
the event.
In addition, any SAE(s) considered “related” to the investigational product and discovered by  the 
investigator at an y interval after the study has comple ted must be reported to the Shire G DS
Department within 24 hours of the first awareness of the event.
8.2.5 Serious Adverse Event Onset and Resolution Dates
The onset date of the SAE is defined as the date the event meets serious criteria. The resolution 
date is the date the event no longer meets serious criteria, the date the s ymptoms resolve, or the 
event is considered chronic. I n the case of hospitalizations, the hospital admission and discharge 
dates are considered the onset and resolution dates, respectivel y.
In addition, any  signs or sy mptoms experienced by  the subject after signing the informed consent 
form, leading up to the onset date of the SAE, or following the resolution date of the SAE must 
be recorded as an AE, if appropriate.
8.2.6 Fatal Outcome
Any SAE t hat results in the subject’s death (ie, the SAE was noted as the primary  cause of death) 
must have “fatal” checked as an outcome with the date of death recorded as the resolution date. 
For all other events ongoing at the time of death that did not contribu te to the subject’s death, the 
outcome should be considered as not resolved, without a resolution date recorded.
For an y SAE that results in the subject’s death or any ongoing events at the time of death, the 
action taken with the investigational product s hould be recorded as “dose not changed” or “not 
applicable” (if the subject never received investigational product).
8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting
Thesponsor and the clinical CRO are responsible for no tifying the relevant regulatory  
authorities/US central Institutional Review Boards (I RBs) of related, unexpected SAEs.
In addition, the sponsor and the clinical CRO are responsible for notify ing active sites of all 
related, unexpected SAEs occurring durin g all interventional studies across the SHP621 
program.
Shire CONFIDENTIAL Page 72
Protocol Am endment 2
SHP621 -301 26 Jan 2018
The investigator is responsible for notify ing the local IRB, local ethics committee (EC), or the 
relevant local regulatory  authority  of all SAEs that occur at his or her site as required.
Shire CONFIDENTIAL Page 73
Protocol Am endment 2
SHP621 -301 26 Jan 2018
9. DATA MANAGE MENT AND STATISTICAL METHODS
9.1 Data Collection
The investigators’ authorized site personnel must enter the information required by  the protocol 
on the CRF. A study  monitor will visit each site in accordance with the monitoring plan and 
review the CRF data ag ainst the source data for completeness and accuracy .Discrepancies 
between source data and data entered on the CRF will be addressed b y qualified site personnel. 
When a data discrepancy warrants correction, the correction will be made by authorized site 
personnel. Data collection procedures will be discussed with the site at the site initiation visit 
and/or at the investigator’s meeting. Once a subject is randomized, it is expected that site 
personnel will complete the CRF entry  within approximately  3 business days of the subject’s 
visit.
9.2 Clinical Data Management
Data are to be entered into a clinical database as specified in the CRO’s data management plan. 
Quality  control and data validation procedures are applied to ensure the validity  and accuracy  of 
the clinical database.
Data are to be reviewed and checked for omissions, errors, and values requiring further 
clarification using computerized and manual procedures. Data queries requiring clarification are 
to be communicated to the site for resolution. Only authorized personnel will make corrections to 
the clinical database, and all corrections are documented in an auditable manner.
9.3 Data Handling Considerations
Data that may  potentiall y unblind the treatment assignment (ie, investigational product serum 
conce ntrations, treatment allocation, and investigational product preparation/accountability  data) 
will be handled with special care during the data cleaning and review process. These data will be 
handled in such a way  that, prior to unblinding, any  data that may  unblind study  team personnel 
will be presented as blinded information or otherwise will not be made available. If applicable, 
unblinded data may  be made available to quality  assurance representatives for the purposes of 
conducting independent drug audits. 
9.4 Statistical Analysis Process
The study  will be anal yzed by  the sponsor or its agent. All statistical anal yses will be performed 
using SAS®(SAS Institute, Cary , NC, USA) version 9.1 or higher.
The statistical anal ysis plan (SAP) will provide the statis tical methods and definitions for the 
analysis of the efficacy  and safet y data, as well as describe the approaches to be taken for 
summarizing other study  information such as subject disposition, demographics and baseline 
characteristics, investigational p roduct exposure, and prior and concomitant medications. The 
SAP will also include a description of how missing, unused and spurious data will be addressed.
Shire CONFIDENTIAL Page 74
Protocol Am endment 2
SHP621 -301 26 Jan 2018
In addition to a final SAP for the final anal ysis, a separate interim SAP for the interim anal ysis 
will be finalized prior to unblinding and performing the anal ysis. The SAP for the final anal ysis 
will be finalized prior to final database lock and performing analy sis (ie, unblinding) to preserve 
the integrit y of the statistical anal ysis and study  conclusions.
9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee
A planned interim anal ysis for each of the co-primary endpoints will take place after 50% of all 
randomized subjects have either completed the study  or prematurely  withdrawn from the study , 
whichever comes first. The purpose of the unblinded interim anal ysis is to reassess the 
appropriateness of assumptions used for each of co-primary efficacy  endpoints when the study  
was designed. The reassessment of the sample size will utilize the conditional power approach 
under certain conditions that do not inflate the ty pe I error ( Mehta and Pocock, 2011). The 
planned interim anal ysis will be conducted by  an external independent statistical (EI S) group; the 
individuals involved in the day -to-day conduct of the trial will not be involved in the interim 
analysis or have access to the results of the interim analy sis. The Sponsor will on ly be notified by  
the EI S group if any  recommendation of increasing the sample size is needed from the 
conditional power; this will be detailed in the prespecified interim SAP including a potential 
maximum sample size to be increased if deemed necessary . 
A very  minimal fraction of alpha (0.0001) will be spent at the interim anal ysis as the trial will 
not stop due to the interim results. The final anal ysis will use 4.99% for each of the co-primary
endpoints in order to preserve an overall ty pe I error at 5% level.
9.6 Sample Size Calculation and Power Considerations
Based on at least a 30 -percentage -point reduction in DSQ score, there is an expected difference 
between treatment response proportions of 69% and 45% in the OBS 2 mg twice dail y (qAM, pc, 
and hs) and placebo groups, respectivel y. The original protocol noted that a total of 228 subjects 
(152 subjects randomized to OBS and 76 subjects randomized to placebo) are required to achieve 
90% power at the significance level of 0.0499 (2 -sided) using a 2 -group c hi-square test with 
unequal allocation 2:1 to treatment groups (OBS 2 mg twice daily  and placebo). With the 
specified number of subjects per treatment group, the study  will be powered at 99% assuming 
histological response proportions of 40% and 3% in the O BS 2 mg twice daily  and placebo 
groups, respectively . The overall study  power for the co-primary endpoints was estimated to be 
at least 85%. Therefore, approximately  228 (approximately  152:76 OBS and placebo subjects, 
respectivel y) were to be randomized in the study  to allow for a loss of approximately  5% of 
subjects due to dropouts or invalid data. Expected response and dropout rates are based on 
observation from the Phase 2 study  (MPI 101- 06).
In this protocol amendment, in order to ensure that a sufficie nt number of subjects will complete 
this study  and enroll in the treatment extension study , up to approximately  420 subjects will be 
enrolled in the placebo lead
-in period to allow for approximately  306 subjects to be randomized 
into the double blind perio d of this study  (approximately  204:102 OBS and placebo subjects, 
respectivel y). With a total of 306 randomized subjects in this study , using the same assumptions 
Shire CONFIDENTIAL Page 75
Protocol Am endment 2
SHP621 -301 26 Jan 2018
for the co-primary endpoints and the dropout rate, the overall study  power for the co -primary
endpoints is estimated to be at least 95%.
9.7 Study Population
The safety set will include all subjects who receive at least 1 dose of any  double -blind 
investigational product.
The intent -to-treat (ITT) set will include all randomized subjects. Subjects will be analy zed 
according to their assigned treatment, regardless of the treatment actuall y received.
The full analysis set (FAS) will include all randomized subjects who received at least 1 dose of 
a double -blind investigational product and have both an evaluable post -baseline biopsy  in the 
treatment period (ie, peak eosinophil count is reported for at least 2 esophageal levels) and a 
post-baseline DSQ score.
The per
-protocol (PP) set will include all subjects in the FAS excluding subjects with protocol 
viola tions. The PP set will be identified prior to unblinding the treatment assignments b y a team 
consisting of, at a minimum, a phy sician and a statistician from Shire.
The pharmacokinetic set will include all subjects in the safet y set for whom the primary  
pharmacokinetic data are considered sufficient and interpretable.
9.8 Efficacy Analyses
The primary , key  secondary  and secondary  efficacy  anal yses will be performed on the ITT set 
and presented b y treatment group.
Data collected at the baseline visit (Visit 1) w ill be used as the baseline for all efficacy  analy ses.
9.8.1
Primary Efficacy Endpoints
The co-primary efficacy  endpoints are the following:
Histologic response, defined as a peak eosinophil count of ≤6/HPF across all available 
esophageal levels at the final tre atment period evaluation (Visit 4)
Dysphagia symptom response, defined as ≥30% reduction in the DSQ combined score 
(questions 2+3) from baseline to the final treatment period evaluation (Visit 4)
The co-primary efficacy  endpoints will be analy zed based on the ITT set. Each of the co-primary
efficacy  endpoints is a binary  response (ie, responders vs non -responders); the endpoint will be 
analyzed using the Cochran -Mantel -Haenszel (CMH) test adjusting for age group (either 
<18years or ≥18 years) and diet res triction for EoE or other health -related conditions (no diet 
restriction or an y diet restriction). The adjusted odds ratio of being a responder on each of the co-
primary endpoints for the OBS 2 mg twice dail y group vs placebo group and associated 95% 
Shire CONFIDENTIAL Page 76
Protocol Am endment 2
SHP621 -301 26 Jan 2018
confi dence interval (CI) will be provided. Subjects who withdraw without providing efficacy  
data at the final treatment period evaluation (Visit 4, Week 16) will be classified as non-
responders in the primary  efficacy  anal ysis.
Additionally , the proportion of r esponders based on each of the co-primary endpoints for each 
treatment group will be summarized, and their respective 95% CI will be reported. The 
difference in the proportion of responders between the 2 treatment groups and the corresponding 
95% CI  will a lso be summarized.
The following sensitivity and supportive anal yses will be performed for the co-primary to 
evaluate the robustness of the results fro m the primary  anal ysis methods:
Each of the co-primary efficacy  endpoints will be analyzed using a logist ic regression 
with the effects of treatment group, age group (either <18 years or ≥18 years) and diet 
restriction for EoE or other health-related conditions (no diet restriction or any diet 
restriction). The odds ratio of being a responder on each of the co-primary  endpoints for 
the OBS 2 mg twice daily  group vs placebo group and associated 95% CI will be 
estimated from the final model. Subjects who withdraw without providing efficacy  data 
at the final treatment period evaluation (Visit 4, Week 16) will be classified as non-
responders in the primary  efficacy  anal ysis.
Analy ses wil l be repeated using the FAS and the PP set.
Analy ses will be repeated by considering subjects who withdraw without providing 
efficacy  data at the final treatment period evaluation (Visit 4) and will be classified as 
responders.
9.8.1.1 Missing Data Imputation
Meth od 1: Distribution -based Imputation
The subjects with missing 
co-primary efficacy  endpoints will be assigned randomly  according to 
the distribution of responders with available data for each of the co-primary endpoints (ie, those 
with non- missing data) acr oss the 2 treatment groups by  strata (see Table 9- 1). 
Table 9-1: Percentage of Responders for All Available Data (ie, Non -missing Data) by 
Strata
Strata No Yes
<18 years X0% X1%
≥18 years Y0% Y1%
For instance, if there are N subjects with missing data in strata 1 (age <18 years), then X0%*N 
subjects will be randomly assigned as non -responders and X1%*N subjects will be randomly  
assigned as responders.
Shire CONFIDENTIAL Page 77
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Conversel y, if there are M subjects with missing data in strata 2 (age ≥18 y ears), the Y0%*M 
subjects will be randomly assigned as non -responders and Y1%* Msubjects will be randomly  
assigned as responders.
Method 2: Multiple Imputations
Multiple imputation (MI) methods will utilize the SAS procedures PROC MI  and PROC 
MIANALYZE. The MI procedure will involve fitting a logistic regression model with the binary  
outcome (responders vs non- responders) as the dependent variable and the age group and the 
treatment group as the independent variables. The MI  procedure will generate 10 version datasets 
with binary  outcome imputed from the subjects with complete data. Once the missing values are 
imputed and each dataset is created, the results will be appropriately  pooled across the multiply  
imputed estimated regression coefficients and their standard errors using PROC MI ANALYZE.
Other sensitivity  analy ses will be explored, and details will be provided in the SAP.
9.8.2 Secondary Efficacy Endpoints
9.8.2.1 Key Secondary Efficacy Endpoint
The key  secondary  efficacy  endpoint is defined as the change in DSQ combined score (questions 
2+3) from baseline to the final treatment period evaluation (Visit 4). The change from baseline 
DSQ score at the final treatment period evaluation (Visit 4) will be anal yzed using an analysis of 
covariance (ANCOVA) model with treatment group and age group as factors and the baseline 
DSQ score as a continuous covariate.
The additional secondary efficacy  endpoints are the following:
Change in total endoscopy  score, as measured by the ERE FS classification, from baseline to 
the final treatment period evaluation (Visit 4)
Peak eosinophil count <15/HPF across all available esophagus levels at the final treatment 
period evaluation (Visit 4)
Peak eosinophil count ≤1/HPF across all available esophagus levels at the final treatment 
period evaluation (Visit 4)
Change from baseline in the peak eosinophil count to the final treatment period evaluation 
(Visit 4) for each available esophageal level ( proximal, mid -, and distal)
Change from baseline in the histopathologic epithelial features combined total score (grade 
and stage) to the final treatment period evaluation (Visit 4)
Dysphagia symptom response (binary  response), defined as a≥50% reduction in the DSQ 
combined score (questions 2+3), from baseline to the final treatment period evaluation (Visit 
4)
Change from baseline in the DSQ combined score (questions 2+3) over time including post 
baseline visits
Shire CONFIDENTIAL Page 78
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Cumulative distribution function curves for the change and the percent change in the DSQ 
score from baseline to the final treatment period evaluation (Visit 4)
Overall binary  response I, defined as a reduction in the DSQ score of ≥30% from baseline to 
the final treatment period evaluation (Visit 4) and a peak eosinophil count of ≤6/HPF across 
all esophageal levels at the final treatment period evaluation (Visit 4 )
Overall binary  response II, defined as a reduction in the DSQ score of ≥50% from baseline to 
the final treatment period evaluation (Visit 4) and a peak eosinophil count of ≤6/HPF across 
all esophageal levels at the final treatment period evaluation (Visi t 4)
Change in the DSQ + pain score (questions 2+3+4) from baseline to the final treatment 
period evaluation (Visit 4)
Change in the DSQ pain score (question 4) from baseline to the final treatment period 
evaluation (Visit 4)
The binary  response endpoints will be analy zed using the same logistic model as the co-primary
efficacy  endpoints.
Continuous endpoints will be anal yzed as a change from baseline using an ANCOVA model that 
includes treatment group and age group as factors and baseline score as a covari ate.
The anal yses for all secondary  efficacy  endpoints (including the key  secondary  efficacy  
endpoint) will be carried out using 2-sided tests at the 5% level of significance. For each of the 
secondary  efficacy  endpoints, the treatment difference, correspo nding 95% CI  for the difference 
and treatment comparison p -value for testing the null hy pothesis of zero treatment effect based 
on the final statistical model (ie, either logistic regression model or ANCOVA model) will be 
provided.
9.8.3 Exploratory Efficacy End point
The exploratory  endpoint that will be explored is the following:
9.9 Safety Analyses
Safety  data will be presented for the safet y set b y treatment group.
The safet y data col lected at the baseline visit (Visit 1) or the last preceding visit if not collected 
at Visit 1 will be used as the baseline value for safety  anal yses.
TEAEs are defined as AEs that start or deteriorate on or after the first dose of investigational 
product (Visit 1) and no later than 3 day s following the last dose of investigational product. 
However, for an y subjects who die during the study (ie, the date of death is between the date of 
first dose of investigational product and the date of study  discontinuat ion entered by  the site, 

Shire CONFIDENTIAL Page 79
Protocol Am endment 2
SHP621 -301 26 Jan 2018
inclusive), all AEs (including those resulting in death) that occur during the study  will be 
considered as TEAEs irrespective of the last dose and will be included in the TEAE summaries.
AEs will be coded using MedDRA. The number of events, incidence, and percentage of TEAEs 
will be calculated overall by  system organ class (SOC), preferred term (PT), and treatment 
group. TEAEs will be further summarized by  severity  and relationship to investigational product. 
AEs related to investig ational product, AEs leading to withdrawal, SAEs, and deaths will be 
similarly  summarized/listed.
Safety  parameters will include monitoring of AEs, phy sical examinations, stadiometry , vital 
signs (temperature, s ystolic and diastolic blood pressure, pulse, and respiratory  rate), weight and 
height assessments, DXA scans for BMD and body  composition measurements (for adolescents 
aged 11 -17years, inclusive), clinical laboratory  tests (hematology , chemistry , urinal ysis; serum 
pregnancy  test, if appropriate), an d ACTH stimulation tests. To account for the effects of puberty  
in adolescent subjects (11 -17 years of age, inclusive), BMD z -scores will be adjusted for height 
z-scores using the Bone Mineral Densit y in Childhood Study  calculator ( BMDCS 2015) 
(http://www.bmdcspublic.com). Safety  parameters will be descriptively  summarized by  
treatment group at baseline and for each post -baseline visit.
9.10 Other Analyses
9.10.1 Health -related Quality -of-life Analyses 
The health economics an d outcomes research endpoints that will be explored are the following:
EoE-QoL-A Questionnaire ( Taft et al., 2011)
EQ-5D (EQ -
5D-3L or EQ -5D- Y, acco rding to subject’s age)
PedsQL -EoE
The submodules of the EoE- QoL-A and PedsQL - EoE will be assessed in addition to the overall 
score with a focus on emotional and phy sical elements. For all HRQoL analy ses, change from 
baseline to the final treatment perio d evaluation (Visit 4) will be assessed.
9.10.2 Pharmacokinetic Analyses
Pharmacokinetic parameters will be determined from the plasma concentration -time data for 
budesonide b y non -compartmental anal ysisfor subjects who provide sufficient number sof 
intensive PK samples . For all subjects who provide PK samples (ie, limited or intensive samples) 
population PK analy sis will be conducted. A report for the population PK anal ysis will be 
provided separatel y from the clinical study report (CSR). 
The pharmacokinetic en dpoints will include but not be limited to those listed in Table 9-2.
Shire CONFIDENTIAL Page 80
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Table 9-2: Pharmacokinetic Parameters
Param eter Definition
AUC 0-tau Area under the curve for the defined interval betw een doses
Cmax Maximum concentration occurring at t max
tmax Time of maximum observed concentration sampled during a dosing interval
Summary  statistics (number of observations, mean, standard deviation, coefficient of variation, 
median, maximum, minimum, and geometric mea n) will be determined for all pharmacokinetic 
parameters b y overall and by week. Plasma concentrations at each nominal sampling time will 
also be summarized using descriptive statistics.
Shire CONFIDENTIAL Page 81
Protocol Am endment 2
SHP621 -301 26 Jan 2018
10. SPONSOR’S AND INVEST IGATOR’S RESPONSIBIL ITIES
This study  is conducted in accordance with current applicable regulations, ICH, EU Directive 
2001/20/EC and its updates, and local ethical and legal requirements.
The name and address of each third -party vendor (eg, CRO) used in this study  will be maintained 
in the investigator ’s and sponsor’s files, as appropriate.
10.1 Sponsor’s Responsibilities
10.1.1 Good Clinical Practice Compliance
The study  sponsor and any  third party  to whom aspects of the study  management or monitoring 
have been delegated will undertake their assigned roles for thi s study  in compliance with all 
applicable industry  regulations, I CH GCP Guideline E6 ( 1996), EU Directive 2001/20/EC, as 
well as all applicable national and local laws and regulations.
Visits to sites are conducted by  representatives of the study  sponsor a nd/or the company  
organizing/managing the research on behalf of the sponsor to inspect study  data, subjects’ 
medical records, and CRFs in accordance with current good clinical p
ractice (GCP )and the 
respective local and (inter)national government regulatio ns and guidelines. Records and data 
may additionally  be reviewed by  auditors or b y regulatory  authorities.
The sponsor ensures that local regulatory  authority requirements are met before the start of the 
study . The sponsor (or a nominated designee) is resp onsible for the preparation, submission, and 
confirmation of receipt of an y regulatory  authority  approvals required prior to release of 
investigational product for shipment to the site.
10.1.2 Indemnity/Liability and Insurance
The sponsor of this research adheres to the recommendations of the Association of British 
Pharmaceutical Industry  Guidelines. If appropriate, a cop y of the indemnity document is 
supplied to the investigator before study  initiation, per local country  guidelines.
The sponsor ensures that suita ble clinical study  insurance coverage is in place prior to the start of 
the study . An insurance certificate is supplied to the CRO as necessary .
10.1.3 Public Posting of Study Information
The sponsor is responsible for posting appropriate study  information on app licable websites.
Information included in clinical study  registries may  include participating investigators’ names 
and contact information.
Shire CONFIDENTIAL Page 82
Protocol Am endment 2
SHP621 -301 26 Jan 2018
10.1.4 Submission of Summary of Clinical Study Report to Competent Authorities 
of Member States Concerned and Ethics Commit tees
The sponsor will provide a summary  of the clinical study  report to the competent authority  of the 
member state(s) concerned as required b y regulatory  requirement(s) and to comply  with the 
community  guideline on GCP. This requirement will be fulfilled within 6 months of the end of 
the study  completion date for pediatric studies and within 1 y ear for non -pediatric studies as per 
guidance. 
10.1.5 Study Suspension, Termination, and Completion
The sponsor may  suspend or terminate the study , or part of the study , at any  time for any  reason. 
If the stud y is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies and IRBs/ECs are notified as appropriate. Additionally , the discontinuation of a 
registered clinical study , which has be en posted to a designated public website, will be updated 
accordingl y.
10.2 Investigator’s Responsibilities
10.2.1 Good Clinical Practice Compliance
The investigator must undertake to perform the study  in accordance with ICH GCP Guideline E6 
(
1996), EU Directive 2001/ 20/EC, and applicable regulatory  requirements and guidelines.
It is the investigator’s responsibility  to ensure that adequate time and appropriately  trained 
resources are available at the site prior to commitment to participate in this study . The 
investiga tor should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable subjects within the agreed recruitment period.
The investigator will maintain a list of appropriately  qualified persons to whom the investigator 
has delegated significant study - related tasks, and shall, upon request of the sponsor, provide 
documented evidence of any  licenses and certifications necessary  to demonstrate such 
qualification. Curriculum vitae for investigators and sub- investigators are p rovided to the study  
sponsor (or designee) before starting the study .
If a potential research subject has a primary  care phy sician, the investigator should, with the 
subject’s consent, inform them of the subject’s participation in the study .
A coordinating
principal investigator is appointed to review the final clinical study  report for 
multicenter studies. Agreement with the final clinical study  report is documented by  the signed 
and dated signature of the principal investigator (single- site study ) or coor dinating principal 
investigator (multicenter study ), in compliance with Directive 2001/83/EC as amended b y 
Directive 2003/63/EC and I CH Guidance E3 ( 1995 ).
Shire CONFIDENTIAL Page 83
Protocol Am endment 2
SHP621 -301 26 Jan 2018
10.2.2 Protocol Adherence and Investigator Agreement
The investigator and an y coinvestigators must adhere t o the protocol as detailed in this 
document. The investigator is responsible for enrolling only  those subjects who have met 
protocol eligibility  criteria. Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to comply  with the study  protocol.
If the investigator suspends or terminates the study  at their site, the investigator will promptly  
inform the sponsor and the I RB/EC and provide them with a detailed written explanation. The 
investigator will also return al l investigational product, containers, and other study  materials to 
the sponsor. Upon study  completion, the investigator will provide the sponsor, I RB/EC, and 
regulatory  agency  with final reports and summaries as required by  (inter)national regulations.
Communication with local IRBs/ECs, to ensure accurate and timel y information is provided at 
all phases during the study , may  be done by  the sponsor, applicable CRO, investigator, or for 
multicenter studies, the coordinating principal investigator according t o national provisions and 
will be documented in the investigator agreement.
10.2.3 Documentation and Retention of Records
10.2.3.1 Case Report Forms
Electronic CRFs are supplied by  the CRO and should be handled in accordance with instructions 
from the sponsor.
The investi gator is responsible for maintaining adequate and accurate medical records from 
which accurate information is recorded onto CRFs, which have been designed to record all 
observations and other data pertinent to the clinical investigation. Case report forms must be 
completed b y the investigator or designee as stated in the site delegation log.
All data from the investigator will have separate source documentation; no data will be recorded 
directly  onto the CRF.
All data sent to the sponsor must be e ndorsed b y the investigator.
The data from the central pathologist will be recorded directl y onto paper CRFs.
The clinical research associate (CRA)/study  monitor will verify  the contents against the source 
data per the monitoring plan. If the data are unc lear or contradictory , queries are sent for 
corrections or verification of data.
10.2.3.2 Recording, Access, and Retention of Source Data and Study Documents
Original source data to be reviewed during this study  will include but are not limited to subject’s 
medical file, original clinical laboratory  reports, and histology  and pathology  reports.
All key  data must be recorded in the subject’s medical records.
Shire CONFIDENTIAL Page 84
Protocol Am endment 2
SHP621 -301 26 Jan 2018
The investigator must permit authorized representatives of the sponsor; the respective national, 
local, or for eign regulatory  authorities; the I RB/EC; and auditors to inspect facilities and to have 
direct access to original source records relevant to this study , regardless of media.
The CRA/study  monitor (and auditors, IRB/EC, or regulatory  inspectors) may  check t he CRF 
entries against the source documents. The consent form includes a statement by  which the 
subject agrees to the monitor/auditor from the sponsor or its representatives, national or local 
regulatory  authorities, or the I RB/EC, having access to source data (eg, subject’s medical file, 
appointment books, original laboratory reports, X -rays, etc.).
These records must be made available within reasonable times for inspection and duplication, if 
required, b y a properly  authorized representative of any  regula tory agency  (eg, the US FDA, 
EMA, UK Medicines and Healthcare products Regulatory  Agency ) or an auditor.
Essential documents must be maintained according to ICH GCP requirements and may  not be 
destroy ed without written permission from the sponsor.
Laborato ry samples (blood and urine) will be stored by  the clinical laboratory  for as long as is 
required to:
Complete the study
Publish data related to the study
Support any  regulatory  applications for the study  drug
Samples could be stored for up to about 15 years.
Biopsy  specimens should be stored by  the local laboratory  per federal and local regulations.
10.2.3.3 Audit/Inspection
To ensure compliance with relevant regulations, data generated b y this study must be available 
for inspection upon request by representatives of, for example, the US FDA (as well as other US 
national and local regulatory  authorities), the EMA, the Medicines and Healthcare products 
Regulatory  Agency , other regulatory  authorities, the sponsor or its representatives, and the 
IRB/EC for each site.
10.2.3.4 F inancial Disclosure
The investigator is required to disclose an y financial arrangement during the study and for 1 year 
after, whereb y the outcome of the study  could be influenced by  the value of the compensation for 
conducting the study , or other pay ments the investigator received from the sponsor. The 
following information is collected: an y significant payments from the sponsor or subsidiaries 
such as a grant to fund ongoing research, compensation in the form of equipment, retainer for 
Shire CONFIDENTIAL Page 85
Protocol Am endment 2
SHP621 -301 26 Jan 2018
ongoing consultation , or honoraria; an y proprietary interest in investigational product; any 
significant equity  interest in the sponsor or subsidiaries as defined in 21 CFR 54 2(b) ( 1998).
10.3 Ethical Considerations
10.3.1 Informed Consent
It is the responsibility  of the investigator to obtain written informed consent (or assent as 
applicable for subjects <18 years of age) from all study  subjects prior to any  study -
related 
procedures including screening assessments. All consent documentation must be in accordance 
with applicable regulati ons and GCP. Each subject or the subject’s legall y authorized 
representative, as applicable, is requested to sign and date the subject’s informed consent form or 
a certified translation, if applicable, after the subject has received and read (or been read) the 
written subject information and received an explanation of what the study  involves, including but 
not limited to the objectives, potential benefits and risk, inconveniences, and the subject’s rights 
and responsibilities. A copy of the informed consent documentation (ie, a complete set of subject 
information sheets and fully  executed signature pages) must be given to the subject or the 
subject’s legall y authorized representative, as applicable. This document may require translation 
into the local langua ge. Signed consent forms must remain in each subject’s study  file and must 
be available for verification at an y time.
Within the source documents, site personnel should document instruction of and understanding 
by the parent/legall y authorized representati ve/caregiver of the safe, responsible storage and 
administration of investigational product to the study  subject.
The principal investigator provides the sponsor with a cop y of the consent form consent (or 
assent as applicable for subjects <18 years of age ) that was reviewed b y the I RB/EC and received 
their favorable opinion/approval. A cop y of the IRB’s/EC’s written favorable opinion/approval 
of these documents must be provided to the sponsor, prior to the start of the study  unless it is 
agreed to and documented (abiding b y regulatory  guidelines and national provisions) prior to 
study  start that another party  (ie, sponsor or coordinating principal investigator) is responsible for 
this action. Additionally , if the I RB/EC requires modification of the sample subject information 
and consent document provided by  the sponsor, the documentation supporting this requirement 
must be provided to the sponsor.
10.3.2 Institutional Review Board or Ethics Committee
For sites outside the EU, it is the responsibility of the investi gator to submit this protocol, the 
informed consent document (approved b y the sponsor or their designee), relevant supporting 
information, and all ty pes of subject recruitment information to the I RB/EC for review, and all 
must be approved prior to site ini tiation .
For sites within the EU, the applicant for an EC opinion can be the sponsor or the investigator or, 
for multicenter studies, the coordinating principal investigator or sponsor, according to national 
provisions.
Shire CONFIDENTIAL Page 86
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Responsibility  for coordinating with IRBs/ECs is defined in the investigator agreement.
Prior to implementing changes in the study , the sponsor and the IRB/EC must approve any  
revisions of all informed consent (or assent as applicable for subjects <18 years of age) 
documents and amendments t o the protocol unless there is a subject safet y issue.
Investigational product supplies will not be released until the CRO has received written IRB/EC 
approval of and copies of revised documents.
For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the 
progress of the stud y and of an y changes made to the protocol, but in an y case at least once a 
year; for sites within the EU, this can be done by  the sponsor or the investigator or, for 
multicenter studies, the coordina
ting principal investigator, according to national provisions. The 
investigator must also keep the local IRB/EC informed of an y serious and significant AEs.
10.4 Privacy and Confidentiality
All US- based sites and laboratories or entities providing support for t his study , must, where 
applicable, compl y with HI PAA of 1996. A site that is not a covered entity  as defined by  HIPAA 
must provide documentation of this fact to the CRO/sponsor.
The confidentialit y of records that may be able to identify subjects will be p rotected in 
accordance with applicable laws, regulations, and guidelines.
After subjects have consented to take part in the study , the sponsor and/or its representatives’
reviews their medical records and data collected during the stud y. These records and data may , in 
addition, be reviewed b y others including the following: independent auditors who validate the 
data on behalf of the sponsor; third parties with whom the sponsor may  develop, register, or 
market SHP621; national or local regulatory  authorities; and the I RBs/ECs which gave approval 
for the stud y to proceed. The sponsor and/or its representatives accessing the records and data 
will take all reasonable precautions in accordance with applicable laws, regulations, and 
guidelines to maintain the conf identialit y of subjects’ identities.
Subjects are assigned a unique identify ing number; however, their initials and date of birth may  
also be collected and used to assist the sponsor to verify  the accuracy  of the data (eg, to confirm 
that laboratory  result s have been assigned to the correct subject).
The results of studies –containing subjects’ unique identify ing number, relevant medical 
records, and possibly  initials and dates of birth –will be recorded. They  may  be transferred to 
and used in other count ries which may  not afford the same level of protection that applies within 
the countries where this study  is conducted. The purposes of an y such transfer would include 
supporting regulatory  submissions, conducting new data analy ses to publish or present th e stud y 
results, or answering questions asked by  regulatory  or health authorities.
Shire CONFIDENTIAL Page 87
Protocol Am endment 2
SHP621 -301 26 Jan 2018
10.5 Study Results/Publication Policy
Shire will endeavor to publish the results of all qualify ing, applicable, and covered studies 
according to external guidelines in a timely  manner regardless of whether the outcomes are 
perceived as positive, neutral, or negative. Additionally , Shire adheres to external guidelines (eg, 
Good Publication Practices 2) when forming a publication steering committee, which is done for 
large, multicen ter Phase 2 -4 and certain other studies as determined b y Shire. The purpose of the 
publication steering committee is to act as a non- commercial body  that advises or decides on 
dissemination of scientific study  data in accordance with the scope of this poli cy.
All publications relating to Shire products or projects must undergo appropriate technical and 
intellectual propert y review, with Shire agreement to publish prior to release of information. The 
review is aimed at protecting the sponsor’s proprietary  information existing either at the 
commencement of the study  or generated during the study . To the extent permitted by  the 
publisher and cop yright law, the principal investigator will own (or share with other authors) the 
copy right on his/her publications. T o the extent that the principal investigator has such sole, joint 
or shared rights, the principal investigator grants the sponsor a perpetual, irrevocable, ro yalty-
free license to make and distribute copies of such publications.
The term “publication” refe rs to an y public disclosure including original research articles, review 
articles, oral presentations, abstracts and posters at medical congresses, journal supplements, 
letters to the editor, invited lectures, opinion pieces, book chapters, electronic post ings on 
medical/scientific websites, or other disclosure of the study  results, in printed, electronic, oral, or 
other form.
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study  results, and any  background information provided by  the sponsor that is necessary  to 
include in an y publication of study results, or necessary for other scholars to verify such stud y 
results. Notwithstanding the foregoing, no publication that incorporates the sponsor’s 
confidential i nformation shall be submitted for publication without the sponsor’s prior written 
agreement to publish, and shall be given to the sponsor for review at least 60 days prior to 
submission for publication. If requested in writing by  Shire, the institution and principal 
investigator shall withhold submission of such publication for up to an additional 60 day s to 
allow for filing of a patent application.
If the stud y is part of a multicenter study, the first publication of the study results shall be made 
by the sponsor in conjunction with the sponsor’s presentation of a joint, multicenter publication 
of the compiled and analy zed study  results. If such a multicenter publication is not submitted to a 
journal for publication by  the sponsor within an 18-month period after conclusion, abandonment, 
or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter 
study  publication of the study  results, an investigator may individuall y publish the study results 
from the specific site in accordance with this section. The investigator must, however, 
acknowledge in the publication the limitations of the single -site data being presented.
Shire CONFIDENTIAL Page 88
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Unless otherwise required by  the journal in which the publication appears, or the forum in which 
it is m ade, authorship will comply  with the International Committee of Medical Journal Editors 
current standards. Participation as an investigator does not confer an y rights to authorship of 
publications.
Shire CONFIDENTIAL Page 89
Protocol Am endment 2
SHP621 -301 26 Jan 2018
11. REFERENCES
Bone Mineral Density  in Childhood Study  (BMDCS) 2015. Available at: 
http://www.bmdcspublic.com. Accessed August 5, 2015.
Bachrach, L. K. & Sills, I. N. 2011. Clinical report -bone densitometry  in children and 
adolescents. Pediatrics, 127, 189 -94.
Dellon, E. S., Jensen, E. T., Martin, C. F., Shaheen, N. J. & Kappelman, M. D. 2014a. 
Prevalence of eosinophilic esophagitis in the United States. Clin Gastroenterol Hepatol,
12, 589- 96.e1.
Dellon, E. S., Kim, H. P., Sperry , S. L ., Ry bnicek, D. A., Woosley , J. T. & Shaheen, N. J. 2014b. 
A phenoty pic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic 
disease. 
Gastrointest Endosc, 79, 577- 85.e4.
EuroQol 1990. EuroQol --
a new facility  for the measurement of health -related quality  of life. 
Health Policy, 16, 199- 208.
FDA 2011. Uceris pharmacology  review. 
NDA 203 -634.
Franciosi, J. P., Hommel, K. A., Bendo, C. B., King, E. C., Collins, M. H., Eby , M. D., Marsolo, 
K., Abonia, J. P., von 
Tiehl, K. F., Putnam, P. E., Greenler, A. J., Greenberg, A. B., 
Bryson, R. A., Davis, C. M., Olive, A. P., Gupta, S. K., Erwin, E. A., Klinnert, M. D., 
Spergel, J. M., Denham, J. M., Furuta, G. T., Rothenberg, M. E. & Varni, J. W. 2013. 
PedsQL eosinophilic esophagitis module: feasibility , reliability , and validity . J Pediatr 
Gastroenterol Nutr, 57, 57-66.
Furuta, G. T., 
Liacouras, C. A., Collins, M. H., Gupta, S. K., Justinich, C., Putnam, P. E., Bonis, 
P., Hassall, E., Straumann, A. & Rothenberg, M. E. 2007. Eosinophilic esophagitis in 
children and adults: a systematic review and consensus recommendations for diagnosis 
and treatment. Gast roenterology, 133, 1342-63.
Gordon, C. M., Bachrach, L . K., Carpenter, T. O., Crabtree, N., El -Hajj Fuleihan, G., Kutilek, S., 
Lorenc, R. S., Tosi, L. L., Ward, K. A., Ward, L. M. & Kalkwarf, H. J. 2008. Dual 
energy  X-ray absorptiometry  interpretation and reporting in children and adolescents: the 
2007 I SCD Pediatric Official Positions. J Clin Densitom, 11, 43-58.
Hirano, I. & Aceves, S. 
S. 2014. Clinical implications and pathogenesis of esophageal 
remodeling in eosinophilic esophagitis. Gastroenterol Clin North Am, 43, 297 -316.
ISCD 2014. International Society  for Clinical Densitometry  2013 Official Positions—Adult & 
Pediatric. 1 -20.
Liacouras, C. A., Furuta, G. T., Hirano, I., Atkins, D., Attwood, S. E., Bonis, P. A., Burks, A. 
W., Chehade, M., Collins, M.H., Dellon, E. S., Dohil, R., Falk, G. W., Gonsalves, N., 
Gupta, S. K., Katzka, D. A., Lucendo, A. J., Markowitz, J. E., Noel, R. J., Odze, R. D., 
Putnam, P. E., Richter, J. E., Romero, Y., Ruchelli, E., Sampson, H. A., Schoepfer, A., 
Shaheen, N. J., Sicherer, S. H., Spechler, S., Spergel, J. M., Straumann, A., Wershil, B. 
K., Rothenberg, M. E. & Aceves, S. S. 2011. Eosinophilic esophagitis: updated 
consensus recommendations for children and adults. J Allergy Clin Immunol, 128, 3-
20.e6; quiz 21 -
2.
Mehta, C. R. & Pocock, S. J. 2011. Adaptive increase in sample size when interim results are 
promising: a practical guide with examples. Statistics in medicine, 30, 3267 -84.
PROQOLID 2015. Patient- Reported Outcome and Quality  of Life Instruments Database 
(PROQOLID ).Available at: http://www.proqolid.org. Accessed August 24, 2015.
Shire CONFIDENTIAL Page 90
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Taft, T. H., Kern, E., Kwiatek, M. A., Hirano, I., Gonsalves, N. & Keefer, L. 2011. The adult 
eosinophilic oesophagitis quality  of life questionnaire: a new measure of health- related 
quali ty of life. Aliment Pharmacol Ther, 34, 790-8.
Wille, N., Badia, X., Bonsel, G., Burstrom, K., Cavrini, G., Devlin, N., Egmar, A. C., Greiner, 
W., Gusi, N., Herdman, M., Jelsma, J., Kind, P., Scalone, L. & Ravens
-Sieberer, U. 2010. 
Development of the EQ-5D-Y: a child- friendl y version of the EQ-5D. Qual Life Res, 19, 
875-86.
Shire CONFIDENTIAL Page 91
Protocol Am endment 2
SHP621 -301 26 Jan 2018
12. APPENDICES
Shire CONFIDENTIAL Page 92
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Appendix 1 Protocol History 
Document Date Global/Country/Site Specific
Protocol Amendment 2 26Jan 2018 Global
Protocol Amendment 1 16 Dec 2015 Global
Original Protocol 31 Aug 20 15 Global
Shire CONFIDENTIAL Page 93
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Appendix 2 Scales and Assessments
The following scales/assessments will be utilized in this study :
Full Title of Scale/Assessment Completed By
DSQ Subject
EQ-5D-3L (for subjects ≥18 years)
EQ-5D-Y (for subjects 11 -17 years of age, inclusive)Subject
PedsQL -EoE (subjects 11 -17 years of age, inclusive) Subject and parent or legal 
guardian
EoE-QoL- A (subjects ≥18 years of age) Subject
PGI-S Subject
Tanner Staging Assessment (for subjects 11 -17 years of age, inclusive) Site
EREFS Site
DSQ=Dysphagia Symptom Questionnaire; EoE- QoL- A=Ad ult Eosinophilic Esophagitis Quality of Life; EQ -
5D=EuroQol; EREFS=EoE Endoscopic Reference Score; PedsQL -EoE=Pediatric Quality of Life Inventory – EoE; 
PGI- S=Patient Global Impression of Severity
A separate master file c ontaining each scale/assessment listed above will be provided to the site. 
Updates to scales/assessments during the stud y (if applicable) will be documented in the table 
above, and a new master file containing the revised scale/assessmen t will be provided to the site.
Shire CONFIDENTIAL Page 94
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Appendix 3 Dysphagia Symptom Questionnaire ePRO for EoE 

Shire CONFIDENTIAL Page 95
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Appendix 4 Patient Global Impression of Severity
How would y ou rate the overall severity  of your dy sphagia (difficult y swallowing) over the past 
7days?
Rating Description
0 No dysphagia
1 Mild dysphagia
2 Moderate dysphagia
3 Severe dysphagia
4 Very  severe dysphagia
Shire CONFIDENTIAL Page 96
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Appendix 5 Biosciences Generic Clinical Protocol Insert
Blood Sample Collection
Blood samples will be collected at the times specified in Table 1-1 to measure plasma 
concentrations of budesonide. Pot ential metabolites may also be determined as appropriate.
Blood samples 4 mL for pharmacokinetic anal ysis will be drawn by  in-dwelling catheters or 
direct venipuncture into K2EDTA tubes, capped and mixed by  inversion (x3), and chilled 
immediately  on crushe d ice. The actual time that the sample was obtained will be recorded in the 
subject’s source document and on the appropriate CRF page. After appl ying a tourniquet, venous 
blood will be drawn with a disposable needle. If a catheter is used, the first millil iter of blood on 
each sampling occasion will be discarded. Saline can be used to keep catheters patent.
Blood/Plasma Sample Handling
Samples should be kept on crushed ice until plasma is separated as soon as possible after 
collection within <15 minutes, un less advised otherwise b y refrigerated centrifugation (4 C, 
1500 rpm 15 minutes). The separated plasma will be decanted into appropriately  labeled 
polypropylene tubes via a plastic pipette. All samples will be stored at approximately  
-20C or 
colder and th
e freezer temperature will be controlled, monitored, and recorded during the storage 
period until they  are transferred in the frozen state to a designated bioanal ytical contract 
laboratory . Samples will remain frozen at -20C or colder until anal ysis.
Plas
ma sample tubes for bioanaly sis must be freezer -safe and identified with freezer -safe labels 
provided b y the central laboratory. The labels will contain the following information:
 Study  number
 Subject identifier (randomization number)
 Matrix identifier (pl asma)
 Visit
 Nominal time
Shipment of Plasma Samples
Plasma samples should be double-bagged to contain leaks and packed with a sufficient quantit y 
of dry  ice to ensure that they  remain frozen for at least 72 hours to allow for delays in shipment. 
All applicable shipping regulations must be followed. Shipments should be scheduled so that no 
samples arrive on the weekend and should be shipped Monday  toWednesday  only.
Shire CONFIDENTIAL Page 97
Protocol Am endment 2
SHP621 -301 26 Jan 2018
Plasma samples, along with the corresponding documentation, will be shipped to:
PPD
2 Tessen eer Drive
Highland Heights, KY 41076, USA
Email: 
Phone:  or , 
Fax:
Plasma samples will be stored nominally  at -20C prior to and after analy sis at Quest 
Pharmaceutical Ser vices (QPS) until their disposal is authorized by  Shire.
Assay Methodology
Drug anal ysis will be performed at QPS under the guidance of the NCE group at Shire. Plasma 
sample anal ysis will be performed according to the bioanal ytical stud y plans prepared for the 
study . 
Plasma samples will be analy zed at QPS for budesonide using the most current validated 
bioanaly tical method. 
In addition, selected plasma samples may  be used to investigate incurred sa mple reproducibility  
(full details will be described in the bioanal ytical study  plan). The presence of other metabolites 
or artifacts may  be monitored or quantified as appropriate.
Raw data will be stored in the archives at QPS.
